


**CUMULATIVE
SUPPLEMENT 10
OCTOBER 2021**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2021

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41th EDITION

**Cumulative Supplement 10
October 2021**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Product Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

**CUMULATIVE SUPPLEMENT 10
OCTOBER 2021**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

AUROBINDO PHARMA LTD
(AUROBINDO PHARMA LTD)

AKORN INC
(AKORN)

AKORN INC
(AKORN INC)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

EUGIA PHARMA SPECIALITIES LTD
(EUGIA PHARMA)

AKORN OPERATING CO LLC
(AKORN)

AKORN OPERATING CO LLC
(AKORN)

JIANGSU HENGRUI MEDICINE CO LTD (JIANGSU HENGRUI MED)	JIANGSU HENGRUI PHARMACEUTICALS CO LTD (JIANGSU PHARMS)
ORCHID HEALTHCARE (ORCHID HLTHCARE)	ORBION PHARMACEUTICALS PRIVATE LTD (ORBION PHARMS)
PADDOCK LABORATORIES LLC (PADDOCK LABS LLC)	PADAGIS US LLC (PADAGIS US)
PADDOCK LABORATORIES LLC (PADDOCK LLC)	PADAGIS US LLC (PADAGIS US)
PAR PHARMACEUTICAL INC (PAR PHARM)	STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)
PERRIGO CO OF TENNESSEE INC (PERRIGO CO)	PADAGIS US LLC (PADAGIS US)
PERRIGO CO TENNESSEE INC (PERRIGO CO TENNESSEE)	PADAGIS US LLC (PADAGIS US)
PERRIGO NEW YORK INC (PERRIGO NEW YORK)	PADAGIS US LLC (PADAGIS US)
PERRIGO PHARMA INTERNATIONAL DAC (PERRIGO PHARMA INTL)	PADAGIS US LLC (PADAGIS US)
PERRIGO UK FINCO LTD PARTNERSHIP (PERRIGO UK FINCO)	PADAGIS ISRAEL PHARMACEUTICALS LTD (PADAGIS ISRAEL)
PERRIGO ISRAEL PHARMACEUTICALS LTD (PERRIGO ISRAEL)	PADAGIS ISRAEL PHARMACEUTICALS LTD (PADAGIS ISRAEL)
WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD (WEST-WARD PHARMS INT)	HIKMA PHARMACEUTICALS USA INC (HIKMA PHARMS)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levotheroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those

now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2020</u>	<u>MAR</u> <u>2021</u>	<u>JUN</u> <u>2021</u>	<u>SEP</u> <u>2021</u>	<u>DEC</u> <u>2021</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	20478 2659 (13.0%)	20726 2671 (12.9%)	20916 2675 (12.8%)	20919 2659 (12.7%)	
MULTISOURCE	17819 (87.0%)	18055 (87.1%)	18241 (87.2%)	18260 (87.3%)	
THERAPEUTICALLY EQUIVALENT	17746 (86.7%)	17990 (86.8%)	18175 (86.9%)	18114 (86.6%)	
NOT THERAPEUTICALLY EQUIVALENT	73 (0.4%)	65 (0.3%)	66 (0.3%)	146 (0.7%)	
EXCEPTIONS ⁴	54 (0.3%)	54 (0.3%)	54 (0.3%)	54 (0.3%)	
NEW MOLECULAR ENTITIES APPROVED	22	29	33	18	
NUMBER OF APPLICANTS	1185	1184	1182	1167	

1.7 CUMULATIVE SUPPLEMENT LEGEND

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET; ORAL		ABIRATERONE ACETATE					
AB	AMNEAL PHARMS	500MG		A208327	002	Dec 23, 2020	Apr NEWA
AB	QILU	500MG		A212462	002	Jun 25, 2021	Jun NEWA

ACARBOSE

TABLET; ORAL		ACARBOSE					
AB	EMCURE PHARMS LTD	25MG		A202271	001	Feb 07, 2012	Apr CMFD
AB		50MG		A202271	002	Feb 07, 2012	Apr CMFD
AB		100MG		A202271	003	Feb 07, 2012	Apr CMFD
	@ HANGZHOU ZHONGMEI	25MG		A213821	001	Aug 18, 2020	Aug DISC
	@	50MG		A213821	002	Aug 18, 2020	Aug DISC
	@	100MG		A213821	003	Aug 18, 2020	Aug DISC

ACETAMINOPHEN

POWDER; INTRAVENOUS		ACETAMINOPHEN					
	+ @ MYLAN LABS LTD	1GM/VIAL		N206610	001	Jan 15, 2021	Jan NEWA
SOLUTION; INTRAVENOUS		ACETAMINOPHEN					
	+! B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)		N204957	001	Feb 18, 2021	Feb NEWA
	+!	1GM/100ML (10MG/ML)		N204957	002	Feb 18, 2021	Feb NEWA
AP	BAXTER HLTHCARE CORP	1GM/100ML (10MG/ML)		A214331	001	Sep 17, 2021	Sep NEWA

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL		CODEINE, ASPIRIN, APAP FORMULA NO. 2					
	+ @ SCHERER LABS	150MG; 180MG; 15MG		A085640	001		Aug CRLD
		CODEINE, ASPIRIN, APAP FORMULA NO. 3					
	+ @ SCHERER LABS	150MG; 180MG; 30MG		A085639	001		Aug CRLD

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL		BUTALBITAL AND ACETAMINOPHEN					
AA	ALVOGEN	300MG; 50MG		A207635	001	Jun 05, 2017	Jun CAHN
AA		325MG; 50MG		A205120	001	Oct 30, 2015	Jun CAHN
	+ @ WATSON LABS	325MG; 50MG		A087550	001	Oct 19, 1984	Aug CRLD
		PHRENILIN					
	+ @ VALEANT	325MG; 50MG		A087811	001	Jun 19, 1985	Aug CRLD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
	+ @ GILBERT LABS	325MG; 50MG; 40MG		A088825	001	Dec 05, 1984	Aug CRLD
AA	HAVIX	300MG; 50MG; 40MG		A214087	001	Aug 13, 2021	Aug NEWA
AA		325MG; 50MG; 40MG		A214087	002	Aug 13, 2021	Aug NEWA
AA	SENORES PHARMS	300MG; 50MG; 40MG		A214087	001	Aug 13, 2021	Aug CAHN
AA		325MG; 50MG; 40MG		A214087	002	Aug 13, 2021	Aug CAHN
AA	XSPIRE PHARMA	300MG; 50MG; 40MG		A206615	001	Aug 04, 2017	Feb CAHN
TABLET; ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA	+ ACTAVIS LABS UT INC	325MG; 50MG; 40MG		A088616	001	Nov 09, 1984	Aug CRLD
AA	ALVOGEN	325MG; 50MG; 40MG		A204984	001	Jan 10, 2017	Jun CAHN
	@ GRANULES	325MG; 50MG; 40MG		A040864	001	Dec 01, 2008	Apr CAHN
>A> AA	! STRIDES PHARMA	325MG; 50MG; 40MG		A040511	001	Aug 27, 2003	Oct CAHN
>D> AA	! VINTAGE PHARMS	325MG; 50MG; 40MG		A040511	001	Aug 27, 2003	Oct CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL		BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE					
AB	NOSTRUM LABS INC	325MG; 50MG; 40MG; 30MG		A075929	001	Apr 22, 2002	Jan CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

XSPIRE PHARMA 320.5MG;30MG;16MG A204785 001 Nov 26, 2014 Jul CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

+ @ ACTAVIS MID ATLANTIC 120MG/5ML;12MG/5ML A085861 001 Aug CRLD
 TYLENOL W/ CODEINE

+ @ ORTHO MCNEIL PHARM 120MG/5ML;12MG/5ML A085057 001 Aug CRLD

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA NOSTRUM LABS INC 300MG;15MG A088629 002 Mar 06, 1985 Aug CMS1

AA 300MG;30MG A088629 003 Mar 06, 1985 Aug CMS1

AA +! 300MG;60MG A088629 001 Mar 06, 1985 Aug CRLD

+ @ PUREPAC PHARM 300MG;15MG A086681 001 Aug CRLD

+ @ SANDOZ 300MG;15MG A087433 001 Aug CRLD

+ @ 300MG;30MG A085917 001 Aug CRLD

>A> @ STRIDES PHARMA 300MG;15MG A089990 001 Sep 30, 1988 Oct CAHN

>A> @ 300MG;30MG A089805 001 Sep 30, 1988 Oct CAHN

>A> @ 300MG;60MG A089828 001 Sep 30, 1988 Oct CAHN

>D> @ VINTAGE 300MG;15MG A089990 001 Sep 30, 1988 Oct CAHN

@ 300MG;15MG A089990 001 Sep 30, 1988 Apr DISC

>D> @ 300MG;30MG A089805 001 Sep 30, 1988 Oct CAHN

@ 300MG;30MG A089805 001 Sep 30, 1988 Apr DISC

>D> @ 300MG;60MG A089828 001 Sep 30, 1988 Oct CAHN

@ 300MG;60MG A089828 001 Sep 30, 1988 Apr DISC

AA 300MG;60MG A089828 001 Sep 30, 1988 Apr CAHN

TYLENOL W/ CODEINE NO. 2

+ @ JANSSEN PHARMS 300MG;15MG A085055 002 Aug CRLD

TYLENOL W/ CODEINE NO. 3

+ @ JANSSEN PHARMS 300MG;30MG A085055 003 Aug CRLD

TYLENOL W/ CODEINE NO. 4

+ @ JANSSEN PHARMS 300MG;60MG A085055 004 Aug CRLD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

ANEXSIA 5/325

AA ! SPECGX LLC 325MG;5MG A040409 001 Oct 20, 2000 Apr CHRS

ANEXSIA 7.5/325

AA ! SPECGX LLC 325MG;7.5MG A040405 001 Sep 08, 2000 Apr CHRS

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ALVOGEN 300MG;5MG A208540 001 Nov 08, 2018 Aug CAHN

@ 300MG;7.5MG A208540 002 Nov 08, 2018 Aug CAHN

@ 300MG;10MG A208540 003 Nov 08, 2018 Aug CAHN

@ 325MG;2.5MG A209958 001 Oct 24, 2018 Aug CAHN

@ 325MG;5MG A209958 002 Oct 24, 2018 Aug CAHN

@ 325MG;7.5MG A209958 003 Oct 24, 2018 Aug CAHN

@ 325MG;10MG A209958 004 Oct 24, 2018 Aug CAHN

AA ! SPECGX LLC 325MG;10MG A040400 001 Jul 26, 2000 Apr CHRS

>A> AA STRIDES PHARMA 325MG;5MG A040655 001 Jan 19, 2006 Oct CAHN

>A> AA 325MG;7.5MG A040656 001 Jan 19, 2006 Oct CAHN

>D> AA VINTAGE PHARMS 325MG;5MG A040655 001 Jan 19, 2006 Oct CAHN

>D> AA 325MG;7.5MG A040656 001 Jan 19, 2006 Oct CAHN

NORCO

@ APIL 325MG;2.5MG A040148 004 Jul 07, 2014 Apr DISC

@ 325MG;5MG A040099 001 Jun 25, 1997 Apr DISC

@ 325MG;5MG A040148 005 Jul 07, 2014 Apr DISC

@ 325MG;7.5MG A040148 003 Sep 12, 2000 Apr DISC

@ 325MG;10MG A040148 001 Feb 14, 1997 Apr DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

AA ! ABHAI LLC 325MG/5ML;5MG/5ML A211499 001 Dec 31, 2018 Aug CTEC

AA NOSTRUM LABS INC 325MG/5ML;5MG/5ML A201448 001 Aug 26, 2021 Aug NEWA

TABLET;ORAL

OXYCODONE 5/APAP 500

+ @ BRISTOL MYERS SQUIBB 500MG;5MG A085911 001 Aug CRLD

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	CHARTWELL	325MG;5MG	A207834	001	Aug 15, 2019	Jan CAHN
AA		325MG;7.5MG	A207834	002	Aug 15, 2019	Jan CAHN
AA		325MG;10MG	A207834	003	Aug 15, 2019	Jan CAHN
	PERCOCET					
	+ @ VINTAGE PHARMS LLC	325MG;5MG	A085106	002		Aug CRLD
	ROXICET					
	+ @ HIKMA PHARMS	325MG;5MG	A087003	001		Aug CRLD
	@	325MG;5MG	A087003	001		Jan DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB	ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018	Apr CMFD
AB	! INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Jun CAHN

TABLET;ORAL

ACETAZOLAMIDE

AB	APPCO	125MG	A211372	001	Feb 22, 2021	Feb NEWA
AB		250MG	A211372	002	Feb 22, 2021	Feb NEWA
AB	RUBICON	125MG	A215101	001	Aug 19, 2021	Aug NEWA
AB		250MG	A215101	002	Aug 19, 2021	Aug NEWA

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

DOMEBORO

	+ @ BAYER PHARMS	2%;0.79%	A084476	001		Aug CRLD
--	------------------	----------	---------	-----	--	----------

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP	EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Apr NEWA
----	--------------	---------------------	---------	-----	--------------	----------

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB	! SIGMAPHARM LABS LLC	25MG	A204633	004	May 22, 2015	Sep CHRS
	SORIATANE					
	+ @ STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996	Sep DISC
	+ @	25MG	N019821	002	Oct 28, 1996	Sep DISC

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

	+! ASTRAZENECA	0.4MG/INH	N202450	001	Jul 23, 2012	Feb CAHN
--	----------------	-----------	---------	-----	--------------	----------

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

	+! ASTRAZENECA	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Jun CHRS
	+	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Jun CRLD
		0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Feb CAHN

ACYCLOVIR

OINTMENT;TOPICAL

ACYCLOVIR

	@ ANDA REPOSITORY	5%	A206437	001	Jul 31, 2017	Jun DISC
AB	MACLEODS PHARMS LTD	5%	A212444	001	May 19, 2021	May NEWA

SUSPENSION;ORAL

ACYCLOVIR

>D>	@ VISTAPHARM	200MG/5ML	A213951	001	Jan 11, 2021	Oct CMFD
>A>	AB	200MG/5ML	A213951	001	Jan 11, 2021	Oct CMFD
	@	200MG/5ML	A213951	001	Jan 11, 2021	Jul DISC
AB		200MG/5ML	A213951	001	Jan 11, 2021	Jan NEWA

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

AP	NAMIGEN LLC	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Jun CAHN
AP	ZYDUS PHARMS	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CHRS
AP	!	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CPOT

ADAPALENE

GEL;TOPICAL
ADAPALENE
@ TOLMAR

0.3%

A200298 001 Jun 14, 2012 Sep DISC

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL
ADAPALENE AND BENZOYL PEROXIDE

>D> @ TARO 0.3%;2.5%
>A> AB @ TOLMAR 0.3%;2.5%
EPIDUO FORTE
>D> +! GALDERMA LABS 0.3%;2.5%
>A> AB +! 0.3%;2.5%
+! 0.3%;2.5%

A209148 001 Oct 17, 2018 Oct CMFD
A209148 001 Oct 17, 2018 Oct CMFD
A206164 001 May 23, 2018 Sep DISC
N207917 001 Jul 15, 2015 Oct CTEC
N207917 001 Jul 15, 2015 Oct CTEC
N207917 001 Jul 15, 2015 Feb CTEC

ADENOSINE

SOLUTION;INTRAVENOUS
ADENOSINE

AP EMCURE PHARMS LTD 60MG/20ML (3MG/ML)
AP 90MG/30ML (3MG/ML)

A202313 001 Sep 15, 2014 Feb CMFD
A202313 002 Sep 15, 2014 Feb CMFD

AIR POLYMER-TYPE A

FOAM;INTRAUTERINE
EXEM FOAM KIT

+! GISKIT 10ML

N212279 001 Nov 07, 2019 Aug CAHN

ALBENDAZOLE

TABLET;ORAL
ALBENDAZOLE

AB DR REDDYS 200MG
@ LUPIN LTD 200MG
AB MSN 200MG

A211034 001 Jan 26, 2021 Jan NEWA
A211636 001 Jun 10, 2020 Jan DISC
A213435 001 Jan 21, 2021 Jan NEWA

ALBUTEROL SULFATE

AEROSOL, METERED;INHALATION
ALBUTEROL SULFATE

AB1 @ PADAGIS US EQ 0.09MG BASE/INH
SANDOZ INC EQ 0.09MG BASE/INH

A203760 001 Feb 24, 2020 Jul CAHN
A207085 001 Jun 01, 2021 May NEWA

SOLUTION;INHALATION
ALBUTEROL SULFATE

AN @ LUOXIN AUROVITAS EQ 0.021% BASE
@ EQ 0.042% BASE
EQ 0.083% BASE

A211888 001 Apr 20, 2020 Aug CAHN
A211888 002 Apr 20, 2020 Aug CAHN
A206224 001 Oct 17, 2017 Aug CAHN

TABLET;ORAL

ALBUTEROL SULFATE

AB AIZANT EQ 2MG BASE
AB EQ 4MG BASE
AB APPCO EQ 2MG BASE
AB EQ 4MG BASE
@ EYWA EQ 2MG BASE
@ EQ 4MG BASE

A210948 001 Mar 15, 2019 Feb CMFD
A210948 002 Mar 15, 2019 Feb CMFD
A210948 001 Mar 15, 2019 Sep CAHN
A210948 002 Mar 15, 2019 Sep CAHN
A213524 001 Oct 08, 2020 Apr DISC
A213524 002 Oct 08, 2020 Apr DISC

TABLET, EXTENDED RELEASE;ORAL

ALBUTEROL SULFATE

@ MYLAN EQ 4MG BASE
@ EQ 8MG BASE

A078092 002 Jan 29, 2007 Sep DISC
A078092 001 Jan 29, 2007 Sep DISC

VOSPIRE ER

DAVA PHARMS INC EQ 4MG BASE

A076130 002 Sep 26, 2002 Sep CTEC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN ! @ AUROBINDO PHARMA LTD EQ 0.083% BASE;0.017%
@ LUOXIN AUROVITAS EQ 0.083% BASE;0.017%
! NEPHRON EQ 0.083% BASE;0.017%

A206532 001 Jul 08, 2020 Jan DISC
A206532 001 Jul 08, 2020 Aug CAHN
A076749 001 Dec 31, 2007 Sep CHRS

ALENDRONATE SODIUM

TABLET;ORAL

ALENDRONATE SODIUM

>D>	AB	IMPAX LABS INC	EQ 5MG BASE	A075710	001	Feb 06, 2008	Oct	DISC
>A>	@		EQ 5MG BASE	A075710	001	Feb 06, 2008	Oct	DISC
>D>	AB		EQ 10MG BASE	A075710	002	Feb 06, 2008	Oct	DISC
>A>	@		EQ 10MG BASE	A075710	002	Feb 06, 2008	Oct	DISC
>D>	AB		EQ 35MG BASE	A075710	003	Feb 06, 2008	Oct	DISC
>A>	@		EQ 35MG BASE	A075710	003	Feb 06, 2008	Oct	DISC
>D>	AB		EQ 40MG BASE	A075710	004	Feb 06, 2008	Oct	DISC
>A>	@		EQ 40MG BASE	A075710	004	Feb 06, 2008	Oct	DISC
>D>	AB		EQ 70MG BASE	A075710	005	Feb 06, 2008	Oct	DISC
>A>	@		EQ 70MG BASE	A075710	005	Feb 06, 2008	Oct	DISC
	@	JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun	DISC
	@		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun	DISC
	@		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun	DISC
	@		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun	DISC
>A>	@	PICKET PHARMS	EQ 5MG BASE	A079049	003	Aug 04, 2008	Oct	CAHN
>A>	@		EQ 10MG BASE	A079049	004	Aug 04, 2008	Oct	CAHN
>A>	@		EQ 35MG BASE	A079049	001	Aug 04, 2008	Oct	CAHN
>A>	@		EQ 70MG BASE	A079049	002	Aug 04, 2008	Oct	CAHN
>D>	@	US ANTIBIOTICS	EQ 5MG BASE	A079049	003	Aug 04, 2008	Oct	CAHN
	@		EQ 5MG BASE	A079049	003	Aug 04, 2008	May	CAHN
>D>	@		EQ 10MG BASE	A079049	004	Aug 04, 2008	Oct	CAHN
	@		EQ 10MG BASE	A079049	004	Aug 04, 2008	May	CAHN
>D>	@		EQ 35MG BASE	A079049	001	Aug 04, 2008	Oct	CAHN
	@		EQ 35MG BASE	A079049	001	Aug 04, 2008	May	CAHN
>D>	@		EQ 70MG BASE	A079049	002	Aug 04, 2008	Oct	CAHN
	@		EQ 70MG BASE	A079049	002	Aug 04, 2008	May	CAHN

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

+	ORGANON	EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005	Jun	CAHN
+	!	EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007	Jun	CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

+	@	NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008	May	DISC
+	@		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008	May	DISC

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB		CHARTWELL	100MG	A077353	001	Sep 08, 2005	Jun	CAHN
AB			300MG	A077353	002	Sep 08, 2005	Jun	CAHN

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

	@	MYLAN	0.25MG	A074215	001	Jan 27, 1994	Jun	DISC
	@		0.5MG	A074215	002	Jan 27, 1994	Jun	DISC
	@		1MG	A074215	003	Jan 27, 1994	Jun	DISC
	@		2MG	A074215	004	Jan 27, 1994	Jun	DISC
AB		NOVITIUM PHARMA	0.25MG	A074174	001	Oct 19, 1993	Apr	CMFD
AB			0.5MG	A074174	002	Oct 19, 1993	Apr	CMFD
AB			1MG	A074174	003	Oct 19, 1993	Apr	CMFD
AB			2MG	A074174	004	Oct 19, 1993	Apr	CMFD
>A>	AB	STRIDES PHARMA	0.25MG	A090248	001	Sep 17, 2010	Oct	CAHN
>A>	AB		0.5MG	A090248	002	Sep 17, 2010	Oct	CAHN
>A>	AB		1MG	A090248	003	Sep 17, 2010	Oct	CAHN
>A>	AB		2MG	A090248	004	Sep 17, 2010	Oct	CAHN
>D>	AB	VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Oct	CAHN
>D>	AB		0.5MG	A090248	002	Sep 17, 2010	Oct	CAHN
>D>	AB		1MG	A090248	003	Sep 17, 2010	Oct	CAHN
>D>	AB		2MG	A090248	004	Sep 17, 2010	Oct	CAHN

ALPROSTADIL

INJECTABLE; INJECTION		CAVERJECT					
	+ @ PFIZER	0.005MG/VIAL		N020379	003	Jun 27, 1996	Jan CAHN
AP	+	0.01MG/VIAL		N020379	001	Jul 06, 1995	Jan CAHN
AP	+!	0.02MG/VIAL		N020379	002	Jul 06, 1995	Jan CAHN
AP	+!	0.04MG/VIAL		N020379	004	May 19, 1997	Jan CAHN
CAVERJECT IMPULSE		PFIZER					
		0.01MG/VIAL		N021212	001	Jun 11, 2002	Jan CAHN
		0.02MG/VIAL		N021212	002	Jun 11, 2002	Jan CAHN
PROSTIN VR PEDIATRIC		PFIZER					
AP	+!	0.5MG/ML		N018484	001		Jan CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL		AMANTADINE HYDROCHLORIDE					
BX	STRIDES PHARMA	100MG		A209047	001	Jun 07, 2017	Sep CTEC
SYRUP; ORAL		AMANTADINE HYDROCHLORIDE					
AA	INVATECH	50MG/5ML		A214178	001	Aug 20, 2021	Aug NEWA
AA	NOVELGENIX THERAPS	50MG/5ML		A214178	001	Aug 20, 2021	Sep CAHN
	@ WOCKHARDT BIO AG	50MG/5ML		A075060	001	Dec 24, 1998	Jan DISC
TABLET; ORAL		AMANTADINE HYDROCHLORIDE					
	@ INVAGEN PHARMS	100MG		A207571	001	Jan 31, 2017	Jan DISC
BX	STRIDES PHARMA	100MG		A209035	001	Jun 09, 2017	Sep CTEC
TABLET, EXTENDED RELEASE; ORAL		OSMOLEX ER					
	+ ADAMAS PHARMA	EQ 129MG BASE		N209410	001	Feb 16, 2018	Jan CAHN
	+ @	EQ 161MG BASE		N209410	004	Apr 22, 2020	Jan CAHN
	+	EQ 193MG BASE		N209410	002	Feb 16, 2018	Jan CAHN
	+ @	EQ 258MG BASE		N209410	003	Feb 16, 2018	May DISC
	+!	EQ 258MG BASE		N209410	003	Feb 16, 2018	Jan CAHN
	+ ADAMAS PHARMS	EQ 129MG BASE		N209410	001	Feb 16, 2018	Jan CAHN
	+ @	EQ 161MG BASE		N209410	004	Apr 22, 2020	Jan CAHN
	+	EQ 193MG BASE		N209410	002	Feb 16, 2018	Jan CAHN
	+!	EQ 258MG BASE		N209410	003	Feb 16, 2018	Jan CAHN

AMILORIDE HYDROCHLORIDE

TABLET; ORAL		AMILORIDE HYDROCHLORIDE					
AB	USPHARMA WINDLAS	5MG		A204180	001	Aug 07, 2015	Sep CAHN

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL		AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	@ CHARTWELL RX	EQ 5MG ANHYDROUS; 50MG		A073357	001	Nov 27, 1991	Aug CAHN

AMINOCAPROIC ACID

SOLUTION; ORAL		AMICAR					
AA	+!	AKORN	0.25GM/ML	N015230	002		Feb CPOT
AA	+!		1.25GM/5ML	N015230	002		Feb CDFR
AMINOCAPROIC ACID							
AA	AIRIS PHARMA PVT LTD	0.25GM/ML		A213825	001	Apr 08, 2021	Apr NEWA
AA	AMNEAL	0.25GM/ML		A212780	001	Aug 23, 2019	Feb CPOT
AA		1.25GM/5ML		A212780	001	Aug 23, 2019	Feb CDFR
AA	BELCHER	0.25GM/ML		A213825	001	Apr 08, 2021	Jul CAHN
AA	LEADING PHARMA LLC	0.25GM/ML		A214140	001	Jan 26, 2021	Feb CPOT
AA		1.25GM/5ML		A214140	001	Jan 26, 2021	Feb CDFR
AA	TULEX PHARMS INC	0.25GM/ML		A212494	001	Aug 11, 2020	Feb CPOT
AA		1.25GM/5ML		A212494	001	Aug 11, 2020	Feb CDFR
AA	VISTAPHARM	0.25GM/ML		A212814	001	Feb 26, 2020	Feb CPOT
AA		1.25GM/5ML		A212814	001	Feb 26, 2020	Feb CDFR
SYRUP; ORAL		AMINOCAPROIC ACID					
AA	LEADING PHARMA LLC	1.25GM/5ML		A214140	001	Jan 26, 2021	Jan NEWA
TABLET; ORAL		AMINOCAPROIC ACID					
AB	EDENBRIDGE PHARMS	500MG		A212110	001	Jun 14, 2021	Jun NEWA
AB	LEADING PHARMA LLC	500MG		A213928	001	Feb 12, 2021	Feb NEWA

TABLET; ORAL
AMINOCAPROIC ACID

AB 1GM A213928 002 Feb 12, 2021 Feb NEWA

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLIN

+ @ GD SEARLE LLC 25MG/ML A087243 001 May 24, 1982 Aug CRLD
+ @ 25MG/ML A087621 001 May 24, 1982 Aug CRLD

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HYDROCHLORIDE

AP ACELLA 50MG/ML A077610 001 Oct 30, 2008 Aug CAHN
AP 50MG/ML A077834 001 Oct 30, 2008 Aug CAHN
>D> AP HOSPIRA INC 50MG/ML A203885 001 Nov 25, 2013 Oct DISC
>A> @ 50MG/ML A203885 001 Nov 25, 2013 Oct DISC

TABLET; ORAL
AMIODARONE HYDROCHLORIDE

AB RUBICON 100MG A078578 002 Feb 26, 2021 Feb NEWA
AB 400MG A078578 003 Feb 26, 2021 Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL
ENDEP

>D> @ ROCHE 40MG/ML A085749 001 Oct CRLD
>A> + @ 40MG/ML A085749 001 Oct CRLD

TABLET; ORAL
AMITRIPTYLINE HYDROCHLORIDE

AB MANKIND PHARMA 10MG A213999 001 Feb 19, 2021 Feb NEWA
AB 25MG A213999 002 Feb 19, 2021 Feb NEWA
AB 50MG A213999 003 Feb 19, 2021 Feb NEWA
AB 75MG A213999 004 Feb 19, 2021 Feb NEWA
AB 100MG A213999 005 Feb 19, 2021 Feb NEWA
AB 150MG A213999 006 Feb 19, 2021 Feb NEWA
@ MYLAN 10MG A086009 002 Jun DISC
@ 25MG A086009 003 Jun DISC
@ 50MG A086009 001 Jun DISC
@ 75MG A086009 004 Jun DISC
@ 100MG A086009 005 Jun DISC
@ 150MG A086009 006 Jun DISC
AB + SANDOZ 10MG A085968 004 Aug CRLD
AB + 50MG A085968 001 Aug CRLD
AB + 75MG A085968 006 Aug CRLD
AB + 100MG A085968 003 Aug CRLD
AB + 150MG A085968 005 Aug CRLD
AB UNICHEM 10MG A214548 001 May 19, 2021 May NEWA
AB 25MG A214548 002 May 19, 2021 May NEWA
AB 50MG A214548 003 May 19, 2021 May NEWA
AB 75MG A214548 004 May 19, 2021 May NEWA
AB 100MG A214548 005 May 19, 2021 May NEWA
AB 150MG A214548 006 May 19, 2021 May NEWA

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

>A> AB CHARTWELL RX EQ 2.5MG BASE A076692 001 Jul 20, 2007 Oct CAHN
>A> AB EQ 5MG BASE A076692 002 Jul 20, 2007 Oct CAHN
>A> AB EQ 10MG BASE A076692 003 Jul 20, 2007 Oct CAHN
@ WOCKHARDT EQ 2.5MG BASE A078500 001 Sep 06, 2007 Jan DISC
@ EQ 5MG BASE A078500 002 Sep 06, 2007 Jan DISC
@ EQ 10MG BASE A078500 003 Sep 06, 2007 Jan DISC
>D> AB YILING EQ 2.5MG BASE A076692 001 Jul 20, 2007 Oct CAHN
>D> AB EQ 5MG BASE A076692 002 Jul 20, 2007 Oct CAHN
>D> AB EQ 10MG BASE A076692 003 Jul 20, 2007 Oct CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

>D> AB MYLAN EQ 2.5MG BASE;EQ 10MG BASE A200465 001 Nov 29, 2013 Oct DISC
>A> @ EQ 2.5MG BASE;EQ 10MG BASE A200465 001 Nov 29, 2013 Oct DISC
>D> AB EQ 2.5MG BASE;EQ 20MG BASE A200465 002 Nov 29, 2013 Oct DISC

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

>A>	@	EQ 2.5MG BASE;EQ 20MG BASE	A200465	002	Nov 29, 2013	Oct	DISC
>D>	AB	EQ 2.5MG BASE;EQ 40MG BASE	A200465	003	Nov 29, 2013	Oct	DISC
>A>	@	EQ 2.5MG BASE;EQ 40MG BASE	A200465	003	Nov 29, 2013	Oct	DISC
>D>	AB	EQ 5MG BASE;EQ 10MG BASE	A200465	004	Nov 29, 2013	Oct	CAHN
>A>	AB	EQ 5MG BASE;EQ 10MG BASE	A200465	004	Nov 29, 2013	Oct	CAHN
>D>	AB	EQ 5MG BASE;EQ 20MG BASE	A200465	005	Nov 29, 2013	Oct	CAHN
>A>	AB	EQ 5MG BASE;EQ 20MG BASE	A200465	005	Nov 29, 2013	Oct	CAHN
>D>	AB	EQ 5MG BASE;EQ 40MG BASE	A200465	006	Nov 29, 2013	Oct	CAHN
>A>	AB	EQ 5MG BASE;EQ 40MG BASE	A200465	006	Nov 29, 2013	Oct	CAHN
>D>	AB	EQ 5MG BASE;EQ 80MG BASE	A200465	007	Nov 29, 2013	Oct	CAHN
>A>	AB	EQ 5MG BASE;EQ 80MG BASE	A200465	007	Nov 29, 2013	Oct	CAHN
>D>	AB	EQ 10MG BASE;EQ 10MG BASE	A200465	008	Nov 29, 2013	Oct	CAHN
>A>	AB	EQ 10MG BASE;EQ 10MG BASE	A200465	008	Nov 29, 2013	Oct	CAHN
>D>	AB	EQ 10MG BASE;EQ 20MG BASE	A200465	009	Nov 29, 2013	Oct	CAHN
>A>	AB	EQ 10MG BASE;EQ 20MG BASE	A200465	009	Nov 29, 2013	Oct	CAHN
>D>	AB	EQ 10MG BASE;EQ 40MG BASE	A200465	010	Nov 29, 2013	Oct	CAHN
>A>	AB	EQ 10MG BASE;EQ 40MG BASE	A200465	010	Nov 29, 2013	Oct	CAHN
>D>	AB	EQ 10MG BASE;EQ 80MG BASE	A200465	011	Nov 29, 2013	Oct	CAHN
>A>	AB	EQ 10MG BASE;EQ 80MG BASE	A200465	011	Nov 29, 2013	Oct	CAHN

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

>D>	+ @	COEPTIS	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	Oct	CAHN
	+ @		EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	Sep	DISC
>D>	+ @		EQ 5MG BASE;200MG	N210045	002	May 31, 2018	Oct	CAHN
	+ @		EQ 5MG BASE;200MG	N210045	002	May 31, 2018	Sep	DISC
>D>	+ @		EQ 10MG BASE;200MG	N210045	003	May 31, 2018	Oct	CAHN
	+ @		EQ 10MG BASE;200MG	N210045	003	May 31, 2018	Sep	DISC
>A>	+ @	PURPLE BIOTECH	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	Oct	CAHN
>A>	+ @		EQ 5MG BASE;200MG	N210045	002	May 31, 2018	Oct	CAHN
>A>	+ @		EQ 10MG BASE;200MG	N210045	003	May 31, 2018	Oct	CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

@ JUBILANT GENERICS

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

	FOR SUSPENSION;ORAL						
	AMOXIL						
	+ @	200MG/5ML		N050760	001	Apr 15, 1999	May CAHN
AB		250MG/5ML		A062226	002		May CAHN
	+ @	400MG/5ML		N050760	002	Apr 15, 1999	May CAHN
	LAROTID						
AB	US ANTIBIOTICS	125MG/5ML		A062226	003		May CAHN
AB		250MG/5ML		A062226	004		May CAHN
	TABLET;ORAL						
	AMOXIL						
	+ @ US ANTIBIOTICS	500MG		N050754	002	Jul 10, 1998	May CAHN
	+ @	875MG		N050754	001	Jul 10, 1998	May CAHN
	TABLET, CHEWABLE;ORAL						
	AMOXICILLIN						
BX	HIKMA	125MG		A205274	001	Jun 25, 2020	Sep CTEC
BX		250MG		A205274	002	Jun 25, 2020	Sep CTEC
	AMOXIL						
	+ @ US ANTIBIOTICS	125MG		N050542	002		May CAHN
	@	200MG		N050761	001	Apr 15, 1999	May CAHN
	+ @	250MG		N050542	001		May CAHN
	@	400MG		N050761	002	Apr 15, 1999	May CAHN
	<u>AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE</u>						
	CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL						
	LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)						
	@ ANI PHARMS	500MG;500MG;30MG		A200218	001	Aug 30, 2013	Jul CTNA
	@	500MG;500MG;30MG		A200218	001	Aug 30, 2013	Jul CPOT
	@	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG		A200218	001	Aug 30, 2013	Jul CDFR
AB	! RISING	500MG;500MG;30MG		A206006	001	Oct 07, 2016	Jul CTNA
AB	!	500MG;500MG;30MG		A206006	001	Oct 07, 2016	Jul CPOT
AB	!	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG		A206006	001	Oct 07, 2016	Jul CDFR
AB	SANDOZ INC	500MG;500MG;30MG		A202588	001	Mar 04, 2014	Jul CTNA
AB		500MG;500MG;30MG		A202588	001	Mar 04, 2014	Jul CPOT
AB		500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG		A202588	001	Mar 04, 2014	Jul CDFR
	PREVPAC (COPACKAGED)						
	+ @ TAKEDA PHARMS USA	500MG;500MG;30MG		N050757	001	Dec 02, 1997	Jul CTNA
	+ @	500MG;500MG;30MG		N050757	001	Dec 02, 1997	Jul CPOT
	+ @	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG		N050757	001	Dec 02, 1997	Jul CDFR
	<u>AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE</u>						
	CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL						
	OMEPRazole AND CLARITHROMYCIN AND AMOXICILLIN						
	+ @ CUMBERLAND PHARMS	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG		N050824	001	Feb 08, 2011	May DISC
	<u>AMOXICILLIN; CLAVULANATE POTASSIUM</u>						
	FOR SUSPENSION;ORAL						
	AMOXICILLIN AND CLAVULANATE POTASSIUM						
AB	MICRO LABS LTD INDIA	200MG/5ML;EQ 28.5MG BASE/5ML		A205187	001	May 21, 2021	May NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML		A205187	002	May 21, 2021	May NEWA
	AUGMENTIN '125'						
AB	+ US ANTIBIOTICS	125MG/5ML;EQ 31.25MG BASE/5ML		N050575	001	Aug 06, 1984	May CAHN
	AUGMENTIN '200'						
	+ @ US ANTIBIOTICS	200MG/5ML;EQ 28.5MG BASE/5ML		N050725	001	May 31, 1996	May CAHN
	AUGMENTIN '250'						
AB	+! US ANTIBIOTICS	250MG/5ML;EQ 62.5MG BASE/5ML		N050575	002	Aug 06, 1984	May CAHN
	AUGMENTIN '400'						
	+ @ US ANTIBIOTICS	400MG/5ML;EQ 57MG BASE/5ML		N050725	002	May 31, 1996	May CAHN
	AUGMENTIN ES-600						
AB	+ US ANTIBIOTICS	600MG/5ML;EQ 42.9MG BASE/5ML		N050755	001	Jun 22, 2001	May CAHN
	TABLET;ORAL						
	AUGMENTIN '250'						
	+ @ US ANTIBIOTICS	250MG;EQ 125MG BASE		N050564	001	Aug 06, 1984	May CAHN
	AUGMENTIN '500'						
	+ @ US ANTIBIOTICS	500MG;EQ 125MG BASE		N050564	002	Aug 06, 1984	May CAHN
	AUGMENTIN '875'						
AB	+ US ANTIBIOTICS	875MG;EQ 125MG BASE		N050720	001	Feb 13, 1996	May CAHN

TABLET, CHEWABLE;ORAL
AUGMENTIN '125'

+ @ US ANTIBIOTICS	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	May CAHN
AUGMENTIN '200'					
+ @ US ANTIBIOTICS	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	May CAHN
AUGMENTIN '250'					
+ @ US ANTIBIOTICS	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	May CAHN
AUGMENTIN '400'					
+ @ US ANTIBIOTICS	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	May CAHN

TABLET, EXTENDED RELEASE;ORAL
AUGMENTIN XR

+ @ US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	May CAHN
--------------------	--------------------	---------	-----	--------------	----------

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL
ADZENYS ER

+ @ NEOS THERAPS INC	EQ 1.25MG BASE/ML	N204325	001	Sep 15, 2017	Sep DISC
----------------------	-------------------	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	RHODES PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A213111	003	Jan 13, 2021	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213111	005	Jan 13, 2021	Jan NEWA
AB		5MG;5MG;5MG;5MG	A213111	006	Jan 13, 2021	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Sep NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Sep NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Sep NEWA
AB		5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Sep NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Sep NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Sep NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A213709	001	Apr 22, 2021	Apr NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213709	002	Apr 22, 2021	Apr NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A213709	003	Apr 22, 2021	Apr NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213709	004	Apr 22, 2021	Apr NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213709	005	Apr 22, 2021	Apr NEWA
AB		5MG;5MG;5MG;5MG	A213709	006	Apr 22, 2021	Apr NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213709	007	Apr 22, 2021	Apr NEWA
AB	LIBERTY PHARMA INC	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Aug CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Aug CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Aug CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Aug CAHN
AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Aug CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Aug CAHN
@	MYLAN	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015	Aug CAHN
@		1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015	Aug DISC
@		1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015	Aug CAHN
@		1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015	Aug DISC
@		2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015	Aug CAHN
@		2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015	Aug DISC
@		3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015	Aug CAHN
@		3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015	Aug DISC
@		3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015	Aug CAHN
@		3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015	Aug DISC
@		5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015	Aug CAHN
@		5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015	Aug DISC
@		7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015	Aug CAHN
@		7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015	Aug DISC
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A213111	001	Jan 13, 2021	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213111	002	Jan 13, 2021	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213111	004	Jan 13, 2021	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213111	007	Jan 13, 2021	Jan NEWA
AB	USPHARMA WINDLAS	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Sep CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Sep CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Sep CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Sep CAHN
AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Sep CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Sep CAHN

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE							
	@ GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021	Jun	DISC
AA		5MG	A212186	001	Jan 27, 2021	Jan	NEWA
	@	10MG	A212186	002	Jan 27, 2021	Jun	DISC
AA		10MG	A212186	002	Jan 27, 2021	Jan	NEWA
	+ @ LANNETT	5MG	A083901	001	Aug 31, 1984	Aug	CRLD
	+ @	10MG	A083901	002	Aug 31, 1984	Aug	CRLD
	@ MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020	Jan	DISC
	@	10MG	A213898	002	Jul 14, 2020	Jan	DISC
	@ NOVAST LABS	5MG	A213763	001	Aug 24, 2020	Mar	DISC
	@	10MG	A213763	002	Aug 24, 2020	Mar	DISC
AA	RHODES PHARMS	5MG	A213852	001	Sep 07, 2021	Aug	NEWA
AA		10MG	A213852	002	Sep 07, 2021	Aug	NEWA
AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Aug	CAHN
AA		10MG	A212901	002	May 22, 2020	Aug	CAHN
AA	SPECGX LLC	5MG	A213583	001	Jan 22, 2021	Jan	NEWA
AA		10MG	A213583	002	Jan 22, 2021	Jan	NEWA
AA	SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Jan	NEWA
AA		10MG	A214574	002	Jan 27, 2021	Jan	NEWA
TABLET, ORALLY DISINTEGRATING; ORAL							
EVEKEO ODT							
	+ @ ARBOR PHARMS LLC	2.5MG	N209905	005	Apr 16, 2021	Jul	DISC
	+	2.5MG	N209905	005	Apr 16, 2021	Apr	NEWA
	+!	20MG	N209905	004	Jan 30, 2019	Apr	CHRS

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM							
	@ HQ SPECLT PHARMA	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Mar	CAHN
AP		EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Mar	CAHN
AP		EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Mar	CAHN
	@	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Mar	CAHN
AP		EQ 1GM BASE/VIAL	A062772	001	Apr 15, 1993	Mar	CAHN
	@	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Mar	CAHN
AP		EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Mar	CAHN
	@	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Mar	CAHN
AP		EQ 10GM BASE/VIAL	A063142	001	Apr 15, 1993	Mar	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

>A>	AP	HIKMA PHARMS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Oct	CAHN
>A>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Oct	CAHN
	AP	HQ SPECLT PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065176	001	Nov 30, 2005	Mar	CAHN
	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065176	002	Nov 30, 2005	Mar	CAHN
	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065188	001	Nov 25, 2005	Mar	CAHN
>D>	AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Oct	CAHN
>D>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Oct	CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

	@ CHARTWELL RX	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Aug	CAHN
	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Aug	CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

	@ FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010	Aug	DISC
>A>	@ PICKET PHARMS	1MG	A090732	001	Jun 28, 2010	Oct	CAHN
>D>	@ US ANTIBIOTICS	1MG	A090732	001	Jun 28, 2010	Oct	CAHN
	@	1MG	A090732	001	Jun 28, 2010	May	CAHN

ANIDULAFUNGINPOWDER; INTRAVENOUS
ERAXIS

+!	VICURON HOLDINGS	50MG/VIAL	N021632	001	Feb 17, 2006	Jul	CAHN
+!		100MG/VIAL	N021632	002	Nov 14, 2006	Jul	CAHN

APIXABANTABLET; ORAL
APIXABAN

>D>	AB	BRECKENRIDGE	2.5MG	A209845	001	Jul 26, 2021	Oct	DISC
>A>		@	2.5MG	A209845	001	Jul 26, 2021	Oct	DISC
	AB		2.5MG	A209845	001	Jul 26, 2021	Jul	NEWA
>D>	AB		5MG	A209845	002	Jul 26, 2021	Oct	DISC
>A>		@	5MG	A209845	002	Jul 26, 2021	Oct	DISC
	AB		5MG	A209845	002	Jul 26, 2021	Jul	NEWA

APREMILASTTABLET; ORAL
APREMILAST

AB		ALKEM LABS LTD	10MG	A211761	001	Sep 21, 2021	Sep	NEWA
AB			20MG	A211761	002	Sep 21, 2021	Sep	NEWA
AB			30MG	A211761	003	Sep 21, 2021	Sep	NEWA
AB		AMNEAL	10MG	A211782	001	Jun 30, 2021	Jun	NEWA
AB			20MG	A211782	002	Jun 30, 2021	Jun	NEWA
AB			30MG	A211782	003	Jun 30, 2021	Jun	NEWA
		@ UNICHEM	10MG	A211819	001	Feb 17, 2021	Aug	DISC
AB			10MG	A211819	001	Feb 17, 2021	Feb	NFTG
		@	20MG	A211819	002	Feb 17, 2021	Aug	DISC
AB			20MG	A211819	002	Feb 17, 2021	Feb	NFTG
		@	30MG	A211819	003	Feb 17, 2021	Aug	DISC
AB			30MG	A211819	003	Feb 17, 2021	Feb	NFTG
AB		ZYDUS PHARMS	10MG	A211859	001	Sep 21, 2021	Sep	NEWA
AB			20MG	A211859	002	Sep 21, 2021	Sep	NEWA
AB			30MG	A211859	003	Sep 21, 2021	Sep	NEWA
		OTEZLA						
AB	+	AMGEN INC	10MG	N205437	001	Mar 21, 2014	Feb	CFTG
AB	+		20MG	N205437	002	Mar 21, 2014	Feb	CFTG
AB	+		30MG	N205437	003	Mar 21, 2014	Feb	CFTG

ARFORMOTEROL TARTRATESOLUTION; INHALATION
ARFORMOTEROL TARTRATE

AN		AXAR PHARMS INC	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Jun	NFTG
AN		CIPLA	EQ 0.015MG BASE/2ML	A207306	001	Jun 22, 2021	Jun	NFTG
AN		GLENMARK PHARMS LTD	EQ 0.015MG BASE/2ML	A213132	001	Jun 22, 2021	Jun	NFTG
>A>	AN	TEVA PHARMS USA	EQ 0.015MG BASE/2ML	A200293	001	Nov 09, 2021	Oct	NEWA
		BROVANA						
AN	+	SUNOVION	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006	Jun	CFTG

ARGATROBANINJECTABLE; INJECTION
ARGATROBAN

AP		CAPLIN	50MG/50ML (1MG/ML)	A214235	001	Jan 21, 2021	Jan	NFTG	
AP	+	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049	002	Sep 30, 2016	Jan	CFTG	
		INJECTABLE; INTRAVENOUS							
		ARGATROBAN IN SODIUM CHLORIDE							
		+ @ EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	May	DISC	
		SOLUTION; INTRAVENOUS							
		ARGATROBAN IN SODIUM CHLORIDE							
		+!	ACCORD HLTHCARE	50MG/50ML (1MG/ML)	N212035	001	Jun 07, 2021	Jun	NEWA
>D>		AUROBINDO PHARMA LTD	50MG/50ML (1MG/ML)	N209552	001	Nov 27, 2018	Oct	CAHN	
>A>		EUGIA PHARMA SPECILTS	50MG/50ML (1MG/ML)	N209552	001	Nov 27, 2018	Oct	CAHN	

ARSENIC TRIOXIDEINJECTABLE; INJECTION
ARSENIC TRIOXIDE

AP		AMNEAL	1MG/ML	A210739	001	Jan 25, 2021	Aug	CMFD
		@	1MG/ML	A210739	001	Jan 25, 2021	May	DISC
AP			1MG/ML	A210739	001	Jan 25, 2021	Jan	NEWA
AP			2MG/ML	A210739	002	Aug 19, 2021	Aug	NEWA
>A>	AP	EUGIA PHARMA	2MG/ML	A214011	001	Oct 15, 2021	Oct	NEWA

INJECTABLE; INJECTION							
ARSENIC TRIOXIDE							
>A>	AP	GLAND PHARMA LTD	2MG/ML	A215059	001	Oct 07, 2021	Oct NEWA
		@ INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021	Feb DISC
	AP		2MG/ML	A209315	002	Jan 14, 2021	Jan NEWA
>A>	<u>ASCIMINIB HYDROCHLORIDE</u>						
>A>	TABLET; ORAL						
>A>	SCEMBLIX						
>A>	+	NOVARTIS	EQ 20MG BASE	N215358	001	Oct 29, 2021	Oct NEWA
>A>	+	!	EQ 40MG BASE	N215358	002	Oct 29, 2021	Oct NEWA
<u>ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K</u>							
INJECTABLE; INTRAVENOUS							
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)							
	+	SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	002	Jan 29, 2004	Feb CAIN
<u>ASENAPINE MALEATE</u>							
TABLET; SUBLINGUAL							
ASENAPINE MALEATE							
AB		ALEMBIC PHARMS LTD	EQ 2.5MG BASE	A206098	003	Jul 19, 2021	Jul NEWA
AB		BRECKENRIDGE	EQ 5MG BASE	A205960	003	Mar 08, 2021	Feb NEWA
<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>							
CAPSULE; ORAL							
BUTALBITAL, ASPIRIN AND CAFFEINE							
>A>		LGM PHARMA	500MG; 50MG; 40MG	A205230	001	Oct 18, 2021	Oct NEWA
<u>ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE</u>							
TABLET; ORAL							
NORGESIC							
	+	@ BAUSCH	385MG; 30MG; 25MG	N013416	003	Oct 27, 1982	May CAHN
			NORGESIC FORTE				
	+	@ BAUSCH	770MG; 60MG; 50MG	N013416	004	Oct 27, 1982	May CAHN
<u>ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
PROPOXYPHENE COMPOUND 65							
	+	@ SANDOZ	389MG; 32.4MG; 65MG	A080044	002	Sep 16, 1983	Aug CRLD
<u>ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE</u>							
TABLET; ORAL							
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE							
	!	INGENUS PHARMS NJ	325MG; 200MG; 16MG	A040860	001	Jan 07, 2010	Jul CHRS
			325MG; 200MG; 16MG	A040860	001	Jan 07, 2010	Jul CTEC
		@ SANDOZ	325MG; 200MG; 16MG	A040118	001	Apr 16, 1996	Jul DISC
<u>ASPIRIN; DIPYRIDAMOLE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
ASPIRIN AND DIPYRIDAMOLE							
		@ LANNETT CO INC	25MG; 200MG	A204552	001	Mar 20, 2019	Apr DISC
AB		MICRO LABS	25MG; 200MG	A209929	001	Aug 11, 2021	Jul NEWA
		@ SUN PHARM	25MG; 200MG	A208572	001	Aug 21, 2018	Aug DISC
<u>ASPIRIN; HYDROCODONE BITARTRATE</u>							
TABLET; ORAL							
HYDROCODONE BITARTRATE AND ASPIRIN							
>D>		LGM PHARMA	500MG; 5MG	A205479	001	May 28, 2021	Oct DISC
>D>		@	500MG; 5MG	A205479	001	May 28, 2021	Oct DISC
>A>			500MG; 5MG	A205479	001	May 28, 2021	May NEWA
<u>ASPIRIN; OXYCODONE HYDROCHLORIDE</u>							
TABLET; ORAL							
OXYCODONE AND ASPIRIN							
		@ MAYNE PHARMA INC	325MG; 4.8355MG	A091670	001	Mar 16, 2011	Jul DISC

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB	LAURUS	EQ 150MG BASE	A212579	001	Apr 30, 2021	Apr	NEWA
AB		EQ 200MG BASE	A212579	002	Apr 30, 2021	Apr	NEWA
AB		EQ 300MG BASE	A212579	003	Apr 30, 2021	Apr	NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

>D>	@ DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992	Oct	CAHN
>D>	@	50MG	A073542	001	Dec 19, 1991	Oct	CAHN
>D>	@	100MG	A073543	001	Dec 19, 1991	Oct	CAHN
>A>	@ STRIDES PHARMA	25MG	A074099	001	Apr 28, 1992	Oct	CAHN
>A>	@	50MG	A073542	001	Dec 19, 1991	Oct	CAHN
>A>	@	100MG	A073543	001	Dec 19, 1991	Oct	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

>A>	AB	NOVITIUM PHARMA	50MG;25MG	A215560	001	Oct 25, 2021	Oct	NEWA
>A>	AB		100MG;25MG	A215560	002	Oct 25, 2021	Oct	NEWA

ATOGEPAANT

TABLET;ORAL

QULIPTA

+	ABBVIE INC	10MG	N215206	001	Sep 28, 2021	Sep	NEWA
+		30MG	N215206	002	Sep 28, 2021	Sep	NEWA
+	!	60MG	N215206	003	Sep 28, 2021	Sep	NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	HETERO LABS LTD V	10MG	A202682	001	Mar 11, 2021	Mar	NEWA
AB		18MG	A202682	002	Mar 11, 2021	Mar	NEWA
AB		25MG	A202682	003	Mar 11, 2021	Mar	NEWA
AB		40MG	A202682	004	Mar 11, 2021	Mar	NEWA
AB		60MG	A202682	005	Mar 11, 2021	Mar	NEWA
AB		80MG	A202682	006	Mar 11, 2021	Mar	NEWA
AB		100MG	A202682	007	Mar 11, 2021	Mar	NEWA
	@ MYLAN	10MG	A079021	001	Feb 18, 2021	Feb	DISC
AB		10MG	A079021	001	Feb 18, 2021	Feb	NEWA
	@	18MG	A079021	002	Feb 18, 2021	Feb	DISC
AB		18MG	A079021	002	Feb 18, 2021	Feb	NEWA
	@	25MG	A079021	003	Feb 18, 2021	Feb	DISC
AB		25MG	A079021	003	Feb 18, 2021	Feb	NEWA
	@	40MG	A079021	004	Feb 18, 2021	Feb	DISC
AB		40MG	A079021	004	Feb 18, 2021	Feb	NEWA
	@	60MG	A079021	005	Feb 18, 2021	Feb	DISC
AB		60MG	A079021	005	Feb 18, 2021	Feb	NEWA
	@	80MG	A079021	006	Feb 18, 2021	Feb	DISC
AB		80MG	A079021	006	Feb 18, 2021	Feb	NEWA
	@	100MG	A079021	007	Feb 18, 2021	Feb	DISC
AB		100MG	A079021	007	Feb 18, 2021	Feb	NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ALKEM LABS LTD	EQ 10MG BASE	A209288	001	Dec 21, 2018	Jan	CAHN	
AB		EQ 20MG BASE	A209288	002	Dec 21, 2018	Jan	CAHN	
AB		EQ 40MG BASE	A209288	003	Dec 21, 2018	Jan	CAHN	
AB		EQ 80MG BASE	A209288	004	Dec 21, 2018	Jan	CAHN	
AB	AUGUST	EQ 10MG BASE	A214969	001	Sep 02, 2021	Aug	NEWA	
AB		EQ 20MG BASE	A214969	002	Sep 02, 2021	Aug	NEWA	
AB		EQ 40MG BASE	A214969	003	Sep 02, 2021	Aug	NEWA	
AB		EQ 80MG BASE	A214969	004	Sep 02, 2021	Aug	NEWA	
>D>	AB	DR REDDYS LABS LTD	EQ 10MG BASE	A214659	001	Jul 14, 2021	Oct	DISC
>A>	@	EQ 10MG BASE	A214659	001	Jul 14, 2021	Oct	DISC	
AB		EQ 10MG BASE	A214659	001	Jul 14, 2021	Jul	NEWA	
>D>	AB	EQ 20MG BASE	A214659	002	Jul 14, 2021	Oct	DISC	
>A>	@	EQ 20MG BASE	A214659	002	Jul 14, 2021	Oct	DISC	
AB		EQ 20MG BASE	A214659	002	Jul 14, 2021	Jul	NEWA	

TABLET;ORAL

ATORVASTATIN CALCIUM

>D>	AB		EQ 40MG BASE	A214659	003	Jul 14, 2021	Oct DISC
>A>		@	EQ 40MG BASE	A214659	003	Jul 14, 2021	Oct DISC
	AB		EQ 40MG BASE	A214659	003	Jul 14, 2021	Jul NEWA
>D>	AB		EQ 80MG BASE	A214659	004	Jul 14, 2021	Oct DISC
>A>		@	EQ 80MG BASE	A214659	004	Jul 14, 2021	Oct DISC
	AB		EQ 80MG BASE	A214659	004	Jul 14, 2021	Jul NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

		@	SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Jul CAHN	
		@		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Jul CAHN	
		@		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Jul CAHN	
		@		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Jul CAHN	
			LIPTRUZET						
		+	@	ORGANON	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb CAHN
		+	@		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb CAHN
		+	@		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb CAHN
		+	@		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb CAHN

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

>A>	AB		ABON PHARMS LLC	750MG/5ML	A214272	001	Oct 25, 2021	Oct NEWA
	AB		BIONPHARMA INC	750MG/5ML	A212918	001	Mar 30, 2021	Mar NEWA

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP			ACCORD HLTHCARE	0.25MG/5ML (0.05MG/ML)	A212868	001	Jul 26, 2021	Jul NFTG
AP				0.5MG/5ML (0.1MG/ML)	A212868	002	Jul 26, 2021	Jul NFTG
AP				1MG/10ML (0.1MG/ML)	A212868	003	Jul 26, 2021	Jul NEWA
AP	+	!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Jul CFTG
AP	+	!		0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017	Jul CFTG
AP	+	!		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Jul CTEC
AP	+	!		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Mar CTEC
AP			INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Mar CTEC

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

AP			ACCORD HLTHCARE	8MG/20ML (0.4MG/ML)	A213424	001	Mar 19, 2021	Mar NFTG
AP	+	!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	Mar CFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA			PHARMA LIFE	0.025MG;2.5MG	A207128	001	Oct 21, 2020	Sep CAHN
AA			WINDER LABS LLC	0.025MG;2.5MG	A211362	001	Jan 27, 2021	Jan NEWA

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

		+	@	MYLAN	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jan CAHN
--	--	---	---	-------	-------------------	---------	-----	--------------	----------

>A> AVACOPAN

>A> CAPSULE;ORAL

>A> TAVNEOS

>A>	+	!	CHEMOCENTRYX	10MG	N214487	001	Oct 07, 2021	Oct NEWA
-----	---	---	--------------	------	---------	-----	--------------	----------

AVAPRITINIB

TABLET;ORAL

AYVAKIT

	+		BLUEPRINT MEDICINES	25MG	N212608	004	Jun 16, 2021	Jun NEWA
	+			50MG	N212608	005	Jun 16, 2021	Jun NEWA

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;INTRAVENOUS

AVYCAZ

	+	!	ALLERGAN	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Jan CDFR
--	---	---	----------	------------------------	---------	-----	--------------	----------

AZATHIOPRINETABLET; ORAL
AZATHIOPRINE

>A>	AB	AMNEAL	75MG	A074069	002	Nov 02, 2021	Oct	NEWA
>A>	AB		100MG	A074069	003	Nov 02, 2021	Oct	NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

>D>		ASTELIN							
>D>	AB	+!	MYLAN SPCLT VIATRIS	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Oct	DISC
>A>		+ @		0.137MG/SPRAY	N020114	001	Nov 01, 1996	Oct	DISC
	AB	+!		0.137MG/SPRAY	N020114	001	Nov 01, 1996	Sep	CAHN
	AB	+!	MYLAN SPECIALITY LP	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Aug	CPOT
			ASTEPRO						
		@	MYLAN SPECIALITY LP	0.137MG/SPRAY	N022203	001	Oct 15, 2008	Aug	CPOT
		+ @		0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Jul	DISC
	AB	+!		0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Jul	CPOT
			AZELASTINE HYDROCHLORIDE						
	AB		AKORN	0.137MG/SPRAY	A207610	001	May 17, 2019	Aug	CPOT
	AB			0.2055MG/SPRAY	A210032	001	Aug 23, 2019	Aug	CPOT
	AB		ALKEM LABS LTD	0.137MG/SPRAY	A208156	001	Aug 18, 2017	Aug	CPOT
	AB		AMNEAL	0.137MG/SPRAY	A204660	001	Aug 28, 2017	Aug	CPOT
	AB			0.2055MG/SPRAY	A208199	001	Dec 15, 2017	Aug	CPOT
>D>	AB		APOTEX INC	0.137MG/SPRAY	A077954	001	Apr 30, 2009	Oct	CHRS
>A>	AB	!		0.137MG/SPRAY	A077954	001	Apr 30, 2009	Oct	CHRS
	AB			0.137MG/SPRAY	A077954	001	Apr 30, 2009	Aug	CPOT
	AB			0.2055MG/SPRAY	A201846	001	Aug 31, 2012	Aug	CPOT
	AB		AUROBINDO PHARMA LTD	0.137MG/SPRAY	A212289	001	May 08, 2020	Aug	CPOT
	AB			0.2055MG/SPRAY	A212775	001	Nov 12, 2020	Aug	CPOT
	AB		BRECKENRIDGE	0.137MG/SPRAY	A090176	001	Jul 28, 2015	Aug	CPOT
	AB		HIKMA PHARMS	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Aug	CPOT
	AB			0.2055MG/SPRAY	A207243	001	Sep 22, 2017	Aug	CPOT
	AB		SUN PHARM	0.137MG/SPRAY	A090423	001	May 23, 2012	Aug	CPOT
	AB		UPSHER SMITH LABS	0.137MG/SPRAY	A202609	001	Mar 17, 2017	Aug	CPOT
	AB		ZYDUS PHARMS	0.137MG/SPRAY	A091409	001	Aug 14, 2017	Aug	CPOT

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB		APOTEX	0.137MG/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Aug	CPOT	
AB		PADAGIS ISRAEL	0.137MG/SPRAY;0.05MG/SPRAY	A208111	001	Feb 18, 2021	Aug	CPOT	
AB		PERRIGO UK FINCO	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A208111	001	Feb 18, 2021	Feb	NEWA	
			DYMISTA						
AB		+!	MYLAN SPECIALITY LP	0.137MG/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Aug	CPOT

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

AB		TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Feb	CMFD	
			INJECTABLE; INJECTION						
			AZITHROMYCIN						
		@	MYLAN ASI	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Feb	DISC
			TABLET; ORAL						
			AZITHROMYCIN						
AB		ALEMBIC PHARMS LTD	EQ 600MG BASE	A211793	001	Jan 27, 2020	Jul	CMFD	
AB		YUNG SHIN PHARM	EQ 500MG BASE	A211318	001	Mar 17, 2021	Mar	NEWA	
AB			EQ 600MG BASE	A211068	001	May 08, 2020	Feb	CMFD	

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

>A>	AP	HOSPIRA INC	1GM/VIAL	A206517	001	Nov 08, 2021	Oct	NEWA
>A>	AP		2GM/VIAL	A206517	002	Nov 08, 2021	Oct	NEWA

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

		@	XELLIA PHARMS APS	50,000 UNITS/VIAL	A203177	001	Aug 25, 2014	Jun	DISC
--	--	---	-------------------	-------------------	---------	-----	--------------	-----	------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT; TOPICAL
CORTISPORIN

+ @ MONARCH PHARMS	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N050168	002	May 04, 1984	Jul	DISC
--------------------	---	---------	-----	--------------	-----	------

BACLOFENINJECTABLE; INTRATHECAL
BACLOFEN

AP	MAIA PHARMS INC	0.05MG/ML	A210777	001	Jan 15, 2021	Jan	NEWA
AP		0.5MG/ML	A210048	001	Sep 11, 2019	Aug	CMFD
AP		2MG/ML	A210048	002	Sep 11, 2019	Aug	CMFD

GABLOFEN

AP	+! PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Mar	CHRS
AP	+	0.05MG/ML	N022462	001	Nov 19, 2010	Mar	CRLD
AP	+!	0.5MG/ML	N022462	002	Nov 19, 2010	Mar	CHRS
AP	+	0.5MG/ML	N022462	002	Nov 19, 2010	Mar	CRLD
AP	+!	2MG/ML	N022462	003	Nov 19, 2010	Mar	CHRS
AP	+	2MG/ML	N022462	003	Nov 19, 2010	Mar	CRLD

TABLET; ORAL

BACLOFEN

AB	AUROBINDO PHARMA LTD	10MG	A214099	001	Jul 13, 2021	Jul	NEWA
AB		20MG	A214099	002	Jul 13, 2021	Jul	NEWA
AB	BEXIMCO PHARMS USA	10MG	A214114	001	Jul 16, 2021	Jul	NEWA
AB		20MG	A214114	002	Jul 16, 2021	Jul	NEWA
AB	IMPAX	5MG	A077971	003	Jul 07, 2021	Jun	NEWA
AB		10MG	A077971	001	Oct 26, 2007	Jun	CAHN
AB		20MG	A077971	002	Oct 26, 2007	Jun	CAHN
AB	INNOGENIX	5MG	A212378	003	Apr 30, 2021	Apr	NEWA
>D>	AB	KARTHA	A214374	001	Mar 05, 2021	Oct	DISC
>A>	@	5MG	A214374	001	Mar 05, 2021	Oct	DISC
AB		5MG	A214374	001	Mar 05, 2021	Feb	NEWA
	@	10MG	A214374	002	Mar 05, 2021	Sep	DISC
AB		10MG	A214374	002	Mar 05, 2021	Feb	NEWA
	@	20MG	A214374	003	Mar 05, 2021	Sep	DISC
AB		20MG	A214374	003	Mar 05, 2021	Feb	NEWA
AB	LANNETT CO INC	5MG	A077241	003	Sep 22, 2021	Sep	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

+ @ UCB INC	10MG	N021589	001	Oct 30, 2003	May	CRLD
+ @	20MG	N021589	002	Oct 30, 2003	May	CRLD

BALOXAVIR MARBOXIL

TABLET; ORAL

XOFLUZA

+ GENENTECH INC	80MG	N210854	003	Mar 18, 2021	Mar	NEWA
-----------------	------	---------	-----	--------------	-----	------

BELUMOSUDIL MESYLATE

TABLET; ORAL

REZUROCK

+! KADMON PHARMS LLC	EQ 200MG BASE	N214783	001	Jul 16, 2021	Jul	NEWA
----------------------	---------------	---------	-----	--------------	-----	------

BELZUTIFAN

TABLET; ORAL

WELIREG

+! MERCK SHARP DOHME	40MG	N215383	001	Aug 13, 2021	Aug	NEWA
----------------------	------	---------	-----	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	CADILA	5MG	A078848	001	May 23, 2008	Aug	CAHN
AB		10MG	A078848	002	May 23, 2008	Aug	CAHN
AB		20MG	A078848	003	May 23, 2008	Aug	CAHN
AB		40MG	A078848	004	May 23, 2008	Aug	CAHN
	LOTENSIN						
AB	+ VALIDUS PHARMS	5MG	N019851	001	Jun 25, 1991	Feb	CAHN
AB	+	10MG	N019851	002	Jun 25, 1991	Feb	CAHN
AB	+	20MG	N019851	003	Jun 25, 1991	Feb	CAHN
AB	+!	40MG	N019851	004	Jun 25, 1991	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL		BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	@ MYLAN	5MG; 6.25MG		A076688	001	Feb 11, 2004	Jul DISC
	@	10MG; 12.5MG		A076688	002	Feb 11, 2004	Jul DISC
	@	20MG; 12.5MG		A076688	003	Feb 11, 2004	Jul DISC
	@	20MG; 25MG		A076688	004	Feb 11, 2004	Jul DISC
	SANDOZ	5MG; 6.25MG		A076631	001	Feb 11, 2004	Jul CTEC
LOTENSIN HCT							
	+ @ VALIDUS PHARMS	5MG; 6.25MG		N020033	001	May 19, 1992	Feb CAHN
AB	+	10MG; 12.5MG		N020033	002	May 19, 1992	Feb CAHN
AB	+	20MG; 12.5MG		N020033	004	May 19, 1992	Feb CAHN
AB	+	20MG; 25MG		N020033	003	May 19, 1992	Feb CAHN

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS; OPHTHALMIC		FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE					
	+!	BAUSCH LOMB IRELAND	0.4%; 0.3%	N211039	001	Mar 09, 2020	May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL		CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE					
AB	ENCUBE	5%; 1.2%		A212433	001	Apr 28, 2021	Apr NEWA
	@ TOLMAR	5%; EQ 1% BASE		A204087	001	Jun 27, 2017	Sep DISC
	@	5%; 1.2%		A203688	001	Aug 25, 2016	Sep DISC
	DUAC						
AB	+ STIEFEL	5%; 1.2%		N050741	001	Aug 26, 2002	Jan CHRS

BENZOYL PEROXIDE; TRETINOIN

CREAM; TOPICAL		TWYNEO					
	+!	SOL-GEL TECHNOLOGIES	3%; 0.1%	N214902	001	Jul 26, 2021	Jul NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL		BENZPHETAMINE HYDROCHLORIDE					
	@ SCINOPHARM TAIWAN	50MG		A040578	001	Apr 17, 2006	Sep CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION		BENZTROPINE MESYLATE					
>A>	AP	HIKMA	1MG/ML	A209442	001	Oct 14, 2021	Oct NEWA

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC		BEPOTASTINE BESILATE					
AT	APOTEX	1.5%		A206066	001	Mar 05, 2019	May CMFD
AT	MYLAN	1.5%		A206220	001	Mar 18, 2019	May CMFD
	BEPREVE						
AT	+!	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	May CTEC

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION		CELESTONE SOLUSPAN					
AB	+!	ORGANON	3MG/ML; EQ 3MG BASE/ML	N014602	001		Aug CAHN

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL		SERNIVO					
	+!	PRIMUS PHARMS	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Mar CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL		CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE					
AB	!	TARO	EQ 0.05% BASE; 1%	A076493	001	Jul 28, 2004	Feb CHRS
	+ @	MERCK SHARP DOHME	EQ 0.05% BASE; 1%	N020010	001	Dec 08, 2000	Feb DISC

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
BETAXOLOL HYDROCHLORIDE

AT ACELLA EQ 0.5% BASE A078694 001 Nov 16, 2009 Aug CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL
BETHANECHOL CHLORIDE

AA BIOPHARM 5MG A040728 002 Oct 26, 2007 Sep CAHN
 AA 10MG A040728 003 Oct 26, 2007 Sep CAHN
 AA 25MG A040728 004 Oct 26, 2007 Sep CAHN
 AA 50MG A040728 001 Oct 26, 2007 Sep CAHN
 @ WOCKHARDT 5MG A040532 001 Sep 29, 2003 Jan DISC
 @ 50MG A040518 001 Sep 29, 2003 Jan DISC
 URECHOLINE
 + @ ODYSSEY PHARMS 10MG A088440 001 May 29, 1984 Aug CRLD
 + @ 25MG A088441 001 May 29, 1984 Aug CRLD

BEXAROTENE

CAPSULE;ORAL
BEXAROTENE

AB TEVA PHARMS USA 75MG A209931 001 Jan 14, 2021 Jan NEWA

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
BIKTARVY

>A> + GILEAD SCIENCES INC EQ 30MG BASE;120MG;EQ 15MG BASE N210251 002 Oct 07, 2021 Oct NEWA

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC
BIMATOPROST

AT ! AKORN 0.03% A203299 001 Nov 08, 2018 Feb CAHN
 AT ! ALEMBIC PHARMS LTD 0.03% A210263 001 Apr 12, 2019 Jan CHRS
 AT LUPIN LTD 0.03% A203991 001 Feb 20, 2015 Jan CHRS

BISOPROLOL FUMARATE

TABLET;ORAL
BISOPROLOL FUMARATE

>A> AB NOVITIUM PHARMA 5MG A215563 001 Oct 29, 2021 Oct NEWA
 >A> AB 10MG A215563 002 Oct 29, 2021 Oct NEWA
 AB UNICHEM 5MG A078635 001 Aug 18, 2009 Apr CAHN
 AB ! 10MG A078635 002 Aug 18, 2009 Apr CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

>A> AB NOVITIUM PHARMA 2.5MG;6.25MG A215562 001 Nov 04, 2021 Oct NEWA
 >A> AB 5MG;6.25MG A215562 002 Nov 04, 2021 Oct NEWA
 >A> AB 10MG;6.25MG A215562 003 Nov 04, 2021 Oct NEWA

BIVALIRUDIN

INJECTABLE;INTRAVENOUS
BIVALIRUDIN

AP HAINAN POLY PHARM 250MG/VIAL A213078 001 May 28, 2021 May NEWA

BLEOMYCIN SULFATE

INJECTABLE;INJECTION
BLEOMYCIN SULFATE

>A> AP @ CIPLA EQ 15 UNITS BASE/VIAL A209439 001 Mar 11, 2019 Aug DISC
 >A> AP HIKMA PHARMS EQ 15 UNITS BASE/VIAL A065042 002 Oct 17, 2001 Oct CAHN
 >A> AP EQ 30 UNITS BASE/VIAL A065042 001 Oct 17, 2001 Oct CAHN
 >D> AP WEST-WARD PHARMS INT EQ 15 UNITS BASE/VIAL A065042 002 Oct 17, 2001 Oct CAHN
 >D> AP EQ 30 UNITS BASE/VIAL A065042 001 Oct 17, 2001 Oct CAHN

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
VELCADE

+! TAKEDA PHARMS USA 3.5MG/VIAL N021602 001 May 13, 2003 May CAHN

BOSENTAN

TABLET; ORAL		BOSENTAN							
	@	ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Aug	DISC	
AB			62.5MG	A211461	001	Jan 23, 2020	May	CMFD	
	@		125MG	A211461	002	Jan 23, 2020	Aug	DISC	
AB			125MG	A211461	002	Jan 23, 2020	May	CMFD	
	@	NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019	Sep	DISC	
	@		125MG	A206987	002	Apr 26, 2019	Sep	DISC	
TRACLEER									
AB	+	ACTELION	62.5MG	N021290	001	Nov 20, 2001	Feb	CAHN	
AB	+	!	125MG	N021290	002	Nov 20, 2001	Feb	CAHN	
TABLET, FOR SUSPENSION; ORAL									
TRACLEER									
	+	!	ACTELION	32MG	N209279	001	Sep 05, 2017	Feb	CAHN

BRIGATINIB

TABLET; ORAL		ALUNBRIG							
	+	TAKEDA PHARMS USA	30MG	N208772	001	Apr 28, 2017	May	CAHN	
	+		90MG	N208772	002	Apr 28, 2017	May	CAHN	
	+	!	180MG	N208772	003	Oct 02, 2017	May	CAHN	

BRIMONIDINE TARTRATE

GEL; TOPICAL		BRIMONIDINE TARTRATE							
AB		PADAGIS ISRAEL	EQ 0.33% BASE	A209158	001	Sep 23, 2021	Sep	NFTG	
AB	+	!	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013	Sep	CFTG

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC		SIMBRINZA							
	+	!	ALCON LABS INC	0.2%; 1%	N204251	001	Apr 19, 2013	Sep	CAHN

BRINCIDOFIVIR

SUSPENSION; ORAL		TEMBEXA							
	+	!	CHIMERIX	10MG/ML	N214460	001	Jun 04, 2021	Jun	NEWA
TABLET; ORAL		TEMBEXA							
	+	!	CHIMERIX	100MG	N214461	001	Jun 04, 2021	Jun	NEWA

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC		BRINZOLAMIDE							
AB		BAUSCH	1%	A204884	001	Aug 18, 2021	Aug	NEWA	

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC		BROMFENAC SODIUM							
	@	NOVITIUM PHARMA	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Sep	CAHN	

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL		PARLODEL							
AB	+	VALIDUS PHARMS	EQ 5MG BASE	N017962	002	Mar 01, 1982	Feb	CAHN	
TABLET; ORAL		PARLODEL							
AB	+	VALIDUS PHARMS	EQ 2.5MG BASE	N017962	001		Feb	CAHN	

BUDESONIDE

CAPSULE, DELAYED RELEASE; ORAL		BUDESONIDE							
	@	ALVOGEN	3MG	A206724	001	Nov 23, 2016	Apr	CDFR	
AB		AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Apr	CDFR	
AB		MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Apr	CDFR	
AB		MYLAN	3MG	A090410	001	May 16, 2011	Apr	CDFR	
AB		RISING	3MG	A207367	001	Apr 07, 2017	Apr	CDFR	
AB		SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Apr	CDFR	

CAPSULE, DELAYED RELEASE;ORAL
BUDESONIDE

AB	ZYDUS PHARMS	3MG	A206134	001	May 04, 2017	Apr	CDFR
SUSPENSION; INHALATION							
BUDESONIDE							
AN	SUN PHARM	0.25MG/2ML	A211922	001	Apr 14, 2021	Apr	NEWA
AN		0.5MG/2ML	A211922	002	Apr 14, 2021	Apr	NEWA
AN		1MG/2ML	A211922	003	Apr 14, 2021	Apr	NEWA

BUMETANIDE

TABLET; ORAL
BUMETANIDE

BX	RISING	0.5MG	A212019	001	Dec 12, 2019	Sep	CTEC
BX		1MG	A212019	002	Dec 12, 2019	Sep	CTEC
BX		2MG	A212019	003	Dec 12, 2019	Sep	CTEC

BUPIVACAINE

SOLUTION, EXTENDED RELEASE; INFILTRATION
POSIMIR

+	@ DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Mar	DISC
+	!	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Feb	NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

AP	HIKMA PHARMS	0.25%	A205141	001	Feb 11, 2021	Feb	NEWA
AP		0.5%	A205141	002	Feb 11, 2021	Feb	NEWA
>D>	AP	HOSPIRA	A070586	001	Mar 03, 1987	Oct	DISC
>A>	@	0.25%	A070586	001	Mar 03, 1987	Oct	DISC
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	HIKMA PHARMS	0.25%	A204842	001	Feb 11, 2021	Feb	NEWA
AP		0.5%	A204842	002	Feb 11, 2021	Feb	NEWA
AP		0.75%	A204842	003	Feb 11, 2021	Feb	NEWA

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE; PERIARTICULAR
ZYNRELEF KIT

+	!	HERON THERAPS INC	60MG/2.3ML (29.25MG/ML); 1.8MG/2.3ML	N211988	001	May 12, 2021	Jun	NEWA
+	!		200MG/7ML (29.25MG/ML); 6MG/7ML (0.88MG/ML)	N211988	002	May 12, 2021	Jun	NEWA
+	!		300MG/10.5ML (29.25MG/ML); 9MG/10.5ML	N211988	003	May 12, 2021	Jun	NEWA
+	!		400MG/14ML (29.25MG/ML); 12MG/14ML (0.88MG/ML)	N211988	004	May 12, 2021	Jun	NEWA

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL
BUPRENORPHINE

AB	AVEVA	5MCG/HR	A210272	001	Sep 23, 2021	Sep	NEWA
AB		7.5MCG/HR	A210272	002	Sep 23, 2021	Sep	NEWA
AB		10MCG/HR	A210272	003	Sep 23, 2021	Sep	NEWA
AB		15MCG/HR	A210272	004	Sep 23, 2021	Sep	NEWA
AB		20MCG/HR	A210272	005	Sep 23, 2021	Sep	NEWA
	@ MYLAN TECH VIATRIS	5MCG/HR	A210162	001	May 03, 2021	Aug	DISC
	@	5MCG/HR	A210162	001	May 03, 2021	Aug	DISC
	@	7.5MCG/HR	A210162	002	May 03, 2021	Aug	DISC
	@	7.5MCG/HR	A210162	002	May 03, 2021	Aug	DISC
	@	10MCG/HR	A210162	003	May 03, 2021	Aug	DISC
	@	10MCG/HR	A210162	003	May 03, 2021	Aug	DISC
	@	15MCG/HR	A210162	004	May 03, 2021	Aug	DISC
	@	15MCG/HR	A210162	004	May 03, 2021	Aug	DISC
	@	20MCG/HR	A210162	005	May 03, 2021	Aug	DISC
	@	20MCG/HR	A210162	005	May 03, 2021	Aug	DISC
AB	MYLAN TECHNOLOGIES	5MCG/HR	A210162	001	May 03, 2021	Apr	NEWA
AB		7.5MCG/HR	A210162	002	May 03, 2021	Apr	NEWA
AB		10MCG/HR	A210162	003	May 03, 2021	Apr	NEWA
AB		15MCG/HR	A210162	004	May 03, 2021	Apr	NEWA
AB		20MCG/HR	A210162	005	May 03, 2021	Apr	NEWA
AB	WATSON LABS TEVA	7.5MCG/HR	A204937	005	Jun 29, 2021	Jun	NEWA

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

AB	+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jul CFTG
AB	+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jul CFTG
AB	+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jul CFTG
AB	+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jul CFTG
AB	+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jul CFTG
AB	+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jul CFTG
AB	+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jul CFTG

BUPRENORPHINE HYDROCHLORIDE

AB		ALVOGEN	EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Aug CAHN
AB			EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Jul NFTG
AB			EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Aug CAHN
AB			EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jul NFTG
AB			EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Aug CAHN
AB			EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Jul NFTG
AB			EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Aug CAHN
AB			EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jul NFTG
AB			EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Aug CAHN
AB			EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jul NFTG
AB			EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Aug CAHN
AB			EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jul NFTG
AB			EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Aug CAHN
AB			EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Jul NFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ALKEM LABS LTD	EQ 2MG BASE;EQ 0.5MG BASE	A214930	001	Jun 15, 2021	Jun NEWA
AB			EQ 8MG BASE;EQ 2MG BASE	A214930	002	Jun 15, 2021	Jun NEWA
		@ MAYNE PHARMA INC	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Jan DISC
		@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Jul DISC
AB			EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	May CMFD
		@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Jan DISC
AB		RHODES PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A205601	001	Mar 30, 2020	Jul CMFD
AB			EQ 8MG BASE;EQ 2MG BASE	A205601	002	Mar 30, 2020	Jul CMFD

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+		BAUSCH	174MG	N022108	001	Apr 23, 2008	Feb CAHN
+			348MG	N022108	002	Apr 23, 2008	Feb CAHN
+		!	522MG	N022108	003	Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

		@ MYLAN	75MG	A075491	001	Apr 17, 2000	Aug DISC
		@	100MG	A075491	002	Apr 17, 2000	Aug DISC
		TABLET, EXTENDED RELEASE;ORAL					
		BUPROPION HYDROCHLORIDE					
		@ IMPAX LABS	150MG	A077415	001	Nov 26, 2008	Aug DISC
		@	200MG	A076711	001	Dec 03, 2004	Aug DISC
		@ TORRENT	100MG	A203969	001	Oct 31, 2014	Jan DISC
		@	150MG	A203969	002	Oct 31, 2014	Jan DISC
		@	200MG	A203969	003	Oct 31, 2014	Jan DISC
		FORFIVO XL					
		+! ALMATICA	450MG	N022497	001	Nov 10, 2011	Sep CAHN
		WELLBUTRIN XL					
AB3	+	BAUSCH	150MG	N021515	001	Aug 28, 2003	Feb CAHN
AB3	+	!	300MG	N021515	002	Aug 28, 2003	Feb CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		RUBICON	5MG	A075521	001	Apr 05, 2002	Feb CMFD
AB			7.5MG	A075521	004	Mar 16, 2021	Mar NEWA
AB			10MG	A075521	002	Apr 05, 2002	Feb CMFD
AB			15MG	A075521	003	Apr 05, 2002	Feb CMFD
AB			30MG	A075521	005	Mar 16, 2021	Mar NEWA

BUSULFAN

	INJECTABLE; INJECTION						
	BUSULFAN						
AP	AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Feb	CAHN

BUTABARBITAL SODIUM

	TABLET; ORAL						
	BUTABARBITAL SODIUM						
	+ @ SANDOZ	15MG	A085938	001		Aug	CRLD

CABERGOLINE

	TABLET; ORAL						
	DOSTINEX						
	+ @ PFIZER	0.5MG	N020664	001	Dec 23, 1996	Jan	CAHN

CABOTEGRAVIR SODIUM

	TABLET; ORAL						
	VOCABRIA						
	+! VIV HLTHCARE	EQ 30MG BASE	N212887	001	Jan 21, 2021	Jan	NEWA

CABOTEGRAVIR; RILPIVIRINE

	SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR						
	CABENUVA KIT						

	+! VIV HLTHCARE	400MG/2ML (200MG/ML); 600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021	Jan	NEWA
	+!	600MG/3ML (200MG/ML); 900MG/3ML (300MG/ML)	N212888	002	Jan 21, 2021	Jan	NEWA

CAFFEINE CITRATE

	SOLUTION; INTRAVENOUS						
	CAFCIT						

AP	+! HIKMA PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Jul	CAHN
	SOLUTION; ORAL						
	CAFCIT						
AA	+! HIKMA PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jul	CAHN

CAFFEINE; ERGOTAMINE TARTRATE

	TABLET; ORAL						
	CAFERGOT						

	+ @ SANDOZ	100MG; 1MG	A084294	001		Aug	CRLD
	@	100MG; 1MG	A084294	001		Jul	DISC
	ERGOTAMINE TARTRATE AND CAFFEINE						
	! MIKART	100MG; 1MG	A040590	001	Sep 16, 2005	Jul	CHRS
		100MG; 1MG	A040590	001	Sep 16, 2005	Jul	CTEC

CALCITONIN SALMON

	INJECTABLE; INJECTION						
	CALCITONIN-SALMON						

AP	CUSTOPHARM INC	200 IU/ML	A212416	001	May 14, 2021	May	NFTG
	MIACALCIN						
AP	+! MYLAN IRELAND LTD	200 IU/ML	N017808	002	Mar 29, 1991	May	CFTG

CALCIUM ACETATE

	CAPSULE; ORAL						
	CALCIUM ACETATE						

>D>	AB	AMNEAL PHARMS	667MG	A201658	001	Oct 06, 2014	Oct	DISC
>A>		@	667MG	A201658	001	Oct 06, 2014	Oct	DISC
	TABLET; ORAL							
	CALCIUM ACETATE							
AB	! CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Apr	CHRS	

CALCIUM CARBONATE; RISEDRONATE SODIUM

	TABLET; ORAL						
	ACTONEL WITH CALCIUM (COPACKAGED)						

	+ @ WARNER CHILCOTT	EQ 500MG BASE; 35MG	N021823	001	Aug 12, 2005	Jul	CPOT
	+ @	EQ 500MG BASE, N/A; N/A, 35MG	N021823	001	Aug 12, 2005	Jul	CDFR

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
 >A> POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
 >A> AP FRESENIUS KABI USA 20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML A211428 001 Nov 09, 2021 Oct NFTG

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
 CALCIUM GLUCEPTATE
 + @ ABBOTT EQ 90MG CALCIUM/5ML A080001 001 Aug CRLD

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS
 CALCIUM GLUCONATE IN SODIUM CHLORIDE
 +! FRESENIUS KABI USA 1GM/50ML (20MG/ML) N208418 004 Jun 17, 2021 Aug NEWA
 +! 2GM/100ML (20MG/ML) N208418 005 Jun 17, 2021 Aug NEWA
 +! HQ SPCLT PHARMA 1GM/100ML (10MG/ML) N210906 003 Jun 04, 2021 Jun NEWA

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION
 CAPASTAT SULFATE
 + @ AKORN EQ 1GM BASE/VIAL N050095 001 Jun DISC

CAPTOPRIL

TABLET; ORAL
 CAPTOPRIL
 AB ANNORA PHARMA 12.5MG A074737 001 Oct 28, 1998 Jul CMFD
 AB 25MG A074737 002 Oct 28, 1998 Jul CMFD
 AB 50MG A074737 003 Oct 28, 1998 Jul CMFD
 AB 100MG A074737 004 Oct 28, 1998 Jul CMFD
 AB ! HIKMA INTL PHARMS 100MG A074505 004 Feb 13, 1996 Sep CHRS
 @ MYLAN 12.5MG A074434 001 Feb 13, 1996 Sep CAHN
 @ 12.5MG A074434 001 Feb 13, 1996 Sep DISC
 @ 25MG A074434 002 Feb 13, 1996 Sep CAHN
 @ 25MG A074434 002 Feb 13, 1996 Sep DISC
 @ 50MG A074434 003 Feb 13, 1996 Sep CAHN
 @ 50MG A074434 003 Feb 13, 1996 Sep DISC
 @ 100MG A074434 004 Feb 13, 1996 Sep CAHN
 @ 100MG A074434 004 Feb 13, 1996 Sep DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE
 @ MYLAN 25MG; 15MG A074896 001 Dec 29, 1997 Aug CAHN
 @ 25MG; 15MG A074896 001 Dec 29, 1997 Aug DISC
 @ 25MG; 25MG A074896 002 Dec 29, 1997 Aug CAHN
 @ 25MG; 25MG A074896 002 Dec 29, 1997 Aug DISC
 @ 50MG; 15MG A074896 004 Dec 29, 1997 Aug CAHN
 @ 50MG; 15MG A074896 004 Dec 29, 1997 Aug DISC
 @ 50MG; 25MG A074896 003 Dec 29, 1997 Aug CAHN
 @ 50MG; 25MG A074896 003 Dec 29, 1997 Aug DISC

CARBAMAZEPINE

TABLET; ORAL
 CARBAMAZEPINE
 AB VGYAAN 200MG A214328 001 Aug 16, 2021 Aug NEWA
 TABLET, EXTENDED RELEASE; ORAL
 CARBAMAZEPINE
 AB ANBISON LAB 100MG A212948 001 Sep 30, 2021 Sep NEWA
 AB 200MG A212948 002 Sep 30, 2021 Sep NEWA
 AB 400MG A212948 003 Sep 30, 2021 Sep NEWA
 AB CSPC OUYI 100MG A213311 001 Apr 13, 2021 Apr NEWA
 AB 200MG A213311 002 Apr 13, 2021 Apr NEWA
 AB 400MG A213311 003 Apr 13, 2021 Apr NEWA

CARBIDOPA; LEVODOPA

TABLET; ORAL
 CARBIDOPA AND LEVODOPA
 AB SCIEGEN PHARMS INC 10MG; 100MG A214092 001 May 07, 2021 Apr NEWA
 AB 25MG; 100MG A214092 002 May 07, 2021 Apr NEWA
 AB 25MG; 250MG A214092 003 May 07, 2021 Apr NEWA

TABLET;ORAL
SINEMET

AB	+	ORGANON	10MG;100MG	N017555	001		Aug	CAHN
AB	+		25MG;100MG	N017555	003		Aug	CAHN
AB	+		25MG;250MG	N017555	002		Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL
CARBIDOPA AND LEVODOPA

AB		SCIEGEN PHARMS INC	25MG;100MG	A214091	001	Oct 05, 2021	Sep	NEWA
AB			50MG;200MG	A214091	002	Oct 05, 2021	Sep	NEWA
		SINEMET CR						
	+	@ ORGANON	25MG;100MG	N019856	002	Dec 24, 1992	Sep	CAHN
	+	@	50MG;200MG	N019856	001	May 30, 1991	Sep	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
CARBIDOPA AND LEVODOPA

	@	MYLAN	10MG;100MG	A078893	001	Sep 18, 2008	Aug	CAHN
	@		10MG;100MG	A078893	001	Sep 18, 2008	Aug	DISC
	@		25MG;100MG	A078893	002	Sep 18, 2008	Aug	CAHN
	@		25MG;100MG	A078893	002	Sep 18, 2008	Aug	DISC
	@		25MG;250MG	A078893	003	Sep 18, 2008	Aug	CAHN
	@		25MG;250MG	A078893	003	Sep 18, 2008	Aug	DISC
	!	SUN PHARM	25MG;250MG	A078690	003	Jul 31, 2009	Aug	CTEC
AB	!		25MG;250MG	A078690	003	Jul 31, 2009	Aug	CHRS

CARBOPLATIN

INJECTABLE;INTRAVENOUS
CARBOPLATIN

AP	!	HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14, 2004	Mar	CHRS
AP	!		150MG/15ML (10MG/ML)	A076517	002	Oct 14, 2004	Mar	CHRS
AP	!		450MG/45ML (10MG/ML)	A076517	003	Oct 14, 2004	Mar	CHRS
AP	!		600MG/60ML (10MG/ML)	A077059	001	Nov 23, 2004	Mar	CHRS
	@	MEITHEAL	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Aug	DISC
	@		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Aug	DISC
	@		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Aug	DISC
	@		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Aug	DISC
AP		PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Mar	CHRS
AP			150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Mar	CHRS
AP			450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Mar	CHRS
AP			600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Mar	CHRS

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION
CARBOPROST TROMETHAMINE

AP		SUNNY	EQ 0.25MG BASE/ML	A213118	001	Mar 25, 2021	Mar	NEWA
----	--	-------	-------------------	---------	-----	--------------	-----	------

CARFILZOMIB

POWDER;INTRAVENOUS
CARFILZOMIB

	@	BRECKENRIDGE	10MG/VIAL	A209330	001	Jun 11, 2021	Aug	DISC
AP			10MG/VIAL	A209330	001	Jun 11, 2021	Jun	NFTG
	@		60MG/VIAL	A209330	002	Jun 11, 2021	Aug	DISC
AP			60MG/VIAL	A209330	002	Jun 11, 2021	Jun	NEWA
		KYPROLIS						
	+	ONYX THERAP	10MG/VIAL	N202714	003	Jun 07, 2018	Aug	CTEC
AP	+		10MG/VIAL	N202714	003	Jun 07, 2018	Jun	CFTG

CARGLUMIC ACID

TABLET, FOR SUSPENSION;ORAL
CARBAGLU

>D>	+	RECORDATI RARE	200MG	N022562	001	Mar 18, 2010	Oct	CFTG
>A>	AB	+	200MG	N022562	001	Mar 18, 2010	Oct	CFTG
>A>		CARGLUMIC ACID						
>A>	AB	NOVITIUM PHARMA	200MG	A213729	001	Oct 13, 2021	Oct	NFTG

CARISOPRODOL

TABLET;ORAL
CARISOPRODOL

AA		MLV	350MG	A040245	001	Sep 08, 1997	Sep	CAHN
>A>	AA		350MG	A211789	001	Oct 20, 2021	Oct	NEWA
BX		STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015	Sep	CTEC
BX			350MG	A205513	002	Nov 12, 2015	Sep	CTEC

CARMUSTINE

	INJECTABLE; INJECTION						
	BICNU						
AP	+!	AVET LIFESCIENCES	100MG/VIAL	N017422	001		Aug CAHN
		CARMUSTINE					
AP		HONG KONG	100MG/VIAL	A213460	001	Aug 02, 2021	Jul NEWA
AP		MEITHEAL	100MG/VIAL	A213460	001	Aug 02, 2021	Sep CAHN

CARVEDILOL

	TABLET; ORAL						
	CARVEDILOL						
	@	ACI	3.125MG	A078786	001	Dec 22, 2009	Sep CAHN
	@		6.25MG	A078786	002	Dec 22, 2009	Sep CAHN
	@		12.5MG	A078786	003	Dec 22, 2009	Sep CAHN
	@		25MG	A078786	004	Dec 22, 2009	Sep CAHN
	@	AXXELENT PHARMA	3.125MG	A078786	001	Dec 22, 2009	Aug CAHN
	@		6.25MG	A078786	002	Dec 22, 2009	Aug CAHN
	@		12.5MG	A078786	003	Dec 22, 2009	Aug CAHN
	@		25MG	A078786	004	Dec 22, 2009	Aug CAHN
	COREG						
AB	+	WOODWARD	3.125MG	N020297	004	May 29, 1997	Jul CAHN
AB	+		6.25MG	N020297	003	Sep 14, 1995	Jul CAHN
AB	+!		12.5MG	N020297	002	Sep 14, 1995	Jul CAHN
AB	+		25MG	N020297	001	Sep 14, 1995	Jul CAHN

CARVEDILOL PHOSPHATE

	CAPSULE, EXTENDED RELEASE; ORAL						
	COREG CR						
AB	+	WOODWARD	10MG	N022012	001	Oct 20, 2006	Jul CAHN
AB	+		20MG	N022012	002	Oct 20, 2006	Jul CAHN
AB	+!		40MG	N022012	003	Oct 20, 2006	Jul CAHN
AB	+		80MG	N022012	004	Oct 20, 2006	Jul CAHN

CASIMERSEN

	SOLUTION; INTRAVENOUS						
	AMONDYS 45						
	+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N213026	001	Feb 25, 2021	Feb NEWA

CASPOFUNGIN ACETATE

	POWDER; INTRAVENOUS						
	CASPOFUNGIN ACETATE						
AP		UBI	50MG/VIAL	A211263	001	Oct 01, 2021	Sep NEWA
AP			70MG/VIAL	A211263	002	Oct 01, 2021	Sep NEWA

CEFAZOLIN SODIUM

	SOLUTION; INTRAVENOUS						
	CEFAZOLIN IN PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	Mar NEWA
	+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar CRLD
	!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar CHRS

CEFDINIR

	CAPSULE; ORAL						
	CEFDINIR						
AB		ALKEM LABS LTD	300MG	A210220	001	Feb 19, 2021	Feb NEWA
	FOR SUSPENSION; ORAL						
	CEFDINIR						
AB		ALKEM LABS LTD	125MG/5ML	A210534	001	Feb 19, 2021	Feb NEWA
AB			250MG/5ML	A210534	002	Feb 19, 2021	Feb NEWA

CEFEPIME HYDROCHLORIDE

	INJECTABLE; INJECTION						
	CEFEPIME HYDROCHLORIDE						
	@	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Mar DISC
	@		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Mar DISC

CEFIXIMEFOR SUSPENSION; ORAL
CEFIXIME

AB	ALKEM LABS LTD	100MG/5ML	A211775	001	Feb 19, 2021	Feb	NEWA
AB		200MG/5ML	A211775	002	Feb 19, 2021	Feb	NEWA

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CLAFORAN

+ @	VALIDUS PHARMS	EQ 500MG BASE/VIAL	N050547	001		Feb	CAHN
+ @		EQ 1GM BASE/VIAL	N050547	002		Feb	CAHN
+ @		EQ 2GM BASE/VIAL	N050547	003		Feb	CAHN
+ @		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Feb	CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER							
@	VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Feb	CAHN
@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Feb	CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
@	VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Feb	CAHN
@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Feb	CAHN

CEFOXITIN SODIUMINJECTABLE; INJECTION
CEFOXITIN

>A>	AP	HIKMA PHARMS	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Oct	CAHN
>A>	AP		EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Oct	CAHN
>A>	AP		EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Oct	CAHN
>D>	AP	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Oct	CAHN
>D>	AP		EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Oct	CAHN
>D>	AP		EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Oct	CAHN

CEFTAROLINE FOSAMILPOWDER; INTRAVENOUS
CEFTAROLINE FOSAMIL

AP	APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Sep	NFTG	
AP		600MG/VIAL	A208075	002	Sep 21, 2021	Sep	NFTG	
TEFLARO								
AP	+!	ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010	Sep	CHRS
AP	+		400MG/VIAL	N200327	001	Oct 29, 2010	Sep	CFTG
AP	+!		600MG/VIAL	N200327	002	Oct 29, 2010	Sep	CFTG

CEFTAZIDIME SODIUMINJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

@	TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Feb	CAHN
+ @		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Feb	CAHN
+ @		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Feb	CAHN

CEFUROXIME SODIUMINJECTABLE; INJECTION
ZINACEF

AP	+!	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb	CAHN
AP	+!		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb	CAHN
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS								
ZINACEF								
AB	+!	TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb	CAHN

CELECOXIBCAPSULE; ORAL
CELEBREX

AB	+	UPJOHN	50MG	N020998	004	Dec 15, 2006	Apr	CAHN
AB	+		100MG	N020998	001	Dec 31, 1998	Apr	CAHN
AB	+		200MG	N020998	002	Dec 31, 1998	Apr	CAHN
AB	+!		400MG	N020998	003	Aug 29, 2002	Apr	CAHN
CELECOXIB								
@	ACIC PHARMS	200MG	A212925	001	Dec 09, 2020	Jun	DISC	
@		400MG	A212925	002	Dec 09, 2020	Jun	DISC	
BX	AMNEAL PHARMS	50MG	A208833	001	May 31, 2018	Sep	CTEC	
BX		100MG	A208833	002	May 31, 2018	Sep	CTEC	
BX		200MG	A208833	003	May 31, 2018	Sep	CTEC	
BX		400MG	A208833	004	May 31, 2018	Sep	CTEC	
@	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Jun	DISC	

	CAPSULE;ORAL						
	CELECOXIB						
	@	100MG	A207061	002	Apr 04, 2017	Jun	DISC
	@	200MG	A207061	003	Apr 04, 2017	Jun	DISC
	@	400MG	A207061	004	Apr 04, 2017	Jun	DISC
AB	UNICHEM	50MG	A213301	001	Jan 12, 2021	Jan	NEWA
AB		100MG	A213301	002	Jan 12, 2021	Jan	NEWA
AB		200MG	A213301	003	Jan 12, 2021	Jan	NEWA
AB		400MG	A213301	004	Jan 12, 2021	Jan	NEWA
AB	YILING	50MG	A211412	001	Mar 06, 2020	Jun	CMFD
AB		100MG	A211412	002	Mar 06, 2020	Jun	CMFD
AB		200MG	A211412	003	Mar 06, 2020	Jun	CMFD
AB		400MG	A211412	004	Mar 06, 2020	Jun	CMFD
	SOLUTION;ORAL						
	ELYXYB						
	+ @ BDSI	25MG/ML	N212157	001	May 05, 2020	Sep	CAHN
>A>	<u>CELECOXIB; TRAMADOL HYDROCHLORIDE</u>						
>A>	TABLET;ORAL						
>A>	SEGLENTIS						
>A>	+!	ESTEVE	56MG;44MG	N213426	001	Oct 15, 2021	Oct NEWA
	<u>CENOAMATE</u>						
	TABLET;ORAL						
	XCOPRI						
	+!	SK LIFE	12.5MG	N212839	001	Mar 10, 2020	Jul CHRS
	+		200MG	N212839	006	Mar 10, 2020	Jul CHRS
	<u>CEPHALEXIN</u>						
	CAPSULE;ORAL						
	CEPHALEXIN						
	!	ALKEM LABS LTD	EQ 750MG BASE	A090836	004	Mar 29, 2013	Sep CTEC
AB	!		EQ 750MG BASE	A090836	004	Mar 29, 2013	Sep CHRS
AB		YUNG SHIN PHARM	EQ 250MG BASE	A065152	001	Feb 24, 2005	Aug CMFD
	@		EQ 250MG BASE	A065152	001	Feb 24, 2005	Mar DISC
AB			EQ 500MG BASE	A065152	002	Feb 24, 2005	Aug CMFD
	@		EQ 500MG BASE	A065152	002	Feb 24, 2005	Mar DISC
	KEFLEX						
	+ @	PRAGMA	EQ 250MG BASE	N050405	002		May DISC
	+ @		EQ 500MG BASE	N050405	003		May DISC
	+ @		EQ 750MG BASE	N050405	005	May 12, 2006	Sep DISC
	<u>CETIRIZINE HYDROCHLORIDE</u>						
	SYRUP;ORAL						
	CETIRIZINE HYDROCHLORIDE						
AA		MICRO LABS	5MG/5ML	A090191	001	Nov 12, 2009	Aug CAHN
AA	!	PADAGIS US	5MG/5ML	A078398	001	Jun 17, 2008	Jul CAHN
	<u>CHLORDIAZEPOXIDE HYDROCHLORIDE</u>						
	CAPSULE;ORAL						
	CHLORDIAZEPOXIDE HYDROCHLORIDE						
	@	CHARTWELL RX	5MG	A084678	001		Apr CAHN
	@		10MG	A084041	001		Apr CAHN
	@		25MG	A084679	002		Apr CAHN
	+ @	UPSHER SMITH LABS	10MG	A084920	001		Aug CRLD
	LIBRIUM						
AB	+!	VALEANT PHARM INTL	25MG	A085475	001		Aug CRLD
	<u>CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE</u>						
	CAPSULE;ORAL						
	CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE						
AB		ALKEM LABS LTD	5MG;2.5MG	A214065	001	Apr 26, 2021	Apr NEWA
>A>	AB	AMNEAL	5MG;2.5MG	A215555	001	Oct 25, 2021	Oct NEWA
AB		DR REDDYS	5MG;2.5MG	A214698	001	May 10, 2021	Apr NEWA
AB		PHARMA LIFE	5MG;2.5MG	A213530	001	Oct 20, 2020	Sep CAHN
>A>	AB	TEVA PHARMS USA	5MG;2.5MG	A211476	001	Nov 02, 2021	Oct NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT	BAJAJ	0.12%	A075561	001	Nov 14, 2000	Feb	CMFD
----	-------	-------	---------	-----	--------------	-----	------

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLOROPROCAINE HYDROCHLORIDE

>D>	AP	HOSPIRA	2%	A087447	001	Apr 16, 1982	Oct	DISC
>A>	@		2%	A087447	001	Apr 16, 1982	Oct	DISC
>D>	AP		3%	A087446	001	Apr 16, 1982	Oct	DISC
>A>	@		3%	A087446	001	Apr 16, 1982	Oct	DISC

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE

AA	SUVEN PHARMS	500MG	A214756	001	Sep 03, 2021	Aug	NEWA
----	--------------	-------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL
CHLORPROMAZINE HYDROCHLORIDE

BX	AMNEAL PHARMS CO	10MG	A209755	001	Sep 10, 2018	Sep	CTEC	
BX		25MG	A209755	002	Sep 10, 2018	Sep	CTEC	
BX		50MG	A209755	003	Sep 10, 2018	Sep	CTEC	
BX		100MG	A209755	004	Sep 10, 2018	Sep	CTEC	
BX		200MG	A209755	005	Sep 10, 2018	Sep	CTEC	
AB	GLENMARK PHARMS LTD	10MG	A212144	001	Mar 23, 2021	Mar	NEWA	
AB		25MG	A212144	002	Mar 23, 2021	Mar	NEWA	
AB		50MG	A212144	003	Mar 23, 2021	Mar	NEWA	
AB		100MG	A212144	004	Mar 23, 2021	Mar	NEWA	
AB		200MG	A212144	005	Mar 23, 2021	Mar	NEWA	
AB	LANNETT CO INC	10MG	A212996	001	Jan 22, 2021	Jan	NEWA	
AB		25MG	A212996	002	Jan 22, 2021	Jan	NEWA	
AB		50MG	A212996	003	Jan 22, 2021	Jan	NEWA	
AB		100MG	A212996	004	Jan 22, 2021	Jan	NEWA	
AB		200MG	A212996	005	Jan 22, 2021	Jan	NEWA	
	@ MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Mar	DISC	
	@	25MG	A213590	002	Aug 31, 2020	Mar	DISC	
	@	50MG	A213590	003	Aug 31, 2020	Mar	DISC	
	@	100MG	A213590	004	Aug 31, 2020	Mar	DISC	
	@	200MG	A213590	005	Aug 31, 2020	Mar	DISC	
>A>	AB	TEVA PHARMS	10MG	A215659	001	Oct 25, 2021	Oct	NEWA
>A>	AB		25MG	A215659	002	Oct 25, 2021	Oct	NEWA
>A>	AB		50MG	A215659	003	Oct 25, 2021	Oct	NEWA
>A>	AB		100MG	A215659	004	Oct 25, 2021	Oct	NEWA
>A>	AB		200MG	A215659	005	Oct 25, 2021	Oct	NEWA
AB	+ UPSHER SMITH LABS	10MG	A083386	001		Aug	CRLD	
AB	+	25MG	A084112	001		Aug	CRLD	
AB	+	50MG	A084113	001		Aug	CRLD	
AB	+	100MG	A084114	001		Aug	CRLD	
AB	+	200MG	A084115	001		Aug	CRLD	

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

	@ RISING	100MG	A088725	001	Aug 31, 1984	Jan	CAHN
	@	250MG	A088726	001	Aug 31, 1984	Jan	CAHN

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

AB	+ MYLAN	25MG	A086831	002		Aug	CRLD
AB	+	50MG	A086831	001		Aug	CRLD
AB	NOVAST LABS	25MG	A206904	001	Mar 30, 2017	Sep	CAHN
AB		50MG	A206904	002	Mar 30, 2017	Sep	CAHN
BX	UMEDICA LABS PVT LTD	25MG	A207222	001	May 24, 2018	Sep	CTEC
BX		50MG	A207222	002	May 24, 2018	Sep	CTEC
	THALITONE						
	+ CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988	May	CMFD
BX	+	25MG	N019574	002	Feb 12, 1992	May	CMFD

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	HAVIX	250MG	A215158	001	Jul 29, 2021	Jul	NEWA
AA	! MIKART	250MG	A207483	001	Jun 24, 2016	Jul	CTEC
AB	PAR PHARM INC	375MG	A212743	002	Apr 29, 2021	Apr	NEWA
AA	SENORES PHARMS	250MG	A215158	001	Jul 29, 2021	Aug	CAHN

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

>A>	AB	ALKEM LABS LTD	EQ 4GM RESIN/PACKET	A211856	001	Oct 19, 2021	Oct	NEWA
>A>	AB		EQ 4GM RESIN/SCOOPFUL	A211856	002	Oct 19, 2021	Oct	NEWA
	AB	TAGI	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Feb	NEWA
	AB		EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Feb	NEWA
		CHOLESTYRAMINE LIGHT						
>A>	AB	ALKEM LABS LTD	EQ 4GM RESIN/PACKET	A211799	001	Oct 19, 2021	Oct	NEWA
>A>	AB		EQ 4GM RESIN/SCOOPFUL	A211799	002	Oct 19, 2021	Oct	NEWA
		LOCHOLEST LIGHT						
		@ CHARTWELL RX	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Apr	CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Apr	CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB	ADAPTIS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Aug	CAHN
AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Aug	CAHN

CICLESONIDE

SPRAY, METERED; NASAL

OMNARIS

+!	COVIS	0.05MG/SPRAY	N022004	001	Oct 20, 2006	May	CPOT
----	-------	--------------	---------	-----	--------------	-----	------

CICLOPIROX

GEL; TOPICAL

CICLOPIROX

AB	+!	ALVOGEN	0.77%	N020519	001	Jul 21, 1997	Jun	CAHN
----	----	---------	-------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

	@	AKORN	8%	A078975	001	Feb 17, 2010	Apr	DISC
AT		RISING	8%	A078124	001	Sep 18, 2007	May	CAHN

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

	@	EPIC PHARMA LLC	50MG	A077022	002	Mar 11, 2005	Jan	CMS1
	@	NOSTRUM LABS INC	50MG	A077708	001	Sep 28, 2009	Mar	DISC
AB			50MG	A077708	001	Sep 28, 2009	Jan	CAHN
	@		100MG	A077708	002	Sep 28, 2009	Mar	DISC
AB			100MG	A077708	002	Sep 28, 2009	Jan	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ NOVITIUM PHARMA

@

@

TAGAMET

	@	GLAXOSMITHKLINE	200MG	N017920	002		Oct	CRLD
>A>	+	@	200MG	N017920	002		Oct	CRLD
>D>		@	300MG	N017920	003		Oct	CRLD
>A>	+	@	300MG	N017920	003		Oct	CRLD
>D>		@	400MG	N017920	004	Dec 14, 1983	Oct	CRLD
>A>	+	@	400MG	N017920	004	Dec 14, 1983	Oct	CRLD
>D>		@	800MG	N017920	005	Apr 30, 1986	Oct	CRLD
>A>	+	@	800MG	N017920	005	Apr 30, 1986	Oct	CRLD

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

@	MYLAN	EQ 30MG BASE	A203422	001	Oct 16, 2018	Aug	CAHN
@		EQ 30MG BASE	A203422	001	Oct 16, 2018	Aug	DISC
@		EQ 60MG BASE	A203422	002	Oct 16, 2018	Aug	CAHN
@		EQ 60MG BASE	A203422	002	Oct 16, 2018	Aug	DISC
@		EQ 90MG BASE	A203422	003	Oct 16, 2018	Aug	CAHN
@		EQ 90MG BASE	A203422	003	Oct 16, 2018	Aug	DISC

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

>D>	AP	HOSPIRA	200MG/20ML (10MG/ML)	A077245	001	Aug 28, 2006	Oct	DISC
>A>		@	200MG/20ML (10MG/ML)	A077245	001	Aug 28, 2006	Oct	DISC
>D>	AP		400MG/40ML (10MG/ML)	A077245	002	Aug 28, 2006	Oct	DISC
>A>		@	400MG/40ML (10MG/ML)	A077245	002	Aug 28, 2006	Oct	DISC

INJECTABLE, SUSPENSION; OTIC

OTIPRIO

+	!	ALK ABELLO	6% (60MG/ML)	N207986	001	Dec 10, 2015	Jun	CAHN
---	---	------------	--------------	---------	-----	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

>A>		@	AMNEAL	EQ 100MG BASE	A075939	001	Mar 03, 2005	Oct	CAHN
>A>		@		EQ 250MG BASE	A075939	002	Jun 09, 2004	Oct	CAHN
>A>		@		EQ 500MG BASE	A075939	003	Jun 09, 2004	Oct	CAHN
>A>		@		EQ 750MG BASE	A075939	004	Jun 09, 2004	Oct	CAHN
>D>		@	ANI PHARMS	EQ 100MG BASE	A075939	001	Mar 03, 2005	Oct	CAHN
>D>		@		EQ 250MG BASE	A075939	002	Jun 09, 2004	Oct	CAHN
>D>		@		EQ 500MG BASE	A075939	003	Jun 09, 2004	Oct	CAHN
>D>		@		EQ 750MG BASE	A075939	004	Jun 09, 2004	Oct	CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

@	SAGENT PHARMS INC	EQ 2MG BASE/ML	A201851	001	Nov 06, 2020	Jul	DISC
@	ZYDUS PHARMS	EQ 2MG BASE/ML	A213527	001	Aug 31, 2020	Feb	DISC

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT:HP

+	!	EXALENZ BIOSCIENCE	4GM; 75MG	N021314	001	Dec 17, 2002	Jul	CPOT
---	---	--------------------	-----------	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

@	WOCKHARDT	250MG	A065266	001	May 31, 2006	Jan	DISC
@		500MG	A065266	002	May 31, 2006	Jan	DISC

CLASCOTERONE

CREAM; TOPICAL

WINLEVI

+	@	CASSIOPEA SPA	1%	N213433	001	Aug 26, 2020	Mar	DISC
+	!	SUN PHARM	1%	N213433	001	Aug 26, 2020	Sep	CMFD
+	@		1%	N213433	001	Aug 26, 2020	Sep	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

AB	+	PFIZER	EQ 75MG BASE	N050162	001		Feb	CAHN
AB	+		EQ 150MG BASE	N050162	002		Feb	CAHN
AB	+	!	EQ 300MG BASE	N050162	003	Apr 14, 1988	Feb	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

AA	!	PFIZER	EQ 75MG BASE/5ML	A062644	001	Apr 07, 1986	Feb	CAHN
----	---	--------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

AT							
	AEROSOL, FOAM;TOPICAL						
	CLINDAMYCIN PHOSPHATE						
AT	GLENMARK PHARMS LTD	1%		A210778	001	Sep 20, 2021	Sep NEWA
	CREAM;VAGINAL						
	CLEOCIN						
	@ PFIZER	EQ 2% BASE		N050680	001	Aug 11, 1992	Feb CAHN
AB	+	EQ 2% BASE		N050680	002	Mar 02, 1998	Feb CAHN
	GEL;TOPICAL						
	CLEOCIN T						
AB1	+	PFIZER	EQ 1% BASE	N050615	001	Jan 07, 1987	Aug CTEC
AB	+		EQ 1% BASE	N050615	001	Jan 07, 1987	Feb CAHN
	CLINDAGEL						
AB2	+	BAUSCH	EQ 1% BASE	N050782	001	Nov 27, 2000	Aug CFTG
	CLINDAMYCIN PHOSPHATE						
AB1	ENCUBE		EQ 1% BASE	A212438	001	Mar 11, 2021	Aug CTEC
AB			EQ 1% BASE	A212438	001	Mar 11, 2021	Mar NEWA
AB1	FOUGERA PHARMS		EQ 1% BASE	A064160	001	Jan 28, 2000	Aug CTEC
AB1	GLENMARK PHARMS LTD		EQ 1% BASE	A214251	001	Feb 10, 2021	Aug CTEC
AB			EQ 1% BASE	A214251	001	Feb 10, 2021	Jan NEWA
AB1	PADAGIS ISRAEL		EQ 1% BASE	A212104	001	Dec 31, 2020	Aug CTEC
AB	PERRIGO UK FINCO		EQ 1% BASE	A212104	001	Dec 31, 2020	Jan CAHN
AB1	SOLARIS PHARMA CORP		EQ 1% BASE	A211872	001	Jul 29, 2020	Aug CTEC
AB2			EQ 1% BASE	A212842	001	Aug 13, 2021	Aug NFTG
AB1	TARO PHARMS		EQ 1% BASE	A214052	001	Nov 10, 2020	Aug CTEC
	INJECTABLE;INJECTION						
	CLEOCIN PHOSPHATE						
AP	PFIZER		EQ 150MG BASE/ML	A062803	001	Oct 16, 1987	Feb CAHN
AP	+		EQ 150MG BASE/ML	N050441	001		Feb CAHN
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
	+ @ PFIZER		EQ 6MG BASE/ML	N050639	001	Aug 30, 1989	Feb CAHN
	+ @		EQ 12MG BASE/ML	N050639	002	Aug 30, 1989	Feb CAHN
	+ @		EQ 18MG BASE/ML	N050639	003	Apr 10, 1991	Feb CAHN
	CLINDAMYCIN PHOSPHATE						
AP	ALMAJECT		EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Jul CAHN
	@		EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Jul CAHN
AP			EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Jul CAHN
	@ MYLAN LABS LTD		EQ 150MG BASE/ML	A204748	001	Oct 10, 2017	Jan DISC
	LOTION;TOPICAL						
	CLEOCIN T						
AB	+	PFIZER	EQ 1% BASE	N050600	001	May 31, 1989	Feb CAHN
	CLINDAMYCIN PHOSPHATE						
AB	TARO PHARMS		EQ 1% BASE	A214526	001	Jun 28, 2021	Jun NEWA
	SOLUTION;TOPICAL						
	CLEOCIN T						
	+ @ PFIZER		EQ 1% BASE	N050537	001		Feb CAHN
	+ @ PHARMACIA AND UPJOHN		EQ 1% BASE	N050537	001		Jan DISC
	SUPPOSITORY;VAGINAL						
	CLEOCIN						
	+	PFIZER	100MG	N050767	001	Aug 13, 1999	Feb CAHN
	SWAB;TOPICAL						
	CLEOCIN						
	+ @ PFIZER		EQ 1% BASE	N050537	002	Feb 22, 1994	Mar DISC
AT	+		EQ 1% BASE	N050537	002	Feb 22, 1994	Feb CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

	GEL;TOPICAL						
	ZIANA						
AB	+	BAUSCH	1.2%;0.025%	N050802	001	Nov 07, 2006	May CAHN

CLOBAZAM

	SUSPENSION;ORAL						
	CLOBAZAM						
AB	ALKEM LABS LTD		2.5MG/ML	A213039	001	May 06, 2021	Apr NEWA
AB	TARO		2.5MG/ML	A210978	001	Apr 15, 2019	Jul CMFD
	TABLET;ORAL						
	CLOBAZAM						
>D>	ALKEM LABS LTD		5MG	A212714	003	Dec 21, 2020	Oct CTEC
>A>	AB		5MG	A212714	003	Dec 21, 2020	Oct CTEC
>A>	AB	BRECKENRIDGE	5MG	A209308	003	Oct 19, 2021	Oct NEWA

TABLET; ORAL									
CLOBAZAM									
	@ CELLTRION	10MG	A211959	001	Dec 09, 2020	Jun	DISC		
	@	20MG	A211959	002	Dec 09, 2020	Jun	DISC		
	@ LANNETT CO INC	10MG	A212092	001	Oct 30, 2019	Mar	DISC		
	@	20MG	A212092	002	Oct 30, 2019	Mar	DISC		
AB	MSN	10MG	A213404	001	May 11, 2021	Apr	NEWA		
AB		20MG	A213404	002	May 11, 2021	Apr	NEWA		
<u>CLOBETASOL PROPIONATE</u>									
CREAM; TOPICAL									
CLOBETASOL PROPIONATE									
AB1	GLASSHOUSE PHARMS	0.05%	A211207	001	Mar 26, 2021	Mar	NEWA		
>D>	AB1 PAI HOLDINGS PHARM	0.05%	A211207	001	Mar 26, 2021	Oct	DISC		
>A>	@	0.05%	A211207	001	Mar 26, 2021	Oct	DISC		
AB1		0.05%	A211207	001	Mar 26, 2021	Sep	CAHN		
IMPOYZ									
+	PRIMUS PHARMS	0.025%	N209483	001	Nov 28, 2017	Mar	CAHN		
OINTMENT; TOPICAL									
CLOBETASOL PROPIONATE									
	@ TORRENT	0.05%	A212926	001	Oct 25, 2019	Jan	DISC		
SHAMPOO; TOPICAL									
CLOBETASOL PROPIONATE									
AB	AMNEAL	0.05%	A214895	001	Jun 14, 2021	Jun	NEWA		
AB	TARO PHARMS	0.05%	A214867	001	Mar 25, 2021	Mar	NEWA		
SOLUTION; TOPICAL									
CLOBETASOL PROPIONATE									
AT	PRINSTON INC	0.05%	A213139	001	Feb 08, 2021	Jan	NEWA		
SPRAY; TOPICAL									
CLOBETASOL PROPIONATE									
	@ AKORN	0.05%	A207218	001	Apr 28, 2017	Apr	DISC		
<u>CLOFARABINE</u>									
SOLUTION; INTRAVENOUS									
CLOFARABINE									
AP	MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jan	CAHN		
	@ NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Mar	DISC		
<u>CLOMIPRAMINE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
CLOMIPRAMINE HYDROCHLORIDE									
AB	ALEMBIC PHARMS LTD	25MG	A211822	001	Aug 04, 2021	Jul	NEWA		
AB		50MG	A211822	002	Aug 04, 2021	Jul	NEWA		
AB		75MG	A211822	003	Aug 04, 2021	Jul	NEWA		
AB	VGYAAN	25MG	A213221	001	Jun 22, 2020	May	CMFD		
AB		50MG	A213221	002	Jun 22, 2020	May	CMFD		
AB		75MG	A213221	003	Jun 22, 2020	May	CMFD		
<u>CLONIDINE</u>									
SYSTEM; TRANSDERMAL									
CATAPRES-TTS-1									
AB	+ LAVIPHARM	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan	CAHN		
AB	+ TECHNOMED	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan	CAHN		
CATAPRES-TTS-2									
AB	+ LAVIPHARM	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan	CAHN		
AB	+ TECHNOMED	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan	CAHN		
CATAPRES-TTS-3									
AB	+! LAVIPHARM	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan	CAHN		
AB	+! TECHNOMED	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan	CAHN		
<u>CLONIDINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
CLONIDINE HYDROCHLORIDE									
AP	! HIKMA FARMACEUTICA	5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Mar	CHRS		
	DURACLON								
	+ @ MYLAN INSTITUTIONAL	5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999	Mar	DISC		
TABLET; ORAL									
CATAPRES									
>D>	AB + BOEHRINGER INGELHEIM	0.1MG	N017407	001		Oct	DISC		
>A>	+ @	0.1MG	N017407	001		Oct	DISC		
>D>	AB +	0.2MG	N017407	002		Oct	DISC		

	TABLET;ORAL						
	CATAPRES						
>A>	+ @	0.2MG		N017407	002		Oct DISC
>D> AB	+!	0.3MG		N017407	003		Oct DISC
>A>	+ @	0.3MG		N017407	003		Oct DISC
	CLONIDINE HYDROCHLORIDE						
>D> AB	UNICHEM	0.3MG		A078895	003	Aug 26, 2009	Oct CHRS
>A> AB	!	0.3MG		A078895	003	Aug 26, 2009	Oct CHRS
	<u>CLOPIDOGREL BISULFATE</u>						
	TABLET;ORAL						
	CLOPIDOGREL BISULFATE						
AB	POLYGEN PHARMS	EQ 75MG BASE		A213351	001	Jul 17, 2020	Feb CMFD
AB		EQ 300MG BASE		A213351	002	Jul 17, 2020	Feb CMFD
AB	RISING	EQ 75MG BASE		A204359	001	Feb 02, 2017	Sep CAHN
	<u>CLORAZEPATE DIPOTASSIUM</u>						
	CAPSULE;ORAL						
	TRANXENE						
	+ @ RECORDATI RARE	3.75MG		N017105	001		May CRLD
	+ @	7.5MG		N017105	002		May CRLD
	+ @	15MG		N017105	003		May CRLD
	TABLET;ORAL						
	CLORAZEPATE DIPOTASSIUM						
AB	AUROLIFE PHARMA LLC	3.75MG		A071858	002	Jul 17, 1987	Jan CAHN
AB		7.5MG		A071858	003	Jul 17, 1987	Jan CAHN
AB	!	15MG		A071858	001	Jul 17, 1987	Jan CAHN
	TRANXENE						
	+ @ RECORDATI RARE	3.75MG		N017105	006		May CRLD
	TRANXENE SD						
	+ @ RECORDATI RARE	11.25MG		N017105	005		May CRLD
	+ @	22.5MG		N017105	004		May CRLD
	<u>CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>						
	SYRUP;ORAL						
	PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE						
AA	AKORN	10MG/5ML;5MG/5ML;6.25MG/5ML		A040674	001	Dec 23, 2014	Feb CAHN
	<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>						
	SYRUP;ORAL						
	PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE						
AA	+! ACTAVIS MID ATLANTIC	10MG/5ML;6.25MG/5ML		A088763	001	Oct 31, 1984	Aug CRLD
	<u>COLCHICINE</u>						
	TABLET;ORAL						
	COLCHICINE						
AB	HETERO LABS LTD V	0.6MG		A208993	001	Aug 13, 2021	Aug NEWA
AB	PAR PHARM INC	0.6MG		A203976	001	Aug 12, 2021	Aug NEWA
	<u>COLCHICINE; PROBENECID</u>						
	TABLET;ORAL						
	COL-PROBENECID						
AB	+! WATSON LABS	0.5MG;500MG		A084279	001		Aug CRLD
	<u>COLESEVELAM HYDROCHLORIDE</u>						
	FOR SUSPENSION;ORAL						
	COLESEVELAM HYDROCHLORIDE						
	GLENMARK PHARMS LTD	1.875GM/PACKET		A202190	001	Jul 16, 2018	Feb CTEC
	@ WATSON LABS INC	1.875GM/PACKET		A202178	001	Sep 01, 2020	Feb DISC
	@	3.75GM/PACKET		A202178	002	Sep 01, 2020	Feb DISC
	TABLET;ORAL						
	COLESEVELAM HYDROCHLORIDE						
>A> AB	BEIJING TIDE PHARM	625MG		A206036	001	Oct 14, 2021	Oct NEWA
	@ WATSON LABS INC	625MG		A200830	001	Sep 02, 2020	Feb DISC
	<u>COLESTIPOL HYDROCHLORIDE</u>						
	GRANULE;ORAL						
	COLESTID						
AB	+ PFIZER	5GM/SCOOPFUL		N017563	003	Sep 22, 1995	Feb CAHN
AB	+!	5GM/PACKET		N017563	004	Sep 22, 1995	Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

@	MYLAN PHARMS INC	5MG	A073144	002	Feb 03, 2006	Aug	DISC
@		7.5MG	A073144	003	Mar 25, 2013	Aug	DISC
@		10MG	A073144	001	May 30, 1991	Aug	DISC

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

AT		AKORN	2%	A040165	001	Jan 13, 1997	Aug	CMFD
		CYCLOGYL						
AT	+	ALCON LABS INC	0.5%	A084109	001		Aug	CRLD
AT	+		1%	A084110	001		Aug	CRLD
AT	+		2%	A084108	001		Aug	CRLD
AT	!		2%	A084108	001		Aug	CTEC

CYCLOPHOSPHAMIDE

SOLUTION; INTRAVENOUS

CYCLOPHOSPHAMIDE

>D>	+	AUROMEDICS PHARMA	500MG/2.5ML (200MG/ML)	N210735	001	Aug 25, 2021	Oct	CAHN
	+		500MG/2.5ML (200MG/ML)	N210735	001	Aug 25, 2021	Aug	NEWA
>D>	+		1GM/5ML (200MG/ML)	N210735	002	Aug 25, 2021	Oct	CAHN
	+		1GM/5ML (200MG/ML)	N210735	002	Aug 25, 2021	Aug	NEWA
>A>	+	EUGIA PHARMA SPECILTS	500MG/2.5ML (200MG/ML)	N210735	001	Aug 25, 2021	Oct	CAHN
>A>	+		1GM/5ML (200MG/ML)	N210735	002	Aug 25, 2021	Oct	CAHN

CYCLOSPORINE

EMULSION; OPHTHALMIC

VERKAZIA

+	SANTEN	0.1%	N214965	001	Jun 23, 2021	Jun	NEWA
---	--------	------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

CYCLOSPORINE

>A>	AP	HIKMA PHARMS	50MG/ML	A065004	001	Oct 29, 1999	Oct	CAHN
>D>	AP	WEST-WARD PHARMS INT	50MG/ML	A065004	001	Oct 29, 1999	Oct	CAHN

SOLUTION; OPHTHALMIC

CEQUA

>A>	+	SUN PHARM	0.09%	N210913	001	Aug 14, 2018	Oct	CAHN
>D>	+	SUN PHARMA GLOBAL	0.09%	N210913	001	Aug 14, 2018	Oct	CAHN

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

+	@	ACTAVIS MID ATLANTIC	2MG/5ML	A086833	001		Aug	CRLD
---	---	----------------------	---------	---------	-----	--	-----	------

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	+	HERITAGE PHARMA	4MG	A087056	001		Aug	CRLD
AA		QUAGEN	4MG	A212491	001	Feb 24, 2021	Feb	NEWA

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

+	HORIZON	EQ 25MG BASE	N203389	001	Apr 30, 2013	May	CAHN
+		EQ 75MG BASE	N203389	002	Apr 30, 2013	May	CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

@	HONG KONG	20MG/ML	A206189	001	Jun 26, 2020	Sep	DISC
@	MEITHEAL	20MG/ML	A206190	001	Nov 09, 2017	Aug	DISC
@	MYLAN LABS LTD	20MG/ML	A200914	001	Dec 13, 2011	May	DISC

DABIGATRAN ETEXILATE MESYLATE

PELLET; ORAL

PRADAXA

+	BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021	Jun	NEWA
+		EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021	Jun	NEWA
+		EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021	Jun	NEWA
+		EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021	Jun	NEWA
+		EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021	Jun	NEWA
+	!	EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021	Jun	NEWA

PELLETS; ORAL
PRADAXA

+	BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021	Jul	CDFR
+		EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021	Jul	CDFR
+		EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021	Jul	CDFR
+		EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021	Jul	CDFR
+		EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021	Jul	CDFR
+	!	EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021	Jul	CDFR

DACTINOMYCIN

INJECTABLE; INJECTION
DACTINOMYCIN

AP	AUROMEDICS PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CAHN
AP	EUGIA PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Aug	CAHN
	@ HIKMA PHARMS	0.5MG/VIAL	A090304	001	Mar 16, 2010	Jul	CAHN
AP	MEITHEAL	0.5MG/VIAL	A213463	001	Nov 13, 2020	Feb	CAHN

DAPSONE

TABLET; ORAL
DAPSONE

AB	ALVOGEN	25MG	A205429	001	Jan 07, 2016	Jun	CAHN
AB		100MG	A205429	002	Jan 07, 2016	Jun	CAHN
AB	+ JACOBUS	25MG	A086841	001		Aug	CRLD
AB	+	100MG	A086842	001		Aug	CRLD

DAPTOMYCIN

POWDER; INTRAVENOUS
DAPTOMYCIN

>D>	AP	HISUN PHARM HANGZHOU	500MG/VIAL	A212250	001	Apr 21, 2021	Oct	DISC
>A>		@	500MG/VIAL	A212250	001	Apr 21, 2021	Oct	DISC
	AP		500MG/VIAL	A212250	001	Apr 21, 2021	Apr	NEWA
	AP	HONG KONG	500MG/VIAL	A213623	001	Jun 29, 2021	Jun	NEWA
	+	HOSPIRA INC	350MG/VIAL	N210282	001	Jun 21, 2021	Jun	NEWA
>D>	AP		500MG/VIAL	A202857	001	Sep 12, 2014	Oct	DISC
>A>		@	500MG/VIAL	A202857	001	Sep 12, 2014	Oct	DISC
	+		500MG/VIAL	N210282	002	Jun 21, 2021	Jun	NEWA
	AP	MEITHEAL	500MG/VIAL	A213623	001	Jun 29, 2021	Aug	CAHN
	AP	QILU	500MG/VIAL	A215316	001	Aug 24, 2021	Aug	NEWA

POWDER; IV (INFUSION)
DAPTOMYCIN

>D>		@ DR REDDYS	350MG/VIAL	A211403	001	Aug 31, 2020	Oct	CMFD
>A>	AP		350MG/VIAL	A211403	001	Aug 31, 2020	Oct	CMFD
		@	350MG/VIAL	A211403	001	Aug 31, 2020	May	DISC
	AP	HONG KONG	350MG/VIAL	A213786	001	Jun 29, 2021	Jun	NEWA
	AP	MEITHEAL	350MG/VIAL	A213786	001	Jun 29, 2021	Aug	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
DARIFENACIN HYDROBROMIDE

	@ JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016	Jun	DISC
	@	EQ 15MG BASE	A205550	002	Oct 12, 2016	Jun	DISC
BX	XIROMED	EQ 7.5MG BASE	A209571	002	Oct 22, 2019	Sep	CTEC
BX		EQ 15MG BASE	A209571	001	Oct 22, 2019	Sep	CTEC

DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR

TABLET; ORAL
VIEKIRA PAK (COPACKAGED)

+	@ ABBVIE INC	EQ 250MG BASE; 12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Sep	DISC
+	!	EQ 250MG BASE; 12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Aug	CPOT

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET; ORAL
VIEKIRA PAK (COPACKAGED)

+	!	ABBVIE INC	250.0MG; 12.5MG; 75.0MG; EQ 250MG	N206619	001	Dec 19, 2014	Aug	CDFR
			BASE, N/A, N/A, N/A;					
			N/A, 12.5MG, 75MG, 50MG					

DASIGLUCAGON HYDROCHLORIDESOLUTION; SUBCUTANEOUS
ZEGALOGUE

+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	May	CAHN
+!		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Mar	NEWA
ZEGALOGUE (AUTOINJECTOR)							
+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	May	CAHN
+!		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Mar	NEWA

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
CERUBIDINE

>A>	AP	!	HIKMA PHARMS	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Oct	CAHN
>D>	AP	!	WEST-WARD PHARMS INT	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Oct	CAHN
DAUNORUBICIN HYDROCHLORIDE									
	AP	+!	HIKMA PHARMS	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Jul	CAHN

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

		@	APOTEX	50MG/VIAL	A205539	001	Nov 23, 2020	May	DISC
		@	CIPLA	50MG/VIAL	A208601	001	Nov 16, 2017	May	DISC
	AP		EUGIA PHARMA	50MG/VIAL	A214569	001	Sep 20, 2021	Sep	NEWA
	AP		GLAND	50MG/VIAL	A205539	001	Nov 23, 2020	Jul	CMFD
		@		50MG/VIAL	A205539	001	Nov 23, 2020	Jul	CAHN
	AP		HONG KONG	50MG/VIAL	A212959	001	Jul 02, 2021	Jun	NEWA
	AP		MEITHEAL	50MG/VIAL	A212959	001	Jul 02, 2021	Sep	CAHN
	AP		QILU	50MG/VIAL	A212826	001	Apr 12, 2021	Apr	NEWA

DEFERASIROXGRANULE; ORAL
DEFERASIROX

	AB		AMNEAL	90MG	A214194	003	Aug 02, 2021	Jul	NEWA
	AB			180MG	A214194	001	Feb 09, 2021	Jan	NEWA
	AB			360MG	A214194	002	Feb 09, 2021	Jan	NEWA
	AB		AUCTA	90MG	A214559	001	Mar 09, 2021	Feb	NEWA
	AB			180MG	A214559	002	Mar 09, 2021	Feb	NEWA
	AB			360MG	A214559	003	Mar 09, 2021	Feb	NEWA
	AB		MSN	180MG	A214650	001	Mar 17, 2021	Mar	NEWA
	AB			360MG	A214650	002	Mar 17, 2021	Mar	NEWA

TABLET; ORAL

DEFERASIROX

	AB		ANNORA PHARMA	90MG	A214341	001	May 14, 2021	May	NEWA
	AB			180MG	A214341	002	May 14, 2021	May	NEWA
	AB			360MG	A214341	003	May 14, 2021	May	NEWA
	AB		CELLTRION	90MG	A212669	001	May 27, 2021	May	NEWA
	AB			180MG	A212669	002	May 27, 2021	May	NEWA
	AB			360MG	A212669	003	May 27, 2021	May	NEWA

DEFERIPRONESOLUTION; ORAL
FERRIPROX

		+	@	CHIESI	80MG/ML	N208030	002	Apr 20, 2018	Aug	DISC
--	--	---	---	--------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

DEFERIPRONE

	AB		HIKMA PHARMS	500MG	A213239	001	Mar 29, 2021	Mar	NEWA
	AB	+!	CHIESI	500MG	N021825	001	Oct 14, 2011	Mar	CTEC

DEOXYCHOLIC ACIDSOLUTION; SUBCUTANEOUS
DEOXYCHOLIC ACID

	AP		SLAYBACK PHARMA LLC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Mar	NFTG
	AP	+!	KYBELLA						
	AP	+!	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Mar	CFTG

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	10MG	A209785	001	Jul 07, 2021	Jun	NEWA
AB			25MG	A209785	002	Jul 07, 2021	Jun	NEWA
AB			50MG	A209785	003	Jul 07, 2021	Jun	NEWA
AB			75MG	A209785	004	Jul 07, 2021	Jun	NEWA
AB			100MG	A209785	005	Jul 07, 2021	Jun	NEWA
AB			150MG	A209785	006	Jul 07, 2021	Jun	NEWA

NORPRAMIN

AB	+	VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Feb	CAHN
AB	+		25MG	N014399	001		Feb	CAHN
AB	+		50MG	N014399	003		Feb	CAHN
AB	+		75MG	N014399	004		Feb	CAHN
AB	+		100MG	N014399	005		Feb	CAHN
AB	+		150MG	N014399	006		Feb	CAHN

DESLORATADINE

TABLET; ORAL

CLARINEX

AB	+	ORGANON	5MG	N021165	001	Dec 21, 2001	Aug	CAHN
		DESCLORATADINE						
		@ SUN PHARM INDS	5MG	A078359	001	Nov 16, 2010	Aug	DISC

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX-D 12 HOUR

+	!	ORGANON	2.5MG;120MG	N021313	001	Feb 01, 2006	Jun	CAHN
---	---	---------	-------------	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

NOCTIVA

+	@	ROIVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Feb	CAHN
+	@		0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Feb	CAHN
+	@	SERENITY PHARMS LLC	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Sep	CAHN
+	@		0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Sep	CAHN

DESONIDE

GEL; TOPICAL

DESONATE

+	@	LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006	Mar	DISC
!		CINTEX SVCS	0.05%	A202470	001	May 11, 2020	Mar	CHRS
			0.05%	A202470	001	May 11, 2020	Mar	CTEC

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

@ AKORN 0.05%

@ 0.25%

OINTMENT; TOPICAL

DESOXIMETASONE

AB	!	GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013	Apr	CHRS
		TOPICORT						
		@ TARO PHARM INDS LTD	0.25%	A074286	001	Jun 07, 1996	Apr	DISC

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	+	WOCKHARDT BIO AG	0.5MG/5ML	A088254	001	Jul 27, 1983	Aug	CRLD
----	---	------------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

DEXAMETHASONE

BP		ALVOGEN	0.5MG	A088481	002	Apr 28, 1983	Jun	CAHN
BP			0.75MG	A088481	003	Apr 28, 1983	Jun	CAHN
BP			4MG	A088481	004	Apr 28, 1983	Jun	CAHN
BP			6MG	A088481	001	Nov 28, 1983	Jun	CAHN
>A>	AB	AMNEAL	4MG	A215106	001	Oct 14, 2021	Oct	CTEC
>A>	AB		6MG	A215106	002	Oct 14, 2021	Oct	NEWA
>D>	BP	HIKMA	4MG	A084612	001		Oct	CTEC
BP	!	HIKMA PHARMS	1MG	A088306	001	Sep 15, 1983	Apr	CHRS
>A>	AB		4MG	A084612	001		Oct	CTEC

TABLET;ORAL

DEXAMETHASONE

>D>	BP	!	6MG	A088316	001	Sep 15, 1983	Oct	CTEC
>A>	AB	!	6MG	A088316	001	Sep 15, 1983	Oct	CTEC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		GLAND PHARMA LTD	EQ 4MG PHOSPHATE/ML	A215654	001	Aug 04, 2021	Jul	NEWA
		+ @ LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982	Aug	CRLD

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRAMYCIN AND DEXAMETHASONE

AB		AMNEAL	0.1%;0.3%	A212991	001	Jul 15, 2021	Jul	NEWA
----	--	--------	-----------	---------	-----	--------------	-----	------

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

AA		+! WOCKHARDT BIO AG	2MG/5ML	A088251	001	Mar 23, 1984	Aug	CRLD
----	--	---------------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

POLARAMINE

		+ @ SCHERING	2MG	A086835	001		Aug	CRLD
--	--	--------------	-----	---------	-----	--	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		GLAND	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	May	CAHN
AP		HIKMA PHARMS	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205046	001	Apr 26, 2017	Jul	CAHN
AP		HONG KONG	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jun	CMFD
AP		PIRAMAL CRITICAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A214794	001	Sep 03, 2021	Aug	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

		@ MYLAN	5MG	A204266	001	Aug 25, 2015	Jul	DISC
		@	10MG	A204266	002	Aug 25, 2015	Jul	DISC
		@	15MG	A204266	003	Aug 25, 2015	Jul	DISC
		@	20MG	A204266	004	Dec 21, 2015	Jul	DISC
		@	25MG	A204266	005	May 04, 2021	Jul	DISC
AB		@	25MG	A204266	005	May 04, 2021	Apr	NEWA
		@	30MG	A202580	001	Aug 28, 2013	Jul	CAHN
		@	30MG	A202580	001	Aug 28, 2013	Jul	DISC
		@	35MG	A204266	006	May 04, 2021	Jul	DISC
AB		@	35MG	A204266	006	May 04, 2021	Apr	NEWA
		@	40MG	A204266	007	Aug 25, 2015	Jul	DISC
>A>	AB	SUN PHARM INDS INC	5MG	A206734	001	Nov 05, 2021	Oct	NEWA
>A>	AB		10MG	A206734	002	Nov 05, 2021	Oct	NEWA
>A>	AB		15MG	A206734	003	Nov 05, 2021	Oct	NEWA
>A>	AB		20MG	A206734	004	Nov 05, 2021	Oct	NEWA
>A>	AB		25MG	A206734	005	Nov 05, 2021	Oct	NEWA
>A>	AB		30MG	A206734	006	Nov 05, 2021	Oct	NEWA
>A>	AB		35MG	A206734	007	Nov 05, 2021	Oct	NEWA
>A>	AB		40MG	A206734	008	Nov 05, 2021	Oct	NEWA

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

		@ BIONPHARMA INC	5MG	A209754	001	Mar 24, 2020	Sep	CAHN
		@	10MG	A209754	002	Mar 24, 2020	Sep	CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE;ORAL

AZSTARYS

		+ COMMAVE THERAP	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021	May	NEWA
		+	EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021	May	NEWA
		+!	EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021	May	NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP	AUROMEDICS PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Jan	CAHN
AP	! EUGIA PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Aug	CHRS
AP		EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Aug	CAHN
AP	!	EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Aug	CHRS
AP		EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Aug	CAHN
	TOTECT						
	+ @ CLINIGEN	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Aug	DISC
	ZINECARD						
	+ @ PFIZER	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Aug	DISC
AP	+	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Mar	CAHN
	+ @	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Aug	DISC
AP	+	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Mar	CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	May	CTEC
AA		7.5MG	A090533	003	Oct 25, 2011	May	CTEC
AA		15MG	A090533	005	Oct 25, 2011	May	CTEC
AA		20MG	A090533	006	Oct 25, 2011	May	CTEC
AA		30MG	A090533	007	Oct 25, 2011	May	CTEC
AA	WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	May	NEWA
AA		5MG	A212160	002	Jun 07, 2021	May	NEWA
AA		7.5MG	A212160	003	Jun 07, 2021	May	NEWA
AA		10MG	A212160	004	Jun 07, 2021	May	NEWA
AA		15MG	A212160	005	Jun 07, 2021	May	NEWA
AA		20MG	A212160	006	Jun 07, 2021	May	NEWA
AA		30MG	A212160	007	Jun 07, 2021	May	NEWA
	DEXTROSTAT						
	+ @ SHIRE	5MG	A084051	001		Aug	CRLD
	+ @	10MG	A084051	002		Aug	CRLD

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 50%

AP	+ HOSPIRA	500MG/ML	N019445	001	Jun 03, 1986	Mar	CFTG
AP	INTL MEDICATION SYS	500MG/ML	A203451	001	Mar 26, 2021	Mar	CFTG

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

@ FRESENIUS KABI USA 5GM/100ML; 75MG/100ML

A212346 001 Sep 10, 2020 Mar DISC

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%

@ FRESENIUS KABI USA 5GM/100ML; 150MG/100ML

A212346 002 Sep 10, 2020 Mar DISC

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5GM/100ML; 224MG/100ML

N017634 003 Mar CTEC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ FRESENIUS KABI USA 5GM/100ML; 149MG/100ML; 225MG/100ML

A212348 001 Jul 30, 2021 Sep DISC

5GM/100ML; 149MG/100ML; 225MG/100ML

A212348 001 Jul 30, 2021 Jul NFTG

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

@ FRESENIUS KABI USA 5GM/100ML; 74.5MG/100ML; 450MG/100ML

A213523 001 Mar 09, 2021 Sep DISC

5GM/100ML; 74.5MG/100ML; 450MG/100ML

A213523 001 Mar 09, 2021 Feb NEWA

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ FRESENIUS KABI USA 5GM/100ML; 149MG/100ML; 225MG/100ML

A212348 002 Jul 30, 2021 Sep DISC

5GM/100ML; 149MG/100ML; 225MG/100ML

A212348 002 Jul 30, 2021 Jul NFTG

+ ICU MEDICAL INC

5GM/100ML; 149MG/100ML; 225MG/100ML

N018365 001 Sep CTEC

+ ICU MEDICAL INC

5GM/100ML; 149MG/100ML; 225MG/100ML

N018365 001 Jul CFTG

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

@ FRESENIUS KABI USA 5GM/100ML; 149MG/100ML; 450MG/100ML

A213523 002 Mar 09, 2021 Sep DISC

5GM/100ML; 149MG/100ML; 450MG/100ML

A213523 002 Mar 09, 2021 Feb NEWA

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

@ FRESENIUS KABI USA 5GM/100ML; 149MG/100ML; 900MG/100ML

A213445 001 Mar 09, 2021 Sep DISC

5GM/100ML; 149MG/100ML; 900MG/100ML

A213445 001 Mar 09, 2021 Feb NFTG

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	@ FRESenius KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Sep	DISC	
		5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Feb	NEWA	
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	@ FRESenius KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Sep	DISC	
		5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Feb	NEWA	
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP	@ FRESenius KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Sep	DISC	
		5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Feb	NFTG	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	FRESenius KABI USA	2.5GM/100ML;450MG/100ML	A211190	001	Dec 20, 2019	May	CMFD	
		DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
AP	FRESenius KABI USA	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	May	CMFD	
	@	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	Feb	DISC	
AP	+! ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001		May	CTEC	
	+!	5GM/100ML;300MG/100ML	N017799	001		Feb	CTEC	
		DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
AP	FRESenius KABI USA	5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	May	CMFD	
	@	5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	Mar	DISC	
		DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
AP	FRESenius KABI USA	5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	May	CMFD	
	@	5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	Mar	DISC	

DIAZEPAM

INJECTABLE; INJECTION

		DIAZEPAM						
AP	! BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Aug	CTEC	

DICLOFENAC POTASSIUM

CAPSULE; ORAL

		DICLOFENAC POTASSIUM						
>A>	AB AUROBINDO PHARMA LTD	25MG	A213875	001	Oct 19, 2021	Oct	NEWA	
		TABLET; ORAL						
		CATAFLAM						
AB	AMICI	25MG	A076561	002	Jul 21, 2021	Sep	CTEC	
		25MG	A076561	002	Jul 21, 2021	Jul	NEWA	
AB		50MG	A076561	001	Mar 18, 2004	May	CTNA	
		DICLOFENAC POTASSIUM						
>A>	AB RICONPHARMA LLC	50MG	A215585	001	Oct 08, 2021	Oct	NEWA	
AB	RUBICON	25MG	A075229	002	Sep 16, 2021	Sep	NEWA	

DICLOFENAC SODIUM

GEL; TOPICAL

		DICLOFENAC SODIUM						
AB	! TARO	3%	A206298	001	Apr 28, 2016	Mar	CHRS	
		SOLARAZE						
	+ @ FOUGERA PHARMS	3%	N021005	001	Oct 16, 2000	Mar	DISC	
		SOLUTION; TOPICAL						
		DICLOFENAC SODIUM						
AT	AKORN	1.5%	A206655	001	Jan 28, 2021	Jan	NEWA	
	@ RISING	1.5%	A206715	001	Aug 07, 2017	May	CAHN	
		SOLUTION/DROPS; OPHTHALMIC						
		DICLOFENAC SODIUM						
AT	! BAUSCH AND LOMB	0.1%	A078792	001	Dec 28, 2007	Aug	CHRS	
		VOLTAREN						
	+ @ NOVARTIS	0.1%	N020037	001	Mar 28, 1991	Aug	DISC	
		TABLET, DELAYED RELEASE; ORAL						
		DICLOFENAC SODIUM						
	@ MICRO LABS	50MG	A074986	001	Feb 26, 1999	Feb	CAHN	
	@	75MG	A074986	002	Feb 26, 1999	Feb	CAHN	

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

		DICLOFENAC SODIUM AND MISOPROSTOL						
AB	MICRO LABS	50MG;0.2MG	A204355	001	Jul 15, 2021	Jul	NEWA	
AB		75MG;0.2MG	A204355	002	Jul 15, 2021	Jul	NEWA	

DICLOXACILLIN SODIUM

	CAPSULE; ORAL						
	DICLOXACILLIN SODIUM						
	@ SANDOZ	EQ 125MG BASE	A 061454	002		Jan	DISC
	@	EQ 250MG BASE	A 061454	001		Jan	DISC
	@	EQ 500MG BASE	A 061454	003		Jan	DISC
	TEVA	EQ 250MG BASE	A 062286	001	Jun 03, 1982	Jan	CTEC
	!	EQ 500MG BASE	A 062286	002	Jun 03, 1982	Jan	CTEC
AB	!	EQ 500MG BASE	A 062286	002	Jun 03, 1982	Jan	CHRS

DICYCLOMINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	DICYCLOMINE HYDROCHLORIDE						
AP	GENE YORK PHARMS	10MG/ML	A 212058	001	Apr 26, 2019	Sep	CAHN
AP	PRAXGEN	10MG/ML	A 212058	001	Apr 26, 2019	Jun	CAHN
	SYRUP; ORAL						
	DICYCLOMINE HYDROCHLORIDE						
AA	NOVITIUM PHARMA	10MG/5ML	A 214721	001	Apr 23, 2021	Apr	NEWA
	TABLET; ORAL						
	DICYCLOMINE HYDROCHLORIDE						
	@ MYLAN	20MG	A 040317	001	Sep 07, 1999	Aug	DISC

DIDANOSINE

	CAPSULE, DELAYED REL PELLETS; ORAL						
	DIDANOSINE						
	@ AUROBINDO PHARMA	125MG	A 090094	001	Sep 24, 2008	Jan	DISC
	@	200MG	A 090094	002	Sep 24, 2008	Jan	DISC
	@	250MG	A 090094	003	Sep 24, 2008	Jan	DISC
	@	400MG	A 090094	004	Sep 24, 2008	Jan	DISC

DIFELIKEFALIN ACETATE

	SOLUTION; INTRAVENOUS						
	KORSUVA						
	+! CARA THERAP	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N 214916	001	Aug 23, 2021	Aug	NEWA

DIFLORASONE DIACETATE

	CREAM; TOPICAL						
	DIFLORASONE DIACETATE						
BX	! ANI PHARMS	0.05%	A 076263	001	Dec 20, 2002	Apr	CAHN
	OINTMENT; TOPICAL						
	DIFLORASONE DIACETATE						
	@ AKORN	0.05%	A 206572	001	Jul 24, 2015	Apr	DISC

DIFLUNISAL

	TABLET; ORAL						
	DIFLUNISAL						
	@ DASTECH INTL	250MG	A 073562	001	Nov 27, 1992	Sep	CAHN
	@	500MG	A 073563	001	Nov 27, 1992	Sep	CAHN

DIFLUPREDNATE

	EMULSION; OPHTHALMIC						
	DIFLUPREDNATE						
AB	CIPLA	0.05%	A 211776	001	Aug 09, 2021	Jul	NFTG
	DUREZOL						
AB	+! NOVARTIS	0.05%	N 022212	001	Jun 23, 2008	Jul	CFTG

DIGOXIN

	ELIXIR; ORAL						
	DIGOXIN						
AA	NOVITIUM PHARMA	0.05MG/ML	A 213000	001	Oct 04, 2019	Sep	CAHN

DIHYDROERGOTAMINE MESYLATE

	INJECTABLE; INJECTION						
	DIHYDROERGOTAMINE MESYLATE						
AP	PROVEPHARM SAS	1MG/ML	A 212046	001	Jan 07, 2020	Jan	CAHN
	SPRAY, METERED; NASAL						
	TRUDHESA						
	+! IMPEL NEUROPHARMA	0.725MG/SPRAY	N 213436	001	Sep 02, 2021	Sep	NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB1	GLENMARK PHARMS LTD	60MG	A212317	001	Mar 22, 2021	Mar	NEWA
AB1		90MG	A212317	002	Mar 22, 2021	Mar	NEWA
AB1		120MG	A212317	003	Mar 22, 2021	Mar	NEWA
AB1	MYLAN	60MG	A074910	001	May 02, 1997	Mar	CTEC
AB1		90MG	A074910	002	May 02, 1997	Mar	CTEC
AB1	!	120MG	A074910	003	May 02, 1997	Mar	CTEC

INJECTABLE; INJECTION
DILTIAZEM HYDROCHLORIDE

	@ INTL MEDICATION	5MG/ML	A075749	001	Nov 21, 2001	Jan	DISC	
>A>	SOLUTION; INTRAVENOUS							
>A>	DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%							
>A>	+!	EXELA PHARMA	125MG/125ML (1MG/ML)	N215252	001	Oct 28, 2021	Oct	NEWA
>A>	+!		250MG/250ML (1MG/ML)	N215252	002	Oct 28, 2021	Oct	NEWA

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

	@ MYLAN	30MG	A072838	004	Nov 05, 1992	Aug	CAHN
	@	30MG	A072838	004	Nov 05, 1992	Aug	DISC
	@	60MG	A072838	003	Nov 05, 1992	Aug	CAHN
	@	60MG	A072838	003	Nov 05, 1992	Aug	DISC
	@	90MG	A072838	002	Nov 05, 1992	Aug	CAHN
	@	90MG	A072838	002	Nov 05, 1992	Aug	DISC
	@	120MG	A072838	001	Nov 05, 1992	Aug	CAHN
	@	120MG	A072838	001	Nov 05, 1992	Aug	DISC

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

	+ @ WATSON LABS TEVA	50MG/ML	A080615	001		Aug	CRLD
--	----------------------	---------	---------	-----	--	-----	------

TABLET; ORAL

DIMENHYDRINATE

	+ @ WATSON LABS	50MG	A085166	001		Aug	CRLD
--	-----------------	------	---------	-----	--	-----	------

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

AB	LUPIN	120MG	A210226	001	Oct 05, 2020	Jul	CAHN
AB		240MG	A210226	002	Oct 05, 2020	Jul	CAHN
AB	PHARMATHEN	120MG	A210436	001	Mar 26, 2021	Mar	NEWA
AB		240MG	A210436	002	Mar 26, 2021	Mar	NEWA
	@ ZYDUS PHARMS	120MG	A210538	001	Sep 24, 2020	Feb	DISC
	@	240MG	A210538	002	Sep 24, 2020	Feb	DISC
	TECFIDERA						
AB	+ BIOGEN INC	120MG	N204063	001	Mar 27, 2013	Apr	CAHN
AB	+!	240MG	N204063	002	Mar 27, 2013	Apr	CAHN

DINOPROSTONE

GEL; ENDOCERVICAL
PREPIDIL

	+! PFIZER	0.5MG/3GM	N019617	001	Dec 09, 1992	Jan	CAHN
--	-----------	-----------	---------	-----	--------------	-----	------

>D> SUPPOSITORY; VAGINAL
>D> PROSTIN E2

>D>	+!	PFIZER	20MG	N017810	001		Oct	DISC
>A>	+ @		20MG	N017810	001		Oct	DISC
	+!		20MG	N017810	001		Jan	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP	+!	WEST-WARD PHARMS INT	50MG/ML	A080817	002		Aug	CRLD
----	----	----------------------	---------	---------	-----	--	-----	------

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB	OXFORD PHARMS	25MG	A040542	001	Apr 21, 2006	Jan	CMFD
AB		50MG	A040542	002	Apr 21, 2006	Jan	CMFD
AB		75MG	A040542	003	Apr 21, 2006	Jan	CMFD

DIROXIMEL FUMARATECAPSULE, DELAYED RELEASE;ORAL
VUMERITY

+! BIOGEN INC 231MG N211855 001 Oct 29, 2019 Apr CAHN

DISOPYRAMIDE PHOSPHATECAPSULE;ORAL
DISOPYRAMIDE PHOSPHATE@ MAYNE PHARMA EQ 100MG BASE A070173 001 May 31, 1985 Feb DISC
@ EQ 150MG BASE A070173 002 May 31, 1985 Feb DISCDISULFIRAMTABLET;ORAL
ANTABUSE+ @ ODYSSEY PHARMS 250MG A088482 001 Dec 08, 1983 Sep DISC
AB + 250MG A088482 001 Dec 08, 1983 Aug CRLD
+ @ 500MG A088483 001 Dec 08, 1983 Sep DISC
AB +! 500MG A088483 001 Dec 08, 1983 Aug CRLD
DISULFIRAM
AB ! HIKMA PHARMS 500MG A202652 002 Feb 05, 2014 Sep CHRSDIVALPROEX SODIUMCAPSULE, DELAYED REL PELLETS;ORAL
DIVALPROEX SODIUM

@ TEVA PHARMS USA EQ 125MG VALPROIC ACID A211505 001 Nov 17, 2020 May DISC

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

@ ANCHEN PHARMS EQ 500MG VALPROIC ACID A078411 001 Nov 03, 2008 May DISC

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM@ AMTA EQ 250MG VALPROIC ACID A214462 001 Mar 15, 2021 Sep DISC
AB EQ 250MG VALPROIC ACID A214462 001 Mar 15, 2021 Mar NEWA
@ EQ 500MG VALPROIC ACID A214462 002 Mar 15, 2021 Sep DISC
AB EQ 500MG VALPROIC ACID A214462 002 Mar 15, 2021 Mar NEWADOCETAXELINJECTABLE;INJECTION
DOCETAXELAP EUGIA PHARMA 20MG/2ML (10MG/ML) A214575 001 Jun 25, 2021 Jun NEWA
AP 80MG/8ML (10MG/ML) A214575 002 Jun 25, 2021 Jun NEWA
AP 160MG/16ML (10MG/ML) A214575 003 Jun 25, 2021 Jun NEWA
AP GLAND PHARMA LTD 20MG/2ML (10MG/ML) A213510 001 Jul 01, 2021 Jun NEWA
AP 80MG/8ML (10MG/ML) A213510 002 Jul 01, 2021 Jun NEWA
AP 160MG/16ML (10MG/ML) A213510 003 Jul 01, 2021 Jun NEWA
AP HIKMA 20MG/ML (20MG/ML) A204490 001 Jan 14, 2021 Jan NEWA
AP 80MG/4ML (20MG/ML) A204490 002 Jan 14, 2021 Jan NEWA
AP HONG KONG 20MG/2ML (10MG/ML) A209634 001 Aug 24, 2018 Jun CMFD
AP 80MG/8ML (10MG/ML) A209634 002 Aug 24, 2018 Jun CMFD
AP 160MG/16ML (10MG/ML) A209634 003 Aug 24, 2018 Jun CMFD
AP @ INGENUS PHARMS LLC 20MG/2ML (10MG/ML) A207563 001 Aug 31, 2017 Apr DISC
AP +! SHILPA 20MG/ML (20MG/ML) N205934 001 Dec 22, 2015 Apr CHRS
AP + 20MG/ML (20MG/ML) N205934 001 Dec 22, 2015 Apr CRLD
AP 20MG/ML (20MG/ML) N205934 001 Dec 22, 2015 Jan CAHN
AP +! 80MG/4ML (20MG/ML) N205934 002 Dec 22, 2015 Apr CHRS
AP + 80MG/4ML (20MG/ML) N205934 002 Dec 22, 2015 Apr CRLD
AP 80MG/4ML (20MG/ML) N205934 002 Dec 22, 2015 Jan CAHN
AP +! 160MG/8ML (20MG/ML) N205934 003 Dec 22, 2015 Apr CHRS
AP + 160MG/8ML (20MG/ML) N205934 003 Dec 22, 2015 Apr CRLD
AP 160MG/8ML (20MG/ML) N205934 003 Dec 22, 2015 Jan CAHNDOFETILIDECAPSULE;ORAL
DOFETILIDE>A> AB GRANULES 0.125MG A212750 001 Oct 14, 2021 Oct NEWA
>A> AB 0.25MG A212750 002 Oct 14, 2021 Oct NEWA
>A> AB 0.5MG A212750 003 Oct 14, 2021 Oct NEWA
@ NOVAST LABS 0.125MG A212410 001 Dec 27, 2019 Sep CAHN
@ 0.25MG A212410 002 Dec 27, 2019 Sep CAHN
@ 0.5MG A212410 003 Dec 27, 2019 Sep CAHN
@ RICONPHARMA LLC 0.125MG A212410 001 Dec 27, 2019 Feb DISC
@ 0.25MG A212410 002 Dec 27, 2019 Feb DISC

CAPSULE;ORAL
DOFETILIDE

@ 0.5MG A212410 003 Dec 27, 2019 Feb DISC

DOLASETRON MESYLATE

INJECTABLE;INJECTION
ANZEMET

+ @ VALIDUS PHARMS 12.5MG/0.625ML (20MG/ML) N020624 002 Sep 11, 1997 Feb CAHN
+ @ 100MG/5ML (20MG/ML) N020624 001 Sep 11, 1997 Feb CAHN
@ 500MG/25ML (20MG/ML) N020624 003 Dec 11, 2001 Feb CAHN

TABLET;ORAL
ANZEMET

+ @ VALIDUS PHARMS 50MG N020623 001 Sep 11, 1997 Feb CAHN
+ @ 100MG N020623 002 Sep 11, 1997 Feb CAHN

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

>D> AB MYLAN 23MG A202656 001 Oct 22, 2015 Oct DISC
>A> @ 23MG A202656 001 Oct 22, 2015 Oct DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT ALEMBIC PHARMS LTD EQ 2% BASE;EQ 0.5% BASE A213099 001 May 04, 2021 Apr NEWA
AT FDC LTD EQ 2% BASE;EQ 0.5% BASE A205295 001 Jun 13, 2019 Feb CMFD

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION
DOPRAM

AP +! HIKMA PHARMS 20MG/ML N014879 001 Jul CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL
DOXAZOSIN MESYLATE

BX HERITAGE PHARMA EQ 1MG BASE A205210 001 Feb 13, 2018 Sep CTEC
BX EQ 2MG BASE A205210 002 Feb 13, 2018 Sep CTEC
BX EQ 4MG BASE A205210 003 Feb 13, 2018 Sep CTEC
BX EQ 8MG BASE A205210 004 Feb 13, 2018 Sep CTEC
@ MYLAN EQ 1MG BASE A075509 001 Oct 19, 2000 Jul DISC
@ EQ 2MG BASE A075509 002 Oct 19, 2000 Jul DISC
@ EQ 4MG BASE A075509 003 Oct 19, 2000 Jul DISC
@ EQ 8MG BASE A075509 004 Oct 19, 2000 Jul DISC

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL
DOXEPIIN HYDROCHLORIDE

AB ALEMBIC PHARMS LTD EQ 10MG BASE A215076 001 Apr 21, 2021 Apr NEWA
AB EQ 25MG BASE A215076 002 Apr 21, 2021 Apr NEWA
AB EQ 50MG BASE A215076 003 Apr 21, 2021 Apr NEWA
AB EQ 75MG BASE A215076 004 Apr 21, 2021 Apr NEWA
AB EQ 100MG BASE A215076 005 Apr 21, 2021 Apr NEWA
AB APPCO EQ 10MG BASE A214908 001 Apr 01, 2021 Mar NEWA
AB EQ 25MG BASE A214908 002 Apr 01, 2021 Mar NEWA
AB EQ 50MG BASE A214908 003 Apr 01, 2021 Mar NEWA
AB EQ 75MG BASE A214908 004 Apr 01, 2021 Mar NEWA
AB EQ 100MG BASE A214908 005 Apr 01, 2021 Mar NEWA
@ CHARTWELL RX EQ 10MG BASE A210268 001 Sep 04, 2020 Aug CAHN
@ EQ 25MG BASE A210268 002 Sep 04, 2020 Aug CAHN
@ EQ 50MG BASE A210268 003 Sep 04, 2020 Aug CAHN
@ EQ 75MG BASE A210268 004 Sep 04, 2020 Aug CAHN
@ EQ 100MG BASE A210268 005 Sep 04, 2020 Aug CAHN
AB LEADING PHARMA LLC EQ 10MG BASE A211619 001 Mar 09, 2021 Feb NEWA
AB EQ 25MG BASE A211619 002 Mar 09, 2021 Feb NEWA
AB EQ 50MG BASE A211619 003 Mar 09, 2021 Feb NEWA
AB EQ 75MG BASE A211619 004 Mar 09, 2021 Feb NEWA
AB EQ 100MG BASE A211619 005 Mar 09, 2021 Feb NEWA
AB EQ 150MG BASE A211618 001 Mar 01, 2021 Feb NEWA
@ UPSHER SMITH LABS EQ 10MG BASE A210268 001 Sep 04, 2020 May CAHN
@ EQ 10MG BASE A210268 001 Sep 04, 2020 Feb DISC
@ EQ 25MG BASE A210268 002 Sep 04, 2020 May CAHN
@ EQ 25MG BASE A210268 002 Sep 04, 2020 Feb DISC

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

@	EQ 50MG BASE	A210268	003	Sep 04, 2020	May CAHN
@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Feb DISC
@	EQ 75MG BASE	A210268	004	Sep 04, 2020	May CAHN
@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Feb DISC
@	EQ 100MG BASE	A210268	005	Sep 04, 2020	May CAHN
@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Feb DISC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB	RK PHARMA	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan CAHN
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

@	SUN PHARM	2MCG/ML (2MCG/ML)	A203875	001	Nov 14, 2019	Aug DISC
@		4MCG/2ML (2MCG/ML)	A203875	002	Nov 14, 2019	Aug DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

@	ALMAJECT	2MG/ML	A065515	001	Nov 08, 2012	Jul CAHN
>A> AP	HIKMA PHARMS	200MG/100ML	A064097	001	Sep 13, 1994	Oct CAHN
>D> AP	WEST-WARD PHARMS INT	200MG/100ML	A064097	001	Sep 13, 1994	Oct CAHN

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE

>A> AB	AYANA PHARMA LTD	20MG/10ML (2MG/ML)	A207228	001	Oct 12, 2021	Oct NEWA
>A> AB		50MG/25ML (2MG/ML)	A207228	002	Oct 12, 2021	Oct NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

@	MYLAN	EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan DISC	
AB		EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan NEWA	
@		EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan DISC	
AB		EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan NEWA	
@		EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan DISC	
AB		EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan NEWA	
AB	+	CHARTWELL RX	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jun CMFD
AB	+		EQ 75MG BASE	N050641	003	Oct 18, 2006	Jun CMFD
AB	+		EQ 100MG BASE	N050641	001	Dec 29, 1989	Jun CMFD

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB	CHARTWELL	EQ 25MG BASE/5ML	A065454	001	Jul 16, 2008	Jun CAHN
----	-----------	------------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB	CHARTWELL	EQ 50MG BASE	A062500	001	Sep 11, 1984	Jun CAHN
AB		EQ 100MG BASE	A062500	002	Sep 11, 1984	Jun CAHN
@	NOSTRUM LABS INC	EQ 50MG BASE	A209393	001	Dec 10, 2020	Jul DISC
@		EQ 100MG BASE	A209393	002	Dec 10, 2020	Jul DISC

CAPSULE, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

@	BAUSCH	EQ 75MG BASE	A065281	001	Dec 21, 2005	May CAHN
@		EQ 100MG BASE	A065281	002	Dec 21, 2005	May CAHN

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

AP	WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	May CMFD
AP		EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	May CMFD

SYSTEM, EXTENDED RELEASE;PERIODONTAL

ATRIDOX

+	@	DEN-MAT	50MG	N050751	001	Sep 03, 1998	Sep DISC
---	---	---------	------	---------	-----	--------------	----------

TABLET;ORAL

DOXYCYCLINE HYCLATE

AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A210536	002	Sep 14, 2021	Sep NEWA
@	AMICI	EQ 100MG BASE	A213475	001	Mar 10, 2021	Sep CAHN
AB	CARIBE HOLDINGS	EQ 50MG BASE	A062269	003	Oct 05, 1983	Jul CTEC
AB	CHARTWELL	EQ 50MG BASE	A062505	002	Jul 27, 2021	Jul NEWA
AB		EQ 100MG BASE	A062505	001	Sep 11, 1984	Jun CAHN

<u>TABLET;ORAL</u>							
DOXYCYCLINE HYCLATE							
AB		EQ 100MG BASE	A062505	001	Sep 11, 1984	Jun	CAHN
	@ MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jul	DISC
	@ ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Apr	DISC
AB		EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb	NEWA
<u>TABLET, DELAYED RELEASE;ORAL</u>							
DOXYCYCLINE HYCLATE							
	@ MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	Aug	CAHN
	@	EQ 50MG BASE	A090431	003	May 23, 2016	Jul	DISC
	@	EQ 75MG BASE	A090431	001	Dec 28, 2010	Aug	CAHN
	@	EQ 80MG BASE	A090431	004	Apr 29, 2016	Aug	CAHN
	@	EQ 100MG BASE	A090431	002	Dec 28, 2010	Aug	CAHN
	@	EQ 200MG BASE	A090431	005	May 19, 2016	Aug	CAHN
<u>DROSPIRENONE; ESTETROL</u>							
TABLET;ORAL							
NEXTSTELLIS							
	+! MAYNE PHARMA	3MG;14.2MG	N214154	001	Apr 15, 2021	Apr	NEWA
<u>DROSPIRENONE; ETHINYL ESTRADIOL</u>							
TABLET;ORAL							
DROSPIRENONE AND ETHINYL ESTRADIOL							
AB	HLTHCARE	3MG;0.02MG	A203291	001	Jul 18, 2017	Jun	CAHN
	@ JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017	Jun	DISC
	KYRA						
	@ SUN PHARM	3MG;0.02MG	A202318	001	Jul 23, 2019	Aug	DISC
TABLET;ORAL-28							
DROSPIRENONE AND ETHINYL ESTRADIOL							
	@ JUBILANT CADISTA	3MG;0.03MG	A210017	001	Sep 10, 2018	Jun	DISC
	KEMEYA						
	@ SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Aug	DISC
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM</u>							
TABLET;ORAL							
BEYAZ							
AB	+! BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep	CHRS
AB	+	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep	CRLD
<u>DROXIDOPA</u>							
CAPSULE;ORAL							
DROXIDOPA							
AB	AJANTA PHARMA LTD	100MG	A214391	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214391	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214391	003	Feb 18, 2021	Feb	NFTG
AB	ALKEM LABS LTD	100MG	A213911	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A213911	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A213911	003	Feb 18, 2021	Feb	NFTG
AB	ANNORA	100MG	A211726	002	Aug 09, 2021	Jul	NEWA
AB		200MG	A211726	003	Aug 09, 2021	Jul	NEWA
AB		300MG	A211726	001	Feb 18, 2021	Feb	NFTG
AB	AUROBINDO PHARMA LTD	100MG	A214387	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214387	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214387	003	Feb 18, 2021	Feb	NFTG
AB	BIONPHARMA INC	100MG	A213033	001	Apr 28, 2021	May	CAHN
AB		200MG	A213033	002	Apr 28, 2021	May	CAHN
AB		300MG	A213033	003	Apr 28, 2021	May	CAHN
AB	BLUEPHARMA	100MG	A214543	001	May 05, 2021	Apr	NEWA
AB		200MG	A214543	002	May 05, 2021	Apr	NEWA
AB		300MG	A214543	003	May 05, 2021	Apr	NEWA
AB	HIKMA PHARMS	100MG	A212835	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A212835	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A212835	003	Feb 18, 2021	Feb	NFTG
AB	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211652	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211652	003	Feb 18, 2021	Feb	NFTG
AB	MSN PHARMS INC	100MG	A211741	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211741	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211741	003	Feb 18, 2021	Feb	NFTG
AB	MYLAN API	100MG	A213033	001	Apr 28, 2021	Apr	NEWA
AB		200MG	A213033	002	Apr 28, 2021	Apr	NEWA
AB		300MG	A213033	003	Apr 28, 2021	Apr	NEWA

CAPSULE;ORAL

DROXIDOPA

AB	SCIEGEN PHARMS INC	100MG	A214017	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214017	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214017	003	Feb 18, 2021	Feb	NFTG
>A>	SLATE	100MG	A215265	001	Nov 01, 2021	Oct	NEWA
>A>		200MG	A215265	002	Nov 01, 2021	Oct	NEWA
>A>		300MG	A215265	003	Nov 01, 2021	Oct	NEWA
AB	SUN PHARM	100MG	A214384	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214384	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214384	003	Feb 18, 2021	Feb	NFTG
AB	TASMAN PHARMA	100MG	A213661	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A213661	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A213661	003	Feb 18, 2021	Feb	NFTG
	@ TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021	Aug	DISC
AB		100MG	A213162	001	Feb 18, 2021	Feb	NFTG
	@	200MG	A213162	002	Feb 18, 2021	Aug	DISC
AB		200MG	A213162	002	Feb 18, 2021	Feb	NFTG
	@	300MG	A213162	003	Feb 18, 2021	Aug	DISC
AB		300MG	A213162	003	Feb 18, 2021	Feb	NFTG
AB	TRIS PHARMA INC	100MG	A214543	001	May 05, 2021	Jun	CAHN
AB		200MG	A214543	002	May 05, 2021	Jun	CAHN
AB		300MG	A214543	003	May 05, 2021	Jun	CAHN
AB	ZYDUS PHARMS	100MG	A211818	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211818	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211818	003	Feb 18, 2021	Feb	NFTG
	NORTHERA						
AB	+ LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014	Feb	CFTG
AB	+	200MG	N203202	002	Feb 18, 2014	Feb	CFTG
AB	+!	300MG	N203202	003	Feb 18, 2014	Feb	CFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr	CDFR
+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr	CDFR
+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr	CDFR
+!		EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr	CDFR
	DULOXETINE HYDROCHLORIDE						
AB	SUNSHINE	EQ 20MG BASE	A212328	001	Feb 11, 2021	Feb	NEWA
AB		EQ 30MG BASE	A212328	002	Feb 11, 2021	Feb	NEWA
AB		EQ 60MG BASE	A212328	003	Feb 11, 2021	Feb	NEWA

DUTASTERIDE

CAPSULE;ORAL

AVODART

AB	+! WOODWARD	0.5MG	N021319	001	Nov 20, 2001	Jul	CAHN
	DUTASTERIDE						
	@ NOSTRUM LABS INC	0.5MG	A204705	001	Nov 20, 2015	Apr	CAHN

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

JALYN

AB	+! WOODWARD	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Jul	CAHN
----	-------------	-------------	---------	-----	--------------	-----	------

DYDROGESTERONE

TABLET;ORAL

GYNOREST

+	@ SOLVAY	5MG	N017388	001		Sep	CRLD
	@	5MG	N017388	001		Jul	CRLD
+	@	10MG	N017388	002		Sep	CRLD
	@	10MG	N017388	002		Jul	CRLD

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC

PHOSPHOLINE IODIDE

	@ FERA PHARMS LLC	0.03%	N011963	002		Aug	CAHN
	@	0.06%	N011963	004		Aug	CAHN
+	!	0.125%	N011963	001		Aug	CAHN
	@	0.25%	N011963	003		Aug	CAHN

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL
ECOZA

+! RESILIA PHARMS 1% N205175 001 Oct 24, 2013 Feb CAHN

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION
CALCIUM DISODIUM VERSENATE

+! BAUSCH 200MG/ML N008922 001 May CAHN

TABLET; ORAL

CALCIUM DISODIUM VERSENATE

@ BAUSCH 500MG N008922 002 May CAHN

EFAVIRENZ

TABLET; ORAL

EFAVIRENZ

AB STRIDES PHARMA 600MG A078509 001 Jun 16, 2021 Jun NEWA

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB MACLEODS PHARMS LTD 600MG;200MG;300MG A204287 001 Sep 13, 2021 Sep NEWA

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+ @ AUROBINDO PHARMA LTD 600MG;300MG;300MG N022343 001 Aug 15, 2018 Feb DISC

EFINACONAZOLE

SOLUTION; TOPICAL

EFINACONAZOLE

AB ACRUX DDS 10% A211969 001 Jun 21, 2021 Jun NEWA

@ AUROBINDO PHARMA LTD 10% A212066 001 Mar 29, 2021 Sep DISC

AB 10% A212066 001 Mar 29, 2021 Mar NEWA

AB TEVA PHARMS USA 10% A211827 001 Dec 16, 2020 Feb CTEC

JUBLIA

AB +! BAUSCH 10% N203567 001 Jun 06, 2014 Feb CTEC

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

TABLET; ORAL

TRIKAFTA (COPACKAGED)

+ VERTEX PHARMS INC 50MG, 37.5MG, 25MG; 75MG N212273 002 Jun 08, 2021 Jun NEWA

+! 100MG, 75MG, 50MG; 150MG N212273 001 Oct 21, 2019 Jun CPOT

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

CERDELGA

AB +! GENZYME CORP EQ 84MG BASE N205494 001 Aug 19, 2014 Aug CFTG

ELIGLUSTAT TARTRATE

AB AIZANT EQ 84MG BASE A212463 001 Sep 08, 2021 Aug NFTG

AB APPCO EQ 84MG BASE A212463 001 Sep 08, 2021 Sep CAHN

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>A> AB HETERO LABS LTD III 200MG;300MG A201806 001 Oct 07, 2021 Oct NEWA

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB APOTEX 200MG;300MG A208740 001 Jun 16, 2021 Jun NEWA

AB CIPLA 200MG;300MG A090958 001 Apr 02, 2021 Mar NEWA

AB LAURUS 200MG;300MG A212114 001 Jul 26, 2019 Jan CMFD

AB LUPIN LTD 200MG;300MG A204131 001 Jun 04, 2021 May NEWA

AB MACLEODS PHARMS LTD 200MG;300MG A203442 001 May 15, 2020 Feb CMFD

AB MYLAN 200MG;300MG A206436 001 Apr 09, 2018 Feb CMFD

AB STRIDES PHARMA 200MG;300MG A091055 001 Jan 13, 2021 Jan NEWA

AB ZYDUS PHARMS 100MG;150MG A212689 002 Jul 01, 2021 Jun NEWA

AB 133MG;200MG A212689 003 Jul 01, 2021 Jun NEWA

AB 167MG;250MG A212689 004 Jul 01, 2021 Jun NEWA

ENALAPRIL MALEATE

	SOLUTION;ORAL							
	ENALAPRIL MALEATE							
AB	BIONPHARMA INC	1MG/ML	A212408	001	Aug 10, 2021	Jul	NFTG	
	EPANED							
AB	+! AZURITY	1MG/ML	N208686	001	Sep 20, 2016	Jul	CFTG	

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

	TABLET;ORAL							
	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE							
	@ MYLAN	5MG;12.5MG	A075624	001	Sep 18, 2001	Jul	DISC	
	@	10MG;25MG	A075624	002	Sep 18, 2001	Jul	DISC	

ENZALUTAMIDE

	CAPSULE;ORAL							
	ENZALUTAMIDE							
AB	ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021	May	NFTG	
	XTANDI							
AB	+! ASTELLAS	40MG	N203415	001	Aug 31, 2012	May	CFTG	

EPHEDRINE HYDROCHLORIDE

	SOLUTION;INTRAVENOUS							
	REZIPRES							
	+! ETON	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun	CAHN	
	+ @	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun	DISC	
	+!	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun	CAHN	
	+ @	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun	DISC	
	+!	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun	CAHN	
	+! SINTETICA SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun	NEWA	
	+!	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun	NEWA	
	+!	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun	NEWA	

EPHEDRINE SULFATE

	SOLUTION;INTRAVENOUS							
	AKOVAZ							
	+! EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Aug	NEWA	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

	INJECTABLE;INJECTION							
	LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE							
AP	B BRAUN MEDICAL INC	0.005MG/ML;1.5%	A208475	001	Sep 08, 2021	Aug	NEWA	

EPLERENONE

	TABLET;ORAL							
	EPLERENONE							
AB	CHARTWELL RX	25MG	A078482	001	Jul 30, 2008	Apr	CAHN	
AB		50MG	A078482	002	Jul 30, 2008	Apr	CAHN	
	@ PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Feb	DISC	
	@	50MG	A212765	002	Aug 10, 2020	Feb	DISC	
>A> AB	WESTMINSTER PHARMS	25MG	A207842	001	Oct 25, 2021	Oct	CAHN	
>A> AB		50MG	A207842	002	Oct 25, 2021	Oct	CAHN	
	INSPRA							
AB	+ UPJOHN	25MG	N021437	001	Sep 27, 2002	Apr	CAHN	
AB	+!	50MG	N021437	002	Sep 27, 2002	Apr	CAHN	
	@	100MG	N021437	003	Sep 27, 2002	Apr	CAHN	

EPOPROSTENOL SODIUM

	INJECTABLE;INJECTION							
	EPOPROSTENOL SODIUM							
AP2	SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb	CTEC	
AP		EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Jan	NFTG	
AP2		EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Feb	CTEC	
AP		EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Jan	NFTG	
AP1	TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Feb	CTEC	
AP1		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Feb	CTEC	
	FLOLAN							
AP1	+! GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL	N020444	001	Sep 20, 1995	Feb	CTEC	
AP1	+!	EQ 1.5MG BASE/VIAL	N020444	002	Sep 20, 1995	Feb	CTEC	
	VELETRI							
AP2	+! ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb	CAHN	
AP2	+!	EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb	CAHN	

INJECTABLE; INJECTION
 VELETRI

AP2	+	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CHRS
AP2	+		EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CTEC
AP	+		EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Jan CFTG
AP2	+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb CTEC
AP	+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Jan CFTG

EPTIFIBATIDE

INJECTABLE; INJECTION
 EPTIFIBATIDE

AP	!	MYLAN LABS LTD	2MG/ML	A203258	001	Jul 20, 2018	Apr CHRS
AP	!		75MG/100ML	A203258	002	Jul 20, 2018	Apr CHRS
AP		SHUANGCHENG	2MG/ML	A213081	001	Sep 07, 2021	Aug NEWA
		INTEGRILIN					
	+	@ SCHERING	2MG/ML	N020718	001	May 18, 1998	Apr DISC
	+	@	75MG/100ML	N020718	002	May 18, 1998	Apr DISC

ERGOCALCIFEROL

CAPSULE; ORAL
 DRISDOL

AA	+	VALIDUS PHARMS	50,000 IU	N003444	001		Feb CAHN
----	---	----------------	-----------	---------	-----	--	----------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL
 ERLOTINIB HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	EQ 25MG BASE	A214719	001	Jul 08, 2021	Jul NEWA
AB			EQ 100MG BASE	A214719	002	Jul 08, 2021	Jul NEWA
AB			EQ 150MG BASE	A214719	003	Jul 08, 2021	Jul NEWA
AB		MSN	EQ 25MG BASE	A214366	001	May 10, 2021	Apr NEWA
AB			EQ 100MG BASE	A214366	002	May 10, 2021	Apr NEWA
AB			EQ 150MG BASE	A214366	003	May 10, 2021	Apr NEWA

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
 ERTAPENEM SODIUM

AP		EUGIA PHARMA	EQ 1GM BASE/VIAL	A209133	001	Jun 25, 2018	Aug CAHN
AP		GLAND PHARMA LTD	EQ 1GM BASE/VIAL	A212040	001	Mar 26, 2021	Mar NEWA

ERYTHROMYCIN

SOLUTION; TOPICAL
 ERYTHRA-DERM

AT		SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Apr CMFD
----	--	-----------------	----	---------	-----	--------------	----------

TABLET; ORAL
 ERYTHROMYCIN

BX		AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018	Sep CTEC
BX			500MG	A209720	002	Mar 09, 2018	Sep CTEC
AB		CADILA PHARMS LTD	250MG	A213628	001	Jun 28, 2021	Sep CAHN
AB			500MG	A213628	002	Jun 28, 2021	Sep CAHN
AB		ORANGE	250MG	A213628	001	Jun 28, 2021	Jun NEWA
AB			500MG	A213628	002	Jun 28, 2021	Jun NEWA
AB		TEVA PHARMS USA INC	250MG	A214549	001	Feb 11, 2021	Feb NEWA
AB			500MG	A214549	002	Feb 11, 2021	Feb NEWA

TABLET, DELAYED RELEASE; ORAL
 ERYTHROMYCIN

AB		TORRENT	250MG	A211975	001	Jul 26, 2021	Jul NEWA
AB			500MG	A211975	002	Jul 26, 2021	Jul NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL
 ERYTHROMYCIN ETHYLSUCCINATE

	@	PAR PHARM INC	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	May DISC
	@		EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	May DISC

ESCITALOPRAM OXALATE

SOLUTION; ORAL
 ESCITALOPRAM OXALATE

	@	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Aug DISC
--	---	-------------------	-----------------	---------	-----	--------------	----------

ESLICARBAZEPINE ACETATE

TABLET; ORAL		APTIOM	
AB	+ SUNOVION PHARMS INC	200MG	N022416 001 Nov 08, 2013 Jun CFTG
AB	+	400MG	N022416 002 Nov 08, 2013 Jun CFTG
AB	+	600MG	N022416 003 Nov 08, 2013 Jun CFTG
AB	+!	800MG	N022416 004 Nov 08, 2013 Jun CFTG
ESLICARBAZEPINE ACETATE			
AB	DR REDDYS LABS LTD	200MG	A211238 001 Jun 29, 2021 Jun NFTG
AB		400MG	A211238 002 Jun 29, 2021 Jun NFTG
AB		600MG	A211238 003 Jun 29, 2021 Jun NFTG
AB		800MG	A211238 004 Jun 29, 2021 Jun NFTG

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL		ESOMEPRAZOLE MAGNESIUM	
	@ AMTA	EQ 20MG BASE	A213859 001 Nov 18, 2020 May DISC
	@	EQ 40MG BASE	A213859 002 Nov 18, 2020 May DISC
AB	ETHYPHARM	EQ 20MG BASE	A090841 001 Mar 31, 2021 Mar NEWA
AB		EQ 40MG BASE	A090841 002 Mar 31, 2021 Mar NEWA
AB	GRAVITI PHARMS	EQ 20MG BASE	A213486 001 Mar 19, 2021 Mar NEWA
AB		EQ 40MG BASE	A213486 002 Mar 19, 2021 Mar NEWA
AB	INDCHEMIE HEALTH	EQ 40MG BASE	A210559 002 Feb 26, 2021 Feb NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL		NAPROXEN AND ESOMEPRAZOLE MAGNESIUM	
AB	MYLAN	EQ 20MG BASE; 375MG	A204920 001 Jul 20, 2021 Jul NEWA
AB		EQ 20MG BASE; 500MG	A204920 002 Jul 20, 2021 Jul NEWA

ESTRADIOL

CREAM; VAGINAL		ESTRACE	
AB	+! ALLERGAN	0.01%	A086069 001 Jan 31, 1984 Aug CRLD
ESTRADIOL			
AB	ALVOGEN	0.01%	A209767 001 Mar 05, 2018 Aug CAHN
AB	PRASCO LABS LLC	0.01%	A212313 001 Jul 15, 2021 Jul NEWA
FILM, EXTENDED RELEASE; TRANSDERMAL		ALORA	
	@ ALLERGAN	0.025MG/24HR	N020655 004 Apr 05, 2002 Jul DISC
	@	0.05MG/24HR	N020655 001 Dec 20, 1996 Jul DISC
	@	0.075MG/24HR	N020655 002 Dec 20, 1996 Jul DISC
	@	0.1MG/24HR	N020655 003 Dec 20, 1996 Jul DISC
INSERT, EXTENDED RELEASE; VAGINAL		ESTRING	
	+! PFIZER	0.0075MG/24HR	N020472 001 Apr 26, 1996 Jan CAHN
SYSTEM; TRANSDERMAL		ESTRADIOL	
BX	AMNEAL	0.025MG/24HR	A211293 001 Feb 04, 2019 Sep CTEC
BX		0.0375MG/24HR	A211293 002 Feb 04, 2019 Sep CTEC
BX		0.05MG/24HR	A211293 003 Feb 04, 2019 Sep CTEC
BX		0.075MG/24HR	A211293 004 Feb 04, 2019 Sep CTEC
BX		0.1MG/24HR	A211293 005 Feb 04, 2019 Sep CTEC
TABLET; ORAL		ESTRACE	
	+ @ BRISTOL MYERS SQUIBB	1MG	A084499 001 Aug CRLD
	+ @	2MG	A084500 001 Aug CRLD
ESTRADIOL			
>D>	AB MYLAN	0.5MG	A040326 001 Apr 21, 1999 Oct DISC
>A>	@	0.5MG	A040326 001 Apr 21, 1999 Oct DISC
>D>	AB	1MG	A040326 002 Apr 21, 1999 Oct DISC
>A>	@	1MG	A040326 002 Apr 21, 1999 Oct DISC
>D>	AB	2MG	A040326 003 Apr 21, 1999 Oct DISC
>A>	@	2MG	A040326 003 Apr 21, 1999 Oct DISC

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION		DEPO-ESTRADIOL	
	@ PFIZER	1MG/ML	A085470 001 Mar CAHN
	@	3MG/ML	A085470 002 Mar CAHN
	!	5MG/ML	A085470 003 Mar CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL		AMABELZ					
BX	LUPIN LTD	0.5MG; 0.1MG	A203339	001	Jun 20, 2016	Sep	CTEC
BX		1MG; 0.5MG	A203339	002	Jun 20, 2016	Sep	CTEC

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

TABLET; ORAL		MYFEMBREE					
+	MYOVANT SCIENCES	1MG; 0.5MG; 40MG	N214846	001	May 26, 2021	May	NEWA

ESTROPIPATE

TABLET; ORAL		OGEN .625					
+	@ PFIZER	0.75MG	A083220	001		Aug	CRLD
	@	0.75MG	A083220	001		Jan	CAHN
OGEN 1.25							
+	@ PFIZER	1.5MG	A083220	002		Aug	CRLD
	@	1.5MG	A083220	002		Jan	CAHN
OGEN 2.5							
+	@ PFIZER	3MG	A083220	003		Aug	CRLD
	@	3MG	A083220	003		Jan	CAHN
OGEN 5							
+	PFIZER	6MG	A083220	004		Aug	CRLD
		6MG	A083220	004		Jan	CAHN

ESZOPICLONE

TABLET; ORAL		ESZOPICLONE					
@	NOSTRUM LABS INC	1MG	A203087	001	May 08, 2019	Jan	CAHN
@		2MG	A203087	002	May 08, 2019	Jan	CAHN
@		3MG	A203087	003	May 08, 2019	Jan	CAHN

ETHACRYNIC ACID

TABLET; ORAL		ETHACRYNIC ACID					
AB	ALVOGEN	25MG	A205709	001	Jul 24, 2018	Jun	CAHN

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL		ETHINYL ESTRADIOL; ETONOGESTREL					
AB	TEVA PHARMS USA INC	0.015MG/24HR; 0.12MG/24HR	A204305	001	Jan 13, 2021	Jan	NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL		SYLEVIA					
@	SUN PHARM	0.03MG; 0.15MG	A202988	001	Feb 06, 2019	Aug	DISC
TABLET; ORAL-28		CERINTA					
@	SUN PHARM	0.02MG; 0.1MG	A202817	001	Jan 07, 2019	Aug	DISC
LEVONORGESTREL AND ETHINYL ESTRADIOL							
BX	LUPIN LTD	0.02MG; 0.1MG	A091425	001	Jan 18, 2013	Sep	CTEC
BX		0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A200248	001	Nov 19, 2015	Sep	CTEC

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL		ETHINYL ESTRADIOL AND NORELGESTROMIN					
BX	AMNEAL	0.035MG/24HR; 0.15MG/24HR	A213950	001	Feb 25, 2021	Sep	CTEC
AB		0.035MG/24HR; 0.15MG/24HR	A213950	001	Feb 25, 2021	Feb	NEWA
ONSURA							
AB	TEVA PHARMS USA	0.035MG/24HR; 0.15MG/24HR	A213977	001	Aug 25, 2021	Aug	NEWA
XULANE							
AB	MYLAN TECHNOLOGIES	0.035MG/24HR; 0.15MG/24HR	A200910	001	Apr 16, 2014	Feb	CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET; ORAL-21							
	NORINYL 1+35 21-DAY							
	@ ALLERGAN	0.035MG; 1MG		N017565	001			Jul DISC
	TABLET; ORAL-28							
	CYCLAFEM 1/35							
	@ VINTAGE PHARMS LLC	0.035MG; 1MG		A076337	001	Nov 12, 2010		Aug DISC
	CYCLAFEM 7/7/7							
	@ VINTAGE PHARMS LLC	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG		A076338	001	Nov 16, 2010		Aug DISC
	NORINYL 1+35 28-DAY							
	@ ALLERGAN	0.035MG; 1MG		N017565	002			Jul DISC
	PIRMELLA 1/35							
BX	LUPIN LTD	0.035MG; 1MG		A201512	001	Apr 24, 2013		Sep CTEC
	PIRMELLA 7/7/7							
BX	LUPIN LTD	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG		A201510	001	Apr 24, 2013		Sep CTEC
	TABLET, CHEWABLE; ORAL							
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
BX	LUPIN LTD	0.035MG; 0.4MG		A091332	001	Mar 23, 2016		Sep CTEC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	CAPSULE; ORAL							
	GEMMILY							
AB	XIROMED	0.02MG; 1MG		A213317	001	Nov 09, 2020		Mar CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	AMNEAL PHARMS	0.02MG; 1MG		A214292	001	Jul 20, 2021		Jul NEWA
	TABLET; ORAL							
	FEMHRT							
	+ @ APIL	0.0025MG; 0.5MG		N021065	001	Jan 14, 2005		Sep CRLD
	@	0.0025MG; 0.5MG		N021065	001	Jan 14, 2005		Sep DISC
	LOESTRIN 24 FE							
	+ @ TEVA BRANDED PHARM	0.02MG; 1MG		N021871	001	Feb 17, 2006		Sep DISC
	TABLET; ORAL-21							
	GILDESS 1/20							
	@ VINTAGE PHARMS LLC	0.02MG; 1MG		A077077	002	Jul 24, 2012		Jul DISC
	TABLET; ORAL-28							
	BLISOVI FE 1.5/30							
BX	LUPIN LTD	0.03MG; 1.5MG		A201585	001	Nov 18, 2015		Sep CTEC
	CHABELINA FE							
AB	! NOVAST LABS	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG		A202962	001	Apr 15, 2020		Sep CHRS
	ESTROSTEP FE							
	+ @ APIL	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG		N020130	002	Oct 09, 1996		Sep DISC
	GILDESS FE 1/20							
	@ VINTAGE PHARMS LLC	0.02MG; 1MG		A077077	001	May 20, 2005		Jul DISC

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET; ORAL-28							
	NORGESTIMATE AND ETHINYL ESTRADIOL							
>A>	@ MYLAN	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG		A201897	001	Jan 27, 2016		Oct CAHN
>A>	@	0.035MG; 0.25MG		A201896	001	Jan 27, 2016		Oct CAHN
>D> AB	MYLAN LABS LTD	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG		A201897	001	Jan 27, 2016		Oct CAHN
>D> AB		0.035MG; 0.25MG		A201896	001	Jan 27, 2016		Oct CAHN

ETHOSUXIMIDE

	CAPSULE; ORAL							
	ETHOSUXIMIDE							
BX	HERITAGE PHARMS INC	250MG		A200892	001	Sep 25, 2012		Sep CTEC
BX	PURACAP PHARM LLC	250MG		A210654	001	Mar 16, 2020		Sep CTEC
	SYRUP; ORAL							
	ZARONTIN							
AA	+! PARKE-DAVIS	250MG/5ML		A080258	001			Aug CRLD

ETODOLAC

TABLET; ORAL

ETODOLAC

AB	BAYSHORE PHARMS LLC	400MG	A210704	001	Dec 16, 2020	Aug	CMFD
	@	400MG	A210704	001	Dec 16, 2020	Jul	DISC
AB		500MG	A210704	002	Dec 16, 2020	Aug	CMFD
	@	500MG	A210704	002	Dec 16, 2020	Jul	DISC

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP	CAPLIN	2MG/ML	A215028	001	Dec 18, 2020	Jul	CMFD
	@	2MG/ML	A215028	001	Dec 18, 2020	Jun	DISC

ETRAVIRINE

TABLET; ORAL

ETRAVIRINE

	@ AMNEAL	25MG	A214196	001	Jun 14, 2021	Jul	DISC
AB		25MG	A214196	001	Jun 14, 2021	Jun	NFTG
AB		100MG	A214196	002	Jun 14, 2021	Jun	NFTG
AB		200MG	A214196	003	Jun 14, 2021	Jun	NFTG
	INTELENCE						
	+ JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012	Jul	CTEC
AB	+	25MG	N022187	003	Mar 26, 2012	Jun	CFTG
AB	+	100MG	N022187	001	Jan 18, 2008	Jun	CFTG
AB	+	200MG	N022187	002	Dec 22, 2010	Jun	CFTG

EVEROLIMUS

TABLET; ORAL

AFINITOR

AB	+ NOVARTIS	10MG	N022334	002	Mar 30, 2009	Feb	CTEC
	EVEROLIMUS						
AB	BIOCON PHARMA	2.5MG	A214182	001	Feb 11, 2021	Aug	CMFD
	@	2.5MG	A214182	001	Feb 11, 2021	Feb	DISC
AB		2.5MG	A214182	001	Feb 11, 2021	Feb	NEWA
AB		5MG	A214182	002	Feb 11, 2021	Aug	CMFD
	@	5MG	A214182	002	Feb 11, 2021	Feb	DISC
AB		5MG	A214182	002	Feb 11, 2021	Feb	NEWA
AB		7.5MG	A214182	003	Feb 11, 2021	Aug	CMFD
	@	7.5MG	A214182	003	Feb 11, 2021	Feb	DISC
AB		7.5MG	A214182	003	Feb 11, 2021	Feb	NEWA
AB		10MG	A214182	004	Feb 11, 2021	Aug	CMFD
	@	10MG	A214182	004	Feb 11, 2021	Feb	DISC
AB		10MG	A214182	004	Feb 11, 2021	Feb	NEWA
AB	BRECKENRIDGE	0.25MG	A205432	001	May 20, 2021	May	NEWA
AB		0.5MG	A205432	002	May 20, 2021	May	NEWA
AB		0.75MG	A205432	003	May 20, 2021	May	NEWA
AB		2.5MG	A205426	001	Mar 05, 2021	Feb	NEWA
AB		5MG	A205426	002	Mar 05, 2021	Feb	NEWA
AB		7.5MG	A205426	003	Mar 05, 2021	Feb	NEWA
AB		10MG	A205426	004	Mar 05, 2021	Feb	NEWA
AB	MYLAN	10MG	A212936	004	Jun 08, 2020	Aug	CMFD
>A>	PAR PHARM	0.25MG	A205775	001	Oct 18, 2021	Oct	NEWA
>A>		0.5MG	A205775	002	Oct 18, 2021	Oct	NEWA
>A>		0.75MG	A205775	003	Oct 18, 2021	Oct	NEWA
>A>		1MG	A205775	004	Oct 18, 2021	Oct	NFTG
	ZORTRESS						
>D>	+! NOVARTIS	1MG	N021560	004	Aug 10, 2018	Oct	CFTG
>A>	AB +!	1MG	N021560	004	Aug 10, 2018	Oct	CFTG
	TABLET, FOR SUSPENSION; ORAL						
	AFINITOR DISPERZ						
AB	+ NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012	Aug	CTEC
AB	+	3MG	N203985	002	Aug 29, 2012	Aug	CTEC
AB	+	5MG	N203985	003	Aug 29, 2012	Aug	CTEC
	EVEROLIMUS						
AB	MYLAN	2MG	A210130	001	Apr 19, 2019	Aug	CMFD
AB		3MG	A210130	002	Apr 19, 2019	Aug	CMFD
AB		5MG	A210130	003	Apr 19, 2019	Aug	CMFD

EXEMESTANE

	TABLET;ORAL								
	AROMASIN								
AB	+!	PFIZER	25MG		N020753	001	Oct 21, 1999	Mar	CAHN

EXENATIDE SYNTHETIC

	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS								
	BYDUREON								
	+ @	ASTRAZENECA AB	2MG/VIAL		N022200	001	Jan 27, 2012	Feb	DISC
		BYDUREON PEN							
	+ @	ASTRAZENECA AB	2MG		N022200	002	Feb 28, 2014	Feb	DISC
	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS								
	BYDUREON BCISE								
	+!	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)		N209210	001	Oct 20, 2017	Aug	CAIN

EZETIMIBE

	TABLET;ORAL								
	ZETIA								
AB	+!	ORGANON	10MG		N021445	001	Oct 25, 2002	Feb	CAHN

EZETIMIBE; ROSUVASTATIN CALCIUM

	TABLET;ORAL								
	ROSZET								
	+ ALTHERA PHARMS		10MG;EQ 5MG BASE		N213072	001	Mar 23, 2021	Mar	NEWA
	+		10MG;EQ 5MG BASE		N213072	001	Mar 23, 2021	Mar	NEWA
	+		10MG;EQ 10MG BASE		N213072	002	Mar 23, 2021	Mar	NEWA
	+		10MG;EQ 10MG BASE		N213072	002	Mar 23, 2021	Mar	NEWA
	+		10MG;EQ 20MG BASE		N213072	003	Mar 23, 2021	Mar	NEWA
	+		10MG;EQ 20MG BASE		N213072	003	Mar 23, 2021	Mar	NEWA
	+!		10MG;EQ 40MG BASE		N213072	004	Mar 23, 2021	Mar	NEWA
	+!		10MG;EQ 40MG BASE		N213072	004	Mar 23, 2021	Mar	NEWA

EZETIMIBE; SIMVASTATIN

	TABLET;ORAL								
	EZETIMIBE AND SIMVASTATIN								
	@ ANI PHARMS		10MG;10MG		A201890	001	Apr 26, 2017	Jul	DISC
	@		10MG;20MG		A201890	002	Apr 26, 2017	Jul	DISC
	@		10MG;40MG		A201890	003	Apr 26, 2017	Jul	DISC
	@		10MG;80MG		A201890	004	Apr 26, 2017	Jul	DISC
	@ MYLAN		10MG;10MG		A200082	001	Dec 17, 2020	Jan	DISC
	@		10MG;20MG		A200082	002	Dec 17, 2020	Jan	DISC
	@		10MG;40MG		A200082	003	Dec 17, 2020	Jan	DISC
	@		10MG;80MG		A200082	004	Dec 17, 2020	Jan	DISC
	VYTORIN								
AB	+	ORGANON	10MG;10MG		N021687	001	Jul 23, 2004	Feb	CAHN
AB	+		10MG;20MG		N021687	002	Jul 23, 2004	Feb	CAHN
AB	+		10MG;40MG		N021687	003	Jul 23, 2004	Feb	CAHN
AB	+!		10MG;80MG		N021687	004	Jul 23, 2004	Feb	CAHN

FAMOTIDINE

	FOR SUSPENSION;ORAL								
	FAMOTIDINE								
AB		AKORN	40MG/5ML		A201995	001	May 30, 2014	Feb	CAHN
AB		NOVITIUM PHARMA	40MG/5ML		A215043	001	Apr 20, 2021	Apr	NEWA
	TABLET;ORAL								
	FAMOTIDINE								
>A>	AB	ANNORA PHARMA	20MG		A215767	001	Nov 04, 2021	Oct	NEWA
>A>	AB		40MG		A215767	002	Nov 04, 2021	Oct	NEWA
>A>	AB	ASCENT PHARMS INC	20MG		A215689	001	Oct 15, 2021	Oct	NEWA
>A>	AB		40MG		A215689	002	Oct 15, 2021	Oct	NEWA
	PEPCID								
>A>	+	@ BAUSCH	20MG		N019462	001	Oct 15, 1986	Oct	CAHN
>A>	+	@	40MG		N019462	002	Oct 15, 1986	Oct	CAHN
>D>	+	@ VALEANT PHARMS NORTH	20MG		N019462	001	Oct 15, 1986	Oct	CAHN
>D>	+	@	40MG		N019462	002	Oct 15, 1986	Oct	CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

AB	+!	HORIZON	26.6MG;800MG	N022519	001	Apr 23, 2011	Jul	CFTG
		IBUPROFEN AND FAMOTIDINE						
AB		ALKEM LABS LTD	26.6MG;800MG	A211890	001	Aug 03, 2021	Jul	NFTG
>A>	AB	TEVA PHARMS USA	26.6MG;800MG	A211278	001	Oct 29, 2021	Oct	NEWA

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

AB		NOVITIUM PHARMA	600MG/5ML	A211333	001	May 31, 2019	Sep	CAHN
----	--	-----------------	-----------	---------	-----	--------------	-----	------

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

@ JUBILANT GENERICS

2.5MG

A203983 001 Aug 19, 2016 Jun DISC

@

5MG

A203983 002 Aug 19, 2016 Jun DISC

@

10MG

A203983 003 Aug 19, 2016 Jun DISC

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB		AUROBINDO PHARMA LTD	67MG	A212232	001	Sep 20, 2021	Sep	NEWA
----	--	----------------------	------	---------	-----	--------------	-----	------

AB			134MG	A212232	002	Sep 20, 2021	Sep	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			200MG	A212232	003	Sep 20, 2021	Sep	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

TABLET; ORAL

FENOFIBRATE

AB		ADAPTIS	54MG	A210606	001	Aug 17, 2018	Aug	CAHN
----	--	---------	------	---------	-----	--------------	-----	------

AB			160MG	A210606	002	Aug 17, 2018	Aug	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

AB		AUSTARPHARMA	48MG	A208476	001	Feb 10, 2021	Jan	NEWA
----	--	--------------	------	---------	-----	--------------	-----	------

AB			145MG	A208476	002	Feb 10, 2021	Jan	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

@ RISING

EQ 200MG BASE

A072394 001 Oct 17, 1988 Jan CAHN

@

EQ 300MG BASE

A072395 001 Oct 17, 1988 Jan CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100

>D>	AB	+	JANSSEN PHARMS	100MCG/HR	N019813	001	Aug 07, 1990	Oct	DISC
>A>		+	@	100MCG/HR	N019813	001	Aug 07, 1990	Oct	DISC

DURAGESIC-12

>D>	AB	+	JANSSEN PHARMS	12.5MCG/HR	N019813	005	Feb 04, 2005	Oct	DISC
>A>		+	@	12.5MCG/HR	N019813	005	Feb 04, 2005	Oct	DISC

DURAGESIC-25

>D>	AB	+!	JANSSEN PHARMS	25MCG/HR	N019813	004	Aug 07, 1990	Oct	DISC
>A>		+	@	25MCG/HR	N019813	004	Aug 07, 1990	Oct	DISC

DURAGESIC-37

>D>	AB	+	JANSSEN PHARMS	37.5MCG/HR	N019813	006	Jan 24, 2018	Oct	DISC
>A>		+	@	37.5MCG/HR	N019813	006	Jan 24, 2018	Oct	DISC

DURAGESIC-50

>D>	AB	+	JANSSEN PHARMS	50MCG/HR	N019813	003	Aug 07, 1990	Oct	DISC
>A>		+	@	50MCG/HR	N019813	003	Aug 07, 1990	Oct	DISC

DURAGESIC-75

>D>	AB	+	JANSSEN PHARMS	75MCG/HR	N019813	002	Aug 07, 1990	Oct	DISC
>A>		+	@	75MCG/HR	N019813	002	Aug 07, 1990	Oct	DISC

FENTANYL-25

>D>	AB		SPECGX LLC	25MCG/HR	A077154	001	Feb 09, 2011	Oct	CHRS
>A>	AB	!		25MCG/HR	A077154	001	Feb 09, 2011	Oct	CHRS

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP		FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Jun	CMFD
----	--	--------------------	-------------------	---------	-----	--------------	-----	------

		@	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Mar	DISC
--	--	---	-------------------	---------	-----	--------------	-----	------

SPRAY, METERED;NASAL
LAZANDA

>D>	+ @	BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Oct	CMFD
>A>	+		EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Oct	CMFD
	+ @		EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep	DISC
>D>	+ @		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Oct	CMFD
>A>	+!		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Oct	CMFD
	+ @		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep	DISC

FERRIC CARBOXYMALTOSE

SOLUTION;INTRAVENOUS
INJECTAFER

+!	AM	REAGENT	1GM IRON/20ML (50MG IRON/ML)	N203565	003	Apr 28, 2021	May	NEWA
----	----	---------	------------------------------	---------	-----	--------------	-----	------

FERRIC MALTOL

CAPSULE;ORAL
ACCRUFER

+!	SHIELD	TX	30MG IRON	N212320	001	Jul 25, 2019	Apr	CMFD
----	--------	----	-----------	---------	-----	--------------	-----	------

FERRIC OXYHYDROXIDE

INJECTABLE;INJECTION
DEXFERRUM

	@	AM	REAGENT	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996	May	CAIN
			FERRLECIT						
AB	+!	SANOFI	AVENTIS US	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	N020955	001	Feb 18, 1999	May	CPOT
AB	+!			62.5MG/5ML	N020955	001	Feb 18, 1999	May	CAIN
			INFED						
BP	+!	ALLERGAN		EQ 100MG IRON/2ML (EQ 50MG IRON/ML)	N017441	001		May	CAIN
			IRON DEXTRAN						
	@	SANOFI	AVENTIS US	EQ 50MG IRON/ML	N010787	002		May	CAIN
			PROFERDEX						
	@	NEW	RIVER	EQ 50MG IRON/ML	N017807	001		May	CAIN
			SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE						
AB		WEST-WARD	PHARMS INT	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	A078215	001	Mar 31, 2011	May	CPOT
AB				62.5MG/5ML	A078215	001	Mar 31, 2011	May	CAIN
			INJECTABLE;INTRAVENOUS						
			VENOFER						
	+	AM	REAGENT	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135	002	Mar 20, 2005	May	CPOT
	+			EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	May	CAIN
	@			EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)	N021135	005	Mar 29, 2013	May	CPOT
	@			EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	May	CAIN
	@			EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)	N021135	003	Mar 29, 2005	May	CPOT
	@			EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005	May	CAIN
	+!			EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N021135	001	Nov 06, 2000	May	CPOT
	+!			EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000	May	CAIN
	+			EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135	004	Feb 09, 2007	May	CPOT
	+			EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007	May	CAIN
			TABLET, CHEWABLE;ORAL						
			VELPHORO						
	+!	VIFOR	FRESENIUS	EQ 500MG IRON	N205109	001	Nov 27, 2013	May	CPOT
	+!			500MG	N205109	001	Nov 27, 2013	May	CAIN

FERUMOXYTOL

SOLUTION;INTRAVENOUS
FERAHEME

AB	+!	AMAG	PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Jan	CFTG
AB	+!	COVIS		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Mar	CAHN
			FERUMOXYTOL						
AB		SANDOZ	INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	A206604	001	Jan 15, 2021	Jan	NFTG

FEXINIDAZOLE

TABLET; ORAL

FEXINIDAZOLE

+!	DNDI	600MG	N214429	001	Jul 16, 2021	Jul	NEWA
+!	SANOFI	600MG	N214429	001	Jul 16, 2021	Jul	CAHN

FINASTERIDE

TABLET; ORAL

FINASTERIDE

@	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007	May	DISC
---	---------------------	-----	---------	-----	--------------	-----	------

FINERENONE

TABLET; ORAL

KERENDIA

+	BAYER HLTHCARE	10MG	N215341	001	Jul 09, 2021	Jul	NEWA
+!		20MG	N215341	002	Jul 09, 2021	Jul	NEWA

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

	@	ALKEM LABS LTD	EQ 0.5MG BASE	A208004	001	Dec 30, 2020	Aug	DISC
	@	APOTEX	EQ 0.5MG BASE	A207993	001	Dec 18, 2020	Jun	DISC
	@	GLENMARK PHARMS LTD	EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Aug	DISC
	@	MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan	DISC
AB			EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan	NEWA
	@	STRIDES PHARMA	EQ 0.5MG BASE	A207971	001	Jun 29, 2020	Aug	DISC
	@	SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Aug	DISC
	@	ZYDUS PHARMS	EQ 0.5MG BASE	A207994	001	Oct 14, 2020	Mar	DISC

FLECAINIDE ACETATE

TABLET; ORAL

TAMBOCOR

+	@	ALVOGEN	50MG	N018830	004	Aug 23, 1988	Jun	CAHN
+	@		100MG	N018830	001	Oct 31, 1985	Jun	CAHN
+	@		150MG	N018830	003	Jun 03, 1988	Jun	CAHN
	@		200MG	N018830	002	Oct 31, 1985	Jun	CAHN
+	@	CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jan	DISC
+	@		100MG	N018830	001	Oct 31, 1985	Jan	DISC
+	@		150MG	N018830	003	Jun 03, 1988	Jan	DISC

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

>D>	+!	LIFE MOLECULAR	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	Oct	CAHN
>A>	+!		30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	Oct	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	Mar	NEWA
>D>	AP	CPDC	20-300mCi/ML	A204525	001	Oct 29, 2014	Oct	CAHN
>A>	AP	ISOLOGIC INNOVATIVE	20-300mCi/ML	A204525	001	Oct 29, 2014	Oct	CAHN
		NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015	Jan	CAHN
AP		PHARMALOGIC HLDGS	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan	CAHN
AP		PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar	CTEC

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP		BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Mar	CMFD
AP			1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Mar	CMFD

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

@	ALLIED	0.01%	A088047	001	Dec 16, 1982	Sep	CAHN
@		0.025%	A088045	001	Dec 16, 1982	Sep	CAHN
@		0.025%	A088045	001	Dec 16, 1982	Sep	CAHN

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

@	AKORN	0.01%	A091514	001	Jun 25, 2015	Jul	DISC
---	-------	-------	---------	-----	--------------	-----	------

OIL;TOPICAL

AT	FLUOCINOLONE ACETONIDE	QUAGEN	0.01%	A212760	001	Apr 02, 2021	Sep CAHN
AT		QUAGEN	0.01%	A212761	001	Apr 02, 2021	Sep CAHN
AT		SOLARIS PHARMA CORP	0.01%	A212760	001	Apr 02, 2021	Mar NEWA
AT			0.01%	A212761	001	Apr 02, 2021	Mar NEWA

OIL/DROPS;OTIC

AT	FLUOCINOLONE ACETONIDE	@ AKORN	0.01%	A202705	001	Sep 09, 2016	Jul DISC
AT		QUAGEN	0.01%	A212762	001	Apr 02, 2021	Sep CAHN
AT		SOLARIS PHARMA CORP	0.01%	A212762	001	Apr 02, 2021	Mar NEWA
AT		TASMAN PHARMA	0.01%	A213264	001	Feb 05, 2021	Jan NEWA

SOLUTION;TOPICAL

AT	FLUOCINOLONE ACETONIDE	@ ALLIED	0.01%	A088048	001	Dec 16, 1982	Sep CAHN
----	------------------------	----------	-------	---------	-----	--------------	----------

FLUOCINONIDE

CREAM;TOPICAL

AB2	LIDEX	+ @ ALVOGEN	0.05%	N016908	002		Jun CAHN
		LIDEX-E					
AB2		ALVOGEN	0.05%	N016908	003		Jun CAHN
		VANOS					
AB		BAUSCH	0.1%	N021758	001	Feb 11, 2005	May CAHN

GEL;TOPICAL

AB	FLUOCINONIDE	+ ALVOGEN	0.05%	N017373	001		Jun CAHN
----	--------------	-----------	-------	---------	-----	--	----------

OINTMENT;TOPICAL

AB	LIDEX	+ ALVOGEN	0.05%	N016909	002		Jun CAHN
----	-------	-----------	-------	---------	-----	--	----------

SOLUTION;TOPICAL

AT	LIDEX	+ ALVOGEN	0.05%	N018849	001	Apr 06, 1984	Jun CAHN
----	-------	-----------	-------	---------	-----	--------------	----------

FLUOROURACIL

CREAM;TOPICAL

>A> AB	FLUOROPLEX	+ @ ALMIRALL	1%	N016988	001		Aug DISC
		FLUOROURACIL					
		ACCORD HLTHCARE	5%	A214845	001	Oct 07, 2021	Oct NEWA

INJECTABLE;INJECTION

AP	FLUOROURACIL	FRESENIUS KABI USA	500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998	May CHRS
AP			1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998	May CHRS
AP			2.5GM/50ML (50MG/ML)	A040278	001	Sep 30, 1998	May CHRS
AP			5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998	May CHRS
		@ NOVAST LABS	5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	Mar CPOT
AP		TEVA PHARMS USA	500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000	May CHRS

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

AB1	FLUOXETINE HYDROCHLORIDE	@ ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020	Feb DISC
		@	EQ 20MG BASE	A202729	002	Aug 27, 2020	Feb DISC
		@	EQ 40MG BASE	A202729	003	Aug 27, 2020	Feb DISC
		@ GRANULES	EQ 10MG BASE	A078143	001	Jan 16, 2008	Jun CAHN
		@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Jun CAHN
		@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Jun CAHN
AB1		HERITAGE PHARMS INC	EQ 10MG BASE	A201336	001	Oct 01, 2012	Aug CMFD
AB1			EQ 20MG BASE	A201336	002	Oct 01, 2012	Aug CMFD
AB			EQ 40MG BASE	A201336	003	Oct 01, 2012	Aug CMFD

TABLET;ORAL

AB	FLUOXETINE HYDROCHLORIDE	+! ALMATICA	EQ 60MG BASE	N202133	001	Oct 06, 2011	Sep CAHN
AB		DR REDDYS LABS LTD	EQ 20MG BASE	A076006	002	Apr 23, 2018	Jul CHRS
		@ MYLAN	EQ 10MG BASE	A075755	001	Aug 02, 2001	Jul DISC
		@	EQ 20MG BASE	A075755	002	Aug 02, 2001	Jul DISC
		TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016	Mar CHRS
		!	EQ 20MG BASE	A206937	002	Oct 21, 2016	Mar CHRS
AB		UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	May CAHN
AB			EQ 20MG BASE	A211696	002	Jan 30, 2019	May CAHN

TABLET;ORAL
SARAFEM

+ @ APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Mar	DISC
+ @	EQ 20MG BASE	N021860	003	May 19, 2006	Mar	DISC

FLUOXYMESTERONE

TABLET;ORAL
FLUOXYMESTERONE

@ UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983	Jan	DISC
---------------------	------	---------	-----	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL
FLUPHENAZINE HYDROCHLORIDE

AB	CEROVENE INC	1MG	A214534	001	Jan 07, 2021	Jan	NEWA
AB		2.5MG	A214534	002	Jan 07, 2021	Jan	NEWA
AB		5MG	A214534	003	Jan 07, 2021	Jan	NEWA
AB		10MG	A214534	004	Jan 07, 2021	Jan	NEWA
>A> AB	ENALTEC	1MG	A215141	001	Oct 20, 2021	Oct	NEWA
>A> AB		2.5MG	A215141	002	Oct 20, 2021	Oct	NEWA
>A> AB		5MG	A215141	003	Oct 20, 2021	Oct	NEWA
>A> AB		10MG	A215141	004	Oct 20, 2021	Oct	NEWA
AB	NOVITIUM PHARMA	1MG	A214674	001	Mar 01, 2021	Feb	NEWA
AB		2.5MG	A214674	002	Mar 01, 2021	Feb	NEWA
AB		5MG	A214674	003	Mar 01, 2021	Feb	NEWA
AB		10MG	A214674	004	Mar 01, 2021	Feb	NEWA
AB	ZYDUS	1MG	A214552	001	May 27, 2021	May	NEWA
AB		2.5MG	A214552	002	May 27, 2021	May	NEWA
AB		5MG	A214552	003	May 27, 2021	May	NEWA
AB		10MG	A214552	004	May 27, 2021	May	NEWA

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC
FLURBIPROFEN SODIUM

! BAUSCH AND LOMB	0.03%	A074447	001	Jan 04, 1995	Jan	CHRS
	0.03%	A074447	001	Jan 04, 1995	Jan	CTEC
OCUFEN						
+ @ ALLERGAN	0.03%	N019404	001	Dec 31, 1986	Jan	DISC

FLUTAMIDE

CAPSULE;ORAL
FLUTAMIDE

@ CIPLA	125MG	A075780	001	Sep 19, 2001	Mar	DISC
! PAR PHARM	125MG	A075298	001	Sep 18, 2001	Mar	CHRS
	125MG	A075298	001	Sep 18, 2001	Mar	CTEC
! WAYLIS THERAP	125MG	A075298	001	Sep 18, 2001	Jun	CAHN

FLUTICASONE PROPIONATE

POWDER;INHALATION
ARMONAIR RESPICLICK

+ @ TEVA PHARM	0.03MG/INH	N208798	007	Jul 09, 2021	Sep	DISC
+	0.03MG/INH	N208798	007	Jul 09, 2021	Jul	NEWA

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL
FLUVASTATIN SODIUM

AB	BEIJING	EQ 80MG BASE	A209397	001	Apr 26, 2021	Apr	NEWA
----	---------	--------------	---------	-----	--------------	-----	------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL
FLUVOXAMINE MALEATE

@ BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Feb	DISC
------------------	-------	---------	-----	--------------	-----	------

FOLIC ACID

TABLET;ORAL
FOLIC ACID

AA	+! WATSON LABS	1MG	A080680	001		Aug	CRLD
----	----------------	-----	---------	-----	--	-----	------

FORMOTEROL FUMARATE

SOLUTION; INHALATION		FORMOTEROL FUMARATE					
AN	TEVA PHARMS USA INC	0.02MG/2ML		A091141	001	Jun 22, 2021	Jun NFTG
PERFOROMIST							
AN	+! MYLAN SPECLT	0.02MG/2ML		N022007	001	May 11, 2007	Jun CFTG

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION		DULERA					
+	ORGANON	0.005MG/INH; 0.05MG/INH		N022518	003	Aug 12, 2019	Jun CAHN
+	!	0.005MG/INH; 0.1MG/INH		N022518	001	Jun 22, 2010	Jun CAHN
+	!	0.005MG/INH; 0.2MG/INH		N022518	002	Jun 22, 2010	Jun CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS		FOSAPREPITANT DIMEGLUMINE					
AP	ASPIRO	EQ 150MG BASE/VIAL		A214616	001	Jul 29, 2021	Jul NEWA
	@ MYLAN LABS LTD	EQ 115MG BASE/VIAL		A204015	001	Sep 05, 2019	Mar DISC
AP	PRAXGEN	EQ 150MG BASE/VIAL		A211624	001	Sep 05, 2019	Jun CAHN
AP		EQ 150MG BASE/VIAL		A213199	001	Oct 04, 2021	Sep NEWA

FOSCARNET SODIUM

INJECTABLE; INJECTION		FOSCARNET SODIUM					
AP	FRESENIUS KABI USA	2.4GM/100ML		A212483	001	Jan 29, 2021	Jan NEWA
AP	GLAND PHARMA LTD	2.4GM/100ML		A213001	001	Apr 21, 2021	Apr NEWA
FOSCAVIR							
AP	+! CLINIGEN HLTHCARE	2.4GM/100ML		N020068	001	Sep 27, 1991	Jan CTEC

FOSDENOPTERIN HYDROBROMIDE

POWDER; INTRAVENOUS		NULIBRY					
+	ORIGIN	EQ 9.5MG BASE/VIAL		N214018	001	Feb 26, 2021	Feb NEWA

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL		FOSFOMYCIN TROMETHAMINE					
>A> AA	ALKEM LABS LTD	EQ 3GM BASE/PACKET		A214554	001	Oct 21, 2021	Oct NEWA

FOSINOPRIL SODIUM

TABLET; ORAL		FOSINOPRIL SODIUM					
AB	CHARTWELL RX	10MG		A076483	001	Apr 23, 2004	Aug CAHN
AB		20MG		A076483	002	Apr 23, 2004	Aug CAHN
AB		40MG		A076483	003	Apr 23, 2004	Aug CAHN

FOSPHENYTOIN SODIUM

SOLUTION; INTRAVENOUS		SESQUIENT					
+	@ SEDOR PHARMS LLC	EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)		N210864	001	Nov 05, 2020	Jul DISC
+	@	EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)		N210864	002	Nov 05, 2020	Jul DISC

FULVESTRANT

INJECTABLE; INTRAMUSCULAR		FULVESTRANT					
AO	APOTEX	50MG/ML		A211730	001	Jun 11, 2021	Jun NEWA
AO	AUROMEDICS PHARMA	50MG/ML		A208811	001	Jul 23, 2019	Jan CAHN
AO	CHEMO RESEARCH SL	50MG/ML		A213553	001	Aug 13, 2021	Aug NEWA
AO	EUGIA PHARMA	50MG/ML		A208811	001	Jul 23, 2019	Aug CAHN
AO	XIROMED	50MG/ML		A213553	001	Aug 13, 2021	Aug CAHN
AO	ZYDUS PHARMS	50MG/ML		A215234	001	Jul 29, 2021	Jul NEWA

FUROSEMIDE

INJECTABLE; INJECTION		FUROSEMIDE					
AP	ACCORD HLTHCARE	10MG/ML		A070017	001	Dec 15, 1986	Apr CMFD
AP	ATHENEX INC	10MG/ML		A214766	001	Jan 27, 2021	Jan NEWA
	@ HIKMA	10MG/ML		N018267	001		Jun CAHN

INJECTABLE; INJECTION
FUROSEMIDE

	@ HIKMA PHARMS	10MG/ML	N018267	001		Jul	CAHN
TABLET; ORAL LASIX							
AB	+ VALIDUS PHARMS	20MG	N016273	002		Feb	CAHN
AB	+	40MG	N016273	001		Feb	CAHN
AB	+!	80MG	N016273	003		Feb	CAHN

GABAPENTIN

CAPSULE; ORAL GABAPENTIN							
AB	ASCENT PHARMS INC	100MG	A214956	001	May 10, 2021	Apr	NEWA
AB		300MG	A214956	002	May 10, 2021	Apr	NEWA
AB		400MG	A214956	003	May 10, 2021	Apr	NEWA
AB	GRAVITI PHARMS	100MG	A207099	001	Mar 24, 2017	Jun	CAHN
AB		300MG	A207099	002	Mar 24, 2017	Jun	CAHN
AB		400MG	A207099	003	Mar 24, 2017	Jun	CAHN
AB	ZHEJIANG YONGTAI	100MG	A213603	001	Aug 17, 2020	Apr	CMFD
	@	100MG	A213603	001	Aug 17, 2020	Feb	DISC
AB		300MG	A213603	002	Aug 17, 2020	Apr	CMFD
	@	300MG	A213603	002	Aug 17, 2020	Feb	DISC
AB		400MG	A213603	003	Aug 17, 2020	Apr	CMFD
	@	400MG	A213603	003	Aug 17, 2020	Feb	DISC
SOLUTION; ORAL GABAPENTIN							
	@ NOVITIUM PHARMA	250MG/5ML	A211330	001	Dec 03, 2019	Sep	CAHN
TABLET; ORAL GABAPENTIN							
AB	ASCENT PHARMS INC	600MG	A214957	001	Oct 01, 2021	Sep	NEWA
AB		800MG	A214957	002	Oct 01, 2021	Sep	NEWA

GALANTAMINE HYDROBROMIDE

TABLET; ORAL GALANTAMINE HYDROBROMIDE							
AB	! YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	May	CHRS
	RAZADYNE						
	+ @ JANSSEN PHARMS	EQ 4MG BASE	N021169	001	Feb 28, 2001	May	DISC
	+ @	EQ 8MG BASE	N021169	002	Feb 28, 2001	May	DISC
	+ @	EQ 12MG BASE	N021169	003	Feb 28, 2001	May	DISC

GANCICLOVIR SODIUM

INJECTABLE; INJECTION CYTOVENE							
	+ @ CHEPLAPHARM	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989	Jul	DISC
GANCICLOVIR SODIUM							
AP	! PHARMASCIENCE INC	EQ 500MG BASE/VIAL	A207645	001	Dec 08, 2017	Jul	CHRS

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC GATIFLOXACIN							
AT	AKORN	0.5%	A203189	001	Sep 03, 2014	Feb	CAHN
	@ MYLAN	0.5%	A206446	001	Jun 08, 2018	Jun	DISC
>A> AT	TORRENT	0.5%	A213542	001	Nov 03, 2021	Oct	NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION GEMCITABINE HYDROCHLORIDE							
AP	HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A206617	001	Jun 25, 2021	Jun	NEWA
AP		EQ 1GM BASE/VIAL	A206617	002	Jun 25, 2021	Jun	NEWA
AP	! JIANGSU HANSON PHARM	EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Feb	CHRS
AP	!	EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Feb	CHRS
AP	MEITHEAL	200MG/5.26ML (38MG/ML)	A212129	001	Dec 11, 2020	Jan	CAHN
AP		1GM/26.3ML (38MG/ML)	A212129	002	Dec 11, 2020	Jan	CAHN
AP		2GM/52.6ML (38MG/ML)	A212129	003	Dec 11, 2020	Jan	CAHN
GEMZAR							
	+ @ LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Feb	DISC
	+ @	EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Feb	DISC

GEMFIBROZIL

TABLET; ORAL
 GEMFIBROZIL
 AB ASCENT PHARMS INC 600MG A214603 001 Jan 13, 2021 Jan NEWA

GLECAPREVIR; PIBRENTASVIR

PELLETS; ORAL
 MAVYRET
 +! ABBVIE INC 50MG; 20MG/PACKET N215110 001 Jun 10, 2021 Jun NEWA

GLIPIZIDE

TABLET; ORAL
 GLUCOTROL
 + @ PFIZER 2.5MG N017783 003 May 11, 1993 Aug CRLD

GLYBURIDE

TABLET; ORAL
 GLYBURIDE
 AB1 SUNNY 1.25MG A203581 001 Apr 14, 2016 Sep CAHN
 AB1 2.5MG A203581 002 Apr 14, 2016 Sep CAHN
 AB1 5MG A203581 003 Apr 14, 2016 Sep CAHN
 GLYNASE
 AB + PFIZER 1.5MG N020051 001 Mar 04, 1992 Feb CAHN
 AB + 3MG N020051 002 Mar 04, 1992 Feb CAHN
 + @ 4.5MG N020051 003 Sep 24, 1993 Feb CAHN
 AB +! 6MG N020051 004 Sep 24, 1993 Feb CAHN
 MICRONASE
 + @ PFIZER 1.25MG N017498 001 May 01, 1984 Feb CAHN
 @ 2.5MG N017498 002 May 01, 1984 Feb CAHN
 + @ 5MG N017498 003 May 01, 1984 Feb CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION
 GLYCOPYRROLATE
 AP ATHENEX INC 0.2MG/ML A210083 001 Feb 21, 2020 Jan CAHN
 AP HONG KONG 0.2MG/ML A212802 001 Jul 06, 2021 Jun NEWA
 AP MEITHEAL 0.2MG/ML A212802 001 Jul 06, 2021 Sep CAHN
 >A> AP NIVAGEN PHARMS INC 0.2MG/ML A212591 001 Oct 13, 2021 Oct NEWA
 AP XIROMED 0.2MG/ML A212227 001 Mar 04, 2021 Feb NEWA
 >A> AP ZYDUS PHARMS 0.2MG/ML A214213 001 Nov 09, 2021 Oct NEWA
 ROBINUL
 + @ HIKMA PHARMS 0.2MG/ML N017558 001 Jul CAHN
 SOLUTION; INTRAMUSCULAR, INTRAVENOUS
 GLYRX-PF
 >D> EXELA PHARMA 0.2MG/ML (0.2MG/ML) N210997 001 Jul 11, 2018 Oct CHRS
 >A> +! 0.2MG/ML (0.2MG/ML) N210997 001 Jul 11, 2018 Oct CHRS
 >D> 0.4MG/2ML (0.2MG/ML) N210997 002 Jul 11, 2018 Oct CHRS
 >A> +! 0.4MG/2ML (0.2MG/ML) N210997 002 Jul 11, 2018 Oct CHRS
 >D> 0.6MG/3ML (0.2MG/ML) N210997 004 Dec 14, 2020 Oct CHRS
 >A> +! 0.6MG/3ML (0.2MG/ML) N210997 004 Dec 14, 2020 Oct CHRS
 >D> 1MG/5ML (0.2MG/ML) N210997 003 Apr 09, 2020 Oct CHRS
 >A> +! 1MG/5ML (0.2MG/ML) N210997 003 Apr 09, 2020 Oct CHRS
 SOLUTION; ORAL
 CUVPOSA
 AA +! MERZ PHARMS 1MG/5ML N022571 001 Jul 28, 2010 Jul CFTG
 GLYCOPYRROLATE
 AA PAR PHARM INC 1MG/5ML A204438 001 Aug 09, 2021 Jul NFTG
 TABLET; ORAL
 ROBINUL
 AA + CASPER PHARMA LLC 1MG N012827 001 Jun CMFD
 ROBINUL FORTE
 AA + CASPER PHARMA LLC 2MG N012827 002 Jun CMFD

GLYCOPYRRONIUM TOSYLATE

CLOTH; TOPICAL
 QBREXZA
 +! JOURNEY EQ 2.4% BASE N210361 001 Jun 28, 2018 May CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

@	HIKMA PHARMS	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Jul	CAHN
@		EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Jul	CAHN
@		EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Jul	CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL

GRANISOL

@	INTRA SANA LABS	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jan	CAHN
---	-----------------	------------------	---------	-----	--------------	-----	------

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

@	CHARTWELL RX	EQ 4MG BASE	A074517	001	Sep 30, 1998	Aug	CAHN
@		EQ 8MG BASE	A074517	002	Sep 30, 1998	Aug	CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	!	AMNEAL PHARM	EQ 2MG BASE	A075109	002	Nov 25, 1998	Jan	CHRS
	@	MYLAN	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jan	DISC
	@		EQ 2MG BASE	A074796	002	Jan 27, 1997	Jan	DISC
AB		UNICHEM	EQ 1MG BASE	A214689	001	Mar 03, 2021	Feb	NEWA
AB			EQ 2MG BASE	A214689	002	Mar 03, 2021	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

	@	YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May	DISC
	@		EQ 2MG BASE	A213428	002	Nov 25, 2020	May	DISC
	@		EQ 3MG BASE	A213428	003	Nov 25, 2020	May	DISC
	@		EQ 4MG BASE	A213428	004	Nov 25, 2020	May	DISC

HALCINONIDE

CREAM; TOPICAL

HALCINONIDE

AB		GLASSHOUSE PHARMS	0.1%	A214723	001	Sep 08, 2021	Aug	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

HALOG

	+	SUN PHARM INDS INC	0.1%	N017823	001		Apr	CRLD
--	---	--------------------	------	---------	-----	--	-----	------

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

	@	COSETTE	0.05%	A077721	001	Sep 07, 2006	Mar	DISC
	+	@ SUN PHARM INDS INC	0.05%	N019968	001	Dec 17, 1990	Mar	DISC

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB		CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Apr	CMFD
AB			5MG	A071131	001	Feb 17, 1987	Apr	CMFD
AB			10MG	A071132	001	May 12, 1987	Apr	CMFD

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO		HONG KONG	EQ 50MG BASE/ML	A214507	001	Jul 26, 2021	Jul	NEWA
AO			EQ 100MG BASE/ML	A214507	002	Jul 26, 2021	Jul	NEWA
AO		MEITHEAL	EQ 50MG BASE/ML	A214507	001	Jul 26, 2021	Sep	CAHN
AO			EQ 100MG BASE/ML	A214507	002	Jul 26, 2021	Sep	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

	+	@ ORTHO MCNEIL	EQ 2MG BASE/ML	N015922	001		Mar	CRLD
--	---	----------------	----------------	---------	-----	--	-----	------

HEPARIN SODIUM

		INJECTABLE; INJECTION							
		HEPARIN SODIUM							
	@ BE PHARMS	1,000 UNITS/ML		A214804	001	Dec 29, 2020		Jun	DISC
AP	+! HIKMA PHARMS	1,000 UNITS/ML		N017037	001			Jul	CAHN
AP	+!	5,000 UNITS/ML		N017037	002			Jul	CAHN
	@	5,000 UNITS/0.5ML		N017037	013	Apr 07, 1986		Jul	CAHN
AP	+!	10,000 UNITS/ML		N017037	003			Jul	CAHN
	@ NANJING KING-FRIEND	5,000 UNITS/ML		A212061	001	Jul 15, 2020		Aug	DISC
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP	FRESENIUS KABI USA	200 UNITS/100ML		A212441	001	Jul 24, 2020		Apr	CMFD
	@	200 UNITS/100ML		A212441	001	Jul 24, 2020		Jan	DISC
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP	FRESENIUS KABI USA	200 UNITS/100ML		A212441	002	Jul 24, 2020		Apr	CMFD
	@	200 UNITS/100ML		A212441	002	Jul 24, 2020		Jan	DISC
HEPARIN SODIUM PRESERVATIVE FREE									
	@ NANJING KING-FRIEND	10,000 UNITS/ML		A212060	001	Apr 02, 2020		Aug	DISC
	@ SHENZHEN TECHDOW	1,000 UNITS/ML		A202732	001	Jun 12, 2014		Apr	DISC

HISTRELIN ACETATE

		IMPLANT; SUBCUTANEOUS							
		VANTAS							
	+ @ ENDO PHARM	50MG		N021732	001	Oct 12, 2004		Sep	DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

		TABLET; ORAL							
		HYCODAN							
AA	+ GENUS	1.5MG; 5MG		N005213	001	Jul 26, 1988		Sep	CMFD

HYDRALAZINE HYDROCHLORIDE

		TABLET; ORAL							
		HYDRALAZINE HYDROCHLORIDE							
AA	+! PLIVA	25MG		A088467	001	May 01, 1984		Aug	CRLD
AA	+!	50MG		A088468	001	May 01, 1984		Aug	CRLD
	@ UPSHER SMITH LABS	10MG		A209251	001	Jul 09, 2018		Aug	DISC
AA		10MG		A209251	001	Jul 09, 2018		May	CAHN
	@	25MG		A209251	002	Jul 09, 2018		Aug	DISC
AA		25MG		A209251	002	Jul 09, 2018		May	CAHN
	@	50MG		A209251	003	Jul 09, 2018		Aug	DISC
AA		50MG		A209251	003	Jul 09, 2018		May	CAHN
	@	100MG		A209251	004	Jul 09, 2018		Aug	DISC
AA		100MG		A209251	004	Jul 09, 2018		May	CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

		CAPSULE; ORAL							
		APRESAZIDE							
	+ @ NOVARTIS	25MG; 25MG		A084735	001			Aug	CRLD
	+ @	50MG; 50MG		A084810	001			Aug	CRLD

HYDROCHLOROTHIAZIDE

		CAPSULE; ORAL							
		MICROZIDE							
AB	+! TEVA BRANDED PHARM	12.5MG		N020504	001	Dec 27, 1996		Mar	CAHN
SOLUTION; ORAL									
HYDROCHLOROTHIAZIDE									
	+ @ ROXANE	50MG/5ML		A088587	001	Jul 02, 1984		Aug	CRLD
TABLET; ORAL									
HYDROCHLOROTHIAZIDE									
AB	+ IVAX SUB TEVA PHARMS	25MG		A083177	001			Aug	CRLD
AB	+!	50MG		A083177	002			Aug	CRLD
	+ @	100MG		A085022	001			Aug	CRLD

HYDROCHLOROTHIAZIDE; LISINOPRIL

		TABLET; ORAL							
		ZESTORETIC							
AB	+ ALMATICA	12.5MG; 10MG		N019888	003	Nov 18, 1993		Jan	CAHN
AB	+!	12.5MG; 20MG		N019888	001	Sep 20, 1990		Jan	CAHN
AB	+!	25MG; 20MG		N019888	002	Jul 20, 1989		Jan	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL		HYZAAR					
AB	+	ORGANON	12.5MG; 50MG	N020387	001	Apr 28, 1995	Aug CMFD
AB	+		25MG; 100MG	N020387	002	Nov 10, 1998	Aug CMFD
TABLET; ORAL		LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE					
AB		JUBILANT CADISTA	12.5MG; 50MG	A201845	001	Sep 18, 2012	Jun CAHN
AB			12.5MG; 100MG	A201845	002	Sep 18, 2012	Jun CAHN
AB			25MG; 100MG	A201845	003	Sep 18, 2012	Jun CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL		METHYLDOPA AND HYDROCHLOROTHIAZIDE					
	@	CHARTWELL RX	15MG; 250MG	A070182	001	Jan 15, 1986	Sep CAHN
	@		25MG; 250MG	A070183	001	Jan 15, 1986	Sep CAHN
	@		30MG; 500MG	A070543	001	Jan 15, 1986	Sep CAHN
	@		50MG; 500MG	A070544	001	Jan 15, 1986	Sep CAHN
	@	MYLAN	15MG; 250MG	A070265	002	Jan 23, 1986	Sep DISC
	@		25MG; 250MG	A070265	001	Jan 23, 1986	Sep DISC

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL		DUTOPIROL					
	+	@ CONCORDIA	12.5MG; EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun DISC
	+	@	12.5MG; EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun DISC
	+	@	12.5MG; EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL		LOPRESSOR HCT					
AB	+	VALIDUS PHARMS	25MG; 50MG	N018303	001	Dec 31, 1984	Feb CAHN
	+	@	25MG; 100MG	N018303	002	Dec 31, 1984	Feb CAHN
	+	@	50MG; 100MG	N018303	003	Dec 31, 1984	Feb CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL		PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	@	ANI PHARMS	25MG; 40MG	A070705	002	Oct 01, 1986	Jul CMS1
	@	MYLAN	25MG; 40MG	A070947	002	Mar 04, 1987	Aug CAHN
	@		25MG; 40MG	A070947	002	Mar 04, 1987	Aug DISC
	@		25MG; 80MG	A070947	001	Apr 01, 1987	Aug CAHN
	@		25MG; 80MG	A070947	001	Apr 01, 1987	Aug DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL		SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE					
	@	CHARTWELL RX	25MG; 25MG	A086881	001		Sep CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL		VALSARTAN AND HYDROCHLOROTHIAZIDE					
	@	CADILA	12.5MG; 80MG	A203000	001	Mar 15, 2019	Aug CAHN
	@		12.5MG; 160MG	A203000	002	Mar 15, 2019	Aug CAHN
	@		12.5MG; 320MG	A203000	003	Mar 15, 2019	Aug CAHN
	@		25MG; 160MG	A203000	004	Mar 15, 2019	Aug CAHN
	@		25MG; 320MG	A203000	005	Mar 15, 2019	Aug CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL		HYDROCODONE BITARTRATE					
>D>	AB	ALVOGEN	10MG	A206986	001	Jan 21, 2020	Oct CTEC
>A>	!		10MG	A206986	001	Jan 21, 2020	Oct CTEC
>D>	AB		15MG	A206986	002	Jan 21, 2020	Oct CTEC
>A>			15MG	A206986	002	Jan 21, 2020	Oct CTEC
>D>	AB		20MG	A206986	003	Jan 21, 2020	Oct CTEC
>A>			20MG	A206986	003	Jan 21, 2020	Oct CTEC
>D>	AB		30MG	A206986	004	Jan 21, 2020	Oct CTEC
>A>			30MG	A206986	004	Jan 21, 2020	Oct CTEC
>D>	AB		40MG	A206986	005	Jan 21, 2020	Oct CTEC
>A>			40MG	A206986	005	Jan 21, 2020	Oct CTEC
>D>	AB		50MG	A206986	006	Jan 21, 2020	Oct CTEC

CAPSULE, EXTENDED RELEASE;ORAL
HYDROCODONE BITARTRATE

>A>		50MG	A206986	006	Jan 21, 2020	Oct	CTEC
>D>	ZOHYDRO ER						
>D>	AB +!	RECRO GAINESVILLE 10MG	N202880	001	Oct 25, 2013	Oct	DISC
>A>	+ @	10MG	N202880	001	Oct 25, 2013	Oct	DISC
	AB +!	10MG	N202880	001	Oct 25, 2013	May	CAHN
>D>	AB +	15MG	N202880	002	Oct 25, 2013	Oct	DISC
>A>	+ @	15MG	N202880	002	Oct 25, 2013	Oct	DISC
	AB +	15MG	N202880	002	Oct 25, 2013	May	CAHN
>D>	AB +	20MG	N202880	003	Oct 25, 2013	Oct	DISC
>A>	+ @	20MG	N202880	003	Oct 25, 2013	Oct	DISC
	AB +	20MG	N202880	003	Oct 25, 2013	May	CAHN
>D>	AB +	30MG	N202880	004	Oct 25, 2013	Oct	DISC
>A>	+ @	30MG	N202880	004	Oct 25, 2013	Oct	DISC
	AB +	30MG	N202880	004	Oct 25, 2013	May	CAHN
>D>	AB +	40MG	N202880	005	Oct 25, 2013	Oct	DISC
>A>	+ @	40MG	N202880	005	Oct 25, 2013	Oct	DISC
	AB +	40MG	N202880	005	Oct 25, 2013	May	CAHN
>D>	AB +	50MG	N202880	006	Oct 25, 2013	Oct	DISC
>A>	+ @	50MG	N202880	006	Oct 25, 2013	Oct	DISC
	AB +	50MG	N202880	006	Oct 25, 2013	May	CAHN

TABLET, EXTENDED RELEASE;ORAL
HYDROCODONE BITARTRATE

AB	ALVOGEN PINE BROOK	20MG	A208269	001	Mar 01, 2021	Feb	NFTG
AB		30MG	A208269	002	Mar 01, 2021	Feb	NFTG
AB		40MG	A208269	003	Mar 01, 2021	Feb	NFTG
AB		60MG	A208269	004	Mar 01, 2021	Feb	NFTG
AB		80MG	A208269	005	Mar 01, 2021	Feb	NFTG
AB		100MG	A208269	006	Mar 01, 2021	Feb	NFTG
AB		120MG	A208269	007	Mar 01, 2021	Feb	NFTG
	HYSINGLA ER						
AB	+!	PURDUE PHARMA LP 20MG	N206627	001	Nov 20, 2014	Feb	CFTG
AB	+	30MG	N206627	002	Nov 20, 2014	Feb	CFTG
AB	+	40MG	N206627	003	Nov 20, 2014	Feb	CFTG
AB	+	60MG	N206627	004	Nov 20, 2014	Feb	CFTG
AB	+	80MG	N206627	005	Nov 20, 2014	Feb	CFTG
AB	+	100MG	N206627	006	Nov 20, 2014	Feb	CFTG
AB	+	120MG	N206627	007	Nov 20, 2014	Feb	CFTG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

	HYDROCODONE BITARTRATE AND IBUPROFEN						
AB	NOSTRUM LABS INC	5MG;200MG	A077727	001	Nov 06, 2006	Jan	CAHN
AB		7.5MG;200MG	A077723	001	Nov 06, 2006	Jan	CAHN
		10MG;200MG	A077723	002	Nov 06, 2006	Mar	CTEC
AB		10MG;200MG	A077723	002	Nov 06, 2006	Jan	CAHN
	REPREXAIN						
	@	AMNEAL PHARMS NY 2.5MG;200MG	A076642	003	Oct 19, 2007	Mar	DISC
	@	10MG;200MG	A076642	004	Oct 19, 2007	Mar	DISC

HYDROCORTISONE

CREAM;TOPICAL

	HYTONE						
	+ @	VALEANT INTL 1%	A080472	003		Aug	CRLD
	+ @	2.5%	A080472	004		Aug	CRLD
	SYNACORT						
	@	BAUSCH 0.5%	A087459	001		May	CAHN
	+ @	1%	A087458	001		Aug	CRLD
	@	1%	A087458	001		May	CAHN
	+ @	2.5%	A087457	001		Aug	CRLD
	@	2.5%	A087457	001		May	CAHN

ENEMA;RECTAL

	COLOCORT						
AB	CHARTWELL	100MG/60ML	A075172	001	Dec 03, 1999	Apr	CAHN

LOTION;TOPICAL

	HYTONE						
	+ @	VALEANT INTL 1%	A080473	003		Aug	CRLD
	+ @	2.5%	A080473	004	Nov 30, 1982	Aug	CRLD

OINTMENT;TOPICAL

	HYDROCORTISONE						
AT	+!	FOUGERA PHARMS 1%	A080692	001		Aug	CRLD

OINTMENT;TOPICAL
HYTONE

+ @ DERMIK LABS 1% A080474 003 Aug CRLD
+ @ 2.5% A080474 004 Aug CRLD

SOLUTION;TOPICAL
PENECORT

+ @ ALLERGAN HERBERT 1% A088214 001 Jun 06, 1984 Aug CRLD

HYDROCORTISONE ACETATE

CREAM;TOPICAL
CARMOL HC

+ @ FOUGERA PHARMS 1% A080505 001 Aug CRLD
HYDROCORTISONE ACETATE
+ @ PUREPAC PHARM 1% A086052 001 Aug CRLD

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL
CORTISPORIN

+ @ MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM N050218 001 Aug 09, 1985 Jul DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL
PROCTOFOAM HC

BX +! MYLAN SPECIALITY LP 1%;1% A086195 001 Aug CHRS
BX + 1%;1% A086195 001 Aug CRLD

HYDROCORTISONE PROBUTATE

CREAM;TOPICAL
PANDEL

+! ANI PHARMS 0.1% N020453 001 Feb 28, 1997 Apr CAHN

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
HYDROCORTONE

+ @ MERCK EQ 50MG BASE/ML N012052 001 Feb CRLD

HYDROCORTISONE VALERATE

CREAM;TOPICAL
HYDROCORTISONE VALERATE

AB COSETTE 0.2% A213724 001 Feb 11, 2021 Feb NEWA
>A> AB ENCUBE ETHICALS 0.2% A211047 001 Nov 04, 2021 Oct NEWA

HYDROMORPHINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
HYDROMORPHINE HYDROCHLORIDE

>D> AB OSMOTICA 8MG A205629 001 Jul 07, 2016 Oct CAHN
>D> AB 12MG A205629 002 Jul 07, 2016 Oct CAHN
>D> AB 16MG A205629 003 Jul 07, 2016 Oct CAHN
>D> AB ! 32MG A205629 004 Jul 07, 2016 Oct CAHN
>A> AB OSMOTICA PHARM US 8MG A205629 001 Jul 07, 2016 Oct CAHN
>A> AB 12MG A205629 002 Jul 07, 2016 Oct CAHN
>A> AB 16MG A205629 003 Jul 07, 2016 Oct CAHN
>A> AB ! 32MG A205629 004 Jul 07, 2016 Oct CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL
HYDROXYCHLOROQUINE SULFATE

ACCORD HLTHCARE 100MG A213342 002 Aug 18, 2021 Aug NEWA
300MG A213342 003 Aug 18, 2021 Aug NEWA
400MG A213342 004 Aug 18, 2021 Aug NEWA
AB SENORES PHARMS 200MG A212902 001 May 14, 2020 Jul CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR
MAKENA

AP1 +! COVIS 1250MG/5ML (250MG/ML) N021945 001 Feb 03, 2011 Mar CAHN
MAKENA PRESERVATIVE FREE
AP +! COVIS 250MG/ML (250MG/ML) N021945 002 Feb 19, 2016 Mar CAHN

SOLUTION;SUBCUTANEOUS								
MAKENA (AUTOINJECTOR)								
+!	COVIS	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Mar	CAHN	
<u>HYDROXYUREA</u>								
TABLET;ORAL								
SIKLOS								
+!	ADDMEDICA SAS	1GM	N208843	002	Dec 21, 2017	Mar	CHRS	
<u>HYDROXYZINE HYDROCHLORIDE</u>								
SYRUP;ORAL								
HYDROXYZINE HYDROCHLORIDE								
AA	+!	WOCKHARDT BIO AG	10MG/5ML	A087294	001	Apr 12, 1982	Aug	CRLD
TABLET;ORAL								
HYDROXYZINE HYDROCHLORIDE								
AB		BIOPHARM	10MG	A040804	001	Jun 30, 2008	Sep	CAHN
AB			25MG	A040804	002	Jun 30, 2008	Sep	CAHN
AB			50MG	A040804	003	Jun 30, 2008	Sep	CAHN
AB	+!	PLIVA	10MG	A088617	001	Jan 10, 1986	Aug	CRLD
AB	+!		25MG	A088618	001	Jan 10, 1986	Aug	CRLD
AB	+!		50MG	A088619	001	Jan 10, 1986	Aug	CRLD
AB		PRINSTON INC	10MG	A040580	003	May 27, 2005	Feb	CMS1
AB			25MG	A040580	002	May 27, 2005	Feb	CMS1
<u>HYDROXYZINE PAMOATE</u>								
CAPSULE;ORAL								
HYDROXYZINE PAMOATE								
BX		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Sep	CTEC
BX			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Sep	CTEC
<u>IBANDRONATE SODIUM</u>								
INJECTABLE;INTRAVENOUS								
IBANDRONATE SODIUM								
AP		NANG KUANG PHARM CO	EQ 3MG BASE/3ML	A204329	001	Jun 16, 2021	Jun	NEWA
<u>IBREXAFUNGERP CITRATE</u>								
TABLET;ORAL								
BREXAFEMME								
+!	SCYNEXIS	EQ 150MG BASE	N214900	001	Jun 01, 2021	Jun	NEWA	
<u>IBRUTINIB</u>								
CAPSULE;ORAL								
IBRUTINIB								
	@	ZYDUS	70MG	A211344	001	Mar 31, 2021	Jul	DISC
AB			70MG	A211344	001	Mar 31, 2021	Mar	NFTG
	@		140MG	A211344	002	Mar 31, 2021	Jul	DISC
AB			140MG	A211344	002	Mar 31, 2021	Mar	NFTG
IMBRUVICA								
	+	PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017	Jul	CTEC
AB	+		70MG	N205552	002	Dec 20, 2017	Mar	CFTG
	+!		140MG	N205552	001	Nov 13, 2013	Jul	CTEC
AB	+!		140MG	N205552	001	Nov 13, 2013	Mar	CFTG
<u>IBUPROFEN</u>								
SUSPENSION;ORAL								
IBUPROFEN								
AB		PADAGIS US	100MG/5ML	A076925	001	Sep 23, 2004	Jul	CAHN
TABLET;ORAL								
IBUPROFEN								
AB		ALKEM LABS LTD	400MG	A214699	001	Sep 13, 2021	Sep	NEWA
AB			600MG	A214699	002	Sep 13, 2021	Sep	NEWA
AB			800MG	A214699	003	Sep 13, 2021	Sep	NEWA
AB		L PERRIGO CO	400MG	A077114	001	Jul 18, 2005	Jul	CAHN
AB			600MG	A077114	002	Jul 18, 2005	Jul	CAHN
AB			800MG	A077114	003	Jul 18, 2005	Jul	CAHN
	@	VINTAGE PHARMS	400MG	A071644	001	Feb 01, 1988	Feb	DISC

<u>IBUTILIDE FUMARATE</u>							
INJECTABLE; INJECTION							
CORVERT							
AP	+	PFIZER	0.1MG/ML	N020491	001	Dec 28, 1995	Feb CAHN
<u>ICATIBANT ACETATE</u>							
INJECTABLE; SUBCUTANEOUS							
ICATIBANT ACETATE							
AP		@ DR REDDYS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213054	001	Oct 05, 2020	May DISC
		GLENMARK PHARMS LTD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213222	001	May 21, 2021	May NEWA
<u>ICOSAPENT ETHYL</u>							
CAPSULE; ORAL							
ICOSAPENT ETHYL							
AB		APOTEX	1GM	A209437	001	Jun 30, 2021	Jun NEWA
		@ TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Mar DISC
		@	1GM	A209525	002	Sep 11, 2020	Mar DISC
VASCEPA							
	+	AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar CTEC
<u>ILOPROST</u>							
SOLUTION; INHALATION							
VENTAVIS							
	+	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Feb CAHN
		@	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004	Feb CAHN
	+		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Feb CAHN
<u>IMIPRAMINE HYDROCHLORIDE</u>							
TABLET; ORAL							
IMIPRAMINE HYDROCHLORIDE							
AB	+	SPECGX LLC	10MG	A087846	002	May 22, 1984	Aug CRLD
AB	+		25MG	A087846	003	May 22, 1984	Aug CRLD
TOFRANIL							
AB	+	SPECGX LLC	50MG	A087846	001	May 22, 1984	Aug CRLD
<u>IMIQUIMOD</u>							
CREAM; TOPICAL							
IMIQUIMOD							
AB		TARO	3.75%	A205971	001	Jan 26, 2021	Jan NFTG
ZYCLARA							
AB	+	BAUSCH	3.75%	N022483	001	Mar 25, 2010	Jan CFTG
<u>INDAPAMIDE</u>							
TABLET; ORAL							
INDAPAMIDE							
AB	!	ANI PHARMS	2.5MG	A074299	001	Jul 27, 1995	Jul CHRS
		@ MYLAN	1.25MG	A074461	002	Mar 26, 1997	Jul DISC
		@	2.5MG	A074461	001	Mar 27, 1996	Jul DISC
<u>INDOCYANINE GREEN</u>							
INJECTABLE; INJECTION							
INDOCYANINE GREEN							
AP		RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	Jun CAHN
<u>INDOMETHACIN</u>							
CAPSULE; ORAL							
INDOMETHACIN							
		@ JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017	Jan DISC
		@	50MG	A205215	002	Aug 25, 2017	Jan DISC
TIVORBEX							
	+	@ GENUS	20MG	N204768	001	Feb 24, 2014	Apr DISC
	+	@	40MG	N204768	002	Feb 24, 2014	Apr DISC
CAPSULE, EXTENDED RELEASE; ORAL							
INDOMETHACIN							
		@ AUROBINDO PHARMA LTD	75MG	A204243	001	Dec 27, 2016	Jan DISC
		@ JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015	Jun DISC

INFIGRATINIB PHOSPHATE

CAPSULE; ORAL

TRUSELTIQ

+	HELSINN HLTHCARE	25MG	N214622	001	May 28, 2021	Sep	CAHN
+	!	100MG	N214622	002	May 28, 2021	Sep	CAHN
+	QED THERAP	25MG	N214622	001	May 28, 2021	May	NEWA
+	!	100MG	N214622	002	May 28, 2021	May	NEWA

IOPAMIDOL

INJECTABLE; INJECTION

ISOVUE-300

+	!	BRACCO	61%	N018735	002	Dec 31, 1985	Jan	CTEC
		ISOVUE-370						
+	!	BRACCO	76%	N018735	003	Dec 31, 1985	Jan	CTEC
		SCANLUX-300						
	@	SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Jan	DISC
		SCANLUX-370						
	@	SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Jan	DISC

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+	@	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	Sep	DISC
---	---	------------------	-----	---------	-----	--------------	-----	------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN		LUOXIN AUROVITAS	0.02%	A206543	001	Oct 27, 2016	Aug	CAHN
>D>	@	PHARMASCIENCE INC	0.02%	A075507	001	Jan 19, 2001	Oct	CAHN
>A>	@	ZENNOVA	0.02%	A075507	001	Jan 19, 2001	Oct	CAHN

IRBESARTAN

TABLET; ORAL

IRBESARTAN

>A>	@	PICKET PHARMS	75MG	A203161	001	Sep 27, 2012	Oct	CAHN
>A>	@		150MG	A203161	002	Sep 27, 2012	Oct	CAHN
>A>	@		300MG	A203161	003	Sep 27, 2012	Oct	CAHN
>D>	@	US ANTIBIOTICS	75MG	A203161	001	Sep 27, 2012	Oct	CAHN
	@		75MG	A203161	001	Sep 27, 2012	May	CAHN
>D>	@		150MG	A203161	002	Sep 27, 2012	Oct	CAHN
	@		150MG	A203161	002	Sep 27, 2012	May	CAHN
>D>	@		300MG	A203161	003	Sep 27, 2012	Oct	CAHN
	@		300MG	A203161	003	Sep 27, 2012	May	CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

>A>	@	PICKET PHARMS	40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010	Oct	CAHN
>A>	@		100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010	Oct	CAHN
>D>	@	US ANTIBIOTICS	40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010	Oct	CAHN
	@		40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010	May	CAHN
>D>	@		100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010	Oct	CAHN
	@		100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010	May	CAHN

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HYDROCHLORIDE

+	@	ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982	Aug	CRLD
+	@		0.125%	A087938	001	Nov 15, 1982	Aug	CRLD
+	@		0.167%	A088470	001	Mar 14, 1984	Aug	CRLD
+	@		0.2%	A088471	001	Mar 14, 1984	Aug	CRLD
+	@		0.25%	A088472	001	Mar 14, 1984	Aug	CRLD
+	@	DEY	1%	A086763	001		Aug	CRLD

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

AN		PIRAMAL PHARMA	99.9%	A074502	001	Jun 27, 1995	Aug	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

ISONIAZIDSYRUP;ORAL
ISONIAZID

+! CMP PHARMA INC 50MG/5ML A088235 001 Nov 10, 1983 Aug CRLD

ISOPROTERENOL HYDROCHLORIDEINJECTABLE;INJECTION
ISOPROTERENOL HYDROCHLORIDE

AP	AMRING PHARMS	0.2MG/ML	A211237	001	May 19, 2021	May NEWA
	@ CIPLA	0.2MG/ML	A211738	001	Jun 28, 2019	Aug DISC
AP	MICRO LABS	0.2MG/ML	A210845	001	Feb 16, 2021	Feb NEWA

ISOSULFAN BLUEINJECTABLE;INJECTION
ISOSULFAN BLUE

>A> AP HONG KONG 1% A213130 001 Nov 03, 2021 Oct NEWA

ISOTRETINOINCAPSULE;ORAL
ABSORICA

AB2	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012	Mar CFTG
AB2	+		20MG	N021951	002	May 25, 2012	Mar CFTG
AB2	+		25MG	N021951	005	Aug 15, 2014	Mar CFTG
AB2	+		30MG	N021951	003	May 25, 2012	Mar CFTG
AB2	+		35MG	N021951	006	Aug 15, 2014	Mar CFTG
AB2	+		40MG	N021951	004	May 25, 2012	Mar CFTG

AMNESTEEM

AB1		MYLAN PHARMS INC	10MG	A075945	001	Nov 08, 2002	Mar CTEC
AB1			20MG	A075945	002	Nov 08, 2002	Mar CTEC
AB1			40MG	A075945	003	Nov 08, 2002	Mar CTEC

CLARAVIS

AB1		TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003	Mar CTEC
AB1			20MG	A076135	002	Apr 11, 2003	Mar CTEC
AB1			30MG	A076135	003	May 11, 2006	Mar CTEC
AB1	!		40MG	A076135	001	Apr 11, 2003	Mar CTEC

ISOTRETINOIN

AB2		ACTAVIS LABS FL	10MG	A205063	001	Mar 31, 2021	Mar NFTG
AB2			20MG	A205063	002	Mar 31, 2021	Mar NFTG
AB2			25MG	A205063	003	Mar 31, 2021	Mar NFTG
AB2			30MG	A205063	004	Mar 31, 2021	Mar NFTG
AB2			35MG	A205063	005	Mar 31, 2021	Mar NFTG
AB2			40MG	A205063	006	Mar 31, 2021	Mar NFTG
AB1		AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Mar CTEC
AB1			20MG	A207792	002	Sep 29, 2017	Mar CTEC
AB1			30MG	A207792	003	Sep 29, 2017	Mar CTEC
AB1			40MG	A207792	004	Sep 29, 2017	Mar CTEC
AB2		UPSHER SMITH LABS	10MG	A212333	001	Sep 21, 2021	Sep NEWA
AB2			20MG	A212333	002	Sep 21, 2021	Sep NEWA
AB2			30MG	A212333	003	Sep 21, 2021	Sep NEWA
AB2			40MG	A213571	001	Apr 12, 2021	Apr NEWA

MYORISAN

AB1		DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Mar CTEC
AB1			20MG	A076485	002	Jan 19, 2012	Mar CTEC
AB1			30MG	A076485	004	Aug 25, 2015	Mar CTEC
AB1			40MG	A076485	003	Jan 19, 2012	Mar CTEC

ZENATANE

AB1		DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar CTEC
AB1			20MG	A202099	002	Mar 25, 2013	Mar CTEC
AB1			30MG	A202099	004	Feb 23, 2015	Mar CTEC
AB1			40MG	A202099	003	Mar 25, 2013	Mar CTEC

ITRACONAZOLECAPSULE;ORAL
ITRACONAZOLE

BX STRIDES PHARMA 100MG A206410 001 Jul 02, 2019 Sep CTEC

TABLET;ORAL
ONMEL

+ @ SEBELA IRELAND LTD 200MG N022484 001 Apr 29, 2010 Apr DISC

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET; ORAL

SYMDEKO (COPACKAGED)

+	VERTEX PHARMS INC	75MG;75MG, 50MG	N210491	002	Jun 21, 2019	Jul	CPOT
+		75MG,N/A;75MG, 50MG	N210491	002	Jun 21, 2019	Jul	CDFR
+	!	150MG;150MG, 100MG	N210491	001	Feb 12, 2018	Jul	CPOT
+	!	150MG,N/A;150MG, 100MG	N210491	001	Feb 12, 2018	Jul	CDFR

IVOSIDENIB

TABLET; ORAL

TIBSOVO

+	!	SERVIER	250MG	N211192	001	Jul 20, 2018	Apr	CAHN
---	---	---------	-------	---------	-----	--------------	-----	------

IXAZOMIB CITRATE

CAPSULE; ORAL

NINLARO

+	TAKEDA PHARMS USA	EQ 2.3MG BASE	N208462	001	Nov 20, 2015	May	CAHN
+		EQ 3MG BASE	N208462	002	Nov 20, 2015	May	CAHN
+	!	EQ 4MG BASE	N208462	003	Nov 20, 2015	May	CAHN

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HYDROCHLORIDE

AP	AUROMEDICS PHARMA	EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Jan	CAHN
AP		EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Jan	CAHN
AP		EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Jan	CAHN
AP	EUGIA PHARMA	EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Aug	CAHN
AP		EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Aug	CAHN
AP		EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Aug	CAHN

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA

AB	+	!	MYLAN	2%	N021738	001	Jun 12, 2007	Sep	CTEC
			KETOCONAZOLE						
AB			PADAGIS ISRAEL	2%	A091550	001	Aug 25, 2011	Sep	CTEC
AB			XIROMED	2%	A213601	001	May 21, 2021	Sep	CTEC
AT				2%	A213601	001	May 21, 2021	May	NEWA

CREAM; TOPICAL

KETOCONAZOLE

AB			ENCUBE	2%	A212443	001	May 20, 2021	May	NEWA
----	--	--	--------	----	---------	-----	--------------	-----	------

TABLET; ORAL

KETOCONAZOLE

			@ MYLAN	200MG	A075597	001	Dec 23, 1999	Mar	DISC
AB			SENORES PHARMS	200MG	A075912	001	Jan 10, 2002	Aug	CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

			!	HERITAGE PHARMS INC	75MG	A074014	003	Jan 29, 1993	Jul	CTEC
AB			!		75MG	A074014	003	Jan 29, 1993	Jul	CHRS
			@	RISING	50MG	A074024	001	Dec 29, 1995	Jan	CAHN
			@		75MG	A074024	002	Dec 29, 1995	Jan	CAHN
			@	TEVA	75MG	A073517	001	Dec 22, 1992	Jul	DISC

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

			@	HOSPIRA	15MG/ML	A074993	001	Jan 27, 1999	Mar	DISC
--	--	--	---	---------	---------	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP			BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002	Mar	CMFD
AP			CAPLIN	5MG/ML	A214533	001	Sep 07, 2021	Aug	NEWA

SOLUTION; INTRAVENOUS

LABETALOL HYDROCHLORIDE IN DEXTROSE

+	!	HIKMA PHARMS	200MG/200ML (1MG/ML)	N213330	001	Nov 09, 2020	Sep	CAHN
---	---	--------------	----------------------	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE

+	!	HIKMA PHARMS	100MG/100ML (1MG/ML)	N213330	002	Nov 09, 2020	Sep	CAHN
+	!		200MG/200ML (1MG/ML)	N213330	003	Nov 09, 2020	Sep	CAHN

SOLUTION;INTRAVENOUS

LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE

+! 300MG/300ML (1MG/ML) N213330 004 Nov 09, 2020 Sep CAHN

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB ! PAR FORM 200MG A200908 002 Jul 10, 2012 Jul CHRS
 AB RUBICON 100MG A211953 001 Aug 18, 2021 Aug NEWA
 AB 200MG A211953 002 Aug 18, 2021 Aug NEWA
 AB 300MG A211953 003 Aug 18, 2021 Aug NEWA

TRANDATE

+ @ ALVOGEN 100MG N018716 001 May 24, 1985 Jul DISC
 AB + 100MG N018716 001 May 24, 1985 Jul CAHN
 >D> + @ 200MG N018716 002 Aug 01, 1984 Oct CMFD
 >A> AB + 200MG N018716 002 Aug 01, 1984 Oct CMFD
 + @ 200MG N018716 002 Aug 01, 1984 Jul DISC
 AB +! 200MG N018716 002 Aug 01, 1984 Jul CAHN
 >D> + @ 300MG N018716 003 Aug 01, 1984 Oct CMFD
 >A> AB + 300MG N018716 003 Aug 01, 1984 Oct CMFD
 + @ 300MG N018716 003 Aug 01, 1984 Jul DISC
 AB + 300MG N018716 003 Aug 01, 1984 Jul CAHN
 + @ 400MG N018716 004 Aug 01, 1984 Jul CAHN
 AB +! CNTY LINE PHARMS 200MG N018716 002 Aug 01, 1984 Apr CHRS

LACTULOSE

SOLUTION;ORAL

LACTULOSE

AA TORRENT 10GM/15ML A207786 001 Jun 11, 2018 Jun CMFD

SOLUTION;ORAL, RECTAL

LACTULOSE

AA TORRENT 10GM/15ML A203762 001 Mar 27, 2015 Jun CMFD

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

AB APPCO 150MG A206974 001 Nov 21, 2016 Sep CAHN
 AB 300MG A206974 002 Nov 21, 2016 Sep CAHN
 AB BRECKENRIDGE 150MG A203586 001 Nov 21, 2016 Sep CAHN
 AB CENTAUR PHARMS PVT 150MG A203586 001 Nov 21, 2016 Jun CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+ @ AUROBINDO PHARMA LTD 300MG;300MG N022344 001 May 15, 2018 Feb DISC

TEMIXYS

+ @ CELLTRION 300MG;300MG N211284 001 Nov 16, 2018 Aug DISC

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

@ GRANULES 25MG A078982 001 Jan 27, 2009 Jun CAHN
 @ 100MG A078982 002 Jan 27, 2009 Jun CAHN
 @ 150MG A078982 003 Jan 27, 2009 Jun CAHN
 @ 200MG A078982 004 Jan 27, 2009 Jun CAHN
 @ ZENNOVA 25MG A078310 001 Feb 04, 2009 Sep CAHN
 @ 100MG A078310 002 Feb 04, 2009 Sep CAHN
 @ 150MG A078310 003 Feb 04, 2009 Sep CAHN
 @ 200MG A078310 004 Feb 04, 2009 Sep CAHN

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

@ JUBILANT GENERICS 5MG A200220 001 Feb 28, 2011 Jun DISC
 @ 25MG A200220 002 Feb 28, 2011 Jun DISC

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB ACTAVIS ELIZABETH 250MG A200672 006 Nov 13, 2013 Jul CMS1

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

AB AJANTA PHARMA LTD 25MG A213271 001 Jan 19, 2021 Jan NEWA
 AB 50MG A213271 002 Jan 19, 2021 Jan NEWA
 AB 100MG A213271 003 Jan 19, 2021 Jan NEWA
 AB 200MG A213271 004 Jan 19, 2021 Jan NEWA

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
PREVACID

+ @ TAKEDA PHARMS USA 15MG

N020406 001 May 10, 1995 Jun DISC

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

AB DR REDDYS LABS LTD 15MG

A210465 001 Feb 01, 2021 Jan NEWA

AB 30MG

A210465 002 Feb 01, 2021 Jan NEWA

LASMIDITAN SUCCINATE

TABLET;ORAL

REYVOW

+ ELI LILLY AND CO EQ 50MG BASE

N211280 001 Jan 31, 2020 May CPOT

+! EQ 100MG BASE

N211280 002 Jan 31, 2020 Aug CHRS

+ EQ 100MG BASE

N211280 002 Jan 31, 2020 May CHRS

+! EQ 100MG BASE

N211280 002 Jan 31, 2020 May CPOT

+ @ EQ 200MG BASE

N211280 003 Dec 18, 2020 Aug DISC

+! EQ 200MG BASE

N211280 003 Dec 18, 2020 May CHRS

+ EQ 200MG BASE

N211280 003 Dec 18, 2020 May CPOT

LATANOPROST

EMULSION;OPHTHALMIC

XELPROS

>A> +! SUN PHARM 0.005%

N206185 001 Sep 12, 2018 Oct CAHN

>D> +! SUN PHARMA GLOBAL 0.005%

N206185 001 Sep 12, 2018 Oct CAHN

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

AB AUROBINDO PHARMA LTD 10MG

A213652 001 Mar 29, 2021 Mar NEWA

AB 20MG

A213652 002 Mar 29, 2021 Mar NEWA

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB ARROW INTL 5MG

A201452 001 May 21, 2021 Jul CAHN

AB 10MG

A201452 002 May 21, 2021 Jul CAHN

AB 15MG

A201452 003 May 21, 2021 Jul CAHN

AB 25MG

A201452 004 May 21, 2021 Jul CAHN

>A> AB DR REDDYS 2.5MG

A209348 001 Oct 14, 2021 Oct NFTG

>A> AB 20MG

A209348 002 Oct 14, 2021 Oct NFTG

AB NATCO PHARMA LTD 5MG

A201452 001 May 21, 2021 May NFTG

AB 10MG

A201452 002 May 21, 2021 May NFTG

AB 15MG

A201452 003 May 21, 2021 May NFTG

AB 25MG

A201452 004 May 21, 2021 May NFTG

REVLIMID

>D> + CELGENE 2.5MG

N021880 005 Dec 21, 2011 Oct CFTG

>A> AB + 2.5MG

N021880 005 Dec 21, 2011 Oct CFTG

AB + 5MG

N021880 001 Dec 27, 2005 May CFTG

AB + 10MG

N021880 002 Dec 27, 2005 May CFTG

AB + 15MG

N021880 003 Jun 29, 2006 May CFTG

>D> + 20MG

N021880 006 Jun 05, 2013 Oct CFTG

>A> AB + 20MG

N021880 006 Jun 05, 2013 Oct CFTG

AB +! 25MG

N021880 004 Jun 29, 2006 May CFTG

LETROZOLE

TABLET;ORAL

LETROZOLE

@ APOTEX INC 2.5MG

A091303 001 Apr 19, 2012 Jan DISC

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET;ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

+! NOVARTIS 2.5MG;EQ 200MG BASE

N209935 001 May 04, 2017 Jul CPOT

+! 2.5MG,N/A;N/A,EQ 200MG BASE

N209935 001 May 04, 2017 Jul CDFR

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION							
LEUCOVORIN CALCIUM							
AP	!	HIKMA PHARMS	EQ 50MG BASE/VIAL	A089384	001	Sep 14, 1987	Jul CAHN
AP	!		EQ 100MG BASE/VIAL	A089717	001	Mar 28, 1988	Jul CAHN
		@ NOVAST LABS	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Sep CAHN
TABLET; ORAL							
LEUCOVORIN CALCIUM							
AB		EPIC PHARMA LLC	EQ 10MG BASE	A074544	003	May 19, 2021	May NEWA
AB			EQ 15MG BASE	A074544	004	May 19, 2021	May NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION							
LEUPROLIDE ACETATE							
AP		VGYAAN	1MG/0.2ML	A213829	001	Aug 13, 2021	Aug NEWA

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL							
LUPANETA PACK							
	+	@ ABBVIE ENDOCRINE	3.75MG/VIAL, N/A; N/A, 5MG	N203696	001	Dec 14, 2012	Aug DISC
	+	@	11.25MG/VIAL, N/A; N/A, 5MG	N203696	002	Dec 14, 2012	Aug DISC

LEUPROLIDE MESYLATE

EMULSION; SUBCUTANEOUS							
CAMCEVI KIT							
	+	! FORESEE PHARMS	EQ 42MG BASE	N211488	001	May 25, 2021	May NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION							
LEVALBUTEROL HYDROCHLORIDE							
AN		LUOXIN AUROVITAS	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Aug CAHN
AN			EQ 0.0103% BASE	A207625	001	Dec 30, 2016	Aug CAHN
AN			EQ 0.021% BASE	A207625	002	Dec 30, 2016	Aug CAHN
AN			EQ 0.042% BASE	A207625	003	Dec 30, 2016	Aug CAHN

LEVETIRACETAM

INJECTABLE; INTRAVENOUS							
LEVETIRACETAM							
		@ JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jun DISC
LEVETIRACETAM IN SODIUM CHLORIDE							
AP		GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Feb CPOT
AP			1.5GM/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Feb CDFR
AP	+	! HQ SPECIALITY PHARMA	1GM/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Feb CPOT
AP	+		1.5GM/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Feb CPOT
AP		NEXUS PHARMS	1GM/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Feb CPOT
AP			1.5GM/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Feb CPOT
SOLUTION; ORAL							
LEVETIRACETAM							
AA		AKORN	100MG/ML	A090601	001	Feb 28, 2012	Feb CAHN
TABLET; ORAL							
LEVETIRACETAM							
		@ LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Aug DISC
		@	750MG	A090906	003	Oct 31, 2016	Aug DISC
		@	1GM	A090906	004	Oct 31, 2016	Aug DISC
		@ NOSTRUM LABS INC	250MG	A090511	001	Aug 18, 2011	Mar DISC
AB			250MG	A090511	001	Aug 18, 2011	Jan CAHN
		@	500MG	A090511	002	Aug 18, 2011	Mar DISC
AB			500MG	A090511	002	Aug 18, 2011	Jan CAHN
		@	750MG	A090511	003	Aug 18, 2011	Mar DISC
AB			750MG	A090511	003	Aug 18, 2011	Jan CAHN
		@	1GM	A090511	004	Aug 18, 2011	Mar DISC
AB			1GM	A090511	004	Aug 18, 2011	Jan CAHN
AB		SCIEGEN PHARMS INC	750MG	A215069	001	Jun 11, 2021	Jun NEWA
AB			1GM	A215069	002	Jun 11, 2021	Jun NEWA
TABLET, EXTENDED RELEASE; ORAL							
ELEPSIA XR							
	+	TRIPOINT	1GM	N204417	001	Dec 20, 2018	Jan CAHN
	+	!	1.5GM	N204417	002	Dec 20, 2018	Jan CAHN
LEVETIRACETAM							
AB		GENUS LIFESCIENCES	500MG	A204754	001	Aug 26, 2016	Sep CAHN
AB			750MG	A204754	002	Aug 26, 2016	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

	@	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	Aug	DISC
	@		750MG	A202095	001	Jun 06, 2016	Aug	DISC
AB		OVERSEAS	750MG	A212688	001	Jun 11, 2020	May	CMFD
>D>	AB	ROUSES POINT PHARMS	500MG	A202524	001	Aug 27, 2012	Oct	DISC
>A>		@	500MG	A202524	001	Aug 27, 2012	Oct	DISC
>D>	AB		750MG	A202524	002	Aug 27, 2012	Oct	DISC
>A>		@	750MG	A202524	002	Aug 27, 2012	Oct	DISC

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA

	@	AKORN	0.25%	A074779	001	Oct 29, 1996	Jul	DISC
	@		0.5%	A074780	001	Oct 29, 1996	Jul	DISC
		BETAGAN						
	+	@ ALLERGAN	0.25%	N019814	001	Jun 28, 1989	Jun	DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA	!	PADAGIS US	2.5MG/5ML	A091263	001	Nov 07, 2011	Jul	CAHN
		XYZAL						
	+	@ SANOFI	2.5MG/5ML	N022157	001	Jan 28, 2008	Apr	DISC

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	!	GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Apr	CHRS
	@	GRANULES	5MG	A090486	001	Mar 26, 2013	Apr	CAHN
	@	NEOPHARMA	5MG	A204323	001	Dec 20, 2016	Mar	DISC
	@	US ANTIBIOTICS	5MG	A204323	001	Dec 20, 2016	May	CAHN
		XYZAL						
	+	@ SANOFI	5MG	N022064	001	May 25, 2007	Apr	DISC

LEVOFLOXACIN

TABLET;ORAL

LEVOFLOXACIN

AB		CADILA	250MG	A077652	001	Sep 07, 2012	Jun	CAHN
AB			500MG	A077652	002	Sep 07, 2012	Jun	CAHN
AB			750MG	A077652	003	Sep 07, 2012	Jun	CAHN
	@	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun	DISC
	@		500MG	A203613	002	Jun 19, 2015	Jun	DISC

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

AP		HIKMA PHARMS	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jul	CAHN
----	--	--------------	-------------------	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

>A>	AP	PRAIXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Oct	NEWA
-----	----	----------	--	---------	-----	--------------	-----	------

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

LILETTA

>D>		MEDICINES360	52MG	N206229	001	Feb 26, 2015	Oct	CRLD
>A>		+	52MG	N206229	001	Feb 26, 2015	Oct	CRLD

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

		NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021	Jul	NEWA
AB			3MG	A213479	002	Jan 12, 2021	Jan	NEWA
AB	!	SENTYNL THERAPS INC	3MG	A074278	003	Jun 18, 2018	Jan	CTEC
AB		SUN PHARM INDS INC	2MG	A213906	001	Jun 17, 2021	Jun	NEWA

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

	@	TEVA PHARMS USA INC	0.075MG	A211369	001	Oct 28, 2020	Apr	DISC
	@		0.088MG	A213256	001	Jan 06, 2021	Jul	DISC
	@		0.1MG	A213256	002	Jan 06, 2021	Jul	DISC
AB			0.112MG	A211369	003	Apr 16, 2021	Apr	NFTG

CAPSULE;ORAL		LEVOTHYROXINE SODIUM						
	@	0.125MG		A213256	003	Jan 06, 2021	Jul	DISC
	@	0.15MG		A211369	002	Oct 28, 2020	Apr	DISC
TIROSINT								
	+	INSTITUT BIOCHIMIQUE	0.075MG	N021924	004	Oct 13, 2006	Apr	CTEC
>D>	AB	+	0.088MG	N021924	010	Oct 02, 2009	Oct	CTEC
>A>		+	0.088MG	N021924	010	Oct 02, 2009	Oct	CTEC
>D>	AB	+	0.1MG	N021924	005	Oct 13, 2006	Oct	CTEC
>A>		+	0.1MG	N021924	005	Oct 13, 2006	Oct	CTEC
	AB	+	0.112MG	N021924	008	Oct 02, 2009	Apr	CFTG
>D>	AB	+	0.125MG	N021924	006	Oct 13, 2006	Oct	CTEC
>A>		+	0.125MG	N021924	006	Oct 13, 2006	Oct	CTEC
	+		0.15MG	N021924	007	Oct 13, 2006	Apr	CTEC
POWDER;INTRAVENOUS		LEVOTHYROXINE SODIUM						
	@	DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020	Feb	DISC
SOLUTION;INTRAVENOUS		LEVOTHYROXINE SODIUM						
	+	CUSTOPHARM INC	100MCG/ML	N214253	001	May 17, 2021	May	NEWA
SOLUTION;ORAL		THYQUIDITY						
	+	VISTAPHARM	100MCG/5ML	N214047	001	Nov 30, 2020	Apr	CAHN
TIROSINT-SOL								
	+	INSTITUT BIOCHIMIQUE	37.5MCG/ML	N206977	013	Jan 13, 2021	Jan	NEWA
	+		44MCG/ML	N206977	014	Jan 13, 2021	Jan	NEWA
	+		62.5MCG/ML	N206977	015	Jan 13, 2021	Jan	NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL		THYRO-TABS						
AB2,	+	ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Sep	CAHN
AB4								
AB2,	+		0.05MG	N021116	002	Oct 24, 2002	Sep	CAHN
AB4								
AB2,	+		0.075MG	N021116	003	Oct 24, 2002	Sep	CAHN
AB4								
AB2,	+		0.088MG	N021116	010	Oct 24, 2002	Sep	CAHN
AB4								
AB2,	+		0.1MG	N021116	004	Oct 24, 2002	Sep	CAHN
AB4								
AB2,	+		0.112MG	N021116	011	Oct 24, 2002	Sep	CAHN
AB4								
AB2,	+		0.125MG	N021116	005	Oct 24, 2002	Sep	CAHN
AB4								
AB2,	+		0.137MG	N021116	012	Dec 07, 2004	Sep	CAHN
AB4								
AB2,	+		0.15MG	N021116	006	Oct 24, 2002	Sep	CAHN
AB4								
AB2,	+		0.175MG	N021116	007	Oct 24, 2002	Sep	CAHN
AB4								
AB2,	+		0.2MG	N021116	008	Oct 24, 2002	Sep	CAHN
AB4								
AB2,	+		0.3MG	N021116	009	Oct 24, 2002	Sep	CAHN
AB4								

LIDOCAINE

OINTMENT;TOPICAL		LIDOCAINE						
AT	+	FOUGERA PHARMS INC	5%	A080198	001		Aug	CRLD
AT		QUAGEN	5%	A212695	001	Apr 20, 2021	Apr	NEWA
	@	RISING	5%	A208604	001	Sep 20, 2017	May	CAHN
PATCH;TOPICAL		LIDOCAINE						
AB		NAL PHARM	5%	A205882	001	Apr 29, 2021	Apr	NEWA
	@	NOVEN PHARMS INC	5%	A203265	001	Dec 01, 2020	Jun	DISC

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION		LIDOCAINE HYDROCHLORIDE						
>A>	AP	ASPIRO	1%	A214336	001	Nov 08, 2021	Oct	NEWA
>A>	AP		1%	A214339	001	Nov 08, 2021	Oct	NEWA
>A>	AP		2%	A214339	002	Nov 08, 2021	Oct	NEWA

	JELLY; TOPICAL								
	XYLOCAINE								
	+ @ AKORN	2%		N008816	001				Jan DISC
	SOLUTION; ORAL								
	LIDOCAINE HYDROCHLORIDE VISCOUS								
AT	LANNETT CO INC	2%		A040708	001	Feb 27, 2007			Jan CMFD
	<u>LIDOCAINE; PRILOCAINE</u>								
	CREAM; TOPICAL								
	LIDOCAINE AND PRILOCAINE								
AB	ACRUX DDS PTY	2.5%; 2.5%		A212482	001	Jul 27, 2021			Jul NEWA
	<u>LINACLOTIDE</u>								
	CAPSULE; ORAL								
	LINACLOTIDE								
	@ MYLAN	145MCG		A209564	001	Feb 09, 2021			Feb DISC
AB		145MCG		A209564	001	Feb 09, 2021			Jan NFTG
	@	290MCG		A209564	002	Feb 09, 2021			Feb DISC
AB		290MCG		A209564	002	Feb 09, 2021			Jan NFTG
	LINZESS								
	+! ALLERGAN	145MCG		N202811	001	Aug 30, 2012			Feb CTEC
AB	+!	145MCG		N202811	001	Aug 30, 2012			Jan CFTG
	+	290MCG		N202811	002	Aug 30, 2012			Feb CTEC
AB	+	290MCG		N202811	002	Aug 30, 2012			Jan CFTG
	<u>LINAGLIPTIN</u>								
	TABLET; ORAL								
	LINAGLIPTIN								
AB	SUNSHINE	5MG		A208335	001	Aug 31, 2021			Aug NFTG
	TRADJENTA								
AB	+! BOEHRINGER INGELHEIM	5MG		N201280	001	May 02, 2011			Aug CFTG
	<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE</u>								
	TABLET; ORAL								
	JENTADUETO								
AB	+ BOEHRINGER INGELHEIM	2.5MG; 500MG		N201281	001	Jan 30, 2012			Aug CFTG
AB	+	2.5MG; 850MG		N201281	002	Jan 30, 2012			Aug CFTG
AB	+!	2.5MG; 1GM		N201281	003	Jan 30, 2012			Aug CFTG
	LINAGLIPTIN AND METFORMIN HYDROCHLORIDE								
AB	SUNSHINE	2.5MG; 500MG		A208336	001	Aug 30, 2021			Aug NFTG
AB		2.5MG; 850MG		A208336	002	Aug 30, 2021			Aug NFTG
AB		2.5MG; 1GM		A208336	003	Aug 30, 2021			Aug NFTG
	<u>LINCOMYCIN</u>								
	INJECTABLE; INJECTION								
	LINCOMYCIN								
>A>	AP MICRO LABS	EQ 300MG BASE/ML		A215082	001	Nov 08, 2021			Oct NEWA
	<u>LINCOMYCIN HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	LINCOCIN								
AP	+! PFIZER	EQ 300MG BASE/ML		N050317	001				Feb CAHN
	LINCOMYCIN HYDROCHLORIDE								
	@ PRAXGEN	EQ 300MG BASE/ML		A212770	001	Mar 12, 2021			Sep DISC
AP		EQ 300MG BASE/ML		A212770	001	Mar 12, 2021			Mar NEWA
	<u>LIOETHYRONINE SODIUM</u>								
	TABLET; ORAL								
	LIOETHYRONINE SODIUM								
AB	ZYDUS	EQ 0.005MG BASE		A214803	001	Jan 22, 2021			Jan NEWA
AB		EQ 0.025MG BASE		A214803	002	Jan 22, 2021			Jan NEWA
AB		EQ 0.05MG BASE		A214803	003	Jan 22, 2021			Jan NEWA
	<u>LISINAPRIL</u>								
	TABLET; ORAL								
	LISINAPRIL								
>D>	@ ASCENT PHARMS INC	2.5MG		A075903	001	Jul 01, 2002			Oct CMFD
>A>	AB	2.5MG		A075903	001	Jul 01, 2002			Oct CMFD
>D>	@	5MG		A075903	002	Jul 01, 2002			Oct CMFD
>A>	AB	5MG		A075903	002	Jul 01, 2002			Oct CMFD
>D>	@	10MG		A075903	003	Jul 01, 2002			Oct CMFD
>A>	AB	10MG		A075903	003	Jul 01, 2002			Oct CMFD

TABLET;ORAL
LISINOPRIL

>D>	@	20MG	A075903	004	Jul 01, 2002	Oct	CMFD
>A>	AB	20MG	A075903	004	Jul 01, 2002	Oct	CMFD
>D>	@	30MG	A075903	005	Jul 01, 2002	Oct	CMFD
>A>	AB	30MG	A075903	005	Jul 01, 2002	Oct	CMFD
>D>	@	40MG	A075903	006	Jul 01, 2002	Oct	CMFD
>A>	AB	40MG	A075903	006	Jul 01, 2002	Oct	CMFD
	AB	YILING	A208920	001	Mar 04, 2021	Feb	NEWA
	AB		A208920	002	Mar 04, 2021	Feb	NEWA
	AB	40MG	A208920	003	Mar 04, 2021	Feb	NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE

>A>	AB	BIONPHARMA INC	2MG	A215579	001	Oct 22, 2021	Oct	NEWA
	AB	EDENBRIDGE PHARMS	2MG	A215001	001	Oct 06, 2021	Sep	NEWA

LOPINAVIR; RITONAVIR

TABLET;ORAL
KALETRA

AB	+	ABBVIE	100MG;25MG	N021906	002	Nov 09, 2007	May	CFTG
AB	+	!	200MG;50MG	N021906	001	Oct 28, 2005	May	CFTG
		LOPINAVIR AND RITONAVIR						
AB		HETERO LABS LTD III	100MG;25MG	A091677	001	Jun 04, 2021	May	NFTG
AB			200MG;50MG	A091677	002	Jun 04, 2021	May	NFTG

LORAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL
LOREEV XR

	+	ALMATICA	1MG	N214826	001	Aug 27, 2021	Aug	NEWA
	+		2MG	N214826	002	Aug 27, 2021	Aug	NEWA
	+	!	3MG	N214826	003	Aug 27, 2021	Aug	NEWA

CONCENTRATE;ORAL
LORAZEPAM

AA		AKORN	2MG/ML	A200169	001	Jan 30, 2012	Feb	CAHN
		INJECTABLE; INJECTION						
		ATIVAN						
AP	+	HIKMA PHARMS	2MG/ML	N018140	001		Jul	CAHN
AP	+	!	4MG/ML	N018140	002		Jul	CAHN

LOSARTAN POTASSIUM

TABLET;ORAL
COZAAR

AB	+	ORGANON	25MG	N020386	001	Apr 14, 1995	Aug	CMFD
AB	+		50MG	N020386	002	Apr 14, 1995	Aug	CMFD
		LOSARTAN POTASSIUM						
AB		HIKMA PHARMS	25MG	A077459	001	Oct 06, 2010	Jul	CMFD
AB			50MG	A077459	002	Oct 06, 2010	Jul	CMFD
AB			100MG	A077459	003	Oct 06, 2010	Jul	CMFD
AB		JUBILANT CADISTA	25MG	A201170	001	Sep 18, 2012	Jun	CAHN
AB			50MG	A201170	002	Sep 18, 2012	Jun	CAHN
AB			100MG	A201170	003	Sep 18, 2012	Jun	CAHN

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC
LOTEMAX

AB	+	BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Jan	CFTG
		LOTEPREDNOL ETABONATE						
AB		AKORN	0.5%	A212080	001	Feb 10, 2021	Jan	NFTG
		SUSPENSION/DROPS;OPHTHALMIC						
		LOTEPREDNOL ETABONATE						
AB		SUN PHARM	0.5%	A212450	001	Feb 26, 2021	Feb	NEWA

LOXAPINE SUCCINATE

CAPSULE;ORAL
LOXAPINE SUCCINATE

	@	MYLAN	EQ 5MG BASE	A076762	001	Nov 01, 2004	Aug	CAHN
	@		EQ 5MG BASE	A076762	001	Nov 01, 2004	Jul	DISC
	@		EQ 10MG BASE	A076762	002	Nov 01, 2004	Aug	CAHN
	@		EQ 10MG BASE	A076762	002	Nov 01, 2004	Jul	DISC
	@		EQ 25MG BASE	A076762	003	Nov 01, 2004	Aug	CAHN

CAPSULE;ORAL

LOXAPINE SUCCINATE

@	EQ 25MG BASE	A076762	003	Nov 01, 2004	Jul	DISC
@	EQ 50MG BASE	A076762	004	Nov 01, 2004	Aug	CAHN
@	EQ 50MG BASE	A076762	004	Nov 01, 2004	Jul	DISC

LULICONAZOLE

CREAM;TOPICAL

LUZU

+!	BAUSCH	1%	N204153	001	Nov 14, 2013	May	CAHN
----	--------	----	---------	-----	--------------	-----	------

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	20MG	A213248	001	May 13, 2021	May	NEWA
AB		40MG	A213248	002	May 13, 2021	May	NEWA
AB		60MG	A213248	003	May 13, 2021	May	NEWA
AB		80MG	A213248	004	May 13, 2021	May	NEWA
AB		120MG	A213248	005	May 13, 2021	May	NEWA
AB	DR REDDYS LABS LTD	20MG	A208047	001	Aug 24, 2021	Aug	NEWA
AB		40MG	A208047	002	Aug 24, 2021	Aug	NEWA
AB		60MG	A208047	003	Aug 24, 2021	Aug	NEWA
AB		80MG	A208047	004	Aug 24, 2021	Aug	NEWA
	@ PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Aug	DISC
	@	40MG	A212091	002	Dec 28, 2020	Aug	DISC
	@	60MG	A212091	003	Dec 28, 2020	Aug	DISC
	@	80MG	A212091	004	Dec 28, 2020	Aug	DISC
	@	120MG	A212091	005	Dec 28, 2020	Aug	DISC
	@ WATSON LABS TEVA	20MG	A208016	001	Feb 02, 2021	Sep	DISC
AB		20MG	A208016	001	Feb 02, 2021	Jan	NEWA
	@	40MG	A208016	002	Feb 02, 2021	Sep	DISC
AB		40MG	A208016	002	Feb 02, 2021	Jan	NEWA
	@	60MG	A208016	003	Feb 02, 2021	Sep	DISC
AB		60MG	A208016	003	Feb 02, 2021	Jan	NEWA
	@	80MG	A208016	004	Feb 02, 2021	Sep	DISC
AB		80MG	A208016	004	Feb 02, 2021	Jan	NEWA
	@	120MG	A208016	005	Feb 02, 2021	Sep	DISC
AB		120MG	A208016	005	Feb 02, 2021	Jan	NEWA

MACITENTAN

TABLET;ORAL

MACITENTAN

	@ ZYDUS	10MG	A211224	001	Apr 06, 2021	Aug	DISC
AB		10MG	A211224	001	Apr 06, 2021	Mar	NFTG
	OPSUMIT						
	+! ACTELION	10MG	N204410	001	Oct 18, 2013	Aug	CTEC
AB	+!	10MG	N204410	001	Oct 18, 2013	Mar	CFTG
	+!	10MG	N204410	001	Oct 18, 2013	Feb	CAHN

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE

AP	B BRAUN MEDICAL INC	2GM/50ML (40MG/ML)	A207967	001	Apr 26, 2021	Apr	NEWA
AP		4GM/100ML (40MG/ML)	A207967	002	Apr 26, 2021	Apr	NEWA
AP		4GM/50ML (80MG/ML)	A207967	003	Apr 26, 2021	Apr	NEWA
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11, 2020	Feb	CMFD
	MAGNESIUM SULFATE IN PLASTIC CONTAINER						
AP	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	Feb	CMFD
AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	Feb	CMFD
AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	Feb	CMFD
>A>	PTS CONSULTING	2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Oct	NEWA
>A>	AP	4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Oct	NEWA
>A>	AP	4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Oct	NEWA

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

MAPROTILINE HYDROCHLORIDE

@	HERITAGE PHARMA	50MG	A072163	001	Jun 01, 1988	Jun	CAHN
@	MYLAN	25MG	A072285	002	Oct 03, 1988	Jul	DISC
@		50MG	A072285	001	Oct 03, 1988	Jul	DISC
@		75MG	A072285	003	Oct 03, 1988	Jul	DISC

MARALIXIBAT CHLORIDE

SOLUTION;ORAL
LIVMARLI

+! MIRUM EQ 9.5MG BASE/ML N214662 001 Sep 29, 2021 Sep NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL
MECLIZINE HYDROCHLORIDE

AA ANI PHARMS 12.5MG A 084657 002 Sep CMFD
AA 25MG A 084657 001 Sep CMFD

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION
DEPO-PROVERA

+ @ PFIZER 100MG/ML N012541 002 Mar CAHN
AB +! 150MG/ML N020246 001 Oct 29, 1992 Mar CAHN
+ @ 400MG/ML N012541 003 May DISC
+! 400MG/ML N012541 003 Mar CAHN

INJECTABLE;SUBCUTANEOUS
DEPO-SUBQ PROVERA 104

+! PFIZER 104MG/0.65ML N021583 001 Dec 17, 2004 Mar CAHN

TABLET;ORAL
PROVERA

AB + PFIZER 2.5MG N011839 001 Mar CAHN
AB + 5MG N011839 003 Mar CAHN
AB +! 10MG N011839 004 Mar CAHN

MEFENAMIC ACID

CAPSULE;ORAL
MEFENAMIC ACID

@ STRIDES PHARMA 250MG A209209 001 Sep 18, 2020 Mar DISC

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL
MEFLOQUINE HYDROCHLORIDE

AB ! BARR 250MG A 076392 001 Dec 29, 2003 Aug CTEC
AB HIKMA PHARMS 250MG A 076523 001 Oct 01, 2004 Aug CMFD

MELOXICAM

CAPSULE;ORAL
MELOXICAM

AB LUPIN LTD 5MG A209487 001 Jun 01, 2020 Feb CTEC
AB ! 10MG A209487 002 Jun 01, 2020 Feb CTEC
AB NOVITIUM PHARMA 5MG A211398 001 Mar 09, 2021 Feb NEWA
AB 10MG A211398 002 Mar 09, 2021 Feb NEWA

TABLET;ORAL
MELOXICAM

>A> @ AIPING PHARM INC 7.5MG A 077920 001 Jul 19, 2006 Oct CAHN
>A> @ 15MG A 077920 002 Jul 19, 2006 Oct CAHN
>D> @ NOSTRUM LABS INC 7.5MG A 077920 001 Jul 19, 2006 Oct CAHN
>D> @ 15MG A 077920 002 Jul 19, 2006 Oct CAHN

MELPHALAN

TABLET;ORAL
MELPHALAN

! ALVOGEN 2MG A207809 001 Mar 22, 2017 Jan CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION
ALKERAN

+ @ APOTEX EQ 50MG BASE/VIAL N020207 001 Nov 18, 1992 Jan DISC
MELPHALAN HYDROCHLORIDE

AP ALMAJECT EQ 50MG BASE/VIAL A204817 001 May 17, 2019 Jul CAHN
AP HIKMA PHARMS EQ 50MG BASE/VIAL A090303 001 Oct 28, 2010 Jul CAHN
AP HONG KONG EQ 50MG BASE/VIAL A212960 001 May 28, 2021 May NEWA
AP MEITHEAL EQ 50MG BASE/VIAL A212960 001 May 28, 2021 Aug CAHN
@ SCINOPHARM TAIWAN EQ 50MG BASE/VIAL A211463 001 Sep 13, 2019 Sep CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	7MG	A214651	001	Aug 09, 2021	Jul	NEWA
AB		14MG	A214651	002	Aug 09, 2021	Jul	NEWA
AB		21MG	A214651	003	Aug 09, 2021	Jul	NEWA
AB		28MG	A214651	004	Aug 09, 2021	Jul	NEWA
	@ MYLAN	7MG	A206032	001	Sep 28, 2016	Jul	DISC
	@	14MG	A206032	002	Sep 28, 2016	Jul	DISC
	@	21MG	A206032	003	Sep 28, 2016	Jul	DISC
	@	28MG	A206032	004	Sep 28, 2016	Jul	DISC
AB	YICHANG HUMANWELL	7MG	A211100	001	Apr 02, 2021	Mar	NEWA
AB		14MG	A211100	002	Apr 02, 2021	Mar	NEWA
AB		21MG	A211100	003	Apr 02, 2021	Mar	NEWA
AB		28MG	A211100	004	Apr 02, 2021	Mar	NEWA

NAMENDA XR

>A>	AB	+	ALLERGAN	7MG	N022525	001	Jun 21, 2010	Oct	CAHN
>A>	AB	+		14MG	N022525	002	Jun 21, 2010	Oct	CAHN
>A>	AB	+		21MG	N022525	003	Jun 21, 2010	Oct	CAHN
>A>	AB	+		28MG	N022525	004	Jun 21, 2010	Oct	CAHN
>D>	AB	+	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Oct	CAHN
>D>	AB	+		14MG	N022525	002	Jun 21, 2010	Oct	CAHN
>D>	AB	+		21MG	N022525	003	Jun 21, 2010	Oct	CAHN
>D>	AB	+		28MG	N022525	004	Jun 21, 2010	Oct	CAHN

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA	SETON PHARMS	2MG/ML	A210319	001	Aug 31, 2020	May	CAHN
----	--------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

	@ JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Jun	DISC
	@	10MG	A091585	002	Oct 13, 2015	Jun	DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

	@ VALIDUS PHARMS	25MG/ML	N005010	007		Feb	CAHN
	@	50MG/ML	N005010	002		Feb	CAHN
	@	75MG/ML	N005010	009		Feb	CAHN
	@	100MG/ML	N005010	003		Feb	CAHN

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

+	@ ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984	Aug	CRLD
---	-------------------	---------	---------	-----	--------------	-----	------

SYRUP;ORAL

DEMEROL

	@ VALIDUS PHARMS	50MG/5ML	N005010	005		Feb	CAHN
--	------------------	----------	---------	-----	--	-----	------

TABLET;ORAL

DEMEROL

+	@ VALIDUS PHARMS	50MG	N005010	001		Feb	CAHN
+	@	100MG	N005010	004		Feb	CAHN

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

AA	!	ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	Mar	CHRS
AA	!		400MG	A090122	002	Feb 18, 2009	Mar	CHRS
	+	@ WATSON LABS	200MG	A083304	001		Aug	CRLD
		@	200MG	A083304	001		Mar	DISC
	+	@	400MG	A083308	001		Aug	CRLD
		@	400MG	A083308	001		Mar	DISC

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP		EUGIA PHARMA	500MG/VIAL	A205835	001	Mar 27, 2017	Aug	CAHN
AP			1GM/VIAL	A205835	002	Mar 27, 2017	Aug	CAHN

MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS

VABOMERE

+	!	REMPEX	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017	Feb	CAHN
---	---	--------	--------------------	---------	-----	--------------	-----	------

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL
MESALAMINE

AB	ALKEM LABS LTD	375MG	A214242	001	Jul 15, 2021	Jul	NEWA
AB	ZYDUS PHARMS	375MG	A208954	001	Aug 12, 2021	Aug	NEWA
SUPPOSITORY;RECTAL							
MESALAMINE							
>D>	AB	APTAPHARMA INC	1GM	A207448	001	Apr 19, 2019	Oct CAHN
	AB		1GM	A207448	001	Apr 19, 2019	Sep CAHN
>A>	AB	PHARM SOURCING	1GM	A207448	001	Apr 19, 2019	Oct CAHN

METARAMINOL BITARTRATE

INJECTABLE;INJECTION
METARAMINOL BITARTRATE

	SLAYBACK PHARMA LLC	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021	Aug	NEWA
--	---------------------	-----------------	---------	-----	--------------	-----	------

METAXALONE

TABLET;ORAL
METAXALONE

>A>	BX	APPCO	800MG	A208774	001	Sep 24, 2018	Oct CAHN
>D>	BX	RISING	800MG	A208774	001	Sep 24, 2018	Oct CAHN
	BX		800MG	A208774	001	Sep 24, 2018	Sep CTEC

METFORMIN HYDROCHLORIDE

TABLET;ORAL
METFORMIN HYDROCHLORIDE

AB	CHARTWELL	500MG	A075972	001	Jan 24, 2002	Jun	CAHN
		625MG	A075972	005	Jan 24, 2002	Jun	CAHN
		750MG	A075972	004	Jan 24, 2002	Jun	CAHN
AB		850MG	A075972	002	Jan 24, 2002	Jun	CAHN
AB		1GM	A075972	003	Jan 24, 2002	Jun	CAHN
	@ INDICUS PHARMA	500MG	A079148	001	Nov 25, 2008	May	DISC
	@	850MG	A079148	002	Nov 25, 2008	May	DISC
	@	1GM	A079148	003	Nov 25, 2008	May	DISC

TABLET, EXTENDED RELEASE;ORAL
METFORMIN HYDROCHLORIDE

AB3	AJANTA PHARMA LTD	500MG	A213962	001	Mar 09, 2021	Feb	NEWA
AB3		1GM	A213962	002	Mar 09, 2021	Feb	NEWA
AB	! ALKEM LABS LTD	750MG	A206145	002	Oct 22, 2018	Sep	CHRS
BX	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Sep	CTEC
BX		750MG	A078596	002	Jan 03, 2008	Sep	CHRS
BX	!	750MG	A078596	002	Jan 03, 2008	Sep	CTEC
AB2	AMTA	500MG	A213394	001	Aug 03, 2021	Jul	NEWA
AB2		1GM	A213394	002	Aug 03, 2021	Jul	NEWA
	@ APOTEX	500MG	A076706	001	Dec 14, 2004	Apr	DISC
AB3	GRANULES	500MG	A213344	001	Jan 12, 2021	Jan	NEWA
AB3		1GM	A213344	002	Jan 12, 2021	Jan	NEWA
AB3	SCIEGEN PHARMS INC	500MG	A213334	001	Apr 16, 2021	Apr	NEWA
AB3		1GM	A213334	002	Apr 16, 2021	Apr	NEWA
AB2	TWI PHARMS	500MG	A213247	001	Sep 29, 2021	Sep	NEWA
AB2		1GM	A213247	002	Sep 29, 2021	Sep	NEWA
AB1	UNICHEM	500MG	A213359	001	Aug 11, 2021	Jul	NEWA
AB		750MG	A213359	002	Aug 11, 2021	Jul	NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

	@ SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Sep	DISC
	@	850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Sep	DISC
	@ TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan	DISC
	@	850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan	DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL
METHADONE HYDROCHLORIDE

	@ LANNETT CO INC	10MG/ML	A212094	001	Mar 03, 2021	Aug	DISC
AA		10MG/ML	A212094	001	Mar 03, 2021	Feb	NEWA

SOLUTION;ORAL
METHADONE HYDROCHLORIDE

AA	+!	HIKMA PHARMS	5MG/5ML	A087393	001		Aug CRLD
AA	+!		10MG/5ML	A087997	001	Aug 30, 1982	Aug CRLD

METHENAMINE HIPPURATE

TABLET; ORAL		HIPREX					
	+ @ VALIDUS PHARMS	1GM		N017681	001		Mar DISC
AB	+	1GM		N017681	001		Feb CAHN
METHENAMINE HIPPURATE							
AB	!	AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Mar CHRS
AB		NOVAST LABS	1GM	A210068	001	Nov 27, 2020	Sep CAHN
UREX							
AB		ALVOGEN	1GM	N016151	001		Jul CAHN

METHIMAZOLE

TABLET; ORAL		METHIMAZOLE					
AB		BIOPHARM	5MG	A040547	001	Feb 18, 2005	Sep CAHN
AB			10MG	A040547	002	Feb 18, 2005	Sep CAHN
	@		20MG	A040547	004	Feb 18, 2005	Sep CAHN

METHOCARBAMOL

SOLUTION; IM-IV		ROBAXIN					
AP	+	HIKMA PHARMS	1GM/10ML (100MG/ML)	N011790	001		Jul CAHN
TABLET; ORAL		METHOCARBAMOL					
	@	AUROBINDO PHARMA LTD	750MG	A213967	001	Aug 12, 2020	Feb DISC
AA		GRANULATION TECH	500MG	A212623	001	Apr 30, 2021	Apr NEWA
AA			750MG	A212623	002	Apr 30, 2021	Apr NEWA
AA		MLV	500MG	A212623	001	Apr 30, 2021	Jun CAHN
AA			750MG	A212623	002	Apr 30, 2021	Jun CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION		FOLEX					
	+ @	PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695	001	Apr 08, 1983	Aug CRLD
	+ @		EQ 100MG BASE/VIAL	A087695	003	Apr 08, 1983	Aug CRLD
METHOTREXATE SODIUM							
AP	!	HIKMA PHARMS	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Jul CAHN
	!		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Jul CAHN
METHOTREXATE SODIUM PRESERVATIVE FREE							
AP	!	HIKMA PHARMS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Jul CAHN
AP	!		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Jul CAHN
	@	MYLAN	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	Aug CAHN
	@	MYLAN LABS LTD	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	May DISC
	@		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	Aug DISC
MEXATE							
	+ @	BRISTOL	EQ 20MG BASE/VIAL	A086358	001		Aug CRLD
	+ @		EQ 50MG BASE/VIAL	A086358	002		Aug CRLD
	+ @		EQ 100MG BASE/VIAL	A086358	003		Aug CRLD
	+ @		EQ 250MG BASE/VIAL	A086358	004		Aug CRLD
TABLET; ORAL		METHOTREXATE SODIUM					
AB		LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787	001	Apr 23, 2021	Apr NEWA

METHYCLOTHIAZIDE

TABLET; ORAL		METHYCLOTHIAZIDE					
	@	CHARTWELL RX	2.5MG	A089835	001	Aug 18, 1988	Sep CAHN
	@		5MG	A089837	001	Aug 18, 1988	Sep CAHN

METHYLDOPA

TABLET; ORAL		METHYLDOPA					
	!	ACCORD HLTHCARE	250MG	A070084	001	Oct 15, 1985	Sep CTEC
	!		500MG	A070085	001	Oct 15, 1985	Sep CHRS
	!		500MG	A070085	001	Oct 15, 1985	Sep CTEC
	@	CHARTWELL RX	125MG	A071700	001	Mar 02, 1988	Sep CAHN
	@		250MG	N018934	001	Jun 29, 1984	Sep CAHN
	@		500MG	N018934	002	Jun 29, 1984	Sep CAHN

TABLET;ORAL
METHYLDOPA

@ MYLAN	250MG	A070076	002	Apr 18, 1985	Sep	DISC
@	500MG	A070076	001	Apr 18, 1985	Sep	DISC

METHYLERGONOVINE MALEATE

TABLET;ORAL
METHYLERGONOVINE MALEATE

AB	RISING	0.2MG	A211919	001	Jan 15, 2021	Jan	NEWA
----	--------	-------	---------	-----	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AA	ASCENT PHARMS INC	5MG/5ML	A207417	001	Jan 29, 2021	Jan	NEWA
AA		10MG/5ML	A207417	002	Jan 29, 2021	Jan	NEWA
	@ LANNETT CO INC	5MG/5ML	A207414	001	Dec 16, 2020	Jan	DISC
	@	10MG/5ML	A207414	002	Dec 16, 2020	Jan	DISC

TABLET;ORAL
METHYLPHENIDATE HYDROCHLORIDE

	@ ALVOGEN	5MG	A206840	001	Sep 15, 2016	Jun	CAHN
	@	10MG	A206840	002	Sep 15, 2016	Jun	CAHN
	@	20MG	A206840	003	Sep 15, 2016	Jun	CAHN
AB	BIONPHARMA INC	5MG	A209753	001	Mar 02, 2018	Sep	CAHN
AB		10MG	A209753	002	Mar 02, 2018	Sep	CAHN
AB		20MG	A209753	003	Mar 02, 2018	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB	ALVOGEN	10MG	A204772	001	Feb 29, 2016	Jun	CAHN
AB		18MG	A210818	001	Nov 30, 2018	Aug	CAHN
AB		20MG	A204772	002	Feb 29, 2016	Jun	CAHN
AB		27MG	A210818	002	Nov 30, 2018	Aug	CAHN
AB		36MG	A210818	003	Nov 30, 2018	Aug	CAHN
AB		54MG	A210818	004	Nov 30, 2018	Aug	CAHN
BX	AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Sep	CTEC
BX		27MG	A207515	002	Feb 01, 2018	Sep	CTEC
BX		36MG	A207515	003	Feb 01, 2018	Sep	CTEC
BX		54MG	A207515	004	Feb 01, 2018	Sep	CTEC

METHYLPREDNISOLONE

TABLET;ORAL
METHYLPREDNISOLONE

AB	AMNEAL	4MG	A207481	001	Sep 21, 2021	Sep	NEWA
AB		8MG	A207481	002	Sep 21, 2021	Sep	NEWA
AB		16MG	A207481	003	Sep 21, 2021	Sep	NEWA
AB		32MG	A207481	004	Sep 21, 2021	Sep	NEWA
AB	PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	GENEYORK PHARMS	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Apr	NEWA
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Apr	NEWA
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Apr	NEWA
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Apr	NEWA
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Apr	NEWA
>D>	AP	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Oct	DISC
>A>	@	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Oct	DISC
AP		EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	May	CAHN
>D>	AP	EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Oct	DISC
>A>	@	EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Oct	DISC
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	May	CAHN
>D>	AP	EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Oct	DISC
>A>	@	EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Oct	DISC
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	May	CAHN
>D>	AP	EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Oct	DISC
>A>	@	EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Oct	DISC
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	May	CAHN
>D>	AP	EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Oct	DISC
>A>	@	EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Oct	DISC
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	May	CAHN

METHYLTESTOSTERONE

CAPSULE; ORAL
TESTRED

+ @ BAUSCH 10MG A083976 001 Aug CRLD

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
REGLAN

@ HIKMA PHARMS EQ 5MG BASE/ML N017862 001 Jul CAHN
@ EQ 10MG BASE/ML N017862 004 May 28, 1987 Jul CAHN

METOLAZONE

TABLET; ORAL
METOLAZONE

AB BAYSHORE PHARMS LLC 2.5MG A214799 001 Mar 30, 2021 Mar NEWA
AB 5MG A214799 002 Mar 30, 2021 Mar NEWA
AB 10MG A214799 003 Mar 30, 2021 Mar NEWA
AB INNOGENIX 2.5MG A213827 001 Mar 30, 2021 Mar NEWA
AB 5MG A213827 002 Mar 30, 2021 Mar NEWA
AB 10MG A213827 003 Mar 30, 2021 Mar NEWA
AB RUBICON 2.5MG A215184 001 Aug 20, 2021 Aug NEWA
AB 5MG A215184 002 Aug 20, 2021 Aug NEWA
AB 10MG A215184 003 Aug 20, 2021 Aug NEWA
AB ! SANDOZ 5MG A076466 001 Dec 19, 2003 May CHRS
AB ! 10MG A076466 002 Dec 19, 2003 May CHRS
ZAROXOLYN
+ @ LANNETT CO INC 2.5MG N017386 001 May DISC
+ @ 5MG N017386 002 May DISC
+ @ 10MG N017386 003 May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

AB ACTAVIS ELIZABETH EQ 25MG TARTRATE A204161 001 Nov 25, 2016 May CMFD
AB EQ 50MG TARTRATE A204161 002 Nov 25, 2016 May CMFD
AB EQ 100MG TARTRATE A204161 003 Nov 25, 2016 May CMFD
AB EQ 200MG TARTRATE A204161 004 Nov 25, 2016 May CMFD
>D> AB TWI PHARMS EQ 25MG TARTRATE A207206 001 Dec 19, 2018 Oct CAHN
>D> AB EQ 50MG TARTRATE A207206 002 Dec 19, 2018 Oct CAHN
>D> AB EQ 100MG TARTRATE A207206 003 Dec 19, 2018 Oct CAHN
>D> AB EQ 200MG TARTRATE A207206 004 Dec 19, 2018 Oct CAHN
>A> AB VISUM PHARM EQ 25MG TARTRATE A207206 001 Dec 19, 2018 Oct CAHN
>A> AB EQ 50MG TARTRATE A207206 002 Dec 19, 2018 Oct CAHN
>A> AB EQ 100MG TARTRATE A207206 003 Dec 19, 2018 Oct CAHN
>A> AB EQ 200MG TARTRATE A207206 004 Dec 19, 2018 Oct CAHN
>A> AB YICHANG HUMANWELL EQ 50MG TARTRATE A213854 003 Nov 08, 2021 Oct NEWA
AB EQ 100MG TARTRATE A213854 001 Feb 12, 2021 Feb NEWA
AB EQ 200MG TARTRATE A213854 002 Feb 12, 2021 Feb NEWA

METOPROLOL TARTRATE

TABLET; ORAL
LOPRESSOR

AB + VALIDUS PHARMS 50MG N017963 001 Feb CAHN
AB + 100MG N017963 002 Feb CAHN

METRONIDAZOLE

GEL; TOPICAL
METRONIDAZOLE

AB ALEOR DERMACEUTICALS 1% A212646 001 Sep 03, 2021 Aug NEWA

GEL; VAGINAL
METRONIDAZOLE

>A> AB SOLARIS PHARMA CORP 0.75% A213648 001 Oct 14, 2021 Oct NEWA

TABLET; ORAL
METRONIDAZOLE

AB AMICI 250MG A070772 001 Jul 16, 1986 Sep CAHN
AB 500MG A070772 002 Jul 16, 1986 Sep CAHN

METYROSINE

	CAPSULE;ORAL					
	DEMSEER					
	+!	BAUSCH	250MG	N017871	001	Sep CTEC
		METYROSINE				
BX		AMNEAL	250MG	A213734	001	Jul 24, 2020 Sep CTEC

MEXILETINE HYDROCHLORIDE

	CAPSULE;ORAL					
	MEXILETINE HYDROCHLORIDE					
>D>	AB	HAVIX	150MG	A214089	001	Oct 01, 2021 Oct CAHN
	AB		150MG	A214089	001	Oct 01, 2021 Sep NEWA
>D>	AB		200MG	A214089	002	Oct 01, 2021 Oct CAHN
	AB		200MG	A214089	002	Oct 01, 2021 Sep NEWA
>D>	AB		250MG	A214089	003	Oct 01, 2021 Oct CAHN
	AB		250MG	A214089	003	Oct 01, 2021 Sep NEWA
	AB	NOVAST LABS	150MG	A214352	001	Jan 25, 2021 Sep CAHN
	AB		200MG	A214352	002	Jan 25, 2021 Sep CAHN
	AB		250MG	A214352	003	Jan 25, 2021 Sep CAHN
	AB	RICONPHARMA LLC	150MG	A214352	001	Jan 25, 2021 Jan NEWA
	AB		200MG	A214352	002	Jan 25, 2021 Jan NEWA
	AB		250MG	A214352	003	Jan 25, 2021 Jan NEWA
>A>	AB	SENORES PHARMS	150MG	A214089	001	Oct 01, 2021 Oct CAHN
>A>	AB		200MG	A214089	002	Oct 01, 2021 Oct CAHN
>A>	AB		250MG	A214089	003	Oct 01, 2021 Oct CAHN

MICAFUNGIN SODIUM

	INJECTABLE;INTRAVENOUS					
	MICAFUNGIN SODIUM					
AP		HIKMA	EQ 50MG BASE/VIAL	A213261	001	Jul 09, 2021 Jul NEWA
AP			EQ 100MG BASE/VIAL	A213261	002	Jul 09, 2021 Jul NEWA
AP		JIANGSU HANSOH PHARM	EQ 50MG BASE/VIAL	A213363	001	Jul 09, 2021 Jul NEWA
AP			EQ 100MG BASE/VIAL	A213363	002	Jul 09, 2021 Jul NEWA
AP		XELLIA PHARMS APS	EQ 50MG BASE/VIAL	A211713	001	Jun 02, 2021 May NEWA
AP			EQ 100MG BASE/VIAL	A211713	002	Jun 02, 2021 May NEWA
	POWDER;INTRAVENOUS					
	MICAFUNGIN					
	+!	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	N212156	001	Jun 16, 2021 Jun NEWA
	+!		EQ 100MG BASE/VIAL	N212156	002	Jun 16, 2021 Jun NEWA
	+ @	TEVA PHARMS USA INC	EQ 50MG BASE/VIAL	N212125	001	Jul 30, 2021 Sep DISC
	+!		EQ 50MG BASE/VIAL	N212125	001	Jul 30, 2021 Jul NEWA
	+ @		EQ 100MG BASE/VIAL	N212125	002	Jul 30, 2021 Sep DISC
	+!		EQ 100MG BASE/VIAL	N212125	002	Jul 30, 2021 Jul NEWA

MIDAZOLAM

	SOLUTION;INTRAVENOUS					
	MIDAZOLAM IN 0.9% SODIUM CHLORIDE					
	+!	INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021 Mar NEWA
	+!		100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021 Mar NEWA

MIDAZOLAM HYDROCHLORIDE

	INJECTABLE;INJECTION					
	MIDAZOLAM HYDROCHLORIDE					
	@	HOSPIRA	EQ 1MG BASE/ML	A075856	001	Jun 13, 2002 Aug DISC
	@		EQ 5MG BASE/ML	A075856	002	Jun 13, 2002 Aug DISC

MIDODRINE HYDROCHLORIDE

	TABLET;ORAL					
	MIDODRINE HYDROCHLORIDE					
AB		ALEMBIC PHARMS LTD	2.5MG	A214734	001	Jan 21, 2021 Jan NEWA
AB			5MG	A214734	002	Jan 21, 2021 Jan NEWA
AB			10MG	A214734	003	Jan 21, 2021 Jan NEWA

MIGALASTAT HYDROCHLORIDE

	CAPSULE;ORAL					
	GALAFOLD					
	+!	AMICUS THERAP US	EQ 123MG BASE	N208623	001	Aug 10, 2018 Sep CAHN

MIGLITOL

TABLET; ORAL		GLYSET							
AB	+	PFIZER	25MG	N020682	001	Dec 18, 1996	Feb	CAHN	
AB	+		50MG	N020682	002	Dec 18, 1996	Feb	CAHN	
AB	+		100MG	N020682	003	Dec 18, 1996	Feb	CAHN	

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL		MILNACIPRAN HYDROCHLORIDE							
	@	LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Aug	CAHN	
	@		25MG	A205071	002	Jan 27, 2016	Aug	CAHN	
	@		50MG	A205071	003	Jan 27, 2016	Aug	CAHN	
	@		100MG	A205071	004	Jan 27, 2016	Aug	CAHN	
	@	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016	Sep	CAHN	
	@		25MG	A205071	002	Jan 27, 2016	Sep	CAHN	
	@		50MG	A205071	003	Jan 27, 2016	Sep	CAHN	
	@		100MG	A205071	004	Jan 27, 2016	Sep	CAHN	

MILRINONE LACTATE

INJECTABLE; INJECTION		MILRINONE LACTATE							
AP		CAPLIN	EQ 1MG BASE/ML	A214380	001	Apr 16, 2021	Apr	NEWA	

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL		AMZEEQ							
	+	VYNE	EQ 4% BASE	N212379	001	Oct 18, 2019	Mar	CAHN	
	+	ZILXI							
	+	VYNE	EQ 1.5% BASE	N213690	001	May 28, 2020	Mar	CAHN	
CAPSULE; ORAL		DYNACIN							
AB		ALVOGEN	EQ 50MG BASE	A063067	003	Aug 14, 1990	Jun	CAHN	
AB			EQ 75MG BASE	A063067	002	Sep 15, 1999	Jun	CAHN	
AB			EQ 100MG BASE	A063067	001	Jul 31, 1990	Jun	CAHN	
INJECTABLE; INJECTION		MINOCIN							
	+	REMPEX	EQ 100MG BASE/VIAL	N050444	001		May	CAHN	
TABLET, EXTENDED RELEASE; ORAL		MINOCYCLINE HYDROCHLORIDE							
	@	BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012	May	DISC	
	@		EQ 80MG BASE	A065485	007	Apr 26, 2017	May	DISC	
	@		EQ 105MG BASE	A065485	008	Apr 26, 2017	May	DISC	
	@		EQ 115MG BASE	A065485	005	May 18, 2012	May	DISC	
>D>	@	MYLAN	EQ 55MG BASE	A203443	001	Aug 21, 2019	Oct	CAHN	
>A>	@		EQ 55MG BASE	A203443	001	Aug 21, 2019	Oct	CAHN	
>D>	AB		EQ 80MG BASE	A203443	002	Aug 22, 2014	Oct	DISC	
>A>	@		EQ 80MG BASE	A203443	002	Aug 22, 2014	Oct	DISC	
>D>	AB		EQ 105MG BASE	A203443	003	Aug 22, 2014	Oct	DISC	
>A>	@		EQ 105MG BASE	A203443	003	Aug 22, 2014	Oct	DISC	
MINOLIRA		EPI HLTH SOLODYN							
	!	EPI HLTH SOLODYN	EQ 135MG BASE	N209269	002	May 08, 2017	Sep	CHRS	
	+	@ BAUSCH	EQ 45MG BASE	N050808	001	May 08, 2006	May	CAHN	
AB	+		EQ 55MG BASE	N050808	008	Aug 27, 2010	May	CAHN	
AB	+		EQ 65MG BASE	N050808	004	Jul 23, 2009	May	CAHN	
AB	+		EQ 80MG BASE	N050808	007	Aug 27, 2010	May	CAHN	
	+	@	EQ 90MG BASE	N050808	002	May 08, 2006	May	CAHN	
AB	+		EQ 105MG BASE	N050808	006	Aug 27, 2010	May	CAHN	
AB	+	!	EQ 115MG BASE	N050808	005	Jul 23, 2009	May	CAHN	
	+	@	EQ 135MG BASE	N050808	003	May 08, 2006	May	CAHN	

MINOXIDIL

TABLET; ORAL		LONITEN							
	+	@ PFIZER	2.5MG	N018154	001		Feb	CAHN	
	+	@	10MG	N018154	003		Feb	CAHN	

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL
MYRBETRIQ GRANULES

+! APGDI 8MG/ML N213801 001 Mar 25, 2021 Mar NEWA

MISOPROSTOL

TABLET;ORAL
CYTOTEC

+ PFIZER 0.1MG N019268 003 Sep 21, 1990 Sep CTEC

+! 0.2MG N019268 001 Dec 27, 1988 Sep CTEC

MISOPROSTOL

BX NOVEL LABS INC 0.1MG A091667 001 Jul 25, 2012 Sep CTEC

BX 0.2MG A091667 002 Jul 25, 2012 Sep CTEC

MITOMYCIN

INJECTABLE;INJECTION
MITOMYCIN

>A> AP GLAND PHARMA LTD 5MG/VIAL A215687 001 Oct 20, 2021 Oct NEWA

>A> AP 20MG/VIAL A215687 002 Oct 20, 2021 Oct NEWA

>A> @ HIKMA PHARMS 5MG/VIAL A064117 001 Apr 19, 1995 Oct CAHN

>A> AP 5MG/VIAL A064180 001 Dec 23, 1999 Oct CAHN

>A> AP 20MG/VIAL A064117 002 Apr 19, 1995 Oct CAHN

>A> AP 20MG/VIAL A064180 002 Dec 23, 1999 Oct CAHN

>A> AP 40MG/VIAL A064117 003 Jun 02, 1999 Oct CAHN

>D> @ WEST-WARD PHARMS INT 5MG/VIAL A064117 001 Apr 19, 1995 Oct CAHN

>D> AP 5MG/VIAL A064180 001 Dec 23, 1999 Oct CAHN

>D> AP 20MG/VIAL A064117 002 Apr 19, 1995 Oct CAHN

>D> AP 20MG/VIAL A064180 002 Dec 23, 1999 Oct CAHN

>D> AP 40MG/VIAL A064117 003 Jun 02, 1999 Oct CAHN

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS
MIVACURIUM CHLORIDE

>A> WOODWARD EQ 10MG BASE/5ML (EQ 2MG BASE/ML) A209708 001 Oct 12, 2021 Oct NFTG

>A> EQ 20MG BASE/10ML (EQ 2MG BASE/ML) A209708 002 Oct 12, 2021 Oct NFTG

MOBOCERTINIB SUCCINATE

CAPSULE;ORAL
EXKIVITY

+! TAKEDA PHARMS USA EQ 40MG BASE N215310 001 Sep 15, 2021 Sep NEWA

MODAFINIL

TABLET;ORAL
MODAFINIL

@ MYLAN PHARMS INC 100MG A076594 001 Jul 16, 2012 Jul DISC

@ 200MG A076594 002 Jul 16, 2012 Jul DISC

MOMETASONE FUROATE

AEROSOL, METERED;INHALATION
ASMANEX HFA

+ ORGANON 0.05MG/INH N205641 003 Aug 12, 2019 Jun CAHN

+ 0.10MG/INH N205641 001 Apr 25, 2014 Jun CAHN

+! 0.20MG/INH N205641 002 Apr 25, 2014 Jun CAHN

OINTMENT;TOPICAL
MOMETASONE FUROATE

@ TORRENT 0.1% A207899 001 Jul 13, 2018 Jan DISC

POWDER;INHALATION
ASMANEX TWISTHALER

+ ORGANON 0.11MG/INH N021067 002 Feb 01, 2008 Jun CAHN

+! 0.22MG/INH N021067 001 Mar 30, 2005 Jun CAHN

SPRAY, METERED;NASAL
MOMETASONE FUROATE

AB ! APOTEX INC 0.05MG/SPRAY A091161 001 Mar 22, 2016 May CHRS

NASONEX

+ @ ORGANON 0.05MG/SPRAY N020762 001 Oct 01, 1997 May DISC

AB +! 0.05MG/SPRAY N020762 001 Oct 01, 1997 Feb CAHN

MONTELUKAST SODIUM

TABLET; ORAL		MONTELUKAST SODIUM						
	@ AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul	DISC	
	@ BRECKENRIDGE	EQ 10MG BASE	A205319	001	Oct 30, 2020	Sep	CAHN	
TABLET, CHEWABLE; ORAL		MONTELUKAST SODIUM						
	@ AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul	DISC	
	@	EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul	DISC	
	@ HIKMA PHARMS	EQ 4MG BASE	A091128	001	Aug 03, 2012	Jul	DISC	
	@	EQ 5MG BASE	A091128	002	Aug 03, 2012	Jul	DISC	
AB	UNICHEM	EQ 4MG BASE	A208621	001	Jul 02, 2018	Aug	CMFD	
AB		EQ 5MG BASE	A208621	002	Jul 02, 2018	Aug	CMFD	

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL		KADIAN						
	+ @ ALLERGAN	10MG	N020616	008	Apr 20, 2007	Sep	DISC	
	+ @	20MG	N020616	001	Jul 03, 1996	Sep	DISC	
	+ @	30MG	N020616	004	Mar 09, 2001	Sep	DISC	
	+ @	40MG	N020616	009	Jul 09, 2012	May	DISC	
	+ @	50MG	N020616	002	Jul 03, 1996	Sep	DISC	
	+ @	60MG	N020616	005	Mar 09, 2001	Sep	DISC	
	+ @	70MG	N020616	010	Jul 09, 2012	May	DISC	
	+ @	80MG	N020616	006	Oct 27, 2006	Sep	DISC	
	+ @	100MG	N020616	003	Jul 03, 1996	Sep	DISC	
	+ @	130MG	N020616	011	Jul 09, 2012	May	DISC	
	+ @	150MG	N020616	012	Jul 09, 2012	May	DISC	
	+ @	200MG	N020616	007	Feb 27, 2007	May	DISC	
MORPHINE SULFATE		IMPAX LABS INC						
		40MG	A200411	007	Jul 25, 2018	May	CTEC	
AB	NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Jul	NEWA	
AB		30MG	A203158	002	Aug 04, 2021	Jul	NEWA	
AB		50MG	A203158	003	Aug 04, 2021	Jul	NEWA	
AB		60MG	A203158	004	Aug 04, 2021	Jul	NEWA	
AB		80MG	A203158	005	Aug 04, 2021	Jul	NEWA	
AB		100MG	A203158	006	Aug 04, 2021	Jul	NEWA	
	! UPSHER SMITH LABS	10MG	A202104	001	Jun 03, 2013	Sep	CHRS	
	!	10MG	A202104	001	Jun 03, 2013	Sep	CTEC	
AB	!	100MG	A202104	007	Jun 03, 2013	Sep	CHRS	
INJECTABLE; INJECTION		MORPHINE SULFATE						
	+! HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021	Apr	NEWA	
SOLUTION; ORAL		MORPHINE SULFATE						
	@ ANI PHARMS	10MG/5ML	A205509	001	Apr 17, 2018	Jan	DISC	
	@	20MG/5ML	A205509	002	Apr 17, 2018	Jan	DISC	
	@	100MG/5ML	A205509	003	Apr 17, 2018	Jan	DISC	
	@ WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Aug	DISC	
AA		10MG/5ML	A211454	001	Feb 12, 2021	Feb	NEWA	
	@	20MG/5ML	A211454	002	Feb 12, 2021	Aug	DISC	
AA		20MG/5ML	A211454	002	Feb 12, 2021	Feb	NEWA	
	@	100MG/5ML	A211454	003	Feb 12, 2021	Aug	DISC	
AA		100MG/5ML	A211454	003	Feb 12, 2021	Feb	NEWA	
TABLET; ORAL		MORPHINE SULFATE						
AB	UPSHER SMITH LABS	15MG	A210610	001	Jul 22, 2019	May	CAHN	
AB		30MG	A210610	002	Jul 22, 2019	May	CAHN	

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC		MOXIFLOXACIN HYDROCHLORIDE						
AT1	UPSHER SMITH LABS	EQ 0.5% BASE	A212616	001	Feb 10, 2021	Jan	NEWA	

MUPIROCIN CALCIUM

CREAM; TOPICAL		MUPIROCIN						
AB	ENCUBE	EQ 2% BASE	A213076	001	Aug 31, 2021	Aug	NEWA	

MYCOPHENOLATE MOFETIL

>A>	FOR SUSPENSION;ORAL							
>A>	CELLCEPT							
>A>	AB	+! ROCHE PALO	200MG/ML	N050759	001	Oct 01, 1998	Oct	CDFR
>A>	MYCOPHENOLATE MOFETIL							
>A>	AB	ALKEM LABS LTD	200MG/ML	A203005	001	Nov 14, 2014	Oct	CDFR
>A>	AB	LANNETT CO INC	200MG/ML	A214525	001	Jul 29, 2021	Oct	CDFR
>A>	AB	VISTAPHARM	200MG/ML	A210370	001	Feb 12, 2019	Oct	CDFR
>D>	SUSPENSION;ORAL							
>D>	CELLCEPT							
>D>	AB	+! ROCHE PALO	200MG/ML	N050759	001	Oct 01, 1998	Oct	CDFR
>D>	MYCOPHENOLATE MOFETIL							
>D>	AB	ALKEM LABS LTD	200MG/ML	A203005	001	Nov 14, 2014	Oct	CDFR
>A>	AB	AMNEAL	200MG/ML	A214871	001	Nov 02, 2021	Oct	NEWA
>D>	AB	LANNETT CO INC	200MG/ML	A214525	001	Jul 29, 2021	Oct	CDFR
>D>	AB		200MG/ML	A214525	001	Jul 29, 2021	Jul	NEWA
>D>	AB	VISTAPHARM	200MG/ML	A210370	001	Feb 12, 2019	Oct	CDFR

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

	INJECTABLE; INJECTION							
	MYCOPHENOLATE MOFETIL HYDROCHLORIDE							
	@ AMNEAL	500MG/VIAL		A211374	001	Mar 05, 2021	Sep	DISC
AP		500MG/VIAL		A211374	001	Mar 05, 2021	Feb	NEWA
AP	MEITHEAL	500MG/VIAL		A212130	001	Jan 15, 2021	Jan	CAHN
AP	NANJING KING-FRIEND	500MG/VIAL		A212130	001	Jan 15, 2021	Jan	NEWA

MYCOPHENOLIC ACID

	TABLET, DELAYED RELEASE;ORAL							
	MYCOPHENOLIC ACID							
AB	ALKEM LABS LTD	180MG		A208315	001	Sep 23, 2021	Sep	NEWA
AB		360MG		A208315	002	Sep 23, 2021	Sep	NEWA
AB	AMTA	180MG		A214376	001	Feb 10, 2021	Jan	NEWA
AB		360MG		A214376	002	Feb 10, 2021	Jan	NEWA
>A>	AB	TWI PHARMS	180MG	A214289	001	Nov 03, 2021	Oct	NEWA
>A>	AB		360MG	A214289	002	Nov 03, 2021	Oct	NEWA

NABUMETONE

	TABLET; ORAL							
	NABUMETONE							
AB	ANNORA PHARMA	500MG		A090445	001	Jan 12, 2011	Mar	CAHN
AB		750MG		A090445	002	Jan 12, 2011	Mar	CAHN

NADOLOL

	TABLET; ORAL							
	NADOLOL							
	@ NOVAST LABS	20MG		A210786	001	Jun 01, 2018	May	DISC
	@	40MG		A210786	002	Jun 01, 2018	May	DISC
	@	80MG		A210786	003	Jun 01, 2018	May	DISC
AB	VGYAAN	20MG		A212856	001	Sep 13, 2019	May	CMFD
AB		40MG		A212856	002	Sep 13, 2019	May	CMFD
AB		80MG		A212856	003	Sep 13, 2019	May	CMFD

NALOXONE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	NALOXONE HYDROCHLORIDE							
	@ BAXTER HLTHCARE CORP	0.4MG/ML		A214785	001	Jan 29, 2021	Jul	DISC
AP		0.4MG/ML		A214785	001	Jan 29, 2021	Jan	NEWA
>D>	AP	! HOSPIRA	0.4MG/ML	A070254	001	Jan 07, 1987	Oct	DISC
>A>	@	0.4MG/ML		A070254	001	Jan 07, 1987	Oct	DISC
>A>	SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS							
>A>	ZIMHI							
>A>	+! ADAMIS PHARMS CORP	5MG/0.5ML (5MG/0.5ML)		N212854	001	Oct 15, 2021	Oct	NEWA
	SPRAY; NASAL							
	KLOXXADO							
	+! HIKMA PHARMS	8MG/SPRAY		N212045	001	Apr 29, 2021	Apr	NEWA

<u>NALTREXONE HYDROCHLORIDE</u>							
TABLET; ORAL							
REVIA							
	+ @ TEVA WOMENS	50MG	N018932	001	Nov 20, 1984	Jul	CRLD
<u>NANDROLONE DECANOATE</u>							
INJECTABLE; INJECTION							
NANDROLONE DECANOATE							
	+ @ WATSON LABS	200MG/ML	A088128	001	Dec 05, 1983	Aug	CRLD
<u>NAPHAZOLINE HYDROCHLORIDE</u>							
SOLUTION/DROPS; OPHTHALMIC							
NAPHCN FORTE							
	+ @ ALCON	0.1%	A080229	001		Aug	CRLD
<u>NAPROXEN</u>							
SUSPENSION; ORAL							
NAPROXEN							
AB	NOVITIUM PHARMA	25MG/ML	A211910	001	Mar 10, 2021	Feb	NEWA
TABLET; ORAL							
NAPROXEN							
AB	GRANULES	250MG	A074140	001	Dec 21, 1993	Feb	CMFD
AB		375MG	A074140	002	Dec 21, 1993	Feb	CMFD
AB		500MG	A074140	003	Dec 21, 1993	Feb	CMFD
AB	L PERRIGO CO	250MG	A077339	001	Apr 27, 2005	Jul	CAHN
AB		375MG	A077339	002	Apr 27, 2005	Jul	CAHN
AB		500MG	A077339	003	Apr 27, 2005	Jul	CAHN
<u>NEBIVOLOL HYDROCHLORIDE</u>							
TABLET; ORAL							
NEBIVOLOL HYDROCHLORIDE							
AB	ANI PHARMS	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Jul	CMFD
AB		EQ 5MG BASE	A203659	002	Apr 16, 2015	Jul	CMFD
AB		EQ 10MG BASE	A203659	003	Apr 16, 2015	Jul	CMFD
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Jul	CMFD
AB	INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul	CMFD
AB		EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul	CMFD
AB		EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul	CMFD
AB		EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul	CMFD
AB	TORRENT	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Aug	CMFD
AB		EQ 5MG BASE	A203966	002	Mar 02, 2018	Aug	CMFD
AB		EQ 10MG BASE	A203966	003	Mar 02, 2018	Aug	CMFD
AB		EQ 20MG BASE	A203966	004	Mar 02, 2018	Aug	CMFD
<u>NEOSTIGMINE METHYLSULFATE</u>							
SOLUTION; INTRAVENOUS							
NEOSTIGMINE METHYLSULFATE							
AP	CAPLIN	5MG/10ML (0.5MG/ML)	A213074	001	Apr 20, 2021	Apr	NEWA
AP		10MG/10ML (1MG/ML)	A213074	002	Apr 20, 2021	Apr	NEWA
AP	HONG KONG	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Mar	NEWA
AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Mar	NEWA
AP	INDOCO	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Sep	NEWA
AP		10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Sep	NEWA
AP	MEITHEAL	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Apr	CAHN
AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Apr	CAHN
<u>NIACIN</u>							
TABLET; ORAL							
NICOLAR							
	+ @ SANOFI AVENTIS US	500MG	A083823	001		Aug	CRLD
TABLET, EXTENDED RELEASE; ORAL							
NIACIN							
	@ JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Jun	DISC
	@	750MG	A209156	002	May 14, 2018	Jun	DISC
	@	1GM	A209156	003	May 14, 2018	Jun	DISC
AB	! SUN PHARM	750MG	A201273	001	Apr 23, 2014	Aug	CHRS
AB	!	1GM	A200484	002	Apr 23, 2014	Aug	CHRS
NIASPAN							
	+ @ ABBVIE	500MG	N020381	002	Jul 28, 1997	Aug	DISC
	+ @	750MG	N020381	003	Jul 28, 1997	Aug	DISC
	+ @	1GM	N020381	004	Jul 28, 1997	Aug	DISC

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB	ANI PHARMS	20MG	A074670	001	Oct 28, 1996	May	CMFD
AB		30MG	A074670	002	Oct 28, 1996	May	CMFD
AB	EPIC PHARMA	20MG	A074928	001	Mar 19, 1998	May	CTEC
AB	!	30MG	A074928	002	Mar 19, 1998	May	CTEC

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP	! AM REGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Apr	CTEC
	!	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Feb	CHRS
AP	SUN PHARM	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	Jun	CMFD
	@	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	Jun	CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB1	AUROBINDO PHARMA LTD	30MG	A213361	001	Jul 19, 2021	Jul	NEWA
AB1		60MG	A213361	002	Jul 19, 2021	Jul	NEWA
AB1		90MG	A213361	003	Jul 19, 2021	Jul	NEWA
	@ ELITE	90MG	A212016	001	Nov 18, 2020	Jun	DISC
>D>	@ ELITE PHARM SOLUTION	90MG	A212016	001	Nov 18, 2020	Oct	CMFD
>A> AB2		90MG	A212016	001	Nov 18, 2020	Oct	CMFD
	@	90MG	A212016	001	Nov 18, 2020	Sep	CAHN
	@ MYLAN	30MG	A201071	001	Dec 03, 2010	Jul	DISC
	@	60MG	A201071	002	Dec 03, 2010	Jul	DISC
	@	90MG	A201071	003	Dec 03, 2010	Jul	DISC
	@ PAR PHARM	30MG	A077899	001	Dec 13, 2006	Apr	DISC
	@	60MG	A077899	002	Dec 13, 2006	Apr	DISC
	@	90MG	A077899	003	May 25, 2012	Apr	DISC

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

BX	SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015	Sep	CTEC
----	---------------	------	---------	-----	--------------	-----	------

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

!	MYLAN	20MG	A079051	001	Jul 25, 2008	Jan	CHRS
		30MG	A079051	002	Jul 25, 2008	Jan	CHRS

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB	ALEMBIC PHARMS LTD	25MG	A211935	001	Jun 25, 2021	Jun	NEWA
AB		50MG	A211935	002	Jun 25, 2021	Jun	NEWA
AB		100MG	A211935	003	Jun 25, 2021	Jun	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@	MYLAN	75MG;25MG	A076648	001	Mar 22, 2004	Jul	DISC
---	-------	-----------	---------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

@	BAUSCH	0.4MG/HR	A089773	001	Aug 30, 1996	May	CAHN
NITRO-DUR							
+	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Aug	CTEC
+		0.2MG/HR	N020145	002	Apr 04, 1995	Aug	CTEC
+		0.4MG/HR	N020145	004	Apr 04, 1995	Aug	CTEC
+		0.6MG/HR	N020145	005	Apr 04, 1995	Aug	CTEC

POWDER;SUBLINGUAL

GONITRO

+	@ POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Sep	DISC
+	!	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jul	CMFD
+	@	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun	DISC

TABLET;SUBLINGUAL

NITROGLYCERIN

AB	RUBICON	0.3MG	A209779	001	May 03, 2021	Apr	NEWA
----	---------	-------	---------	-----	--------------	-----	------

TABLET;SUBLINGUAL
NITROGLYCERIN

AB		0.4MG	A209779	002	May 03, 2021	Apr	NEWA
AB		0.6MG	A209779	003	May 03, 2021	Apr	NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP	ANDERSEN GLOBAL	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Jan	NEWA
AP	BRECKENRIDGE	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Mar	CAHN
AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A214323	001	May 06, 2021	Apr	NEWA
AP	SUN PHARM	EQ 1MG BASE/ML	A211980	001	Jan 29, 2021	Jan	NEWA

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

+	!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Sep	CMFD
+	@		EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Jul	DISC
+	!		EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Jan	NEWA
+	!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Sep	CMFD
+	@		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Jul	DISC
+	!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Jan	NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

	@	ZYDUS	EQ 10MG BASE	A213441	001	Feb 24, 2021	Aug	DISC
AB			EQ 10MG BASE	A213441	001	Feb 24, 2021	Feb	NEWA
	@		EQ 25MG BASE	A213441	002	Feb 24, 2021	Aug	DISC
AB			EQ 25MG BASE	A213441	002	Feb 24, 2021	Feb	NEWA
	@		EQ 50MG BASE	A213441	003	Feb 24, 2021	Aug	DISC
AB			EQ 50MG BASE	A213441	003	Feb 24, 2021	Feb	NEWA
	@		EQ 75MG BASE	A213441	004	Feb 24, 2021	Aug	DISC
AB			EQ 75MG BASE	A213441	004	Feb 24, 2021	Feb	NEWA

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT		MACLEODS PHARMS LTD	100,000 UNITS/GM	A213566	001	Aug 10, 2021	Jul	NEWA
----	--	---------------------	------------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

NYSTATIN

AT		MACLEODS PHARMS LTD	100,000 UNITS/GM	A213826	001	Jan 14, 2021	Jan	NEWA
----	--	---------------------	------------------	---------	-----	--------------	-----	------

POWDER;TOPICAL

NYSTATIN

AT		ZYDUS PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	Jul	CAHN
----	--	--------------	------------------	---------	-----	--------------	-----	------

SUSPENSION;ORAL

NYSTATIN

>A>	AA	DASTECH GENERICS	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Oct	CAHN
>D>	AA	NIVAGEN PHARMS INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Oct	CAHN
	AA		100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jun	CAHN

TABLET;ORAL

NYSTATIN

>A>	@	CHARTWELL RX	500,000 UNITS	A062524	001	Nov 26, 1985	Oct	CAHN
>D>	@	UPSHER SMITH LABS	500,000 UNITS	A062524	001	Nov 26, 1985	Oct	CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		ALEOR DERMACEUTICALS	100,000 UNITS/GM;0.1%	A214090	001	Mar 31, 2021	Mar	NEWA
----	--	----------------------	-----------------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		MACLEODS PHARMS LTD	100,000 UNITS/GM;0.1%	A214751	001	Aug 17, 2021	Aug	NEWA
----	--	---------------------	-----------------------	---------	-----	--------------	-----	------

ODEVIXIBAT

CAPSULE;ORAL

BYLVAY

+		ALBIREO	0.4MG	N215498	002	Jul 20, 2021	Jul	NEWA
+	!		1.2MG	N215498	004	Jul 20, 2021	Jul	NEWA

CAPSULE, PELLETS;ORAL
BYLVAY

+	ALBIREO	0.2MG	N215498	001	Jul 20, 2021	Jul NEWA
+	!	0.6MG	N215498	003	Jul 20, 2021	Jul NEWA

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

@	ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Jun CAHN
@		0.3%	A076830	001	Aug 31, 2004	Jan DISC

SOLUTION/DROPS;OTIC

OFLOXACIN

@	ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Jun CAHN
---	---------	------	---------	-----	--------------	----------

TABLET;ORAL

FLOXIN

+	@	JANSSEN PHARMS	200MG	N019735	001	Dec 28, 1990	Jan CRLD
+	@		300MG	N019735	002	Dec 28, 1990	Jan CRLD
+	@		400MG	N019735	003	Dec 28, 1990	Jan CRLD

OFLOXACIN

AB		LARKEN LABS	400MG	A076093	003	Sep 02, 2003	May CMFD
----	--	-------------	-------	---------	-----	--------------	----------

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB	@	HISUN PHARM HANGZHOU	2.5MG	A206924	001	Dec 31, 2020	Jul DISC
			2.5MG	A206924	001	Dec 31, 2020	Feb CAHN
	@		5MG	A206924	002	Dec 31, 2020	Jul DISC
AB			5MG	A206924	002	Dec 31, 2020	Feb CAHN
	@		7.5MG	A206924	003	Dec 31, 2020	Jul DISC
AB			7.5MG	A206924	003	Dec 31, 2020	Feb CAHN
	@		10MG	A206924	004	Dec 31, 2020	Jul DISC
AB			10MG	A206924	004	Dec 31, 2020	Feb CAHN
	@		15MG	A206924	005	Dec 31, 2020	Jul DISC
AB			15MG	A206924	005	Dec 31, 2020	Feb CAHN
	@		20MG	A206924	006	Dec 31, 2020	Jul DISC
AB			20MG	A206924	006	Dec 31, 2020	Feb CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

>D>	@	HEC PHARM	5MG	A208146	001	Jul 02, 2018	Oct CMFD
>A>	AB		5MG	A208146	001	Jul 02, 2018	Oct CMFD
>D>	@		10MG	A208146	002	Jul 02, 2018	Oct CMFD
>A>	AB		10MG	A208146	002	Jul 02, 2018	Oct CMFD
>D>	@		15MG	A208146	003	Jul 02, 2018	Oct CMFD
>A>	AB		15MG	A208146	003	Jul 02, 2018	Oct CMFD
>D>	@		20MG	A208146	004	Jul 02, 2018	Oct CMFD
>A>	AB		20MG	A208146	004	Jul 02, 2018	Oct CMFD
	@	HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020	Jul DISC
AB			5MG	A206892	001	Dec 31, 2020	Feb CAHN
	@		10MG	A206892	002	Dec 31, 2020	Jul DISC
AB			10MG	A206892	002	Dec 31, 2020	Feb CAHN
	@		15MG	A206892	003	Dec 31, 2020	Jul DISC
AB			15MG	A206892	003	Dec 31, 2020	Feb CAHN
	@		20MG	A206892	004	Dec 31, 2020	Jul DISC
AB			20MG	A206892	004	Dec 31, 2020	Feb CAHN
AB		TORRENT	5MG	A091415	001	Oct 25, 2011	Aug CAHN
AB			10MG	A091415	002	Oct 25, 2011	Aug CAHN
AB			15MG	A091415	003	Oct 25, 2011	Aug CAHN
AB			20MG	A091415	004	Oct 25, 2011	Aug CAHN

OLANZAPINE; SAMIDORPHAN L-MALATE

TABLET;ORAL

LYBALVI

+	!	ALKERMES INC	5MG;EQ 10MG BASE	N213378	001	May 28, 2021	May NEWA
+			10MG;EQ 10MG BASE	N213378	002	May 28, 2021	May NEWA
+			15MG;EQ 10MG BASE	N213378	003	May 28, 2021	May NEWA
+			20MG;EQ 10MG BASE	N213378	004	May 28, 2021	May NEWA

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

@ LUPIN LTD	5MG	A206631	001	Apr 27, 2017	Aug	DISC
@	20MG	A206631	002	Apr 27, 2017	Aug	DISC
@	40MG	A206631	003	Apr 27, 2017	Aug	DISC
@ MYLAN	5MG	A078276	001	Oct 26, 2016	Jul	DISC
@	20MG	A078276	002	Oct 26, 2016	Jul	DISC
@	40MG	A078276	003	Oct 26, 2016	Jul	DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AKORN	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Mar	CTEC
SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Jul	CTEC
@ WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jul	DISC

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

AB	AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Mar	CMFD
	@	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan	DISC

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

>A>	+	MYLAN SPCLT VIATRIS	250MG	N019715	001	Jul 31, 1990	Oct	CAHN
>D>	+	MYLAN SPECIALITY LP	250MG	N019715	001	Jul 31, 1990	Oct	CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZA

AB	+	WOODWARD	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb	CAHN
----	---	----------	--	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE; ORAL

OMTRYG

>D>	+	@ OSMOTICA	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Oct	CAHN
>A>	+	@ OSMOTICA PHARM US	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Oct	CAHN

ONDANSETRON

FILM; ORAL

ZUPLLENZ

+	@	AQUESTIVE	4MG	N022524	001	Jul 02, 2010	Feb	CAHN
+	@		8MG	N022524	002	Jul 02, 2010	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

>D>	AB	AUROBINDO PHARMA	8MG	A090469	002	Apr 12, 2010	Oct	CHRS	
>A>	AB	!	8MG	A090469	002	Apr 12, 2010	Oct	CHRS	
		ZOFRAN ODT							
>D>	AB	+	NOVARTIS	4MG	N020781	001	Jan 27, 1999	Oct	DISC
>A>		+	@	4MG	N020781	001	Jan 27, 1999	Oct	DISC
>D>	AB	+	!	8MG	N020781	002	Jan 27, 1999	Oct	DISC
>A>		+	@	8MG	N020781	002	Jan 27, 1999	Oct	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

@ HOSPIRA	EQ 2MG BASE/ML	A077840	001	Jan 19, 2007	Jun	DISC
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
@ EMCURE PHARMS LTD	EQ 2MG BASE/ML	A078945	001	Jan 03, 2013	May	DISC

ORITAVANCIN DIPHOSPHATE

POWDER; INTRAVENOUS
KIMYRSA

+!	MELINTA THERAP	EQ 1.2GM BASE/VIAL	N214155	001	Mar 12, 2021	Mar	NEWA
	ORBACTIV						
+!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	May	CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
NORFLEX

+	@ BAUSCH	100MG	N012157	001		May	CAHN
	ORPHENADRINE CITRATE						
	@ IMPAX PHARMS	100MG	A040368	001	Jun 23, 2000	Jan	DISC

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL
OSELTAMIVIR PHOSPHATE

AB	EPIC PHARMA LLC	EQ 30MG BASE	A215208	001	Oct 01, 2021	Sep	NEWA
AB		EQ 45MG BASE	A215208	002	Oct 01, 2021	Sep	NEWA
AB		EQ 75MG BASE	A215208	003	Oct 01, 2021	Sep	NEWA
	@ MYLAN	EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan	DISC
AB		EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan	NEWA
	@	EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan	DISC
AB		EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan	NEWA
	@	EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan	DISC
AB		EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan	NEWA
>D>	AB	NESHER PHARMS	A208578	001	Feb 24, 2017	Oct	CAHN
>D>	AB		A208578	002	Feb 24, 2017	Oct	CAHN
>D>	AB		A208578	003	Feb 24, 2017	Oct	CAHN
>A>	AB	ZYDUS PHARMS	A208578	001	Feb 24, 2017	Oct	CAHN
>A>	AB		A208578	002	Feb 24, 2017	Oct	CAHN
>A>	AB		A208578	003	Feb 24, 2017	Oct	CAHN
	FOR SUSPENSION; ORAL						
	OSELTAMIVIR PHOSPHATE						
AB	APTAPHARMA INC	EQ 6MG BASE/ML	A212858	001	Aug 30, 2021	Aug	NEWA
>D>	AB	NESHER PHARMS	A209113	001	Sep 14, 2017	Oct	CAHN
>A>	AB	ZYDUS PHARMS	A209113	001	Sep 14, 2017	Oct	CAHN

OXALIPLATIN

INJECTABLE; INTRAVENOUS
OXALIPLATIN

	@ CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	May	DISC
	@	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	May	DISC
AP	NOVAST LABS	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Sep	CAHN
AP		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Sep	CAHN
AP	QILU PHARM HAINAN	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	Aug	CAHN
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	Aug	CAHN
	!	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Aug	CAHN

OXCARBAZEPINE

SUSPENSION; ORAL
OXCARBAZEPINE

AB	AKORN	300MG/5ML	A211420	001	Jul 09, 2021	Jul	NEWA
AB	GLASSHOUSE PHARMS	300MG/5ML	A212428	001	Jun 21, 2021	Jun	NEWA

OXICONAZOLE NITRATE

LOTION; TOPICAL
OXISTAT

+!	ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr	CAHN
----	------------	------------	---------	-----	--------------	-----	------

OXYBUTYNIN CHLORIDE

TABLET; ORAL
OXYBUTYNIN CHLORIDE

AB	APPCO	5MG	A209025	001	Dec 21, 2017	Jan	CAHN
BX	EMCURE PHARMS LTD	5MG	A211682	001	May 10, 2019	Sep	CTEC
BX	EYWA	5MG	A211062	001	Feb 06, 2019	Sep	CTEC
>A>	AB	! STRIDES PHARMA	A075079	001	Oct 31, 1997	Oct	CAHN
	@	5MG	A208165	001	Dec 17, 2020	Jun	DISC
>D>	AB	! VINTAGE PHARMS	A075079	001	Oct 31, 1997	Oct	CAHN

OXYCODONE HYDROCHLORIDE

	CAPSULE;ORAL						
	OXYCODONE HYDROCHLORIDE						
	@ LANNETT CO INC	5MG	A203823	001	Aug 01, 2014	Apr	DISC
	SOLUTION;ORAL						
	OXYCODONE HYDROCHLORIDE						
AA	QUAGEN	5MG/5ML	A213761	001	Jun 02, 2021	May	NEWA
AA		100MG/5ML	A213761	002	Jun 02, 2021	May	NEWA
	TABLET;ORAL						
	OXAYDO						
	+ ZYLA	5MG	N202080	001	Jun 17, 2011	Mar	CRLD
	+	7.5MG	N202080	002	Jun 17, 2011	Mar	CRLD
	OXYCODONE HYDROCHLORIDE						
AB	ALVOGEN	5MG	A202116	001	Dec 30, 2011	Apr	CAHN
AB		15MG	A202116	002	Dec 30, 2011	Apr	CAHN
AB		30MG	A202116	003	Dec 30, 2011	Apr	CAHN
>A>	AB	SPECGX LLC	A076758	004	Oct 12, 2021	Oct	NEWA
>A>	AB		A076758	005	Oct 12, 2021	Oct	NEWA

OXYMETAZOLINE HYDROCHLORIDE

	CREAM;TOPICAL						
	OXYMETAZOLINE HYDROCHLORIDE						
>D>	AB	TARO PHARMS	A213584	001	Oct 04, 2021	Oct	DISC
>A>		@	A213584	001	Oct 04, 2021	Oct	DISC
	AB		A213584	001	Oct 04, 2021	Sep	NFTG
	RHOFADE						
>D>	AB	+! EPI HLTH	N208552	001	Jan 18, 2017	Oct	CTEC
>A>		+!	N208552	001	Jan 18, 2017	Oct	CTEC
	AB	+!	N208552	001	Jan 18, 2017	Sep	CFTG

OXYMETHOLONE

	TABLET;ORAL						
	ANADROL-50						
	+ @ MYLAN SPECIALITY LP	50MG	N016848	001		Apr	DISC

OXYTOCIN

	INJECTABLE;INJECTION						
	OXYTOCIN						
AP	+!	HIKMA PHARMS	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Jul CAHN
AP	+!		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Jul CAHN

OZANIMOD HYDROCHLORIDE

	CAPSULE;ORAL						
	ZEPOSIA						
	+ CELGENE INTL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	May	CPOT
	+	EQ 0.46MG BASE	N209899	002	Mar 25, 2020	May	CPOT
	+!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	May	CPOT

PACLITAXEL

	INJECTABLE;INJECTION						
	PACLITAXEL						
AP		ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	May CMFD
	@ MYLAN LABS LTD		6MG/ML	A091540	001	Sep 29, 2011	Mar DISC

PALIPERIDONE

	TABLET, EXTENDED RELEASE;ORAL						
	PALIPERIDONE						
BX		AMNEAL PHARMS	1.5MG	A204707	001	Sep 23, 2019	Sep CTEC
BX			3MG	A204707	002	Sep 23, 2019	Sep CTEC
BX			6MG	A204707	003	Sep 23, 2019	Sep CTEC
BX			9MG	A204707	004	Sep 23, 2019	Sep CTEC

PALIPERIDONE PALMITATE

	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR						
	INVEGA HAFYERA						
	+ JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021	Sep	NEWA
	+	1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021	Sep	NEWA
	INVEGA SUSTENNA						
AB	+ JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jul	CTEC
AP	+	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jun	CFTG
AB	+	78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jul	CTEC

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA SUSTENNA

AP	+	78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jun CFTG
AB	+	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jul CTEC
AP	+	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jun CFTG
AB	+	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jul CTEC
AP	+	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jun CFTG
AB	+	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jul CTEC
AP	+	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jun CFTG

PALIPERIDONE PALMITATE

AB	TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	Jul CTEC
AP		39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	Jun NFTG
AB		78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	Jul CTEC
AP		78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	Jun NFTG
AB		117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	Jul CTEC
AP		117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	Jun NFTG
AB		156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	Jul CTEC
AP		156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	Jun NFTG
AB		234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	Jul CTEC
AP		234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	Jun NFTG

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

+	@ HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008	Apr DISC
+	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003	Apr DISC

PALONOSETRON HYDROCHLORIDE

@	ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Sep DISC
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Mar NEWA
AP	! DR REDDYS LABS LTD	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr CHRS
	EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jun NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jun NEWA
@	HOSPIRA INC	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018	Apr DISC
@	QILU	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018	Apr DISC
@	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Apr DISC

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

+	@ FRESenius KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017	May DISC
---	----------------------	--	---------	-----	--------------	----------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	+	HIKMA PHARMS	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Jul CAHN
AP	+		90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Jul CAHN

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

AP		ACIC PHARMS	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Aug NEWA
----	--	-------------	-------------------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

@	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jun DISC
@		EQ 40MG BASE	A090901	002	Aug 30, 2011	Jun DISC

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

AB		NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Aug NEWA
AB	+	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Aug CTEC

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

>A>	AB	YILING	EQ 10MG BASE	A211248	001	Nov 02, 2021	Oct NEWA
-----	----	--------	--------------	---------	-----	--------------	----------

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

>A>	AB		EQ 20MG BASE	A211248	002	Nov 02, 2021	Oct	NEWA
>A>	AB		EQ 30MG BASE	A211248	003	Nov 02, 2021	Oct	NEWA
>A>	AB		EQ 40MG BASE	A211248	004	Nov 02, 2021	Oct	NEWA

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB		CADILA PHARMS LTD	EQ 12.5MG BASE	A212645	001	Aug 27, 2021	Aug	NEWA
AB			EQ 25MG BASE	A212645	002	Aug 27, 2021	Aug	NEWA
AB			EQ 37.5MG BASE	A212645	003	Aug 27, 2021	Aug	NEWA
AB		CSPC OUYI	EQ 12.5MG BASE	A213485	001	Feb 16, 2021	Feb	NEWA
AB			EQ 25MG BASE	A213485	002	Feb 16, 2021	Feb	NEWA
AB			EQ 37.5MG BASE	A213485	003	Feb 16, 2021	Feb	NEWA
AB		SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jul	NEWA
AB			EQ 25MG BASE	A213612	002	Aug 11, 2021	Jul	NEWA

PATIROMER SORBITE X CALCIUM

POWDER;ORAL

VELTASSA

+		VIFOR PHARMA	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015	Jun	CAHN
+			EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jun	CAHN
+	!		EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jun	CAHN

PEGCETACOPLAN

SOLUTION;SUBCUTANEOUS

EMPAVELI

+	!	APELLIS PHARMS	1080MG/20ML (54MG/ML)	N215014	001	May 14, 2021	May	NEWA
---	---	----------------	-----------------------	---------	-----	--------------	-----	------

PEMETREXED

SOLUTION;INTRAVENOUS

PEMETREXED

+	@	ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	Jan	DISC
+	@		500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	Jan	DISC
+	@		1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	Jan	DISC

PENICILLAMINE

CAPSULE;ORAL

PENICILLAMINE

AB		AGGREGA	250MG	A215409	001	Aug 23, 2021	Aug	NEWA
AB		BRECKENRIDGE	250MG	A215409	001	Aug 23, 2021	Sep	CAHN
AB		INVAGEN PHARMS	250MG	A213293	001	Aug 19, 2021	Aug	NEWA
>A>	AB	NAVINTA LLC	250MG	A214363	001	Oct 08, 2021	Oct	NEWA

PENICILLIN G POTASSIUM

INJECTABLE;INJECTION

PENICILLIN G POTASSIUM

		HQ SPECLT PHARMA	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009	Mar	CAHN
AP			5,000,000 UNITS/VIAL	A065149	002	Jul 23, 2009	Mar	CAHN
AP			20,000,000 UNITS/VIAL	A065149	003	Jul 23, 2009	Mar	CAHN

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN V POTASSIUM

	@	DAVA PHARMS INC	EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Mar	DISC
	@		EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Mar	DISC
		PENICILLIN-VK						
		TEVA	EQ 125MG BASE/5ML	A060456	001		Mar	CTEC
	!		EQ 250MG BASE/5ML	A060456	002		Mar	CTEC

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION

PENTAMIDINE ISETHIONATE

AP		EMCURE PHARMS LTD	300MG/VIAL	A213806	001	Jan 07, 2021	Jan	NEWA
----	--	-------------------	------------	---------	-----	--------------	-----	------

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

NEMBUTAL SODIUM

AP	+	AKORN	50MG/ML	A083246	001		Aug	CRLD
----	---	-------	---------	---------	-----	--	-----	------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIL

@ UPSHER SMITH LABS 400MG A074962 001 Mar 31, 1999 May DISC
 TRENENTAL
 + @ VALIDUS PHARMS 400MG N018631 001 Aug 30, 1984 Feb CAHN

PERAMPANEL

TABLET;ORAL

FYCOMPA

+ EISAI INC 2MG N202834 001 Oct 22, 2012 Jun CTEC
 AB + 2MG N202834 001 Oct 22, 2012 May CFTG
 + 4MG N202834 002 Oct 22, 2012 Jun CTEC
 AB + 4MG N202834 002 Oct 22, 2012 May CFTG
 + 6MG N202834 003 Oct 22, 2012 Jun CTEC
 AB + 6MG N202834 003 Oct 22, 2012 May CFTG
 + 8MG N202834 004 Oct 22, 2012 Jun CTEC
 AB + 8MG N202834 004 Oct 22, 2012 May CFTG
 + 10MG N202834 005 Oct 22, 2012 Jun CTEC
 AB + 10MG N202834 005 Oct 22, 2012 May CFTG
 +! 12MG N202834 006 Oct 22, 2012 Jun CTEC
 AB +! 12MG N202834 006 Oct 22, 2012 May CFTG

PERMETHRIN

CREAM;TOPICAL

ELIMITE

+ @ MYLAN 5% N019855 001 Aug 25, 1989 Sep CAHN

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

BONTRIL PDM

AA +! VALEANT 35MG A085272 001 Aug CRLD

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

ADIPEX-P

AA +! TEVA 37.5MG A088023 001 Aug 02, 1983 Aug CRLD
 PHENTERMINE HYDROCHLORIDE
 AA +! SANDOZ 15MG A087190 002 Aug CRLD
 AA +! 30MG A086945 001 Jul 20, 1983 Aug CRLD

TABLET;ORAL

ADIPEX-P

AA +! TEVA 37.5MG A085128 001 Aug CRLD
 PHENTERMINE HYDROCHLORIDE
 AA MERRO PHARM USA 37.5MG A206342 001 Nov 18, 2016 Sep CAHN
 + @ USL PHARMA 8MG A083804 001 Aug CRLD

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

BIORPHEN

+! ETON PHARMS 0.5MG/5ML (0.1MG/ML) N212909 001 Oct 21, 2019 Feb CPOT
 + @ 10MG/ML (10MG/ML) N212909 002 Mar 11, 2021 Apr DISC
 +! 10MG/ML (10MG/ML) N212909 002 Mar 11, 2021 Mar NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP1 CAPLIN 10MG/ML (10MG/ML) A213318 001 Jun 11, 2020 Jul CMFD
 AP1 50MG/5ML (10MG/ML) A213318 002 Jun 11, 2020 Jul CMFD
 AP1 100MG/10ML (10MG/ML) A213318 003 Jun 11, 2020 Jul CMFD
 AP1 GLAND PHARMA LTD 10MG/ML (10MG/ML) A211920 003 Apr 08, 2021 Apr NEWA
 AP2 +! HIKMA 10MG/ML (10MG/ML) N203826 001 Dec 20, 2012 Jan CAHN
 AP2 +! 50MG/5ML (10MG/ML) N203826 002 Jun 19, 2019 Jan CAHN
 AP2 +! 100MG/10ML (10MG/ML) N203826 003 Jun 19, 2019 Jan CAHN
 AP1 PROVEPHARM SAS 10MG/ML (10MG/ML) A211081 001 Jul 17, 2020 Jan CAHN
 AP1 50MG/5ML (10MG/ML) A211081 002 Jul 17, 2020 Jan CAHN
 AP1 100MG/10ML (10MG/ML) A211081 003 Jul 17, 2020 Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA AKORN 5MG/5ML;6.25MG/5ML A040675 001 Dec 23, 2014 Feb CAHN
 PROMETH VC PLAIN
 + @ G AND W LABS INC 5MG/5ML;6.25MG/5ML A088761 001 Nov 08, 1984 Aug CRLD

PHENYTOIN

TABLET, CHEWABLE;ORAL
DILANTIN
AB +! PHARMACIA 50MG A 084427 001 Aug CRLD

PHENYTOIN SODIUM

CAPSULE;ORAL
DILANTIN
+! UPJOHN 30MG EXTENDED A 084349 001 Aug CRLD
AB +! 100MG EXTENDED A 084349 002 Aug CRLD
INJECTABLE;INJECTION
PHENYTOIN SODIUM
AP +! WEST-WARD PHARMS INT 50MG/ML A 084307 001 Aug CRLD

PHYTONADIONE

INJECTABLE;INJECTION
PHYTONADIONE
BP +! INTL MEDICATION 1MG/0.5ML A 083722 001 May CRLD
VITAMIN K1
>D> BP ! HOSPIRA 1MG/0.5ML A 087954 001 Jul 25, 1983 Oct CRLD
>A> BP +! 1MG/0.5ML A 087954 001 Jul 25, 1983 Oct CRLD
AB +! 10MG/ML A 087955 001 Jul 25, 1983 Aug CRLD

PIFLUFOLASTAT F-18

SOLUTION;INTRAVENOUS
PYLARIFY
+! PROGENICS PHARMS INC 50ML (1-80mCi/ML) N214793 001 May 26, 2021 May NEWA

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC
VUITY
>A> +! ABBVIE INC 1.25% N214028 001 Oct 28, 2021 Oct NEWA
TABLET;ORAL
PILOCARPINE HYDROCHLORIDE
AB AMICI 5MG A 076963 001 Dec 22, 2004 Sep CAHN
AB 7.5MG A 076963 002 Feb 27, 2007 Sep CAHN
AB INNOGENIX 5MG A 076963 001 Dec 22, 2004 Aug CAHN
AB 7.5MG A 076963 002 Feb 27, 2007 Aug CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE
AB ANNORA PHARMA EQ 15MG BASE A204133 001 Apr 07, 2014 Jan CAHN
AB EQ 30MG BASE A204133 002 Apr 07, 2014 Jan CAHN
AB EQ 45MG BASE A204133 003 Apr 07, 2014 Jan CAHN
>A> @ PICKET PHARMS EQ 15MG BASE A078383 001 Mar 12, 2013 Oct CAHN
>A> @ EQ 30MG BASE A078383 002 Mar 12, 2013 Oct CAHN
>A> @ EQ 45MG BASE A078383 003 Mar 12, 2013 Oct CAHN
AB SHUANGCHENG EQ 15MG BASE A210165 001 Jan 22, 2021 Jan NEWA
AB EQ 30MG BASE A210165 002 Jan 22, 2021 Jan NEWA
AB EQ 45MG BASE A210165 003 Jan 22, 2021 Jan NEWA
>D> @ US ANTIBIOTICS EQ 15MG BASE A078383 001 Mar 12, 2013 Oct CAHN
@ EQ 15MG BASE A078383 001 Mar 12, 2013 May CAHN
>D> @ EQ 30MG BASE A078383 002 Mar 12, 2013 Oct CAHN
@ EQ 30MG BASE A078383 002 Mar 12, 2013 May CAHN
>D> @ EQ 45MG BASE A078383 003 Mar 12, 2013 Oct CAHN
@ EQ 45MG BASE A078383 003 Mar 12, 2013 May CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION
PIPERACILLIN AND TAZOBACTAM
@ MYLAN LABS LTD EQ 2GM BASE/VIAL;EQ 250MG A 065458 001 Aug 15, 2014 Apr DISC
BASE/VIAL
@ EQ 3GM BASE/VIAL;EQ 375MG A 065458 002 Aug 15, 2014 Mar DISC
BASE/VIAL
@ EQ 4GM BASE/VIAL;EQ 500MG A 065458 003 Aug 15, 2014 Jul DISC
BASE/VIAL
AP PROVEPHARM SAS EQ 2GM BASE/VIAL;EQ 250MG A207847 001 Jan 13, 2017 Jan CAHN
BASE/VIAL
AP EQ 3GM BASE/VIAL;EQ 375MG A207847 002 Jan 13, 2017 Jan CAHN
BASE/VIAL
AP EQ 36GM BASE/VIAL;EQ 4.5GM A207848 002 Jan 13, 2017 Jan CAHN

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP		BASE/VIAL EQ 4GM BASE/VIAL;EQ 500MG	A207847	003	Jan 13, 2017	Jan CAHN
AP		BASE/VIAL EQ 12GM BASE/VIAL;EQ 1.5GM	A207848	001	May 11, 2018	Jan CAHN
AP	SAGENT PHARMS INC	BASE/VIAL EQ 2GM BASE/VIAL;EQ 250MG	A208674	001	Feb 16, 2021	Feb NEWA
AP		BASE/VIAL EQ 3GM BASE/VIAL;EQ 375MG	A208674	002	Feb 16, 2021	Feb NEWA
AP		BASE/VIAL EQ 4GM BASE/VIAL;EQ 500MG	A208674	003	Feb 16, 2021	Feb NEWA
AP		BASE/VIAL EQ 36GM BASE/VIAL;EQ 4.5GM	A208675	001	Feb 16, 2021	Feb NEWA
AP	SANDOZ INC	BASE/VIAL EQ 36GM BASE/VIAL;EQ 4.5GM	A203557	002	Jul 08, 2021	Jul NEWA
AP	! WOCKHARDT BIO AG	BASE/VIAL EQ 2GM BASE/VIAL;EQ 250MG	A206996	001	Mar 22, 2017	Jan CHRS
AP	!	BASE/VIAL EQ 3GM BASE/VIAL;EQ 375MG	A206996	002	Mar 22, 2017	Jan CHRS
AP	!	BASE/VIAL EQ 4GM BASE/VIAL;EQ 500MG	A206996	003	Mar 22, 2017	Jan CHRS
AP	!	BASE/VIAL EQ 36GM BASE/VIAL;EQ 4.5GM	A207146	001	Mar 17, 2017	Jan CHRS
ZOSYN						
+	@ WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG	N050684	001	Oct 22, 1993	Jan DISC
+	@	BASE/VIAL EQ 3GM BASE/VIAL;EQ 375MG	N050684	002	Oct 22, 1993	Jan DISC
+	@	BASE/VIAL EQ 4GM BASE/VIAL;EQ 500MG	N050684	003	Oct 22, 1993	Jan DISC
+	@	BASE/VIAL EQ 36GM BASE/VIAL;EQ 4.5GM	N050684	004	Oct 22, 1993	Jan DISC

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION
MAXAIR

@ BAUSCH	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	May CAHN
----------	-------------------	---------	-----	--------------	----------

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	NOSTRUM LABS INC	10MG	A074118	002	Jun 15, 1993	Jan CMS1
BX	UNICHEM	10MG	A208340	001	Apr 13, 2017	Sep CTEC
BX		20MG	A208340	002	Apr 13, 2017	Sep CTEC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL
LAX-LYTE WITH FLAVOR PACKS

AA	L PERRIGO CO	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A079232	001	Feb 25, 2010	Aug CAHN
>D>	TRILYTE					
>D>	AA MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A076491	001	Feb 05, 2004	Oct DISC
>A>	@	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A076491	001	Feb 05, 2004	Oct DISC

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
POLYMYXIN B SULFATE

AP	! @ GLAND	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	May DISC
	! XELLIA PHARMS APS	EQ 500,000 UNITS BASE/VIAL	A202766	001	Jan 15, 2014	May CHRS

POMALIDOMIDE

CAPSULE; ORAL
POMALIDOMIDE

@ BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Feb DISC
@	2MG	A210111	002	Oct 30, 2020	Feb DISC
@	3MG	A210111	003	Oct 30, 2020	Feb DISC
@	4MG	A210111	004	Oct 30, 2020	Feb DISC
@ EUGIA PHARMA	1MG	A210249	001	Oct 30, 2020	Apr DISC
@	2MG	A210249	002	Oct 30, 2020	Apr DISC
@	3MG	A210249	003	Oct 30, 2020	Apr DISC
@	4MG	A210249	004	Oct 30, 2020	Apr DISC

CAPSULE;ORAL
POMALYST

+	CELGENE	1MG	N204026	001	Feb 08, 2013	Apr	CTEC
+		2MG	N204026	002	Feb 08, 2013	Apr	CTEC
+		3MG	N204026	003	Feb 08, 2013	Apr	CTEC
+	!	4MG	N204026	004	Feb 08, 2013	Apr	CTEC

PONATINIB HYDROCHLORIDE

TABLET;ORAL
ICLUSIG

+	TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020	May	CAHN
+		EQ 15MG BASE	N203469	001	Dec 14, 2012	May	CAHN
+		EQ 30MG BASE	N203469	003	Apr 23, 2015	May	CAHN
+	!	EQ 45MG BASE	N203469	002	Dec 14, 2012	May	CAHN

PONESIMOD

TABLET;ORAL
PONVORY

+	JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021	Mar	NEWA
+		3MG	N213498	002	Mar 18, 2021	Mar	NEWA
+		4MG	N213498	003	Mar 18, 2021	Mar	NEWA
+		5MG	N213498	004	Mar 18, 2021	Mar	NEWA
+		6MG	N213498	005	Mar 18, 2021	Mar	NEWA
+		7MG	N213498	006	Mar 18, 2021	Mar	NEWA
+		8MG	N213498	007	Mar 18, 2021	Mar	NEWA
+		9MG	N213498	008	Mar 18, 2021	Mar	NEWA
+		10MG	N213498	009	Mar 18, 2021	Mar	NEWA
+	!	20MG	N213498	010	Mar 18, 2021	Mar	NEWA

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL
NOXAFIL POWDERMIX KIT

+	MSD MERCK CO	300MG	N214770	001	May 31, 2021	May	NEWA
---	--------------	-------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL
POSACONAZOLE

AB	AET PHARMA	100MG	A213454	001	Feb 01, 2021	Jan	NEWA
----	------------	-------	---------	-----	--------------	-----	------

POTASSIUM ACETATE

INJECTABLE;INJECTION
POTASSIUM ACETATE

>A>	AP	EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Oct	NEWA
-----	----	--------------	---------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB		GRANULES	8MEQ	A214686	001	Feb 16, 2021	Feb	NEWA
AB			10MEQ	A214686	002	Feb 16, 2021	Feb	NEWA

FOR SOLUTION;ORAL
POTASSIUM CHLORIDE

AA		@ STRIDES PHARMA	20MEQ	A211667	001	Mar 11, 2021	Aug	DISC
AA			20MEQ	A211667	001	Mar 11, 2021	Mar	NEWA

INJECTABLE;INJECTION
POTASSIUM CHLORIDE

AP	+	@ ABRAXIS PHARM	2MEQ/ML	A080204	001		Aug	CRLD
AP	+	FRESENIUS KABI USA	2MEQ/ML	A080225	001		Aug	CRLD

POTASSIUM CHLORIDE 10MEQ

AP		@ FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar	DISC
AP		@	746MG/100ML	A211087	002	Sep 09, 2020	Mar	DISC
AP		NEXUS PHARMS	14.9MG/ML	A214727	001	Mar 18, 2021	Mar	NFTG
AP			745MG/100ML	A214727	002	Mar 18, 2021	Mar	NFTG

POTASSIUM CHLORIDE 20MEQ

AP		@ FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar	DISC
AP			1.49GM/100ML	A211087	005	May 07, 2021	Apr	NEWA
AP		NEXUS PHARMS	29.8MG/ML	A214727	003	Mar 18, 2021	Mar	NFTG
AP			1.49GM/100ML	A214727	004	Mar 18, 2021	Mar	NFTG

POTASSIUM CHLORIDE 40MEQ

AP		@ FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar	DISC
AP		NEXUS PHARMS	2.98GM/100ML	A214727	005	Mar 18, 2021	Mar	NFTG

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA		GRANULES	20MEQ/15ML	A213392	001	Jan 29, 2021	Jan	NEWA
AA			40MEQ/15ML	A213392	002	Jan 29, 2021	Jan	NEWA

SOLUTION;ORAL							
POTASSIUM CHLORIDE							
AA	SAPTALIS PHARMS	20MEQ/15ML	A211648	001	May 21, 2021	May	NEWA
AA		40MEQ/15ML	A211648	002	May 21, 2021	May	NEWA
TABLET, EXTENDED RELEASE;ORAL							
POTASSIUM CHLORIDE							
	@ AMTA	10MEQ	A214395	001	Jan 28, 2021	Jul	DISC
AB1		10MEQ	A214395	001	Jan 28, 2021	Jan	NEWA
	@	20MEQ	A214395	002	Jan 28, 2021	Jul	DISC
AB1		20MEQ	A214395	002	Jan 28, 2021	Jan	NEWA
	@ AUROBINDO PHARMA LTD	10MEQ	A214728	001	Mar 31, 2021	Sep	DISC
AB1		10MEQ	A214728	001	Mar 31, 2021	Mar	NEWA
	@	15MEQ	A214728	002	Mar 31, 2021	Sep	DISC
AB1		15MEQ	A214728	002	Mar 31, 2021	Mar	NEWA
	@	20MEQ	A214728	003	Mar 31, 2021	Sep	DISC
AB1		20MEQ	A214728	003	Mar 31, 2021	Mar	NEWA
	@ BRECKENRIDGE	10MEQ	A213588	001	Aug 21, 2020	Sep	CAHN
	@	20MEQ	A213588	002	Aug 21, 2020	Sep	CAHN
	@ CENTAUR PHARMS PVT	10MEQ	A213588	001	Aug 21, 2020	Mar	DISC
	@	20MEQ	A213588	002	Aug 21, 2020	Mar	DISC
<u>POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>							
INJECTABLE;INJECTION							
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%							
	+! BAXTER HLTHCARE	150MG/100ML;450MG/100ML	N017648	005	Nov 26, 2002	Mar	CTNA
	+!	150MG/100ML;450MG/100ML	N017648	005	Nov 26, 2002	Mar	CTEC
	@ FRESENIUS KABI USA	150MG/100ML;450MG/100ML	A212347	001	Sep 17, 2020	Mar	DISC
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%							
AP	+! BAXTER HLTHCARE	150MG/100ML;900MG/100ML	N017648	001		Mar	CTNA
AP	+!	150MG/100ML;900MG/100ML	N017648	001		Mar	CHRS
AP	FRESENIUS KABI USA	150MG/100ML;900MG/100ML	A212347	003	Jun 02, 2021	May	NEWA
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%							
	+! BAXTER HLTHCARE	300MG/100ML;900MG/100ML	N017648	002		Mar	CTNA
	+!	300MG/100ML;900MG/100ML	N017648	002		Mar	CHRS
	+	300MG/100ML;900MG/100ML	N017648	002		Mar	CTEC
	@ FRESENIUS KABI USA	300MG/100ML;900MG/100ML	A212347	002	Sep 17, 2020	Mar	DISC
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%							
	@ BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004		Mar	CTNA
<u>POTASSIUM CITRATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
POTASSIUM CITRATE							
AB	ASCENT PHARMS INC	5MEQ	A214420	001	Feb 05, 2021	Jan	NEWA
AB		10MEQ	A214420	002	Feb 05, 2021	Jan	NEWA
AB		15MEQ	A214420	003	Feb 05, 2021	Jan	NEWA
AB	BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Apr	CMFD
	@	10MEQ	A212799	001	Jun 29, 2020	Feb	DISC
AB		15MEQ	A212799	002	Jun 29, 2020	Apr	CMFD
	@	15MEQ	A212799	002	Jun 29, 2020	Feb	DISC
AB	EYWA	5MEQ	A214426	001	Feb 19, 2021	Feb	NEWA
AB		10MEQ	A214426	002	Feb 19, 2021	Feb	NEWA
AB		15MEQ	A214426	003	Feb 19, 2021	Feb	NEWA
<u>PRALSETINIB</u>							
CAPSULE;ORAL							
GAVRETO							
	+! GENENTECH INC	100MG	N213721	001	Sep 04, 2020	Mar	CAHN
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>							
TABLET;ORAL							
PRAMIPEXOLE DIHYDROCHLORIDE							
	@ NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010	Jul	DISC
AB		0.125MG	A091450	001	Oct 08, 2010	Apr	CAHN
	@	0.25MG	A091450	002	Oct 08, 2010	Jul	DISC
AB		0.25MG	A091450	002	Oct 08, 2010	Apr	CAHN
	@	0.5MG	A091450	003	Oct 08, 2010	Jul	DISC
AB		0.5MG	A091450	003	Oct 08, 2010	Apr	CAHN
	@	1MG	A091450	004	Oct 08, 2010	Jul	DISC
AB		1MG	A091450	004	Oct 08, 2010	Apr	CAHN
	@	1.5MG	A091450	005	Oct 08, 2010	Jul	DISC
AB		1.5MG	A091450	005	Oct 08, 2010	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB	XIAMEN LP PHARM CO	0.375MG	A212797	001	Jun 11, 2021	Jun NEWA
AB		0.75MG	A212797	002	Jun 11, 2021	Jun NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL
PRASUGREL

BX	AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Sep CTEC
BX		EQ 10MG BASE	A205913	002	Jun 19, 2018	Sep CTEC
	@ DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan DISC
	@	EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan DISC
AB	PANACEA	EQ 5MG BASE	A205897	001	Oct 16, 2017	Jul CAHN
AB		EQ 10MG BASE	A205897	002	Oct 16, 2017	Jul CAHN
AB	USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Sep CAHN
AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Sep CAHN

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVACHOL

	+ @ BRISTOL MYERS SQUIBB	20MG	N019898	003	Oct 31, 1991	Jun DISC
	+ @	40MG	N019898	004	Mar 22, 1993	Jun DISC
	+ @	80MG	N019898	008	Dec 18, 2001	Jun DISC
	PRAVASTATIN SODIUM					
AB	BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Jan CAHN
AB		20MG	A209869	002	Apr 13, 2018	Jan CAHN
AB		40MG	A209869	003	Apr 13, 2018	Jan CAHN
AB		80MG	A209869	004	Apr 13, 2018	Jan CAHN
	@ HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018	Jan DISC
	@	40MG	A206061	002	Nov 23, 2018	Jan DISC
	@	80MG	A206061	003	Nov 23, 2018	Jan DISC
AB	! TEVA PHARMS	80MG	A077793	001	Jan 15, 2008	Jun CHRS

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

AB	ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989	Feb CMFD
AB		EQ 2MG BASE	A072577	001	May 16, 1989	Feb CMFD
AB		EQ 5MG BASE	A072577	003	May 16, 1989	Feb CMFD

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Mar CMFD
----	--------------	----------	---------	-----	--------------	----------

TABLET;ORAL

PREDNISOLONE

	@ RISING	5MG	A084773	001		Jan CAHN
--	----------	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

	@ BAUSCH	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	May CAHN
--	----------	------------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

INFLAMASE FORTE

	+ @ NOVARTIS	EQ 0.9% PHOSPHATE	A080751	002		Aug CRLD
--	--------------	-------------------	---------	-----	--	----------

INFLAMASE MILD

	+ @ NOVARTIS	EQ 0.11% PHOSPHATE	A080751	001		Aug CRLD
--	--------------	--------------------	---------	-----	--	----------

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

	+ CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Jul CTEC
	+	EQ 15MG BASE	N021959	002	Jun 01, 2006	Jul CTEC
	+!	EQ 30MG BASE	N021959	003	Jun 01, 2006	Jul CTEC

PREDNISOLONE SODIUM PHOSPHATE

	@ MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Jul DISC
	@	EQ 15MG BASE	A202179	002	Apr 10, 2013	Jul DISC
	@	EQ 30MG BASE	A202179	003	Apr 10, 2013	Jul DISC

PREDNISONE

TABLET; ORAL
PREDNISONE

>D>	@	AMNEAL	1MG	A213385	001	Jun 16, 2020	Oct	CMFD
>A>	AB		1MG	A213385	001	Jun 16, 2020	Oct	CMFD
>D>	@		5MG	A213385	002	Jun 16, 2020	Oct	CMFD
>A>	AB		5MG	A213385	002	Jun 16, 2020	Oct	CMFD
>D>	@		10MG	A213386	001	Jun 24, 2020	Oct	CMFD
>A>	AB		10MG	A213386	001	Jun 24, 2020	Oct	CMFD
>D>	@		20MG	A213386	002	Jun 24, 2020	Oct	CMFD
>A>	AB		20MG	A213386	002	Jun 24, 2020	Oct	CMFD
AB	+	HIKMA PHARMS	1MG	A087800	001	Apr 22, 1982	Aug	CRLD
AB	+		10MG	A084122	001		Aug	CRLD
AB	+		20MG	A087342	001		Aug	CRLD
AB		NOVITIUM PHARMA	1MG	A215246	001	Jul 06, 2021	Jun	NEWA
	@	RISING	10MG	A089983	001	Jan 12, 1989	Jan	CAHN
	@		20MG	A085813	001		Jan	CAHN
	@		50MG	A089984	001	Jan 12, 1989	Jan	CAHN
AB		STRIDES PHARMA	10MG	A208412	001	Feb 11, 2021	Feb	NEWA
AB			20MG	A208412	002	Feb 11, 2021	Feb	NEWA

TABLET, DELAYED RELEASE; ORAL
RAYOS

+		HORIZON	1MG	N202020	001	Jul 26, 2012	Apr	CAHN
+			2MG	N202020	002	Jul 26, 2012	Apr	CAHN
+			5MG	N202020	003	Jul 26, 2012	Apr	CAHN

PREGABALIN

CAPSULE; ORAL
LYRICA

AB	+	UPJOHN	25MG	N021446	001	Dec 30, 2004	Apr	CAHN
AB	+		50MG	N021446	002	Dec 30, 2004	Apr	CAHN
AB	+		75MG	N021446	003	Dec 30, 2004	Apr	CAHN
AB	+		100MG	N021446	004	Dec 30, 2004	Apr	CAHN
AB	+		150MG	N021446	005	Dec 30, 2004	Apr	CAHN
AB	+		200MG	N021446	006	Dec 30, 2004	Apr	CAHN
AB	+		225MG	N021446	007	Dec 30, 2004	Apr	CAHN
AB	+		300MG	N021446	008	Dec 30, 2004	Apr	CAHN

PREGABALIN

AB		ALKEM LABS LTD	25MG	A207799	007	Sep 30, 2019	Feb	CMS1
AB			50MG	A207799	008	Sep 30, 2019	Feb	CMS1
AB		APOTEX	25MG	A211685	001	Jul 07, 2021	Jun	NEWA
AB			50MG	A211685	002	Jul 07, 2021	Jun	NEWA
AB			75MG	A211685	003	Jul 07, 2021	Jun	NEWA
AB			100MG	A211685	004	Jul 07, 2021	Jun	NEWA
AB			150MG	A211685	005	Jul 07, 2021	Jun	NEWA
AB			200MG	A211685	006	Jul 07, 2021	Jun	NEWA
AB			225MG	A211685	007	Jul 07, 2021	Jun	NEWA
AB			300MG	A211685	008	Jul 07, 2021	Jun	NEWA
AB		CHANGZHOU PHARM	50MG	A214322	001	Jul 15, 2021	Jul	NEWA
AB			75MG	A214322	002	Jul 15, 2021	Jul	NEWA
AB			100MG	A214322	003	Jul 15, 2021	Jul	NEWA
AB			150MG	A214322	004	Jul 15, 2021	Jul	NEWA
AB			200MG	A214322	005	Jul 15, 2021	Jul	NEWA
AB			225MG	A214322	006	Jul 15, 2021	Jul	NEWA
AB			300MG	A214322	007	Jul 15, 2021	Jul	NEWA

SOLUTION; ORAL
LYRICA

AA	+	UPJOHN	20MG/ML	N022488	001	Jan 04, 2010	Apr	CAHN
----	---	--------	---------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL
LYRICA CR

AB	+	PFIZER	82.5MG	N209501	001	Oct 11, 2017	Apr	CFTG
AB	+		165MG	N209501	002	Oct 11, 2017	Apr	CFTG
AB	+		330MG	N209501	003	Oct 11, 2017	Apr	CFTG
AB	+	UPJOHN	82.5MG	N209501	001	Oct 11, 2017	Apr	CAHN
AB	+		165MG	N209501	002	Oct 11, 2017	Apr	CAHN
AB	+		330MG	N209501	003	Oct 11, 2017	Apr	CAHN

PREGABALIN

AB		ALVOGEN	82.5MG	A211687	001	Jul 06, 2021	Jun	NEWA
AB			165MG	A211687	002	Jul 06, 2021	Jun	NEWA
AB			330MG	A211687	003	Jul 06, 2021	Jun	NEWA
AB		ALVOGEN PINE BROOK	82.5MG	A211593	001	Apr 13, 2021	Apr	NFTG
AB			165MG	A211593	002	Apr 13, 2021	Apr	NFTG

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

AB		330MG	A211593	003	Apr 13, 2021	Apr	NFTG
AB	APOTEX	165MG	A213313	001	Apr 13, 2021	Apr	NFTG
AB		330MG	A213313	002	Apr 13, 2021	Apr	NFTG
AB	MSN	82.5MG	A213226	001	Apr 13, 2021	Apr	NFTG
AB		165MG	A213226	002	Apr 13, 2021	Apr	NFTG
AB		330MG	A213226	003	Apr 13, 2021	Apr	NFTG
AB	MYLAN	82.5MG	A211948	001	Apr 13, 2021	Apr	NFTG
>A>	AB	165MG	A211967	001	Nov 04, 2021	Oct	NEWA
AB		330MG	A211431	001	Jul 02, 2021	Jun	NEWA
AB	SUN PHARM	82.5MG	A211889	001	Apr 13, 2021	Apr	NFTG
AB		165MG	A211889	002	Apr 13, 2021	Apr	NFTG
AB		330MG	A211889	003	Apr 13, 2021	Apr	NFTG

PROBENECID

TABLET;ORAL
PROBENECID

	@ MYLAN	500MG	A084211	002		Aug	CAHN
	@	500MG	A084211	002		Aug	DISC
AB	! WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983	Aug	CTEC

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PROCAN SR

	+ @ PARKE DAVIS	250MG	A086468	001		Aug	CRLD
	+ @ PARKEDALE	500MG	A086065	001		Aug	CRLD
	+ @	750MG	A087510	001	Apr 01, 1982	Aug	CRLD

PROCHLORPERAZINE EDISYLATE

CONCENTRATE;ORAL
COMPAZINE

>D>	@ GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276	001		Oct	CRLD
>A>	+ @	EQ 10MG BASE/ML	N011276	001		Oct	CRLD

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

AP	CAPLIN	EQ 5MG BASE/ML	A214379	001	Apr 22, 2021	Apr	NEWA
AP	GLAND PHARMA LTD	EQ 5MG BASE/ML	A214107	001	Sep 22, 2021	Sep	NEWA
	@ HIKMA PHARMS	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jul	CAHN
AP		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jul	CAHN
AP	VIWIT PHARM	EQ 5MG BASE/ML	A213626	001	Sep 28, 2021	Sep	NEWA

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

BX	SOFGEN PHARMS	100MG	A200456	001	Sep 28, 2012	Sep	CTEC
BX		200MG	A200456	002	Sep 28, 2012	Sep	CTEC

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Aug	CMFD
	@	6.25MG/5ML	A040882	001	Dec 30, 2009	Feb	DISC
AA	QUAGEN	6.25MG/5ML	A213890	001	Jul 12, 2021	Jul	NEWA
AA	PROMETHAZINE PLAIN						
AA	+! WOCKHARDT BIO AG	6.25MG/5ML	A087953	001	Nov 15, 1982	Aug	CRLD

TABLET;ORAL
PROMETHAZINE HYDROCHLORIDE

AB	+ SANDOZ	25MG	A084176	003		Aug	CRLD
AB	+!	50MG	A084176	001		Aug	CRLD

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

	@ MYLAN	225MG	A203803	001	Apr 29, 2016	Jul	DISC
	@	325MG	A203803	002	Apr 29, 2016	Jul	DISC
	@	425MG	A203803	003	Apr 29, 2016	Jul	DISC
BX	SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019	Sep	CTEC
BX		325MG	A210339	002	Jan 04, 2019	Sep	CTEC
BX		425MG	A210339	003	Jan 04, 2019	Sep	CTEC
AB	ZYDUS	225MG	A214184	001	Apr 21, 2021	Apr	NEWA
AB		325MG	A214184	002	Apr 21, 2021	Apr	NEWA

CAPSULE, EXTENDED RELEASE;ORAL
PROPAPFENONE HYDROCHLORIDE

AB		425MG	A214184	003	Apr 21, 2021	Apr	NEWA
<u>TABLET;ORAL</u>							
PROPAPFENONE HYDROCHLORIDE							
>A>	AB	STRIDES PHARMA	150MG	A075938	001	Oct 17, 2002	Oct CAHN
>A>	AB		225MG	A075938	002	Oct 17, 2002	Oct CAHN
>A>	AB	!	300MG	A075938	003	Oct 17, 2002	Oct CAHN
>D>	AB	VINTAGE PHARMS	150MG	A075938	001	Oct 17, 2002	Oct CAHN
>D>	AB		225MG	A075938	002	Oct 17, 2002	Oct CAHN
>D>	AB	!	300MG	A075938	003	Oct 17, 2002	Oct CAHN

PROPANTHELINE BROMIDE

TABLET;ORAL
PROPANTHELINE BROMIDE
@ HIKMA PHARMS

15MG

A080927 002

Apr DISC

PROPOFOL

INJECTABLE;INJECTION
PROPOFOL

>A>	AB	EMCURE PHARMS LTD	10MG/ML	A206408	001	Oct 12, 2021	Oct NEWA
-----	----	-------------------	---------	---------	-----	--------------	----------

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL
PROPRANOLOL HYDROCHLORIDE

AB		IMPAX LABS INC	10MG	A071972	001	Apr 06, 1988	Sep CMFD
AB			20MG	A071972	002	Apr 06, 1988	Sep CMFD
AB			40MG	A071972	003	Apr 06, 1988	Aug CMFD
		@ WATSON LABS	60MG	A070178	002	Apr 23, 2018	Apr DISC

PROPYLTHIOURACIL

TABLET;ORAL
PROPYLTHIOURACIL

BD		QUAGEN	50MG	A080154	001		Mar CMFD
----	--	--------	------	---------	-----	--	----------

PROTAMINE SULFATE

INJECTABLE;INJECTION
PROTAMINE SULFATE

		@ HIKMA PHARMS	10MG/ML	A089474	001	Nov 05, 1986	Jul CAHN
		@	10MG/ML	A089475	001	Nov 05, 1986	Jul CAHN

PYRAZINAMIDE

TABLET;ORAL
PYRAZINAMIDE

AB	+	NOVITIUM PHARMA	500MG	A080157	001		Aug CRLD
AB			500MG	A080157	001		Apr CMFD

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION
PYRIDOXINE HYDROCHLORIDE

	+	FRESENIUS KABI USA	100MG/ML	A080618	001		Aug CRLD
--	---	--------------------	----------	---------	-----	--	----------

PYRIMETHAMINE

TABLET;ORAL
PYRIMETHAMINE

AB		ALVOGEN	25MG	A211271	001	Jul 27, 2021	Aug CAHN
AB		FERA PHARMS LLC	25MG	A211271	001	Jul 27, 2021	Jul NEWA
AB		TEVA PHARMS	25MG	A215506	001	Aug 13, 2021	Aug NEWA

QUETIAPINE FUMARATE

TABLET;ORAL
QUETIAPINE FUMARATE
@ JUBILANT GENERICS EQ 25MG BASE

A203150 001

Nov 26, 2013 Jun DISC

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE
@ ANCHEN PHARMS EQ 150MG BASE
@ EQ 200MG BASE
@ EQ 300MG BASE
@ EQ 400MG BASE
@ MYLAN EQ 50MG BASE
AB EQ 50MG BASE
@ EQ 150MG BASE

A090757	001	Dec 01, 2017	Jun DISC
A090757	002	Dec 01, 2017	Jun DISC
A090757	003	Dec 01, 2017	Jun DISC
A090757	004	Dec 01, 2017	Jun DISC
A202228	001	Feb 02, 2021	Feb DISC
A202228	001	Feb 02, 2021	Jan NEWA
A202228	002	Feb 02, 2021	Feb DISC

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

AB		EQ 150MG BASE	A202228	002	Feb 02, 2021	Jan NEWA
	@	EQ 200MG BASE	A202228	003	Feb 02, 2021	Feb DISC
AB		EQ 200MG BASE	A202228	003	Feb 02, 2021	Jan NEWA
	@	EQ 300MG BASE	A202228	004	Feb 02, 2021	Feb DISC
AB		EQ 300MG BASE	A202228	004	Feb 02, 2021	Jan NEWA
	@	EQ 400MG BASE	A202228	005	Feb 02, 2021	Feb DISC
AB		EQ 400MG BASE	A202228	005	Feb 02, 2021	Jan NEWA
BX	SCIEGEN PHARMS INC	EQ 50MG BASE	A209635	005	Nov 16, 2018	Sep CTEC
BX		EQ 150MG BASE	A209635	001	Nov 29, 2017	Sep CTEC
BX		EQ 200MG BASE	A209635	002	Nov 29, 2017	Sep CTEC
BX		EQ 300MG BASE	A209635	003	Nov 29, 2017	Sep CTEC
BX		EQ 400MG BASE	A209635	004	Nov 29, 2017	Sep CTEC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE GLUCONATE

AB	EYWA	324MG	A212589	001	Sep 17, 2021	Sep NEWA
	@ RISING	324MG	A089894	001	Dec 15, 1988	Jan CAHN
AB	! SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987	Sep CTEC

QUINIDINE SULFATE

TABLET;ORAL
CIN-QUIN

	+ @ SOLVAY	100MG	A085299	001		Aug CRLD
	+ @	200MG	A084932	001		Aug CRLD
	QUINORA					
	+ @ SCHERING	300MG	A085222	001		Aug CRLD

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
ACIPHEX

	+ @ WOODWARD	10MG	N020973	001	May 29, 2002	Jul CAHN
AB	+!	20MG	N020973	002	Aug 19, 1999	Jul CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

	@ AUROBINDO PHARMA LTD	EQ 150MG BASE	A211058	001	Jul 16, 2018	Jun DISC
	@	EQ 300MG BASE	A211058	002	Jul 16, 2018	Jun DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

	@ AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010	Jun DISC
--	------------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@ WOCKHARDT LTD	EQ 150MG BASE	A075208	001	Dec 17, 1998	Jan DISC
	@	EQ 300MG BASE	A075208	002	Dec 17, 1998	Jan DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

AB	ACCORD HLTHCARE	500MG	A212930	001	May 18, 2021	May NEWA
AB		1GM	A212930	002	May 18, 2021	May NEWA
	@ AMNEAL	500MG	A207690	001	Mar 11, 2021	Apr DISC
AB		500MG	A207690	001	Mar 11, 2021	Mar NEWA
	@	1GM	A207690	002	Mar 11, 2021	Apr DISC
AB		1GM	A207690	002	Mar 11, 2021	Mar NEWA
AB	GRAVITI PHARMS	500MG	A212889	001	Jan 28, 2021	Jan NEWA
AB		1GM	A212889	002	Jan 28, 2021	Jan NEWA
AB	PRAXGEN	500MG	A212781	001	Mar 23, 2020	Feb CAHN
AB		1GM	A212781	002	Mar 23, 2020	Feb CAHN

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB	PADAGIS US	0.5MG	A201189	001	Jul 17, 2013	Jul CAHN
AB		0.5MG	A201189	001	Jul 17, 2013	Jul CAHN
AB		1MG	A201189	002	Jan 22, 2014	Jul CAHN
AB		1MG	A201189	002	Jan 22, 2014	Jul CAHN
AB		2MG	A201189	003	Jan 22, 2014	Jul CAHN
AB		2MG	A201189	003	Jan 22, 2014	Jul CAHN

RIFAMPININJECTABLE; INJECTION
RIFAMPIN

>A>	AP	HIKMA PHARMS	600MG/VIAL	A064217	001	Oct 29, 1999	Oct	CAHN
>D>	AP	WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999	Oct	CAHN

RIFAXIMINTABLET; ORAL
XIFAXAN

+!	SALIX PHARMS	550MG	N021361	002	Mar 24, 2010	Aug	CMS1
----	--------------	-------	---------	-----	--------------	-----	------

RILUZOLEFILM; ORAL
EXSERVAN

+!	mitsubishi holdings	50MG	N212640	001	Nov 22, 2019	Feb	CAHN
----	---------------------	------	---------	-----	--------------	-----	------

RIMEGEPANT SULFATETABLET, ORALLY DISINTEGRATING; ORAL
NURTEC ODT

+!	BIOHAVEN IRELAND	EQ 75MG BASE	N212728	001	Feb 27, 2020	Jul	CAHN
----	------------------	--------------	---------	-----	--------------	-----	------

RISPERIDONETABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

+ @	JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003	Feb	DISC	
+ @		1MG	N021444	002	Apr 02, 2003	Feb	DISC	
+ @		2MG	N021444	003	Apr 02, 2003	Feb	DISC	
+ @		3MG	N021444	004	Dec 23, 2004	Feb	DISC	
+ @		4MG	N021444	005	Dec 23, 2004	Feb	DISC	
AB	!	JUBILANT GENERICS	1MG	A090839	002	Nov 04, 2011	Feb	CHRS

RITONAVIRCAPSULE; ORAL
RITONAVIR

@	HIKMA PHARMS	100MG	A205801	001	Dec 03, 2020	Mar	DISC
---	--------------	-------	---------	-----	--------------	-----	------

RIZATRIPTAN BENZOATETABLET, ORALLY DISINTEGRATING; ORAL
RIZATRIPTAN BENZOATE

@	JUBILANT GENERICS	EQ 5MG BASE	A203334	001	Oct 16, 2015	Jun	DISC	
@		EQ 10MG BASE	A203334	002	Oct 16, 2015	Jun	DISC	
AB		PANACEA	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jul	CAHN
AB			EQ 10MG BASE	A204722	002	Jan 11, 2017	Jul	CAHN

ROFLUMILASTTABLET; ORAL
ROFLUMILAST

>D>	AB	BRECKENRIDGE	500MCG	A208236	001	Oct 03, 2018	Oct	DISC
>A>		@	500MCG	A208236	001	Oct 03, 2018	Oct	DISC

ROMIDEPSINPOWDER; INTRAVENOUS
ISTODAX

>D>	+!	CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009	Oct	CFTG
>A>	AP	+!	10MG/VIAL	N022393	001	Nov 05, 2009	Oct	CFTG
>A>	AP	FRESENIUS KABI USA	10MG/VIAL	A206254	001	Oct 12, 2021	Oct	NFTG

ROPINIROLE HYDROCHLORIDETABLET; ORAL
REQUIP

+ @	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Jul	DISC
+ @		EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Jul	DISC
+ @		EQ 1MG BASE	N020658	003	Sep 19, 1997	Jul	DISC
+ @		EQ 2MG BASE	N020658	004	Sep 19, 1997	Jul	DISC
+ @		EQ 3MG BASE	N020658	006	Jan 27, 1999	Jul	DISC
+ @		EQ 4MG BASE	N020658	007	Jan 27, 1999	Jul	DISC
+ @		EQ 5MG BASE	N020658	005	Sep 19, 1997	Jul	DISC

TABLET;ORAL								
ROPINIROLE HYDROCHLORIDE								
AB	!	PRINSTON INC	EQ 0.25MG BASE	A078110	001	May 05, 2008	Jul	CHRS
TABLET, EXTENDED RELEASE;ORAL								
REQUIP XL								
	+ @	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Jun	DISC
AB	+		EQ 2MG BASE	N022008	001	Jun 13, 2008	Jun	CHRS
	+ @		EQ 6MG BASE	N022008	006	Apr 10, 2009	Jun	DISC
	+ @		EQ 12MG BASE	N022008	005	Oct 31, 2008	Jun	DISC
ROPINIROLE HYDROCHLORIDE								
AB	!	DR REDDYS LABS LTD	EQ 2MG BASE	A201576	001	Jun 06, 2012	Jun	CHRS
<u>ROPIVACAINE HYDROCHLORIDE</u>								
SOLUTION;INJECTION								
NAROPIN								
	+ @	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	Mar	CRLD
	+ @		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Mar	CRLD
ROPIVACAINE HYDROCHLORIDE								
	@	MYLAN ASI	150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Jan	DISC
	@		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Jan	DISC
<u>ROSIGLITAZONE MALEATE</u>								
TABLET;ORAL								
AVANDIA								
	+	WOODWARD	EQ 2MG BASE	N021071	002	May 25, 1999	Jul	CAHN
	+		EQ 4MG BASE	N021071	003	May 25, 1999	Jul	CAHN
	+ @		EQ 8MG BASE	N021071	004	May 25, 1999	Jul	CAHN
<u>ROSUVASTATIN CALCIUM</u>								
TABLET;ORAL								
CRESTOR								
AB	+	IPR	EQ 5MG BASE	N021366	002	Aug 12, 2003	Apr	CPOT
AB	+		EQ 10MG BASE	N021366	003	Aug 12, 2003	Apr	CPOT
AB	+!		EQ 40MG BASE	N021366	005	Aug 12, 2003	Apr	CPOT
ROSUVASTATIN CALCIUM								
AB		ACCORD HLTHCARE	EQ 5MG BASE	A206434	001	Oct 31, 2016	Apr	CPOT
AB			EQ 10MG BASE	A206434	002	Oct 31, 2016	Apr	CPOT
AB			EQ 20MG BASE	A206434	003	Oct 31, 2016	Apr	CPOT
AB			EQ 40MG BASE	A206434	004	Oct 31, 2016	Apr	CPOT
AB		ALKEM LABS LTD	EQ 5MG BASE	A206465	001	Mar 21, 2017	Apr	CPOT
AB			EQ 10MG BASE	A206465	002	Mar 21, 2017	Apr	CPOT
AB			EQ 20MG BASE	A206465	003	Mar 21, 2017	Apr	CPOT
AB			EQ 40MG BASE	A206465	004	Mar 21, 2017	Apr	CPOT
AB		ALLIED	EQ 5MG BASE	A079168	001	Jul 19, 2016	Apr	CPOT
AB			EQ 10MG BASE	A079168	002	Jul 19, 2016	Apr	CPOT
AB			EQ 20MG BASE	A079168	003	Jul 19, 2016	Apr	CPOT
AB			EQ 40MG BASE	A079168	004	Jul 19, 2016	Apr	CPOT
	@	AMNEAL PHARMS CO	EQ 5MG BASE	A208850	001	Oct 16, 2018	Apr	CPOT
	@		EQ 10MG BASE	A208850	002	Oct 16, 2018	Apr	CPOT
	@		EQ 20MG BASE	A208850	003	Oct 16, 2018	Apr	CPOT
	@		EQ 40MG BASE	A208850	004	Oct 16, 2018	Apr	CPOT
	@	APOTEX INC	EQ 5MG BASE	A079145	001	Jul 19, 2016	Apr	CPOT
	@		EQ 10MG BASE	A079145	002	Jul 19, 2016	Apr	CPOT
	@		EQ 20MG BASE	A079145	003	Jul 19, 2016	Apr	CPOT
	@		EQ 40MG BASE	A079145	004	Jul 19, 2016	Apr	CPOT
AB		AUROBINDO PHARMA LTD	EQ 5MG BASE	A079170	001	Jul 19, 2016	Apr	CPOT
AB			EQ 10MG BASE	A079170	002	Jul 19, 2016	Apr	CPOT
AB			EQ 20MG BASE	A079170	003	Jul 19, 2016	Apr	CPOT
AB			EQ 40MG BASE	A079170	004	Jul 19, 2016	Apr	CPOT
AB		BIOCON LTD	EQ 5MG BASE	A207752	001	Oct 31, 2016	Apr	CPOT
AB			EQ 10MG BASE	A207752	002	Oct 31, 2016	Apr	CPOT
AB			EQ 20MG BASE	A207752	003	Oct 31, 2016	Apr	CPOT
AB			EQ 40MG BASE	A207752	004	Oct 31, 2016	Apr	CPOT
AB		BIOCON PHARMA	EQ 5MG BASE	A207752	001	Oct 31, 2016	Jul	CAHN
AB			EQ 10MG BASE	A207752	002	Oct 31, 2016	Jul	CAHN
AB			EQ 20MG BASE	A207752	003	Oct 31, 2016	Jul	CAHN
AB			EQ 40MG BASE	A207752	004	Oct 31, 2016	Jul	CAHN
AB		CADILA PHARMS LTD	EQ 5MG BASE	A207453	001	Nov 23, 2016	Apr	CPOT
AB			EQ 10MG BASE	A207453	002	Nov 23, 2016	Apr	CPOT
AB			EQ 20MG BASE	A207453	003	Nov 23, 2016	Apr	CPOT
AB			EQ 40MG BASE	A207453	004	Nov 23, 2016	Apr	CPOT
AB		CHANGZHOU PHARM	EQ 5MG BASE	A207408	001	Oct 31, 2016	Apr	CPOT
AB			EQ 10MG BASE	A207408	002	Oct 31, 2016	Apr	CPOT

TABLET;ORAL
ROSUVASTATIN CALCIUM

AB		EQ 20MG BASE	A207408	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A207408	004	Oct 31, 2016	Apr	CPOT
AB	CHARTWELL RX	EQ 5MG BASE	A079168	001	Jul 19, 2016	Sep	CAHN
AB		EQ 10MG BASE	A079168	002	Jul 19, 2016	Sep	CAHN
AB		EQ 20MG BASE	A079168	003	Jul 19, 2016	Sep	CAHN
AB		EQ 40MG BASE	A079168	004	Jul 19, 2016	Sep	CAHN
AB	GLENMARK PHARMS	EQ 5MG BASE	A079172	001	Jul 19, 2016	Apr	CPOT
AB		EQ 10MG BASE	A079172	002	Jul 19, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079172	003	Jul 19, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079172	004	Jul 19, 2016	Apr	CPOT
AB	HETERO LABS LTD V	EQ 5MG BASE	A207616	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A207616	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A207616	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A207616	004	Oct 31, 2016	Apr	CPOT
AB	@ INVENTIA	EQ 5MG BASE	A207653	001	Feb 05, 2021	May	DISC
AB		EQ 5MG BASE	A207653	001	Feb 05, 2021	Apr	CPOT
AB		5MG	A207653	001	Feb 05, 2021	Jan	NEWA
AB	@	EQ 10MG BASE	A207653	002	Feb 05, 2021	May	DISC
AB		EQ 10MG BASE	A207653	002	Feb 05, 2021	Apr	CPOT
AB		10MG	A207653	002	Feb 05, 2021	Jan	NEWA
AB	@	EQ 20MG BASE	A207653	003	Feb 05, 2021	May	DISC
AB		EQ 20MG BASE	A207653	003	Feb 05, 2021	Apr	CPOT
AB		20MG	A207653	003	Feb 05, 2021	Jan	NEWA
AB	@	EQ 40MG BASE	A207653	004	Feb 05, 2021	May	DISC
AB		EQ 40MG BASE	A207653	004	Feb 05, 2021	Apr	CPOT
AB		40MG	A207653	004	Feb 05, 2021	Jan	NEWA
AB	LUPIN	EQ 5MG BASE	A205587	001	Jul 31, 2017	Apr	CPOT
AB		EQ 10MG BASE	A205587	002	Jul 31, 2017	Apr	CPOT
AB		EQ 20MG BASE	A205587	003	Jul 31, 2017	Apr	CPOT
AB		EQ 40MG BASE	A205587	004	Jul 31, 2017	Apr	CPOT
AB	MSN	EQ 5MG BASE	A208898	001	Nov 22, 2017	Apr	CPOT
AB		EQ 10MG BASE	A208898	002	Nov 22, 2017	Apr	CPOT
AB		EQ 20MG BASE	A208898	003	Nov 22, 2017	Apr	CPOT
AB		EQ 40MG BASE	A208898	004	Nov 22, 2017	Apr	CPOT
AB	@ MYLAN	EQ 5MG BASE	A079161	001	Jul 19, 2016	Apr	CPOT
AB	@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Apr	CPOT
AB	@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Apr	CPOT
AB	@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Apr	CPOT
AB	RENATA	EQ 5MG BASE	A207062	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A207062	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A207062	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A207062	004	Oct 31, 2016	Apr	CPOT
AB	SANDOZ INC	EQ 5MG BASE	A079171	001	Jul 19, 2016	Apr	CPOT
AB		EQ 10MG BASE	A079171	002	Jul 19, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079171	003	Jul 19, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079171	004	Jul 19, 2016	Apr	CPOT
AB	@ SCIEGEN PHARMS INC	EQ 5MG BASE	A206381	001	Apr 24, 2019	Apr	CPOT
AB	@	EQ 10MG BASE	A206381	002	Apr 24, 2019	Apr	CPOT
AB	@	EQ 20MG BASE	A206381	003	Apr 24, 2019	Apr	CPOT
AB	@	EQ 40MG BASE	A206381	004	Apr 24, 2019	Apr	CPOT
AB	SHANDONG	EQ 5MG BASE	A207375	001	May 07, 2019	Apr	CPOT
AB		EQ 10MG BASE	A207375	002	May 07, 2019	Apr	CPOT
AB		EQ 20MG BASE	A207375	003	May 07, 2019	Apr	CPOT
AB		EQ 40MG BASE	A207375	004	May 07, 2019	Apr	CPOT
AB	SUN PHARM	EQ 5MG BASE	A079169	001	Jul 19, 2016	Apr	CPOT
AB		EQ 10MG BASE	A079169	002	Jul 19, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079169	003	Jul 19, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079169	004	Jul 19, 2016	Apr	CPOT
AB	@ SUNSHINE	EQ 5MG BASE	A210667	001	Apr 01, 2020	Apr	CPOT
AB	@	EQ 10MG BASE	A210667	002	Apr 01, 2020	Apr	CPOT
AB	@	EQ 20MG BASE	A210667	003	Apr 01, 2020	Apr	CPOT
AB	@	EQ 40MG BASE	A210667	004	Apr 01, 2020	Apr	CPOT
AB	@ TEVA PHARMS USA	EQ 5MG BASE	A079166	001	Jul 19, 2016	Apr	CPOT
AB	@	EQ 10MG BASE	A079166	002	Jul 19, 2016	Apr	CPOT
AB	@	EQ 20MG BASE	A079166	003	Jul 19, 2016	Apr	CPOT
AB	@	EQ 40MG BASE	A079166	004	Jul 19, 2016	Apr	CPOT
AB	TORRENT	EQ 5MG BASE	A201619	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A201619	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A201619	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A201619	004	Oct 31, 2016	Apr	CPOT
AB	@ UMEDICA LABS PVT LTD	EQ 5MG BASE	A207626	001	Apr 09, 2019	Apr	CPOT
AB	@	EQ 10MG BASE	A207626	002	Apr 09, 2019	Apr	CPOT

<u>TABLET;ORAL</u>						
ROSUVASTATIN CALCIUM						
	@	EQ 20MG BASE	A207626	003	Apr 09, 2019	Apr CPOT
	@	EQ 40MG BASE	A207626	004	Apr 09, 2019	Apr CPOT
AB	WATSON LABS INC	EQ 5MG BASE	A079167	001	Apr 29, 2016	Apr CPOT
AB		EQ 10MG BASE	A079167	002	Apr 29, 2016	Apr CPOT
AB		EQ 20MG BASE	A079167	003	Apr 29, 2016	Apr CPOT
AB		EQ 40MG BASE	A079167	004	Apr 29, 2016	Apr CPOT
AB	ZHEJIANG YONGTAI	EQ 5MG BASE	A212059	001	Nov 04, 2019	Apr CPOT
AB		5MG	A212059	001	Nov 04, 2019	Feb CMFD
AB		EQ 10MG BASE	A212059	002	Nov 04, 2019	Apr CPOT
AB		10MG	A212059	002	Nov 04, 2019	Feb CMFD
AB		EQ 20MG BASE	A212059	003	Nov 04, 2019	Apr CPOT
AB		20MG	A212059	003	Nov 04, 2019	Feb CMFD
AB		EQ 40MG BASE	A212059	004	Nov 04, 2019	Apr CPOT
AB		40MG	A212059	004	Nov 04, 2019	Feb CMFD
	@ ZYDUS PHARMS	EQ 5MG BASE	A206513	001	Mar 01, 2019	Apr CPOT
	@	EQ 10MG BASE	A206513	002	Mar 01, 2019	Apr CPOT
	@	EQ 20MG BASE	A206513	003	Mar 01, 2019	Apr CPOT
	@	EQ 40MG BASE	A206513	004	Mar 01, 2019	Apr CPOT
<u>RUFINAMIDE</u>						
SUSPENSION;ORAL						
RUFINAMIDE						
AB	ALKEM LABS LTD	40MG/ML	A213410	001	Feb 23, 2021	Feb NEWA
TABLET;ORAL						
RUFINAMIDE						
AB	HETERO LABS LTD III	200MG	A204993	001	May 11, 2021	Apr NEWA
AB		400MG	A204993	002	May 11, 2021	Apr NEWA
AB	MYLAN	200MG	A205095	001	May 16, 2016	May CMFD
AB		400MG	A205095	002	May 16, 2016	May CMFD
<u>RUXOLITINIB PHOSPHATE</u>						
CREAM;TOPICAL						
OPZELURA						
+!	INCYTE CORP	EQ 1.5% BASE	N215309	001	Sep 21, 2021	Sep NEWA
<u>SAFINAMIDE MESYLATE</u>						
TABLET;ORAL						
XADAGO						
+	MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Jul CPOT
+!		EQ 100MG BASE	N207145	002	Mar 21, 2017	Jul CPOT
<u>SAPROPTERIN DIHYDROCHLORIDE</u>						
POWDER;ORAL						
SAPROPTERIN DIHYDROCHLORIDE						
AB	DR REDDYS	100MG/PACKET	A209452	001	Mar 30, 2021	Mar NEWA
TABLET;ORAL						
SAPROPTERIN DIHYDROCHLORIDE						
AB	DR REDDYS	100MG	A207685	001	Jun 15, 2021	Jun NEWA
<u>SCOPOLAMINE</u>						
SYSTEM;TRANSDERMAL						
SCOPOLAMINE						
AB	PADAGIS US	1MG/72HR	A078830	001	Jan 30, 2015	Jul CAHN
TRANSDERM SCOP						
AB	+! BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Mar CAHN
<u>SELEGILINE HYDROCHLORIDE</u>						
CAPSULE;ORAL						
SELEGILINE HYDROCHLORIDE						
AB	NOVITIUM PHARMA	5MG	A075352	001	Nov 30, 1998	Apr CMFD
<u>SELENIOUS ACID</u>						
SOLUTION;INTRAVENOUS						
SELENIOUS ACID						
+!	AM REGENT	EQ 12MCG BASE/2ML (EQ 6MCG BASE/ML)	N209379	003	Aug 30, 2021	Aug NEWA
+!		EQ 60MCG BASE/ML (EQ 60MCG BASE/ML)	N209379	002	Jan 25, 2021	Jan NEWA

SELEXIPAG

POWDER; INTRAVENOUS

UPTRAVI

+! ACTELION 1.8MG/VIAL N214275 001 Jul 29, 2021 Jul NEWA

TABLET; ORAL

UPTRAVI

+ ACTELION 0.2MG N207947 001 Dec 21, 2015 Feb CAHN

+! 0.4MG N207947 002 Dec 21, 2015 Feb CAHN

+ 0.6MG N207947 003 Dec 21, 2015 Feb CAHN

+ 0.8MG N207947 004 Dec 21, 2015 Feb CAHN

+ 1MG N207947 005 Dec 21, 2015 Feb CAHN

+ 1.2MG N207947 006 Dec 21, 2015 Feb CAHN

+ 1.4MG N207947 007 Dec 21, 2015 Feb CAHN

+ 1.6MG N207947 008 Dec 21, 2015 Feb CAHN

SELINEXOR

TABLET; ORAL

XPROVIO

+ KARYOPHARM THERAPS 40MG N212306 002 Apr 15, 2021 Apr NEWA

+ 50MG N212306 003 Apr 15, 2021 Apr NEWA

+ 60MG N212306 004 Apr 15, 2021 Apr NEWA

SEMAGLUTIDE

SOLUTION; SUBCUTANEOUS

WEGOVY

+! NOVO 0.25MG/0.5ML (0.25MG/0.5ML) N215256 001 Jun 04, 2021 Jun NEWA

+! 0.5MG/0.5ML (0.5MG/0.5ML) N215256 002 Jun 04, 2021 Jun NEWA

+! 1MG/0.5ML (1MG/0.5ML) N215256 003 Jun 04, 2021 Jun NEWA

+! 1.7MG/0.75ML (1.7MG/0.75ML) N215256 004 Jun 04, 2021 Jun NEWA

+! 2.4MG/0.75ML (2.4MG/0.75ML) N215256 005 Jun 04, 2021 Jun NEWA

SERTRALINE HYDROCHLORIDE

>A> CAPSULE; ORAL

>A> SERTRALINE HYDROCHLORIDE

>A> + ALMATICA EQ 150MG BASE N215133 001 Oct 04, 2021 Oct NEWA

>A> +! EQ 200MG BASE N215133 002 Oct 04, 2021 Oct NEWA

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB ACI EQ 25MG BASE A076881 001 Feb 06, 2007 Jan CMFD

AB EQ 50MG BASE A076881 002 Feb 06, 2007 Jan CMFD

AB EQ 100MG BASE A076881 003 Feb 06, 2007 Jan CMFD

AB ASCENT PHARMS INC EQ 25MG BASE A214790 001 May 03, 2021 Apr NEWA

AB EQ 50MG BASE A214790 002 May 03, 2021 Apr NEWA

AB EQ 100MG BASE A214790 003 May 03, 2021 Apr NEWA

AB GRANULES EQ 25MG BASE A078403 001 Jan 08, 2008 May CAHN

AB EQ 50MG BASE A078403 002 Jan 08, 2008 May CAHN

AB EQ 100MG BASE A078403 003 Jan 08, 2008 May CAHN

AB HANGZHOU BINJIANG EQ 25MG BASE A078677 001 Mar 04, 2009 Sep CAHN

AB EQ 50MG BASE A078677 002 Mar 04, 2009 Sep CAHN

AB EQ 100MG BASE A078677 003 Mar 04, 2009 Sep CAHN

AB SCIEGEN PHARMS INC EQ 25MG BASE A076442 001 Apr 30, 2007 Apr CMFD

AB EQ 50MG BASE A076442 002 Apr 30, 2007 Apr CMFD

AB EQ 100MG BASE A076442 003 Apr 30, 2007 Apr CMFD

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

SEVELAMER CARBONATE

AB BIONPHARMA INC 800MG/PACKET A209374 001 May 17, 2021 May NEWA

AB IMPAX 800MG/PACKET A211316 001 Nov 20, 2020 Aug CMFD

@ 800MG/PACKET A211316 001 Nov 20, 2020 Mar DISC

AB 2.4GM/PACKET A211316 002 Nov 20, 2020 Aug CMFD

@ 2.4GM/PACKET A211316 002 Nov 20, 2020 Mar DISC

TABLET; ORAL

SEVELAMER CARBONATE

AB ANXIN 800MG A212970 001 Apr 09, 2020 Mar CMFD

AB LUPIN LTD 800MG A204600 001 Jan 14, 2021 Jan NEWA

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

SEVELAMER HYDROCHLORIDE

AB	LUPIN LTD	400MG	A213145	001	Jun 16, 2021	Jun	NEWA
AB		800MG	A213145	002	Jun 16, 2021	Jun	NEWA

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

SILDENAFIL CITRATE

AB	APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Apr	NEWA
AB	HETERO LABS LTD V	EQ 10MG BASE/ML	A213014	001	May 11, 2021	Apr	NEWA

TABLET; ORAL

SILDENAFIL CITRATE

>A>	AB	CHARTWELL RX	EQ 20MG BASE	A202598	001	Nov 06, 2012	Oct	CAHN
	AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Mar	CAHN
	AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Mar	CAHN
	AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Mar	CAHN
	AB	UMEDICA LABS PVT LTD	EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun	NEWA
	@	WATSON LABS INC	EQ 25MG BASE	A202506	001	Nov 25, 2020	May	DISC
	@		EQ 50MG BASE	A202506	002	Nov 25, 2020	May	DISC
	@		EQ 100MG BASE	A202506	003	Nov 25, 2020	May	DISC
>D>	AB	YILING	EQ 20MG BASE	A202598	001	Nov 06, 2012	Oct	CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	BIOCON PHARMA	5MG	A078034	001	Dec 20, 2006	Mar	CAHN
AB		10MG	A078034	002	Dec 20, 2006	Mar	CAHN
AB		20MG	A078034	003	Dec 20, 2006	Mar	CAHN
AB		40MG	A078034	004	Dec 20, 2006	Mar	CAHN
AB		80MG	A078034	005	Dec 20, 2006	Mar	CAHN
AB	HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Apr	CMFD
AB		20MG	A206557	002	Nov 13, 2017	Apr	CMFD
AB		40MG	A206557	003	Nov 13, 2017	Apr	CMFD
AB		80MG	A206557	004	Nov 13, 2017	Apr	CMFD
AB	! LUPIN	80MG	A078103	004	May 11, 2007	Jun	CHRS
	ZOCOR						
AB	+ ORGANON	5MG	N019766	001	Dec 23, 1991	Feb	CAHN
AB	+	10MG	N019766	002	Dec 23, 1991	Feb	CAHN
AB	+	20MG	N019766	003	Dec 23, 1991	Feb	CAHN
AB	+	40MG	N019766	004	Dec 23, 1991	Feb	CAHN
	+ @	80MG	N019766	005	Jul 10, 1998	Jun	DISC
AB	+!	80MG	N019766	005	Jul 10, 1998	Feb	CAHN

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+!	ANI PHARMS	15%	N021902	001	Oct 31, 2006	Apr	CAHN
----	------------	-----	---------	-----	--------------	-----	------

SIPONIMOD FUMARIC ACID

TABLET; ORAL

MAYZENT

+	NOVARTIS	EQ 1MG BASE	N209884	003	Aug 24, 2021	Aug	NEWA
---	----------	-------------	---------	-----	--------------	-----	------

SIROLIMUS

TABLET; ORAL

SIROLIMUS

AB	ALKEM LABS LTD	0.5MG	A214753	001	Mar 12, 2021	Mar	NEWA
AB		1MG	A214753	002	Mar 12, 2021	Mar	NEWA
AB		2MG	A214753	003	Mar 12, 2021	Mar	NEWA

SODIUM ACETATE

INJECTABLE; INJECTION

SODIUM ACETATE

AP	+! HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Apr	CFTG
AP	MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Apr	NFTG

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; INTRAVENOUS

SODIUM PHENYLACETATE AND SODIUM BENZOATE

	+!	MAIA PHARMS INC	10%;10% (2GM/20ML;2GM/20ML)	N215025	001	Jun 10, 2021	Jun	NEWA
--	----	-----------------	-----------------------------	---------	-----	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

		HIKMA PHARMS	9MG/ML	A201833	001	Sep 24, 2013	Jul	CAHN
AP			9MG/ML	A201850	001	Jan 20, 2012	Jul	CAHN
	+ @	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Aug	DISC
	+ @		18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Aug	DISC
	+ @		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Aug	DISC
	+ @		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Aug	DISC
	+ @		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Aug	DISC
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	@	JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016	Jun	DISC
		SODIUM CHLORIDE 23.4%						
		FRESENIUS KABI USA	234MG/ML	A212248	001	Apr 28, 2021	Apr	NFTG
		SOLUTION; INTRAVENOUS						
		SODIUM CHLORIDE 14.6%						
AP		FRESENIUS KABI USA	50MEQ/20ML (2.5MEQ/ML)	A212070	001	Apr 28, 2021	Apr	NFTG
AP			100MEQ/40ML (2.5MEQ/ML)	A212070	002	Apr 28, 2021	Apr	NFTG
AP	+!	HOSPIRA	100MEQ/40ML (2.5MEQ/ML)	N018897	002	Jul 20, 1984	Apr	CFTG
		SOLUTION FOR SLUSH; IRRIGATION						
		SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER						
	+!	BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985	Jul	CHRS
	+		900MG/100ML	N019319	002	May 17, 1985	Jul	CRLD

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

	@	DECATUR	10-200mCi/ML	A204464	001	Oct 21, 2014	Aug	DISC
AP		NUKEMED	10-200mCi/ML	A203912	001	Apr 22, 2015	Jan	CAHN

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

AP		BE PHARMS	25MG/ML	A214971	001	Jul 12, 2021	Jul	NEWA
	@	CIPLA	25MG/ML	A210855	001	Jul 16, 2018	Aug	DISC

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB		NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Jan	CMFD
AB	+!	SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Jan	CTEC

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KIONEX

AA		ANI PHARMS	454GM/BOT	A040029	001	Feb 06, 1998	Mar	CAHN
AA		L PERRIGO CO	454GM/BOT	A040029	001	Feb 06, 1998	Mar	CAHN
		SODIUM POLYSTYRENE SULFONATE						
AA		BIOPHARM	453.6GM/BOT	A090313	001	Dec 21, 2011	Sep	CAHN
AA		CHARTWELL RX	454GM/BOT	A206815	001	Feb 18, 2016	Sep	CAHN
	+ @	WOCKHARDT	453.6GM/BOT	A088786	001	Sep 11, 1984	Aug	CRLD
		SUSPENSION; ORAL, RECTAL						
		KIONEX						
	@	ANI PHARMS	15GM/60ML	A040028	001	Sep 17, 2007	Mar	CAHN
	@	L PERRIGO CO	15GM/60ML	A040028	001	Sep 17, 2007	Mar	CAHN
		SODIUM POLYSTYRENE SULFONATE						
	@	ANI PHARMS	15GM/60ML	A090590	001	May 13, 2011	Mar	CAHN
	@	L PERRIGO CO	15GM/60ML	A090590	001	May 13, 2011	Mar	CAHN
		SPS						
	+!	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Aug	CRLD

SOFOSBUVIR; VELPATASVIR

PELLETS; ORAL
EPCLUSA

	+	GILEAD SCIENCES INC	150MG; 37.5MG/PACKET	N214187	001	Jun 10, 2021	Jun NEWA
	+	!	200MG; 50MG/PACKET	N214187	002	Jun 10, 2021	Jun NEWA

SOLIFENACIN SUCCINATE

TABLET; ORAL

		SOLIFENACIN SUCCINATE					
		@ AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	Jun DISC
		@	10MG	A205483	002	May 20, 2019	Jun DISC
AB		AUSTARPHARMA	5MG	A210281	001	May 20, 2019	Sep CAHN
AB		@	10MG	A210281	002	May 20, 2019	Sep CAHN
		@ BRECKENRIDGE	5MG	A209818	001	May 20, 2019	Aug DISC
		@	10MG	A209818	002	May 20, 2019	Aug DISC
		@ ZYDUS PHARMS	5MG	A207721	001	Oct 19, 2020	Mar DISC
		@	10MG	A207721	002	Oct 19, 2020	Mar DISC

SORAFENIB TOSYLATE

TABLET; ORAL

NEXAVAR

	+	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005	May CTEC
		SORAFENIB TOSYLATE					
		@ TEVA PHARMS USA INC	EQ 200MG BASE	A209567	001	Nov 12, 2020	May DISC

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

		@ MYLAN	80MG	A077616	001	Feb 07, 2007	Feb DISC
		@	120MG	A077616	002	Feb 07, 2007	Feb DISC
		@	160MG	A077616	003	Feb 07, 2007	Feb DISC

SOTORASIB

TABLET; ORAL

LUMAKRAS

	+	!	AMGEN INC	120MG	N214665	001	May 28, 2021	May NEWA
--	---	---	-----------	-------	---------	-----	--------------	----------

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

		@ OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006	Aug DISC
		@	50MG	A040750	002	Aug 29, 2006	Aug DISC
		@	100MG	A040750	003	Aug 29, 2006	Aug DISC

STERILE WATER FOR INJECTION

LIQUID; N/A

STERILE WATER FOR INJECTION

AP		HIKMA PHARMS	100% (10ML)	A206369	001	Sep 02, 2015	Jul CAHN
		@	100% (20ML)	A206369	002	Sep 02, 2015	Jul CAHN
>D>	!	NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Oct DISC
>A>	@		100% (5ML)	A211222	001	Feb 10, 2021	Oct DISC
	!		100% (5ML)	A211222	001	Feb 10, 2021	Jan NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

AP		ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	Mar CMFD
AP		HIKMA	20MG/ML	A213229	001	Jun 12, 2020	Apr CMFD
		@	20MG/ML	A213229	001	Jun 12, 2020	Feb DISC
>A>	AP	HONG KONG	20MG/ML	A214514	001	Oct 19, 2021	Oct NEWA
AP		SAGENT PHARMS INC	20MG/ML	A215022	001	Mar 29, 2021	Mar NEWA

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

	+	!	HIKMA PHARMS	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Aug NEWA
--	---	---	--------------	---------------------	---------	-----	--------------	----------

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10

AT	+	!	ALLERGAN	10%	A080028	001	Aug CRLD
----	---	---	----------	-----	---------	-----	----------

SULFADIAZINE

	TABLET; ORAL						
	SULFADIAZINE						
>D>	@ IMPAX LABS	500MG	A 080081	001		Oct	CRLD
>A>	+ @	500MG	A 080081	001		Oct	CRLD

SULFAMETHOXAZOLE

	TABLET; ORAL						
	SULFAMETHOXAZOLE						
	@ RISING	500MG	A 085844	001		Jan	CAHN

SULFASALAZINE

	TABLET; ORAL						
	AZULFIDINE						
AB	+! PFIZER	500MG	N 007073	001		Mar	CAHN
	SULFASALAZINE						
AB	CHARTWELL	500MG	A 080197	001		Jun	CMFD
	TABLET, DELAYED RELEASE; ORAL						
	AZULFIDINE EN-TABS						
AB	+! PFIZER	500MG	N 007073	002	Apr 06, 1983	Mar	CAHN

SULFISOXAZOLE

	TABLET; ORAL						
	SULFISOXAZOLE						
	@ RISING	500MG	A 085628	001		Jan	CAHN

SULINDAC

	TABLET; ORAL						
	SULINDAC						
	@ MYLAN	150MG	A 073039	002	Jun 22, 1993	Aug	CAHN
	@	150MG	A 073039	002	Jun 22, 1993	Aug	DISC
	@	200MG	A 073039	001	Jun 22, 1993	Aug	CAHN
	@	200MG	A 073039	001	Jun 22, 1993	Aug	DISC

SUMATRIPTAN

	SPRAY; NASAL						
	SUMATRIPTAN						
AB	CIPLA	20MG/SPRAY	A 214209	001	Feb 22, 2021	Feb	NEWA
AB	FLORIDA	20MG/SPRAY	A 208967	001	Feb 17, 2021	Mar	CAHN
AB	PHARMASERVE NW	20MG/SPRAY	A 208967	001	Feb 17, 2021	Feb	NEWA

SUMATRIPTAN SUCCINATE

	INJECTABLE; SUBCUTANEOUS						
	SUMATRIPTAN SUCCINATE						
AP	CAPLIN	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 213998	001	Jul 13, 2021	Jul	NEWA
	@ MYLAN ASI	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 090314	001	Jun 10, 2010	May	DISC
	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 090641	001	Jul 28, 2010	Jan	DISC

SUNITINIB MALATE

	CAPSULE; ORAL						
	SUNITINIB MALATE						
AB	SUN PHARM	EQ 12.5MG BASE	A 213914	001	Aug 16, 2021	Aug	NFTG
AB		EQ 25MG BASE	A 213914	002	Aug 16, 2021	Aug	NFTG
AB		EQ 37.5MG BASE	A 213914	003	Aug 16, 2021	Aug	NFTG
AB		EQ 50MG BASE	A 213914	004	Aug 16, 2021	Aug	NFTG
	SUTENT						
AB	+ CPPI CV	EQ 12.5MG BASE	N 021938	001	Jan 26, 2006	Aug	CTEC
AB	+	EQ 25MG BASE	N 021938	002	Jan 26, 2006	Aug	CTEC
AB	+	EQ 37.5MG BASE	N 021938	004	Mar 31, 2009	Aug	CTEC
AB	+!	EQ 50MG BASE	N 021938	003	Jan 26, 2006	Aug	CTEC

TACROLIMUS

	CAPSULE; ORAL						
	TACROLIMUS						
	@ CONCORD BIOTECH LTD	EQ 0.5MG BASE	A 213112	001	Nov 10, 2020	Apr	DISC
AB	PANACEA	EQ 0.5MG BASE	A 090802	001	Sep 28, 2012	Jul	CAHN
AB		EQ 1MG BASE	A 090802	002	Sep 28, 2012	Jul	CAHN
AB		EQ 5MG BASE	A 090802	003	Sep 28, 2012	Jul	CAHN

TADALAFIL

TABLET; ORAL

CIALIS

AB1	+	LILLY	2.5MG	N021368	004	Jan 07, 2008	Feb CTEC
AB1	+		5MG	N021368	001	Nov 21, 2003	Feb CTEC
AB1	+		10MG	N021368	002	Nov 21, 2003	Feb CTEC
		TADALAFIL					
AB1		ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209167	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209167	003	Oct 23, 2019	Feb CTEC
AB1		AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209654	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209654	003	Mar 26, 2019	Feb CTEC
AB1		ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A204809	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A204809	003	Mar 26, 2019	Feb CTEC
AB1		AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209744	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209744	003	Mar 26, 2019	Feb CTEC
AB1		AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A206285	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A206285	003	Mar 26, 2019	Feb CTEC
AB1		CIPLA	2.5MG	A209539	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209539	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209539	003	Mar 26, 2019	Feb CTEC
AB1		DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A210069	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A210069	003	Mar 26, 2019	Feb CTEC
	@	GLENMARK PHARMS LTD	2.5MG	A210716	001	Dec 29, 2020	Feb DISC
	@		5MG	A210716	002	Dec 29, 2020	Feb DISC
	@		10MG	A210716	003	Dec 29, 2020	Feb DISC
	@		20MG	A210716	004	Dec 29, 2020	Feb DISC
AB1		HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209908	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209908	003	Mar 26, 2019	Feb CTEC
AB1		LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A210567	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A210567	003	Mar 26, 2019	Feb CTEC
AB1		MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07, 2019	Feb CTEC
AB1			5MG	A207244	002	Oct 07, 2019	Feb CTEC
AB1			10MG	A207244	003	Oct 07, 2019	Feb CTEC
	@	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Aug CAHN
	@		2.5MG	A206956	001	Apr 29, 2019	Aug DISC
AB1			2.5MG	A206956	001	Apr 29, 2019	Feb CTEC
	@		5MG	A206957	001	Apr 29, 2019	Aug CAHN
	@		5MG	A206957	001	Apr 29, 2019	Aug DISC
AB1			5MG	A206957	001	Apr 29, 2019	Feb CTEC
	@		10MG	A206956	002	Apr 29, 2019	Aug CAHN
	@		10MG	A206956	002	Apr 29, 2019	Aug DISC
AB1			10MG	A206956	002	Apr 29, 2019	Feb CTEC
>D>	AB2		20MG	A200630	001	Aug 03, 2018	Oct DISC
>A>	@		20MG	A200630	001	Aug 03, 2018	Oct DISC
	@		20MG	A206956	003	Apr 29, 2019	Aug CAHN
	@		20MG	A206956	003	Apr 29, 2019	Aug DISC
AB1		QILU	2.5MG	A210420	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A210420	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A210420	003	Mar 26, 2019	Feb CTEC
AB1		SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A208934	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A208934	003	Mar 26, 2019	Feb CTEC
AB1		SUNSHINE	2.5MG	A211335	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A211335	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A211335	003	Mar 26, 2019	Feb CTEC
AB1		TEVA PHARMS USA	2.5MG	A090141	001	May 22, 2018	Feb CTEC
AB1			5MG	A090141	002	May 22, 2018	Feb CTEC
AB1			10MG	A090141	003	May 22, 2018	Feb CTEC
AB1		TORRENT	2.5MG	A211839	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A211839	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A211839	003	Mar 26, 2019	Feb CTEC
AB1		UMEDICA LABS PVT LTD	2.5MG	A211298	001	Oct 23, 2020	Feb CTEC
AB1			5MG	A211298	002	Oct 23, 2020	Feb CTEC
AB1			10MG	A211298	003	Oct 23, 2020	Feb CTEC
BX		UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Sep CTEC

TABLET;ORAL
TADALAFIL

AB1		2.5MG	A209250	001	Mar 26, 2019	Feb	CTEC	
BX		5MG	A209250	002	Mar 26, 2019	Sep	CTEC	
AB1		5MG	A209250	002	Mar 26, 2019	Feb	CTEC	
BX		10MG	A209250	003	Mar 26, 2019	Sep	CTEC	
AB1		10MG	A209250	003	Mar 26, 2019	Feb	CTEC	
BX		20MG	A209250	004	Mar 26, 2019	Sep	CTEC	
>A>	AB1	VKT PHARMA	2.5MG	A215556	001	Nov 04, 2021	Oct	NEWA
>A>	AB1		5MG	A215556	002	Nov 04, 2021	Oct	NEWA
>A>	AB1		10MG	A215556	003	Nov 04, 2021	Oct	NEWA
>A>	AB1		20MG	A215556	004	Nov 04, 2021	Oct	NEWA
AB1		YANGLING BUCHANG	2.5MG	A208824	001	Oct 27, 2020	Feb	CTEC
AB1			5MG	A208824	002	Oct 27, 2020	Feb	CTEC
AB1			10MG	A208824	003	Oct 27, 2020	Feb	CTEC
AB1		ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Feb	CTEC
AB1			5MG	A206693	002	Mar 26, 2019	Feb	CTEC
AB1			10MG	A206693	003	Mar 26, 2019	Feb	CTEC

TAFAMIDIS

CAPSULE;ORAL
VYNDAMAX

>D>	+	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019	Oct	CAHN
>A>	+		61MG	N212161	001	May 03, 2019	Oct	CAHN

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL
VYNDAQEL

>D>	+	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	Oct	CAHN
>A>	+		20MG	N211996	001	May 03, 2019	Oct	CAHN

TALAZOPARIB TOSYLATE

CAPSULE;ORAL
TALZENNA

>A>	+	PFIZER	EQ 0.5MG BASE	N211651	003	Sep 20, 2021	Oct	NEWA
>A>	+		EQ 0.75MG BASE	N211651	004	Sep 20, 2021	Oct	NEWA

TALC

AEROSOL;INTRAPLEURAL
SCLEROSOL

+! SCIARRA LABS 4GM/SPRAY

N020587 001 Dec 24, 1997 Sep CAHN

POWDER;INTRAPLEURAL
TALC

+! SCIARRA LABS 5GM/BOT

N021388 001 Dec 15, 2003 Sep CAHN

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL
TAMSULOSIN HYDROCHLORIDE

AB	ANBISON LAB	0.4MG	A211885	001	Oct 17, 2019	Aug	CMFD
	@ ANCHEN PHARMS	0.4MG	A202010	001	Jan 04, 2013	Jun	DISC

TAVABOROLE

SOLUTION;TOPICAL
TAVABOROLE

AB	CIPLA	5%	A212224	001	Feb 09, 2021	Jan	NEWA
AB	FLATWING	5%	A211963	001	Feb 03, 2021	Feb	CPOT
AB		5.0%	A211963	001	Feb 03, 2021	Jan	NEWA
	@ IDENTIRX	5%	A211963	001	Feb 03, 2021	Sep	DISC
AB		5%	A211963	001	Feb 03, 2021	Feb	CAHN
AB	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Jan	NEWA
AB	TARO PHARMS	5%	A212215	001	May 07, 2021	Apr	NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION
CIS-MDP

AP	SUN PHARM INDS INC	N/A	N018124	001		Jul	CTEC
	TECHNETIUM TC-99M MEDRONATE KIT						
AP	CARDINAL HEALTH 414	N/A	N018107	001		Jul	CTNA
AP		N/A	N018107	001		Jul	CMFD

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION
MPI DMSA KIDNEY REAGENT
+ @ GE HEALTHCARE N/A

N017944 001 May 18, 1982 Sep CRLD

TELMISARTAN

TABLET; ORAL
TELMISARTAN

AB	CELLTRION	20MG	A 078710	001	Jan 08, 2014	Feb	CMFD
AB		40MG	A 078710	002	Jan 08, 2014	Feb	CMFD
AB		80MG	A 078710	003	Jan 08, 2014	Feb	CMFD
AB	MYLAN	20MG	A 202397	001	Jul 07, 2014	Aug	CAHN
AB		40MG	A 202397	002	Jul 07, 2014	Aug	CAHN
AB		80MG	A 202397	003	Jul 07, 2014	Aug	CAHN

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

@	MYLAN	7.5MG	A 070920	002	May 21, 2010	Sep	CAHN
@		7.5MG	A 070920	002	May 21, 2010	Sep	DISC
@		15MG	A 070920	004	Jul 07, 1986	Sep	CAHN
@		15MG	A 070920	004	Jul 07, 1986	Sep	DISC
@		22.5MG	A 070920	003	Jun 12, 2009	Sep	CAHN
@		22.5MG	A 070920	003	Jun 12, 2009	Sep	DISC
@		30MG	A 070920	001	Jul 10, 1986	Sep	CAHN
@		30MG	A 070920	001	Jul 10, 1986	Sep	DISC

TEMOZOLOMIDE

CAPSULE; ORAL
TEMOZOLOMIDE

@	HERITAGE	5MG	A 078879	001	Mar 01, 2010	Feb	CAHN
@		20MG	A 078879	002	Mar 01, 2010	Feb	CAHN
@		100MG	A 078879	003	Mar 01, 2010	Feb	CAHN
@		140MG	A 078879	005	Mar 01, 2010	Feb	CAHN
@		180MG	A 078879	006	Mar 01, 2010	Feb	CAHN
@		250MG	A 078879	004	Mar 01, 2010	Feb	CAHN
@	WATSON LABS TEVA	5MG	A 203959	001	Apr 18, 2017	Jan	DISC
@		20MG	A 203959	002	Apr 18, 2017	Jan	DISC
@		100MG	A 203959	003	Apr 18, 2017	Jan	DISC
@		140MG	A 203959	004	Apr 18, 2017	Jan	DISC
@		250MG	A 203959	005	Apr 18, 2017	Jan	DISC

TEPOTINIB HYDROCHLORIDE

TABLET; ORAL
TEPMETKO

+! EMD SERONO INC EQ 225MG BASE N214096 001 Feb 03, 2021 Feb NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 1MG BASE	A 075614	002	Jan 30, 2001	May	CMFD
AB		EQ 2MG BASE	A 075614	001	Jan 30, 2001	May	CMFD
AB		EQ 5MG BASE	A 075614	003	Jan 30, 2001	May	CMFD
AB		EQ 10MG BASE	A 075614	004	Jan 30, 2001	May	CMFD
@	MYLAN	EQ 1MG BASE	A 075140	002	Feb 11, 2000	Aug	CAHN
@		EQ 1MG BASE	A 075140	002	Feb 11, 2000	Aug	DISC
@		EQ 2MG BASE	A 075140	003	Feb 11, 2000	Aug	CAHN
@		EQ 2MG BASE	A 075140	003	Feb 11, 2000	Aug	DISC
@		EQ 5MG BASE	A 075140	001	Feb 11, 2000	Aug	CAHN
@		EQ 5MG BASE	A 075140	001	Feb 11, 2000	Aug	DISC
@		EQ 10MG BASE	A 075140	004	Feb 11, 2000	Aug	CAHN
@		EQ 10MG BASE	A 075140	004	Feb 11, 2000	Aug	DISC

TERBINAFFINE HYDROCHLORIDE

TABLET; ORAL
TERBINAFFINE HYDROCHLORIDE

AB ! AUROBINDO PHARMA EQ 250MG BASE A 078297 001 Jul 02, 2007 Sep CHRS

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AB	BRECKENRIDGE	7MG	A209583	001	Sep 24, 2021	Sep	NEWA
AB		14MG	A209583	002	Sep 24, 2021	Sep	NEWA
>D>	@ IMPAX	14MG	A209677	001	Jun 17, 2020	Oct	CAHN
	@	14MG	A209677	001	Jun 17, 2020	Feb	DISC
>A>	@ SOLA PHARMS	14MG	A209677	001	Jun 17, 2020	Oct	CAHN

TESTOSTERONE

GEL; TRANSDERMAL

TESTOSTERONE

AB2	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM PACKET)	A204570	002	Jul 17, 2020	Feb	NEWA
AB2		1.62% (40.5MG/2.5GM PACKET)	A204570	003	Jul 17, 2020	Feb	NEWA
>A>	ENCUBE	50MG/5GM PACKET	A212984	001	Nov 09, 2021	Oct	NEWA

GEL, METERED; TRANSDERMAL

TESTOSTERONE

	@ ALEOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021	Sep	DISC
AB		1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021	Feb	NEWA

SOLUTION, METERED; TRANSDERMAL

TESTOSTERONE

AT	ALEOR DERMACEUTICALS	30MG/1.5ML ACTUATION	A212882	001	Jun 14, 2021	Jun	NEWA
	@ APOTEX	30MG/1.5ML ACTUATION	A209181	001	Nov 25, 2020	May	DISC
AT	DASH PHARMS	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	May	CAHN
AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan	NEWA
AT	TWI PHARMS	30MG/1.5ML ACTUATION	A209836	001	Sep 03, 2021	Aug	NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

	@ PFIZER	50MG/ML	A085635	001		Mar	CAHN
AO	+	100MG/ML	A085635	002		Aug	CRLD
AO	!	100MG/ML	A085635	002		Mar	CAHN
AO	+	200MG/ML	A085635	003		Aug	CRLD
AO	!	200MG/ML	A085635	003		Mar	CAHN
	TESTOSTERONE CYPIONATE						
AO	HIKMA PHARMS	100MG/ML	A090387	001	Jul 15, 2010	Jul	CAHN
AO		200MG/ML	A090387	002	Jul 15, 2010	Jul	CAHN

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

	@ AJANTA PHARMA LTD	12.5MG	A213621	001	Dec 04, 2020	May	DISC
	@	25MG	A213621	002	Dec 04, 2020	May	DISC

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

+	!	BAUSCH LOMB IRELAND	0.5%	N210821	001	Mar 12, 2019	May	CAHN
---	---	---------------------	------	---------	-----	--------------	-----	------

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

+	@	GE HEALTHCARE	1mCi/ML	N018110	002	Feb 27, 1996	Jun	DISC
---	---	---------------	---------	---------	-----	--------------	-----	------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

SLO-PHYLLIN

+	@	SANOFI AVENTIS US	125MG	A085203	001	May 24, 1982	Aug	CRLD
		SOMOPHYLLIN-CRT						
+	@	GRAHAM DM	250MG	A087193	001		Aug	CRLD
		THEO-24						
+		AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983	Aug	CRLD
		ELIXIR; ORAL						
		THEOPHYLLINE						
+	@	PRECISION DOSE	80MG/15ML	A085863	001		Aug	CRLD
		SOLUTION; ORAL						
		THEOPHYLLINE						
+	@	ROXANE	80MG/15ML	A087449	001	Sep 15, 1983	Aug	CRLD

	SOLUTION, ELIXIR;ORAL						
	ELIXOPHYLLIN						
AA	+!	NOSTRUM LABS INC 80MG/15ML	A085186	001		Aug	CRLD
		SYRUP;ORAL					
		THEOPHYLLINE					
	+ @	ALPHARMA US PHARMS 150MG/15ML	A086545	001		Aug	CRLD
		TABLET, EXTENDED RELEASE;ORAL					
		THEO-DUR					
	+ @	SCHERING 200MG	A086998	001		Aug	CRLD
	+ @	300MG	A085328	002		Sep	CRLD
		THEOPHYLLINE					
AB		ALEMBIC PHARMS LTD 300MG	A090430	001	Oct 27, 2010	May	CTEC
AB	!	450MG	A090430	002	Oct 27, 2010	May	CTEC
AB		GLENMARK PHARMS LTD 300MG	A212184	001	Jun 03, 2021	May	NEWA
AB		450MG	A212184	002	Jun 03, 2021	May	NEWA
	@	HERITAGE PHARMA 100MG	A089807	001	Apr 30, 1990	Jul	DISC
	@	200MG	A089808	001	Apr 30, 1990	Jul	DISC
AB	+	RHODES PHARMS 400MG	A040086	002	Sep 01, 1982	Aug	CRLD

THIAMINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	BETALIN S						
	+ @	LILLY 100MG/ML	A080853	001		Aug	CRLD
		THIAMINE HYDROCHLORIDE					
AP	+!	FRESENIUS KABI USA 100MG/ML	A080556	001		Aug	CRLD
AP		WEST-WARD PHARMS INT 100MG/ML	A080575	001		Apr	CMFD

THIORIDAZINE HYDROCHLORIDE

	TABLET;ORAL						
	THIORIDAZINE HYDROCHLORIDE						
		MYLAN 10MG	A088004	002	Mar 15, 1983	Jan	CTEC
		25MG	A088004	003	Mar 15, 1983	Jan	CTEC
		50MG	A088004	004	Mar 15, 1983	Jan	CTEC
	!	100MG	A088004	001	Nov 18, 1983	Jan	CTEC
	@	SUN PHARM INDUSTRIES 10MG	A089953	004	Aug 01, 1986	Jan	DISC
	@	25MG	A089953	003	Aug 01, 1986	Jan	DISC
	@	50MG	A089953	002	Aug 01, 1986	Jan	DISC
	@	100MG	A089953	001	Oct 07, 1988	Jan	DISC

THIOTEPA

	POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL						
	THIOTEPA						
AP		GLAND PHARMA LTD 15MG/VIAL	A214222	001	Mar 08, 2021	Feb	NEWA

THIOTHIXENE HYDROCHLORIDE

	CONCENTRATE;ORAL						
	NAVANE						
>D>	@	PFIZER EQ 5MG BASE/ML	N016758	001		Oct	CRLD
>A>	+ @	EQ 5MG BASE/ML	N016758	001		Oct	CRLD

TIAGABINE HYDROCHLORIDE

	TABLET;ORAL						
	TIAGABINE HYDROCHLORIDE						
	@	WILSHIRE PHARMS INC 2MG	A206857	001	Oct 13, 2017	Jan	DISC
	@	4MG	A206857	002	Oct 13, 2017	Jan	DISC
	@	12MG	A206857	003	Oct 13, 2017	Jan	DISC
	@	16MG	A206857	004	Oct 13, 2017	Jan	DISC

TICAGRELOR

	TABLET;ORAL						
	BRILINTA						
AB	+	ASTRAZENECA 60MG	N022433	002	Sep 03, 2015	Jul	CFTG
		TICAGRELOR					
AB		MYLAN 60MG	A208597	001	Jul 09, 2021	Jul	NFTG
AB		90MG	A208597	002	Jul 09, 2021	Jul	NEWA

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

@	CHARTWELL RX	250MG	A075318	001	Aug 20, 1999	Aug	CAHN
@		250MG	A075326	001	Aug 20, 1999	Aug	CAHN

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

AP	HONG KONG	50MG/VIAL	A214020	001	May 13, 2021	May	NEWA
AP	MEITHEAL	50MG/VIAL	A214020	001	May 13, 2021	Aug	CAHN

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AB	!	ALEMBIC PHARMS LTD	EQ 0.25% BASE	A212942	001	Oct 22, 2020	Apr	CHRS
AB	!		EQ 0.5% BASE	A212942	002	Oct 22, 2020	Apr	CHRS
		TIMOPTIC-XE						
AB	+	VALEANT PHARMS LLC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Apr	CHRS
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Apr	CHRS
		SOLUTION/DROPS; OPHTHALMIC						
		TIMOLOL MALEATE						
AT		MANKIND PHARMA	EQ 0.25% BASE	A078771	001	Sep 28, 2009	Apr	CAHN
AT1			EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr	CAHN

TIOPRONIN

TABLET; ORAL

THIOLA

AB	+!	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988	Apr	CFTG
		TIOPRONIN						
AB		TEVA PHARMS USA INC	100MG	A214326	001	Apr 26, 2021	Apr	NFTG

TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

+!	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015	Mar	CHRS
----	----------------------	-----------------------	---------	-----	--------------	-----	------

TIROFIBAN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

AGGRASTAT

	+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Apr	CDFR
AP	+!		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	N020913	003	Apr 20, 2000	Apr	CFTG
	@		EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998	Apr	CDFR
		TIROFIBAN HYDROCHLORIDE						
AP		GLAND PHARMA LTD	EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A206888	001	Apr 08, 2021	Apr	NFTG

TIVOZANIB HYDROCHLORIDE

CAPSULE; ORAL

FOTIVDA

	+	AVEO PHARMS	EQ 0.89MG BASE	N212904	001	Mar 10, 2021	Mar	NEWA
	+!		EQ 1.34MG BASE	N212904	002	Mar 10, 2021	Mar	NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

@	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Jun	DISC
@		EQ 4MG BASE	A207199	002	Mar 14, 2017	Jun	DISC
@		EQ 6MG BASE	A207199	003	Mar 14, 2017	Jun	DISC

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB		CADILA	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb	CAHN
AB			EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb	CAHN
	@	MYLAN	EQ 2MG BASE	A076354	001	Mar 28, 2003	Jan	DISC
	@		EQ 4MG BASE	A076354	002	Mar 28, 2003	Feb	DISC

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

AN	ALKEM LABS LTD	300MG/5ML	A212848	001	Apr 01, 2021	Mar	NEWA
	@ AUROBINDO PHARMA LTD	300MG/5ML	A210871	001	Jan 22, 2021	Jul	DISC
AN		300MG/5ML	A210871	001	Jan 22, 2021	Jan	NEWA
	@ LUOXIN AUROVITAS	300MG/5ML	A210871	001	Jan 22, 2021	Aug	CAHN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	GLAND PHARMA LTD	0.3%	A212628	001	Mar 09, 2021	Feb	NEWA
----	------------------	------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	GLAND PHARMA LTD	EQ 10MG BASE/ML	A209621	001	Feb 11, 2021	Feb	NEWA
AP		EQ 40MG BASE/ML	A209621	002	Feb 11, 2021	Feb	NEWA
AP		EQ 1.2GM BASE/VIAL	A211189	001	May 18, 2021	May	NEWA
	TOBRAMYCIN SULFATE (PHARMACY BULK)						
AP	! FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jan	CTEC
AP	GLAND PHARMA LTD	EQ 40MG BASE/ML	A209346	001	Feb 09, 2021	Jan	NEWA

TOFACITINIB CITRATE

SOLUTION; ORAL

XELJANZ

	+! PFIZER	EQ 1MG/ML BASE	N213082	001	Sep 25, 2020	Feb	CMS1
	TABLET, EXTENDED RELEASE; ORAL						
	TOFACITINIB						
AB	ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Aug	NFTG
AB		EQ 22MG BASE	A214264	002	Aug 19, 2021	Aug	NFTG
	XELJANZ XR						
AB	+ PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Aug	CFTG
AB	+!	EQ 22MG BASE	N208246	002	Dec 12, 2019	Aug	CFTG

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

	@ CHARTWELL RX	100MG	A071633	001	Dec 09, 1987	Aug	CAHN
	@	250MG	A070289	001	Mar 13, 1986	Aug	CAHN
	@	500MG	A070290	001	Mar 13, 1986	Aug	CAHN

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

	@ CHARTWELL RX	500MG	A086574	001		Aug	CAHN
>D>	! MYLAN PHARMS INC	500MG	A086445	001		Oct	DISC
>A>	@	500MG	A086445	001		Oct	DISC

TOLCAPONE

TABLET; ORAL

TOLCAPONE

	@ ALVOGEN	100MG	A207729	001	Jul 29, 2020	Jan	DISC
	@ MAYNE PHARMA	100MG	A210095	001	Aug 01, 2019	Sep	DISC

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

	@ MYLAN	EQ 400MG BASE	A073393	001	May 27, 1993	Aug	DISC
	@ TEVA	EQ 400MG BASE	A073290	001	Nov 27, 1991	Aug	DISC

TABLET; ORAL

TOLMETIN SODIUM

	@ MYLAN	EQ 600MG BASE	A074473	001	Aug 30, 1994	Aug	DISC
--	---------	---------------	---------	-----	--------------	-----	------

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TOLTERODINE TARTRATE

AB	AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020	Jan	CMFD
AB		4MG	A213397	002	May 19, 2020	Jan	CMFD
AB	AMTA	2MG	A213858	001	Feb 02, 2021	Jan	NEWA
AB		4MG	A213858	002	Feb 02, 2021	Jan	NEWA
	@ MYLAN	2MG	A201486	001	Oct 31, 2013	Jul	DISC
	@	4MG	A201486	002	Oct 31, 2013	Jul	DISC

<u>TABLET;ORAL</u>						
TOLTERODINE TARTRATE						
AB	HETERO LABS LTD V	1MG	A204397	001	Aug 02, 2021	Jul NEWA
AB		2MG	A204397	002	Aug 02, 2021	Jul NEWA
<u>TOLVAPTAN</u>						
TABLET;ORAL						
SAMSCA						
	+ OTSUKA	15MG	N022275	001	May 19, 2009	Feb CAHN
AB	+!	30MG	N022275	002	May 19, 2009	Feb CAHN
	+ @	60MG	N022275	003	May 19, 2009	Feb CAHN
TOLVAPTAN						
	ALKEM LABS LTD	60MG	A211891	002	May 19, 2020	Jul CTEC
AB	APOTEX	30MG	A207605	001	May 19, 2020	Aug CMFD
AB	HETERO LABS LTD V	30MG	A205646	001	Jul 16, 2021	Jul NEWA
<u>TOPIRAMATE</u>						
CAPSULE, EXTENDED RELEASE;ORAL						
QUDEXY XR						
AB2	+ UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Jan CFTG
AB2	+	50MG	N205122	002	Mar 11, 2014	Jan CFTG
AB2	+	100MG	N205122	003	Mar 11, 2014	Jan CFTG
AB2	+	150MG	N205122	004	Mar 11, 2014	Jan CFTG
AB2	+!	200MG	N205122	005	Mar 11, 2014	Jan CFTG
TOPIRAMATE						
AB2	GLENMARK PHARMS LTD	25MG	A210278	001	Feb 01, 2021	Jan NFTG
AB2		50MG	A210278	002	Feb 01, 2021	Jan NFTG
AB2		100MG	A210278	003	Feb 01, 2021	Jan NFTG
AB2		150MG	A210278	004	Feb 01, 2021	Jan NFTG
AB2		200MG	A210278	005	Feb 01, 2021	Jan NFTG
AB1	ZYDUS PHARMS	25MG	A207382	001	Nov 24, 2017	Jan CTEC
AB1		50MG	A207382	002	Nov 24, 2017	Jan CTEC
AB1		100MG	A207382	003	Nov 24, 2017	Jan CTEC
TROKENDI XR						
AB1	+ SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013	Jan CTEC
AB1	+	50MG	N201635	002	Aug 16, 2013	Jan CTEC
AB1	+	100MG	N201635	003	Aug 16, 2013	Jan CTEC
TABLET;ORAL						
TOPIRAMATE						
AB	ASCENT PHARMS INC	25MG	A215414	001	Aug 26, 2021	Aug NEWA
AB		50MG	A215414	002	Aug 26, 2021	Aug NEWA
AB		100MG	A215414	003	Aug 26, 2021	Aug NEWA
AB		200MG	A215414	004	Aug 26, 2021	Aug NEWA
<u>TOPOTECAN HYDROCHLORIDE</u>						
INJECTABLE;INJECTION						
TOPOTECAN HYDROCHLORIDE						
	@ MEITHEAL	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Aug DISC
<u>TORSEMIDE</u>						
TABLET;ORAL						
SOAANZ						
	+! SARFE PHARMS	20MG	N213218	001	Jun 14, 2021	Jul CHRS
	+	20MG	N213218	001	Jun 14, 2021	Jun NEWA
	+	60MG	N213218	002	Jun 14, 2021	Jul CHRS
	+!	60MG	N213218	002	Jun 14, 2021	Jun NEWA
<u>TRAMADOL HYDROCHLORIDE</u>						
TABLET;ORAL						
TRAMADOL HYDROCHLORIDE						
	@ GRAVITI PHARMS	50MG	A075968	001	Jun 25, 2002	Apr CAHN
AB	MERRO PHARM USA	50MG	A206706	001	Jul 02, 2019	Sep CAHN
AB	POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Feb CMFD
	@ RISING	50MG	A075968	001	Jun 25, 2002	Aug CAHN
TABLET, EXTENDED RELEASE;ORAL						
TRAMADOL HYDROCHLORIDE						
	@ ANCHEN PHARMS	100MG	A200491	001	Jun 27, 2012	Apr DISC
	@	200MG	A200491	002	Jun 27, 2012	Apr DISC
	@	300MG	A200491	003	Jun 27, 2012	Apr DISC

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL		TARKA					
	+ @ ABBVIE	2MG;180MG	N020591	001	Oct 22, 1996	Aug	DISC
	+ @	2MG;240MG	N020591	004	Oct 22, 1996	Aug	DISC
	+ @	4MG;240MG	N020591	002	Oct 22, 1996	Aug	DISC
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE		GLENMARK GENERICS					
		2MG;180MG	A079135	001	May 26, 2010	Aug	CTEC
		2MG;240MG	A079135	002	May 26, 2010	Aug	CTEC
	!	4MG;240MG	A079135	003	May 05, 2010	Aug	CTEC
AB	!	4MG;240MG	A079135	003	May 05, 2010	Aug	CHRS

TRANEXAMIC ACID

INJECTABLE;INJECTION		CYKLOKAPRON					
AP	+! PFIZER	100MG/ML	N019281	001	Dec 30, 1986	Mar	CAHN
TRANEXAMIC ACID		CAPLIN					
AP		100MG/ML	A212360	001	Jul 17, 2019	Jun	CMFD
AP	PROVEPHARM SAS	100MG/ML	A212676	001	Jul 17, 2019	Jan	CAHN
	@ ZYDUS PHARMS	100MG/ML	A205228	001	Jul 17, 2017	Apr	DISC
TABLET;ORAL		TRANEXAMIC ACID					
AB	ANI PHARMS	650MG	A203256	001	Jul 25, 2016	Jun	CMFD
	@ APOTEX INC	650MG	A202286	001	Jan 27, 2014	Mar	DISC

TRANLYCYPROMINE SULFATE

TABLET;ORAL		TRANLYCYPROMINE SULFATE					
AB	NOVITIUM PHARMA	EQ 10MG BASE	A206856	001	Apr 17, 2018	Apr	CAHN
>D>	AB	PAR PHARM	A040640	001	Jun 29, 2006	Oct	CAHN
>A>	AB	STRIDES PHARMA	A040640	001	Jun 29, 2006	Oct	CAHN
>A>	AB	EQ 10MG BASE	A040640	001	Jun 29, 2006	Oct	CAHN

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC		TRAVOPROST					
AT	MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Mar	NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL		TRAZODONE HYDROCHLORIDE					
	@ ALVOGEN	50MG	A071636	001	Apr 18, 1988	Jun	DISC
	@	100MG	A071514	001	Apr 18, 1988	Jun	DISC
AB	AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Feb	CMFD
AB		100MG	A204852	002	Feb 05, 2020	Feb	CMFD
AB		150MG	A204852	003	Feb 05, 2020	Feb	CMFD
AB		300MG	A204852	004	Feb 05, 2020	Feb	CMFD
	@ RISING	50MG	A072484	001	Apr 30, 1990	Jan	CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS		REMODULIN					
	+! UNITED THERAP	20MG/ML	N021272	005	Jul 30, 2021	Aug	NEWA
TREPROSTINIL		ALEMBIC GLOBAL					
AP		1MG/ML	A211574	001	Feb 11, 2021	Feb	NEWA
AP		2.5MG/ML	A211574	002	Feb 11, 2021	Feb	NEWA
AP		5MG/ML	A211574	003	Feb 11, 2021	Feb	NEWA
AP		10MG/ML	A211574	004	Feb 11, 2021	Feb	NEWA
SOLUTION;INTRAVENOUS, SUBCUTANEOUS		REMODULIN					
	@ UNITED THERAP	20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018	Jun	DISC
	@	50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018	Jun	DISC
	@	100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018	Jun	DISC
	@	200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018	Jun	DISC

TRETINOIN

CREAM;TOPICAL		RENOVA					
	+! VALEANT PHARMS NORTH	0.05%	N019963	001	Dec 29, 1995	Sep	CTEC

CREAM; TOPICAL

TRETINOIN

@ ZO SKIN HEALTH 0.05% A076498 001 Sep 15, 2005 Sep DISC

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

ARISTOCORT

+ @ ASTELLAS 0.5% A083015 002 Aug CRLD

KENALOG

+ @ DELCOR ASSET CORP 0.5% A083943 001 Aug CRLD

TRIAMCINOLONE ACETONIDE

AT +! FOUGERA PHARMS 0.025% A085692 001 Aug CRLD

AT +! 0.1% A085692 003 Aug CRLD

AT +! 0.5% A085692 002 Aug CRLD

AT MICRO LABS 0.025% A040671 001 Jun 09, 2006 Aug CAHN

AT 0.1% A040671 002 Jun 09, 2006 Aug CAHN

AT SAPTALIS PHARMS 0.025% A040671 001 Jun 09, 2006 Jan CAHN

AT 0.1% A040671 002 Jun 09, 2006 Jan CAHN

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

BX AMNEAL 40MG/ML A207550 001 Dec 11, 2017 Sep CTEC

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT MICRO LABS 0.1% A040672 002 Dec 13, 2006 Aug CAHN

OINTMENT; TOPICAL

ARISTOCORT

+ @ ASTELLAS 0.5% A080745 002 Aug CRLD

ARISTOCORT A

+ @ ASTELLAS 0.5% A080745 003 Aug CRLD

KENALOG

+ @ DELCOR ASSET CORP 0.5% A083944 001 Aug CRLD

TRIAMCINOLONE ACETONIDE

AT +! PADAGIS US 0.025% A087385 002 Aug CRLD

AT +! 0.1% A087385 003 Aug CRLD

AT +! 0.5% A087385 001 Aug CRLD

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

@ PERRIGO

0.055MG/SPRAY A078104 001 Jul 30, 2009 Jul CAHN

SUSPENSION; INJECTION

XIPERE

>A> +! CLEARSIDE 40MG/ML N211950 001 Oct 22, 2021 Oct NEWA

TRIAZOLAM

TABLET; ORAL

HALCION

AB + PFIZER 0.125MG N017892 003 Apr 26, 1985 Feb CAHN

AB +! 0.25MG N017892 001 Nov 15, 1982 Feb CAHN

@

0.5MG N017892 002 Nov 15, 1982 Feb CAHN

TRIAZOLAM

AB NOVAST LABS 0.125MG A214219 001 Oct 20, 2020 Sep CAHN

AB 0.25MG A214219 002 Oct 20, 2020 Sep CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

CLOVIQUE

@ CHARTWELL RX

250MG A209731 001 Oct 21, 2019 Jun DISC

AB 250MG A209731 001 Oct 21, 2019 Mar CAHN

TRIENTINE HYDROCHLORIDE

AB ACCORD HLTHCARE 250MG A212929 001 Aug 30, 2021 Aug NEWA

@ AMNEAL

250MG A210619 001 Feb 08, 2019 Sep DISC

@ CHARTWELL RX

250MG A209415 001 Sep 16, 2019 Jun DISC

AB 250MG A209415 001 Sep 16, 2019 Mar CAHN

AB ECI PHARMS LLC 250MG A209945 001 Aug 13, 2021 Aug NEWA

BX MSN 250MG A211134 001 May 22, 2019 Sep CTEC

AB PHARMA LIFE 250MG A209945 001 Aug 13, 2021 Sep CAHN

TRILACICLIB DIHYDROCHLORIDE

POWDER; INTRAVENOUS
COSELA

+! G1 THERAP EQ 300MG BASE/VIAL N214200 001 Feb 12, 2021 Feb NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL
TIGAN

+ @ KING PHARMS LLC 300MG N017531 006 Dec 13, 2001 Apr DISC
TRIMETHOBENZAMIDE HYDROCHLORIDE
AB ! SUN PHARM INDUSTRIES 300MG A076570 001 Aug 28, 2003 Apr CHRS

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
MYDRIACYL

AT +! ALCON LABS INC 1% A084306 001 Aug CRLD
AT +! SANDOZ INC 0.5% A084305 001 Aug CRLD

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
TROSPIUM CHLORIDE

AB AMTA 60MG A214760 001 Apr 30, 2021 Apr NEWA

UMBRALISIB TOSYLATE

TABLET; ORAL
UKONIQ

+! TG THERAPS EQ 200MG BASE N213176 001 Feb 05, 2021 Feb NEWA

URSODIOL

CAPSULE; ORAL
URSODIOL

>A> AB CHARTWELL RX 300MG A213555 001 Aug 17, 2020 Oct CAHN
AB STRIDES PHARMA 300MG A210344 001 Jan 22, 2021 Jan NEWA
>D> AB UPSHER SMITH LABS 300MG A213555 001 Aug 17, 2020 Oct CAHN
AB VGYAAN 300MG A214329 001 Jul 28, 2021 Jul NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALACYCLOVIR HYDROCHLORIDE

AB CADILA EQ 500MG BASE A079137 001 Dec 29, 2017 Aug CAHN
AB EQ 1GM BASE A079137 002 Dec 29, 2017 Aug CAHN

VALBENZAZINE TOSYLATE

CAPSULE; ORAL
INGREZZA

+ NEUROCRINE EQ 60MG BASE N209241 003 Apr 23, 2021 May NEWA

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL
VALGANCICLOVIR HYDROCHLORIDE

>D> AB ENDO PHARMS INC EQ 450MG BASE A200790 001 Nov 04, 2014 Oct CAHN
AB MYLAN EQ 450MG BASE A205151 001 Mar 03, 2021 Feb NEWA
>A> AB STRIDES PHARMA EQ 450MG BASE A200790 001 Nov 04, 2014 Oct CAHN

VALPROIC ACID

CAPSULE; ORAL
VALPROIC ACID

BX EYWA 250MG A207611 001 Aug 05, 2019 Sep CTEC

SYRUP; ORAL
VALPROIC ACID

AA BIOPHARM 250MG/5ML A090517 001 May 28, 2010 Sep CAHN
AA CHARTWELL RX 250MG/5ML A075782 001 Dec 22, 2000 Mar CMFD

VALSARTAN

SOLUTION; ORAL
VALSARTAN

>A> NOVITIUM PHARMA 20MG/5ML A214102 001 Nov 02, 2021 Oct NFTG

TABLET; ORAL
VALSARTAN

AB DR REDDYS 40MG A201618 001 Oct 05, 2021 Sep NEWA

TABLET;ORAL
VALSARTAN

AB		80MG	A201618	002	Oct 05, 2021	Sep	NEWA	
AB		160MG	A201618	003	Oct 05, 2021	Sep	NEWA	
AB		320MG	A201618	004	Oct 05, 2021	Sep	NEWA	
>A>	AB	SCIENGEN PHARMS INC	40MG	A204038	001	Oct 27, 2021	Oct	NEWA
>A>	AB		80MG	A204038	002	Oct 27, 2021	Oct	NEWA
>A>	AB		160MG	A204038	003	Oct 27, 2021	Oct	NEWA
>A>	AB		320MG	A204038	004	Oct 27, 2021	Oct	NEWA

VANCOMYCIN

SOLUTION;INTRAVENOUS, ORAL
VANCOMYCIN

+	!	XELLIA PHARMS APS	5GM/100ML (50MG/ML)	N213895	001	Aug 26, 2021	Aug	NEWA
---	---	-------------------	---------------------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

@		HIKMA	EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020	Feb	DISC
@			EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Feb	DISC
!		HOSPIRA	EQ 1.5GM BASE/VIAL	A062912	003	Jul 10, 2020	May	CMFD

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL
LEVITRA

+	@	BAYER HLTHCARE	EQ 5MG BASE	N021400	001	Aug 19, 2003	Apr	DISC
+	@		EQ 10MG BASE	N021400	002	Aug 19, 2003	Apr	DISC

VARENICLINE

TABLET;ORAL
VARENICLINE TARTRATE

AB		PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jul	NFTG
AB			EQ 1MG BASE	A201785	002	Aug 11, 2021	Jul	NFTG

VARENICLINE TARTRATE

>A>		SOLUTION;NASAL							
>A>		TYRVAYA							
>A>	+	!	OYSTER POINT PHARMA	EQ 0.03MG BASE/SPRAY	N213978	001	Oct 15, 2021	Oct	NEWA
			TABLET;ORAL						
			CHANTIX						
AB	+		PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Jul	CFTG
AB	+	!		EQ 1MG BASE	N021928	002	May 10, 2006	Jul	CFTG
			VARENICLINE TARTRATE						
AB			PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Sep	CTNA
AB				EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Sep	CAIN
AB				EQ 1MG BASE	A201785	002	Aug 11, 2021	Sep	CTNA
AB				EQ 1MG BASE	A201785	002	Aug 11, 2021	Sep	CAIN

VASOPRESSIN

SOLUTION;INTRAVENOUS
VASOSTRICT

+	!	PAR STERILE PRODUCTS	20UNITS/100ML (0.2UNITS/ML)	N204485	005	Apr 21, 2021	Apr	NEWA
---	---	----------------------	-----------------------------	---------	-----	--------------	-----	------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB		TORRENT	EQ 37.5MG BASE	A090899	001	Jun 01, 2011	Aug	CAHN
AB			EQ 75MG BASE	A090899	002	Jun 01, 2011	Aug	CAHN
AB			EQ 150MG BASE	A090899	003	Jun 01, 2011	Aug	CAHN
AB		YICHANG HUMANWELL	EQ 37.5MG BASE	A214654	001	Aug 06, 2021	Jul	NEWA
AB			EQ 75MG BASE	A214654	002	Aug 06, 2021	Jul	NEWA
AB			EQ 150MG BASE	A214654	003	Aug 06, 2021	Jul	NEWA

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

@		MYLAN	EQ 25MG BASE	A077166	001	Jun 13, 2008	Jan	DISC
@			EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Jan	DISC
@			EQ 50MG BASE	A077166	003	Jun 13, 2008	Jan	DISC
@			EQ 75MG BASE	A077166	004	Jun 13, 2008	Jan	DISC
@			EQ 100MG BASE	A077166	005	Jun 13, 2008	Jan	DISC

TABLET, EXTENDED RELEASE;ORALVENLAFAXINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 37.5MG BASE	A214127	001	Jun 10, 2021	Jun	NEWA
AB		EQ 75MG BASE	A214127	002	Jun 10, 2021	Jun	NEWA
AB		EQ 150MG BASE	A214127	003	Jun 10, 2021	Jun	NEWA
AB		EQ 225MG BASE	A214127	004	Jun 10, 2021	Jun	NEWA
AB	APPCO	EQ 150MG BASE	A214609	001	Jun 30, 2021	Jun	NEWA
AB		EQ 225MG BASE	A214609	002	Jun 30, 2021	Jun	NEWA
AB	DEXCEL PHARMA	EQ 75MG BASE	A213927	001	Jan 21, 2021	Jan	NEWA

VERAPAMIL HYDROCHLORIDETABLET, EXTENDED RELEASE;ORALVERAPAMIL HYDROCHLORIDE

@	MYLAN	120MG	A074587	002	Feb 21, 1997	Sep	CAHN
@		120MG	A074587	002	Feb 21, 1997	Sep	DISC
@		180MG	A074587	003	Sep 09, 1997	Sep	CAHN
@		180MG	A074587	003	Sep 09, 1997	Sep	DISC
@		240MG	A074587	001	Mar 23, 1996	Sep	CAHN
@		240MG	A074587	001	Mar 23, 1996	Sep	DISC

VERICIGUATTABLET;ORALVERQUVO

+	MERCK SHARP DOHME	2.5MG	N214377	001	Jan 19, 2021	Jan	NEWA
+		5MG	N214377	002	Jan 19, 2021	Jan	NEWA
+	!	10MG	N214377	003	Jan 19, 2021	Jan	NEWA

VIGABATRINFOR SOLUTION;ORALVIGABATRIN

AA	ANNORA PHARMA	500MG/PACKET	A213519	001	Jan 26, 2021	Jan	NEWA
AA	AUROBINDO PHARMA LTD	500MG/PACKET	A213899	001	Sep 29, 2021	Sep	NEWA
AA	DEXCEL PHARMA	500MG/PACKET	A214992	001	May 13, 2021	May	NEWA
AA	SPECGX LLC	500MG/PACKET	A212626	001	Jul 28, 2021	Jul	NEWA

TABLET;ORALVIGABATRIN

AB	DEXCEL PHARMA	500MG	A215109	001	Sep 23, 2021	Sep	NEWA
AB	DR REDDYS	500MG	A211539	001	Jan 29, 2021	Jan	NEWA

VILAZODONE HYDROCHLORIDETABLET;ORALVILAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	10MG	A208209	001	Apr 27, 2021	Apr	NEWA
AB		20MG	A208209	002	Apr 27, 2021	Apr	NEWA
AB		40MG	A208209	003	Apr 27, 2021	Apr	NEWA
AB	INVAGEN PHARMS	10MG	A208200	001	Apr 07, 2021	Mar	NEWA
AB		40MG	A208200	002	Apr 07, 2021	Mar	NEWA

VILOXAZINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORALQELBREE

+	SUPERNUS PHARMS	EQ 100MG BASE	N211964	001	Apr 02, 2021	Apr	NEWA
+		EQ 150MG BASE	N211964	002	Apr 02, 2021	Apr	NEWA
+	!	EQ 200MG BASE	N211964	003	Apr 02, 2021	Apr	NEWA

VINBLASTINE SULFATEINJECTABLE;INJECTIONVINBLASTINE SULFATE

!	HIKMA PHARMS	10MG/VIAL	A089395	001	Apr 09, 1987	Jul	CAHN
---	--------------	-----------	---------	-----	--------------	-----	------

VINORELBINE TARTRATEINJECTABLE;INJECTIONVINORELBINE TARTRATE

@	FRESENIUS KABI USA	EQ 10MG BASE/ML	A076849	001	Apr 18, 2005	Jan	DISC
---	--------------------	-----------------	---------	-----	--------------	-----	------

VOCLOSPORINCAPSULE;ORALLUPKYNIS

+	AURINIA	7.9MG	N213716	001	Jan 22, 2021	Jan	NEWA
---	---------	-------	---------	-----	--------------	-----	------

VORICONAZOLEINJECTABLE; INTRAVENOUS
VORICONAZOLE

AP	ALMAJECT	200MG/VIAL	A206398	001	Mar 23, 2016	Feb	CAHN
----	----------	------------	---------	-----	--------------	-----	------

VORTIOXETINE HYDROBROMIDETABLET; ORAL
TRINTELLIX

AB	+	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Sep	CFTG
AB	+		EQ 10MG BASE	N204447	002	Sep 30, 2013	Sep	CFTG
AB	+	!	EQ 20MG BASE	N204447	004	Sep 30, 2013	Sep	CFTG
VORTIOXETINE HYDROBROMIDE								
AB		ZYDUS PHARMS	EQ 5MG BASE	A211146	001	Sep 17, 2021	Sep	NFTG
AB			EQ 10MG BASE	A211146	002	Sep 17, 2021	Sep	NFTG
AB			EQ 20MG BASE	A211146	003	Sep 17, 2021	Sep	NFTG

ZIDOVUDINEINJECTABLE; INJECTION
RETROVIR

+	!	VIIV HLTHCARE	10MG/ML	N019951	001	Feb 02, 1990	Sep	CTEC
---	---	---------------	---------	---------	-----	--------------	-----	------

ZILEUTONTABLET, EXTENDED RELEASE; ORAL
ZILEUTON

AB		DASH PHARMS	600MG	A211390	001	Oct 23, 2020	Sep	CAHN
BX		LUPIN LTD	600MG	A211972	001	Nov 05, 2019	Sep	CTEC

ZINC CHLORIDEINJECTABLE; INJECTION
ZINC CHLORIDE

AP		EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	May	NFTG	
ZINC CHLORIDE IN PLASTIC CONTAINER									
AP	+	!	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	May	CFTG

ZIPRASIDONE HYDROCHLORIDECAPSULE; ORAL
ZIPRASIDONE HYDROCHLORIDE

AB		CHARTWELL RX	EQ 20MG BASE	A090348	001	Sep 05, 2012	Jul	CAHN
AB			EQ 40MG BASE	A090348	002	Sep 05, 2012	Jul	CAHN
AB			EQ 60MG BASE	A090348	003	Sep 05, 2012	Jul	CAHN
AB			EQ 80MG BASE	A090348	004	Sep 05, 2012	Jul	CAHN

ZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS
ZOLEDRONIC ACID

@	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Aug	DISC
---	-------------------	-----------------	---------	-----	--------------	-----	------

ZOLMITRIPTANSPRAY; NASAL
ZOLMITRIPTAN

AB		PADAGIS ISRAEL	2.5MG/SPRAY	A212469	001	Sep 30, 2021	Sep	NFTG	
AB			5MG/SPRAY	A212469	002	Sep 30, 2021	Sep	NFTG	
ZOMIG									
AB	+	!	ASTRAZENECA	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Sep	CFTG
AB	+	!		5MG/SPRAY	N021450	004	Sep 30, 2003	Sep	CFTG

ZOLPIDEM TARTRATETABLET, EXTENDED RELEASE; ORAL
ZOLPIDEM TARTRATE

>D>	AB	ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010	Oct	DISC
>A>		@	6.25MG	A078179	002	Oct 13, 2010	Oct	DISC
>D>	AB		12.5MG	A078179	001	Jun 06, 2011	Oct	DISC
>A>		@	12.5MG	A078179	001	Jun 06, 2011	Oct	DISC

TABLET, ORALLY DISINTEGRATING; ORAL
TOVALT ODT

+	@	BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007	Apr	CRLD
+	@		10MG	N021412	002	Apr 25, 2007	Apr	CRLD

ZONISAMIDE

	CAPSULE; ORAL							
	ZONEGRAN							
AB	+	CONCORDIA	25MG	N020789	003	Aug 22, 2003	Mar	CAHN
		+ @	50MG	N020789	002	Aug 22, 2003	Mar	CAHN
AB		+!	100MG	N020789	001	Mar 27, 2000	Mar	CAHN
	ZONISAMIDE							
AB		CADILA	25MG	A077625	001	Oct 16, 2006	Jul	CAHN
AB			50MG	A077625	002	Oct 16, 2006	Jul	CAHN
AB			100MG	A077625	003	Oct 16, 2006	Jul	CAHN
AB		GRANULES	25MG	A077636	003	Jul 27, 2006	Jun	CAHN
AB			50MG	A077636	002	Jul 27, 2006	Jun	CAHN
AB			100MG	A077636	001	Dec 22, 2005	Jun	CAHN
AB		UNICHEM	25MG	A214492	001	Jan 26, 2021	Jan	NEWA
AB			50MG	A214492	002	Jan 26, 2021	Jan	NEWA
AB			100MG	A214492	003	Jan 26, 2021	Jan	NEWA

ACETAMINOPHEN

SUPPOSITORY;RECTAL
 NEOPAP
 @ POLYMEDICA 120MG N016401 001 Sep DISC
 TABLET, EXTENDED RELEASE;ORAL
 ACETAMINOPHEN
 MARKSANS PHARMA 650MG A215486 001 Aug 25, 2021 Aug NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL
 ACETAMINOPHEN, ASPIRIN AND CAFFEINE
 GRANULES 250MG;250MG;65MG A214039 001 Feb 23, 2021 Feb NEWA

ASPIRIN

CAPSULE;ORAL
 VAZALORE
 + PLX PHARMA 81MG N203697 002 Feb 26, 2021 Jun NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL
 ASTEPRO ALLERGY
 +! BAYER HLTHCARE 0.2055MG/SPRAY N213872 001 Jun 17, 2021 Jun NEWA
 CHILDREN'S ASTEPRO ALLERGY
 +! BAYER HLTHCARE 0.2055MG/SPRAY N213872 002 Jun 17, 2021 Jun NEWA

BUDESONIDE

SPRAY, METERED;NASAL
 RHINOCORT ALLERGY
 +! J AND J CONSUMER INC 0.032MG/SPRAY N020746 003 Mar 23, 2015 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL
 CETIRIZINE HYDROCHLORIDE ALLERGY
 APOTEX 10MG A207235 001 Aug 12, 2016 Mar CMFD
 @ 10MG A207235 001 Aug 12, 2016 Jan DISC
 >D> @ CATALENT 10MG A213105 001 Sep 21, 2020 Oct CMFD
 >A> @ 10MG A213105 001 Sep 21, 2020 Oct CMFD
 SYRUP;ORAL
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY
 MICRO LABS 5MG/5ML A091327 001 Oct 17, 2011 Sep CAHN
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
 MICRO LABS 5MG/5ML A091327 002 Oct 17, 2011 Sep CAHN
 TABLET;ORAL
 CETIRIZINE HYDROCHLORIDE ALLERGY
 @ CIPLA LTD 5MG A077318 001 Jul 25, 2013 May DISC
 @ 10MG A077318 002 Jul 25, 2013 May DISC
 TABLET, CHEWABLE;ORAL
 CHILDREN'S ZYRTEC ALLERGY
 + @ J AND J CONSUMER INC 2.5MG N021621 007 Nov 30, 2020 Apr DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE
 SUN PHARM 30MG;600MG A214781 001 Jul 01, 2021 Jun NEWA
 60MG;1.2GM A214781 002 Jul 01, 2021 Jun NEWA

DICLOFENAC SODIUM

GEL;TOPICAL
 DICLOFENAC SODIUM
 AUROLIFE PHARMA LLC 1% A204306 001 May 06, 2019 May CAHN
 PERRIGO 1% A211253 001 May 16, 2019 Jun CAHN
 PERRIGO PHARMA INTL 1% A211253 001 May 16, 2019 Jul CAHN

FAMOTIDINE

TABLET;ORAL
 FAMOTIDINE
 >A> ANNORA PHARMA 10MG A215766 001 Nov 08, 2021 Oct NEWA
 >A> 20MG A215766 002 Nov 08, 2021 Oct NEWA
 >A> ASCENT PHARMS INC 10MG A216030 001 Nov 03, 2021 Oct NEWA

TABLET;ORAL									
FAMOTIDINE									
>A>		20MG	A216030	002	Nov 03, 2021	Oct	NEWA		
<u>FEXOFENADINE HYDROCHLORIDE</u>									
SUSPENSION;ORAL									
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY									
	TARO	30MG/5ML	A208123	001	Nov 09, 2017	Jun	CMFD		
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES									
	TARO	30MG/5ML	A208123	002	Nov 09, 2017	Jun	CMFD		
TABLET;ORAL									
FEXOFENADINE HYDROCHLORIDE									
	L PERRIGO CO	60MG	A212971	001	Feb 24, 2020	Jun	CMFD		
		180MG	A212971	002	Feb 24, 2020	Jun	CMFD		
<u>FLUTICASONE PROPIONATE</u>									
SPRAY, METERED;NASAL									
FLONASE ALLERGY RELIEF									
+	GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014	Apr	CHRS		
FLUTICASONE PROPIONATE									
!	HIKMA PHARMS	0.05MG/SPRAY	A207957	001	May 26, 2016	Apr	CHRS		
<u>GUAIFENESIN</u>									
TABLET, EXTENDED RELEASE;ORAL									
GUAIFENESIN									
	OHM LABS INC	600MG	A209254	001	Jul 16, 2018	Aug	CMFD		
		1.2GM	A209254	002	Jul 16, 2018	Aug	CMFD		
<u>IBUPROFEN</u>									
SUSPENSION;ORAL									
IBUPROFEN									
	GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018	Jan	CMFD		
@	STRIDES PHARMA	100MG/5ML	A211666	001	Feb 22, 2021	Aug	DISC		
		100MG/5ML	A211666	001	Feb 22, 2021	Feb	NEWA		
TABLET;ORAL									
IBUPROFEN									
@	YICHANG HUMANWELL	200MG	A214003	001	Oct 19, 2020	Apr	DISC		
<u>ISOPROPYL ALCOHOL</u>									
SOLUTION;TOPICAL									
ZURAGARD									
+	@ ZUREX PHARMA	70%	N210872	001	Apr 26, 2019	Jul	CPOT		
<u>IVERMECTIN</u>									
LOTION;TOPICAL									
IVERMECTIN									
	TARO	0.5%	A210720	001	May 06, 2020	May	CMKT		
<u>KETOCONAZOLE</u>									
SHAMPOO;TOPICAL									
NIZORAL ANTI-DANDRUFF									
+	! KRAMER	1%	N020310	001	Oct 10, 1997	Feb	CTNA		
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>									
TABLET;ORAL									
LEVOCETIRIZINE DIHYDROCHLORIDE									
	APOTEX	5MG	A211443	001	Apr 21, 2021	Apr	NEWA		
<u>LOPERAMIDE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
LOPERAMIDE HYDROCHLORIDE									
	STRIDES PHARMA	2MG	A213070	001	Aug 11, 2021	Jul	NEWA		
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE</u>									
TABLET;ORAL									
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE									
	BIONPHARMA INC	2MG;125MG	A213484	001	Sep 10, 2021	Sep	NEWA		
	GUARDIAN DRUG	2MG;125MG	A214541	001	May 27, 2021	May	NEWA		
	HETERO LABS LTD V	2MG;125MG	A211438	001	Jun 17, 2021	Jun	NEWA		

LORATADINE

SYRUP;ORAL

LORATADINE

HETERO LABS LTD III 1MG/ML

A210409 001 May 07, 2021 Apr NEWA

TABLET;ORAL

LORATADINE

APPCO 10MG

A207569 001 Mar 12, 2019 Sep CAHN

UNIQUE PHARM 10MG

A214684 001 Jan 07, 2021 Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

@ GLAXOSMITHKLINE 10MG

A075822 001 Feb 10, 2003 Jan DISC

TENSHI 5MG

A212795 001 Sep 18, 2020 Jun CMFD

@ 5MG

A212795 001 Sep 18, 2020 Mar DISC

10MG

A213294 001 Oct 30, 2020 Jun CMFD

@ 10MG

A213294 001 Oct 30, 2020 Mar DISC

MICONAZOLE NITRATE

CREAM, INSERT;TOPICAL, VAGINAL

MICONAZOLE NITRATE

PERRIGO R AND D 2%,1.2GM

A079114 001 Jun 02, 2010 Jul CDFR

MONISTAT 1 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,1.2GM

N021308 001 Jun 29, 2001 Jul CDFR

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MICONAZOLE NITRATE COMBINATION PACK

L PERRIGO CO 2%,200MG

A075329 001 Apr 20, 1999 Sep CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL

PERRIGO 5%

A091344 001 Apr 28, 2011 Jul CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICORETTE

+ GLAXOSMITHKLINE EQ 2MG BASE

N022360 001 May 18, 2009 Mar CAHN

+! EQ 4MG BASE

N022360 002 May 18, 2009 Mar CAHN

NICOTINE POLACRILEX

AUROBINDO PHARMA LTD EQ 2MG BASE

A213266 001 Aug 03, 2021 Jul NEWA

EQ 4MG BASE

A213266 002 Aug 03, 2021 Jul NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AKORN EQ 0.1% BASE

A204532 001 Jan 10, 2017 Jun CMKT

EQ 0.2% BASE

A204723 001 Dec 05, 2017 Jun CMKT

ALEMBIC PHARMS LTD EQ 0.1% BASE

A209919 001 Dec 07, 2018 Feb CMKT

EQ 0.2% BASE

A209420 001 Apr 29, 2019 Jan CMKT

APOTEX INC EQ 0.2% BASE

A090918 001 Dec 05, 2017 Jan CMKT

BARR LABS INC EQ 0.2% BASE

A090848 001 Jul 13, 2015 Feb CMKT

@ BAUSCH EQ 0.1% BASE

A206046 001 Jul 26, 2017 Jun CAHN

@ CIPLA EQ 0.2% BASE

A206087 001 Dec 05, 2017 Mar CMKT

FDC LTD EQ 0.1% BASE

A209282 001 Sep 26, 2019 Oct DISC

@ EQ 0.1% BASE

A209282 001 Sep 26, 2019 Oct DISC

EQ 0.1% BASE

A209282 001 Sep 26, 2019 Feb CMKT

MYLAN EQ 0.1% BASE

A204392 001 Mar 21, 2018 Feb CMKT

EQ 0.2% BASE

A204620 001 Jun 16, 2020 Jun CAHN

USV EQ 0.1% BASE

A203152 001 Dec 07, 2015 Apr CMKT

@ WOCKHARDT LTD EQ 0.1% BASE

A200810 001 Jun 28, 2017 Aug CMKT

>D>

>A>

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

APOTEX 20MG

A210070 001 Feb 11, 2019 May CMFD

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

ANNORA PHARMA 17GM/SCOOPFUL

A214990 001 Apr 14, 2021 Apr NEWA

POTASSIUM IODIDE

TABLET;ORAL
 THYROSAFE

! BTG INTL 65MG A076350 001 Sep 10, 2002 Sep CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD EQ 75MG BASE A207579 001 Nov 13, 2017 Jun DISC
 @ EQ 150MG BASE A207578 001 Nov 13, 2017 Jun DISC
 @ WOCKHARDT EQ 75MG BASE A076760 001 Feb 24, 2006 Jan DISC
 ZANTAC 150
 + @ SANOFI US EQ 150MG BASE N021698 001 Aug 31, 2004 Apr DISC
 + @ EQ 150MG BASE N021698 002 Mar 13, 2007 Apr DISC
 ZANTAC 75
 + @ SANOFI US EQ 75MG BASE N020520 001 Dec 19, 1995 Apr DISC

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

PERRIGO 0.055MG/SPRAY A078104 002 Nov 14, 2014 Jul CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2021

NO OCTOBER 2021 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2021 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	10996208	Apr 30, 2038	DP		>A> M-270	Sep 20, 2024
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	>A> 7855211	Dec 15, 2029	DS DP U-2132			
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
	>A> 7855211	Dec 15, 2029	DS DP U-2251			
	>A> 7855211	Dec 15, 2029	DS DP U-3241			
	>A> 7855211	Dec 15, 2029	DS DP U-3242			
	>A> 7855211	Dec 15, 2029	DS DP U-3243			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	>A> 7855211	Dec 15, 2029	DS DP U-2132			
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
	>A> 7855211	Dec 15, 2029	DS DP U-2251			
	>A> 7855211	Dec 15, 2029	DS DP U-3241			
	>A> 7855211	Dec 15, 2029	DS DP U-3242			
	>A> 7855211	Dec 15, 2029	DS DP U-3243			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	>A> 7855211	Dec 15, 2029	DS DP U-2132			
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
	>A> 7855211	Dec 15, 2029	DS DP U-2251			
	>A> 7855211	Dec 15, 2029	DS DP U-3241			
	>A> 7855211	Dec 15, 2029	DS DP U-3242			
	>A> 7855211	Dec 15, 2029	DS DP U-3243			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	11000517	Mar 13, 2029	DP U-2513			
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	11000517	Mar 13, 2029	DP U-2513			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10918816	Dec 14, 2035	DP			
	11000653	Dec 18, 2038	DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	9592195	Dec 05, 2031	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001	11060128	Jun 29, 2032	U-2956			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038	U-3163			
	11077192	Jan 12, 2038	U-3163			
	>A> 11135293	Jan 12, 2038	U-3163			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10894039	Oct 06, 2037	U-185			
	10894039	Oct 06, 2037	U-3			
	10952998	Oct 06, 2037	DP			
	10959991	Oct 06, 2037	U-158			
	10959991	Oct 06, 2037	U-39			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	>A> 11135172	Feb 12, 2034	DP U-2660			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 005	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	>A> 9481663	Jun 04, 2033	DS			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	10953018	Sep 18, 2035	U-2161			
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ARIPIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001 >A>	11097006	Oct 24, 2033	DP U-764			
<u>ARIPIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002 >A>	11097006	Oct 24, 2033	DP U-764			
<u>ARIPIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003 >A>	11097006	Oct 24, 2033	DP U-764			
<u>ARIPIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004 >A>	11097006	Oct 24, 2033	DP U-764			
<u>ARIPIPIRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001 >A>	11154552	Aug 17, 2035	DP			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	10918723	Sep 10, 2033	U-2310			
<u>ASENAPINE - SECUADO</u>						
N 212268 001 >A>	11123305	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 002 >A>	11123305	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 003 >A>	11123305	Jul 25, 2033	DP			
<u>ASENAPINE MALEATE - ASENAPINE MALEATE</u>						
A 206098 002					PC	Jun 08, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 001	>A> 10117836	Jan 30, 2035	DP		>A> NCE	Sep 28, 2026
	>A> 8754096	Jul 19, 2032	DS DP U-3142			
	>A> 9499545	Nov 10, 2031	DS DP U-3142			
	>A> 9850246	Mar 13, 2033	DS			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 002	>A> 10117836	Jan 30, 2035	DP		>A> NCE	Sep 28, 2026
	>A> 8754096	Jul 19, 2032	DS DP U-3142			
	>A> 9499545	Nov 10, 2031	DS DP U-3142			
	>A> 9850246	Mar 13, 2033	DS			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 003	>A> 10117836	Jan 30, 2035	DP		>A> NCE	Sep 28, 2026
	>A> 8754096	Jul 19, 2032	DS DP U-3142			
	>A> 9499545	Nov 10, 2031	DS DP U-3142			
	>A> 9850246	Mar 13, 2033	DS			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 212868 001					>A> CGT	Jan 26, 2022
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 212868 002					>A> CGT	Jan 26, 2022
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 212868 003					>A> CGT	Jan 26, 2022
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 213424 001					CGT	Sep 21, 2021
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	>A> 8445515	Feb 03, 2031	DS DP		>A> NCE	Oct 07, 2026
	>A> 8906938	Dec 21, 2029	DS DP			
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		I-863	Jun 16, 2024
	9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-2726		ODE-356	Jun 16, 2028
	9944651	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-3168			
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		I-863	Jun 16, 2024
	9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-2726		ODE-356	Jun 16, 2028
	9944651	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-3168			
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 003					ODE-356	Jun 16, 2028
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 004	9200002	Oct 15, 2034	DS DP U-3168		I-863	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9994575	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025
					ODE-356	Jun 16, 2028
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 005	9200002	Oct 15, 2034	DS DP U-3168		I-863	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9994575	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025
					ODE-356	Jun 16, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005	9200002	Oct 15, 2034	DS DP U-3168		I-863	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9994575	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025
					ODE-356	Jun 16, 2028
<u>AXITINIB - INLYTA</u>						
N 202324 001	10869924	Nov 05, 2036	U-3044			
<u>AXITINIB - INLYTA</u>						
N 202324 002	10869924	Nov 05, 2036	U-3044			
<u>AZACITIDINE - ONUREG</u>						
N 214120 001					ODE-320	Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120 002					ODE-320	Sep 01, 2027
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY</u>						
N 213872 001	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-3166			
	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE - CHILDREN'S ASTEPRO ALLERGY</u>						
N 213872 002	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-3166			
	9919050	Nov 22, 2025	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	10392406	Apr 27, 2036	DS		I-811	Oct 16, 2022
	10633397	Apr 27, 2036			NCE	Oct 24, 2023
	10633397	Apr 27, 2036			U-2816	
	10759814	Aug 09, 2037	DS DP		U-3000	
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					NCE	Oct 24, 2023
<u>BELINOSTAT - BELEODAQ</u>						
N 206256 001	6888027	Aug 10, 2026	DS DP U-1544			
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001					NCE	Jul 16, 2026
					ODE-362	Jul 16, 2028
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	9908845	Sep 05, 2034	DS DP U-3201		NCE	Aug 13, 2026
	9969689	Sep 05, 2034	DS DP U-3201		ODE-364	Aug 13, 2028
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10941095	Dec 23, 2023	U-2747			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001 >A>	10912751	Mar 14, 2036	U-3224			
	10941095	Dec 23, 2023	U-2746			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11103483	Jan 28, 2031	DP U-1971			
	11103483	Jan 28, 2031	DP U-1972			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11103483	Jan 28, 2031	DP U-1971			
	11103483	Jan 28, 2031	DP U-1972			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	11071878	Dec 30, 2030	DP		NC	Jul 26, 2024
	9868103	Aug 08, 2028	DP U-3194			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	10125102	Apr 07, 2035	DS U-3010		NCE	Dec 03, 2025
	>A> 11117867	Nov 01, 2039	DP U-3010		ODE-333	Dec 03, 2027
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	10125102	Apr 07, 2035	DS U-3010		NCE	Dec 03, 2025
	>A> 11117867	Nov 01, 2039	DP U-3010		ODE-333	Dec 03, 2027
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	>A> 7390791	Apr 17, 2025	DS DP		M-82	Feb 24, 2024
	>A> 7390791*PED	Oct 17, 2025				
	>A> 8754065	Aug 15, 2032	DS DP U-257			
	>A> 8754065*PED	Feb 15, 2033				
	>A> 9296769	Aug 15, 2032	DS DP U-257			
	>A> 9296769*PED	Feb 15, 2033				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	>A> 10385067	Jun 19, 2035			U-257	
	>A> 7390791	Apr 17, 2025	DS DP			
	>A> 7803788	Feb 02, 2022			U-257	
	>A> 8754065	Aug 15, 2032	DS DP U-257			
	>A> 9216996	Dec 19, 2033	DS DP			
	>A> 9296769	Aug 15, 2032	DS DP U-257			
	>A> 9708342	Jun 19, 2035	DS DP			
	>A> 9732092	Dec 19, 2033	DS DP			
<u>BOSENTAN - TRACLEER</u>						
N 021290 001					ODE*	Sep 05, 2024
<u>BOSENTAN - TRACLEER</u>						
N 021290 002					ODE*	Sep 05, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001	11103497	Feb 28, 2034	U-3216			
	11103497	Feb 28, 2034	U-3217			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	11103497	Feb 28, 2034	U-3216			
	11103497	Feb 28, 2034	U-3217			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	11103497	Feb 28, 2034	U-3216			
	11103497	Feb 28, 2034	U-3217			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	6794489	Jun 28, 2025	DS DP			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10940156	Mar 08, 2037	U-2552			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	RE48059	Dec 23, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	RE48059	Dec 23, 2028	DS			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	9259425	Jul 14, 2030		U-2222		
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214460 001	9303051	Aug 31, 2031	DS DP U-3165		NP ODE-354	Jun 04, 2024 Jun 04, 2028
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214461 001	10112909	Oct 10, 2034		U-3165	NP	Jun 04, 2024
	10487061	Oct 10, 2034		DP U-3165	ODE-354	Jun 04, 2028
	8962829	Oct 10, 2034	DS DP			
	9303051	Aug 31, 2031	DS DP U-3165			
	9371344	Oct 10, 2034	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001					NPP >A> NPP	May 10, 2021 Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002					NPP >A> NPP	May 10, 2021 Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003					NPP >A> NPP	May 10, 2021 Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004					NPP >A> NPP	May 10, 2021 Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005					NPP >A> NPP	May 10, 2021 Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001					>A> NPP	Aug 27, 2024
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001					NPP >A> NPP	May 10, 2021 Aug 27, 2024
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	11000522	Apr 30, 2032		U-3119		
	11000522	Apr 30, 2032		U-3120		
	11000522	Apr 30, 2032		U-3121		
	11000522	Apr 30, 2032		U-3122		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	8153149	Sep 15, 2025	DP		NP	Feb 01, 2024
	8153661	Sep 15, 2025	U-3074			
	8753665	Sep 15, 2025	DP U-3074			
	8846072	Sep 15, 2025	DP U-3074			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	11000520	Nov 06, 2035	U-3111			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	11000520	Nov 06, 2035	U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001 >A>	11135216	Aug 07, 2029	DP U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002 >A>	11135216	Aug 07, 2029	DP U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003 >A>	11135216	Aug 07, 2029	DP U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004 >A>	11135216	Aug 07, 2029	DP U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	10874661	Sep 18, 2032	DP			
	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001 >A>	10403170	Jun 05, 2033	U-1583			
	11033543	Jan 10, 2031	U-1583			
	>A> 11139056	Jun 05, 2033	U-1583			
	>A> 9633575	Jun 25, 2033	U-1583			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	8927592	Oct 27, 2030	U-3200		M-128	Dec 18, 2023
	8927592*PED	Apr 27, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	8410103	Apr 28, 2026	DS DP U-3061			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	11091440	Jan 15, 2030	DP		>A> I-873	Sep 17, 2024
	>A> 11098015	Jan 15, 2030	U-1220			
	>A> 11098015	Jan 15, 2030	U-1480			
	>A> 11098015	Jan 15, 2030	U-2488			
	>A> 11098015	Jan 15, 2030	U-3225			
	>A> 11141413	Apr 17, 2037	U-3239			
	>A> 8877776	Oct 08, 2030	DS DP U-3225			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	11091440	Jan 15, 2030	DP		>A> I-873	Sep 17, 2024
	>A> 11098015	Jan 15, 2030	U-1220			
	>A> 11098015	Jan 15, 2030	U-1480			
	>A> 11098015	Jan 15, 2030	U-2488			
	>A> 11098015	Jan 15, 2030	U-3225			
	>A> 11141413	Apr 17, 2037	U-3239			
	>A> 8877776	Oct 08, 2030	DS DP U-3225			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	11091440	Jan 15, 2030	DP		>A> I-873	Sep 17, 2024
	>A> 11098015	Jan 15, 2030	U-1220			
	>A> 11098015	Jan 15, 2030	U-1480			
	>A> 11098015	Jan 15, 2030	U-2488			
	>A> 11098015	Jan 15, 2030	U-3225			
	>A> 11141413	Apr 17, 2037	U-3239			
	>A> 8877776	Oct 08, 2030	DS DP U-3225			
<u>CALCITONIN SALMON - CALCITONIN-SALMON</u>						
A 212416 001					CGT	Nov 10, 2021
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 003	>A> 10130646	Jul 25, 2037	DP			
	>A> 10342813	Jul 25, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10864181	Mar 15, 2033	U-3017		I-870	Aug 12, 2024
	8772306	Mar 15, 2033	U-1532		ODE-361	Jul 21, 2027
	8772306	Mar 15, 2033	U-3198			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	8680052	Mar 09, 2033	U-2979			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608	Oct 14, 2035	U-3071		ODE-326	Jul 31, 2027
	10918608	Oct 14, 2035	U-3072		ODE-332	Jul 31, 2027
	10918608	Oct 14, 2035	U-3073			
	10966939	Jun 17, 2035	DP U-2780			
	10966939	Jun 17, 2035	DP U-2781			
	11065209	Oct 14, 2035	U-3071			
	11096905	Oct 14, 2035	DS DP U-2780			
	11096905	Oct 14, 2035	DS DP U-2781			
	>A> 11154516	Jun 17, 2034	U-3235			
	>A> 11154516	Jun 17, 2034	U-3236			
	>A> 11160795	Mar 01, 2041	U-3233			
<u>CAPSAICIN - QUTENZA</u>						
N 022395 001	>A> 10869827	Sep 05, 2023	DP			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001					ODE-345	Jan 22, 2028
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	10287586	Nov 12, 2030	DS DP		NCE	Feb 25, 2026
	10533174	May 04, 2021	DP		ODE-347	Feb 25, 2028
	10781450	Nov 12, 2030	U-3089			
	8524880	Apr 02, 2026	DS DP U-3087			
	8524880	Apr 02, 2026	DS DP U-3088			
	9228187	Nov 12, 2030	DS DP			
	9416361	May 04, 2021	DS			
	9447415	Jun 28, 2025	DS DP			
	9758783	Nov 12, 2030	U-3088			
	9758783	Nov 12, 2030	U-3089			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001					ODE*	Apr 29, 2021
					ODE*	May 26, 2024
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 001					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 002					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 003					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 004					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 005					CGT	Sep 20, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 214542	001				CGT	Jan 29, 2022
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 214542	002				CGT	Jan 29, 2022
<u>CHLORZOAZONE - CHLORZOAZONE</u>						
A 215158	001				>A> CGT	Mar 29, 2022
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819	001				NCE GAIN	Jul 16, 2024 Jul 16, 2029
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986	001	11040004	Nov 12, 2037	U-2252		
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352	001	6706276	Mar 06, 2022	DP		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589	001				NPP	Aug 15, 2021
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	001	11103490	Oct 10, 2031	DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	002	11103490	Oct 10, 2031	DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	003	11103490	Oct 10, 2031	DP		
<u>COBICISTAT - TYBOST</u>						
N 203094	001	>A> 10039718	Oct 06, 2032	DP		
		>A> 10039718*PED	Apr 06, 2033			
		>A> 8148374	Sep 03, 2029	DS DP U-1279		
		>A> 8148374*PED	Mar 03, 2030			
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455	001	10786518	Jul 19, 2038	U-2978		
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561	001	10039718	Oct 06, 2032	DP		
		10039718*PED	Apr 06, 2033			
		7176220	Aug 27, 2026	DS DP U-257		
		7176220*PED	Feb 27, 2027			
		7390791	Apr 17, 2025	DS DP		
		7390791*PED	Oct 17, 2025			
		7635704	Oct 26, 2026	DS DP U-257		
		7635704*PED	Apr 26, 2027			
		8148374	Sep 03, 2029	DS DP U-1279		
		8148374*PED	Mar 03, 2030			
		8633219	Apr 24, 2030	DP U-257		
		8633219*PED	Oct 24, 2030			
		8754065	Aug 15, 2032	DS DP U-257		
		8754065*PED	Feb 15, 2033			
		8981103	Oct 26, 2026	DS DP		
		8981103*PED	Apr 26, 2027			
		9296769	Aug 15, 2032	DS DP U-257		
		9296769*PED	Feb 15, 2033			
		9891239	Sep 03, 2029	DP U-257		
		9891239*PED	Mar 03, 2030			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	>A> 10039718	Oct 06, 2032	DP			
	>A> 10039718*PED	Apr 06, 2033				
	>A> 7176220	Aug 27, 2026	DS DP U-257			
	>A> 7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	>A> 8633219	Apr 24, 2030	DP U-257			
	>A> 8633219*PED	Oct 24, 2030				
	>A> 8981103	Oct 26, 2026	DS DP			
	>A> 8981103*PED	Apr 26, 2027				
	>A> 9891239	Sep 03, 2029	DP U-257			
	>A> 9891239*PED	Mar 03, 2030				
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	11087354	Jun 22, 2034	U-1776			
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001					NCE NP	Dec 14, 2022 Jan 10, 2023
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-2226			
	10987347	Feb 07, 2037	U-2225			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002					NCE	Apr 30, 2024
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRY5</u>						
N 209376 003					NCE	Apr 30, 2024
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210735 001	9662342	Jun 26, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210735 002	9662342	Jun 26, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 001	10993952	Feb 15, 2036	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 002	10993952	Feb 15, 2036	DP			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	10918694	Feb 28, 2037	DP			
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	7973081	Jan 27, 2026	DP		NP	Jun 23, 2023
	8298568	Nov 03, 2027	DP		ODE-358	Jun 23, 2028
	8524779	Jan 27, 2026	DP			
	9132071	Jun 02, 2029	DP			
	9220694	Jan 27, 2026	DP			
	9956289	Jan 27, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10905662	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	8026284	Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
	8026284*PED	Mar 22, 2028			PED	Feb 14, 2023
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10905662	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	8026284	Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
	8026284*PED	Mar 22, 2028			PED	Feb 14, 2023
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11045438	Mar 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Sep 29, 2034	DP U-3149		NPP	Mar 30, 2024
	10028912	Sep 29, 2034	DP U-3150		ODE-350	Mar 30, 2028
	10166184	Oct 15, 2032	DP U-3149			
	10835492	Oct 15, 2032	U-3150			
	7850990	Jan 23, 2027	DP U-3147			
	8022279	Sep 14, 2027	DP U-3147			
	8092828	Apr 01, 2029	U-3147			
	8431806	Apr 22, 2025	DP U-3147			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	7866474	Aug 31, 2027	DP	Y		
	7866474*PED	Mar 02, 2028				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 001	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 002	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 003	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 004	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 005	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 006	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869	Aug 30, 2033		U-3185		
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	9233956	May 04, 2029		U-1811		
	9233956	May 04, 2029		U-2031		
	9233956	May 04, 2029		U-2032		
	9233956	May 04, 2029		U-2296		
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	10869869	Aug 30, 2033		U-3185		
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	9233956	May 04, 2029		U-1811		
	9233956	May 04, 2029		U-2031		
	9233956	May 04, 2029		U-2032		
	9233956	May 04, 2029		U-2296		
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					NFP	Jul 22, 2024
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					I-857	Apr 30, 2024
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040		U-3127	I-857	Apr 30, 2024
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 210282 001	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 210282 002	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	11046713	Oct 27, 2030	DS			
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</u>						
N 214231 001	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</u>						
N 214231 002	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<u>DEFERIPRONE - DEFERIPRONE</u>						
A 208800 001					PC	Mar 27, 2021
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001	7049328	Jun 28, 2021		U-3083	I-859	Apr 30, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	10780055	Oct 25, 2038	DP U-3083		I-859	Apr 30, 2024
	10940115	Oct 25, 2038	DP U-3083			
	10940116	Oct 25, 2038	DP			
	7049328	Jun 28, 2021	U-3083			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	11085043	Jun 22, 2032	DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	10973870	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	10973870	Feb 10, 2029	U-1978			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	11020448	May 21, 2029	U-2327			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEXAMETHASONE - DEXAMETHASONE</u>						
A 215106 001					>A> CGT	Apr 20, 2022
<u>DEXAMETHASONE - DEXAMETHASONE</u>						
A 215106 002					>A> CGT	Apr 19, 2022
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10799642	May 11, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 001	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 002	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 003	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001					NPP	May 25, 2024
<u>DIFELIKEFALIN ACETATE - KORSUVA</u>						
N 214916 001	10017536	Nov 12, 2027	DS U-3204		NCE	Aug 23, 2026
	10138270	Nov 12, 2027	U-3204			
	10793596	Nov 12, 2027	DS DP U-3204			
	7402564	Nov 12, 2027	DS DP U-3204			
	7713937	Nov 12, 2027	DS DP U-3204			
	7727963	Nov 12, 2027	DS DP U-3204			
	8217007	Nov 12, 2027	U-3204			
	8236766	Nov 12, 2027	U-3204			
	8486894	Nov 12, 2027	U-3204			
	8536131	Nov 12, 2027	DS DP U-3204			
	9334305	Nov 12, 2027	U-3204			
	9359399	Nov 12, 2027	U-3204			
<u>DIHYDROERGOTAMINE MESYLATE - TRUDHESA</u>						
N 213436 001	10507295	Dec 25, 2032	DP		>A> NP	Sep 02, 2024
	10940278	Jan 23, 2033	DP			
	9550036	Sep 05, 2032	DP			
	9919117	Mar 17, 2033	DP U-3218			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317	001				CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317	002				CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317	003				CGT	Sep 26, 2021
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	001	10391160	Mar 13, 2035	U-3148		
		10555993	Mar 13, 2035	U-3148		
		10959972	Nov 16, 2035	U-1384		
		10994003	Mar 13, 2035	U-3148		
		11007166	Nov 16, 2035	U-1384		
		11007167	Nov 16, 2035	U-1384		
	>A>	11129806	Nov 16, 2035	U-1384		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	002	10391160	Mar 13, 2035	U-3148		
		10555993	Mar 13, 2035	U-3148		
		10959972	Nov 16, 2035	U-1384		
		10994003	Mar 13, 2035	U-3148		
		11007166	Nov 16, 2035	U-1384		
		11007167	Nov 16, 2035	U-1384		
	>A>	11129806	Nov 16, 2035	U-1384		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	001	10842770	Aug 07, 2031	DP U-2998		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	002	10842770	Aug 07, 2031	DP U-2998		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	003	10842770	Aug 07, 2031	DP U-2998		
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036	001	11096920	Apr 11, 2028	U-620		
		11110074	Jul 20, 2027	U-620		
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036	002	11096920	Apr 11, 2028	U-620		
		11110074	Jul 20, 2027	U-620		
<u>DROSPIRENONE - SLYND</u>						
N 211367	001	10603281	Jun 28, 2031	U-2553		
		10849857	Jun 28, 2031	DP U-2553		
		10987364	Jun 28, 2031	DP		
		11123299	Jun 28, 2031	DP		
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154	001	7732430	Mar 02, 2025	DP U-3152	NCE	Apr 15, 2026
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	001	10959982	Apr 13, 2037	DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	002	10959982	Apr 13, 2037	DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	003	10959982	Apr 13, 2037	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	10959982	Apr 13, 2037	DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 002					ODE*	May 05, 2024
<u>EDOXYBAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Apr 18, 2027	DS			
<u>EDOXYBAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Apr 18, 2027	DS			
<u>EDOXYBAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Apr 18, 2027	DS			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10864274	Oct 02, 2034	U-2720			
	7214506	Feb 22, 2026	U-281			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	10881659	Mar 14, 2034	U-2842			
	11045470	Mar 14, 2034	U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10022352	Apr 09, 2027	DP U-2651		NPP	Jun 08, 2024
	10022352	Apr 09, 2027	DP U-3156		ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031	DP U-2652		ODE-357	Jun 08, 2028
	10081621	Mar 25, 2031	DP U-3032			
	10081621	Mar 25, 2031	DP U-3157			
	10239867	Apr 09, 2027	DS DP U-2653			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-2646			
	8354427	Jul 06, 2026	U-3029			
	8354427	Jul 06, 2026	U-3145			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	9012496	Jul 15, 2033	U-2649			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-2650			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10022352	Apr 09, 2027	DP U-3156		NCE	Feb 12, 2023
	10081621	Mar 25, 2031	DP U-3157		NCE	Oct 21, 2024
	10239867	Apr 09, 2027	DS DP U-3158		NPP	Jun 08, 2024
	10646481	Aug 13, 2029	DP		ODE-357	Jun 08, 2028
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-3144			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027			U-3144	
	8354427	Jul 06, 2026			U-3145	
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027			U-3144	
	8598181	May 01, 2027			U-3144	
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025			U-3146	
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033			U-3154	
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-3144			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001					ODE*	Nov 16, 2025
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002					ODE*	Aug 26, 2021
					ODE*	Nov 16, 2025
					PED	Feb 26, 2022
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	>A> 7176220	Aug 27, 2026	DS DP U-257			
	>A> 7176220*PED	Feb 27, 2027				
	>A> 7635704	Oct 26, 2026	DS DP U-257			
	>A> 7635704*PED	Apr 26, 2027				
	>A> 8981103	Oct 26, 2026	DS DP			
	>A> 8981103*PED	Apr 26, 2027				
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	>A> 7176220	Aug 27, 2026	DS DP U-257			
	>A> 7176220*PED	Feb 27, 2027				
	>A> 7635704	Oct 26, 2026	DS DP U-257			
	>A> 7635704*PED	Apr 26, 2027				
	>A> 8981103	Oct 26, 2026	DS DP			
	>A> 8981103*PED	Apr 26, 2027				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	11090323	Apr 03, 2034	U-3191		I-869	Aug 18, 2024
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	11090323	Apr 03, 2034	U-3191			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	11033552	May 04, 2027	DP			
	11090323	Apr 03, 2034	U-3191			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	11033552	May 04, 2027	DP			
	11090323	Apr 03, 2034	U-3191			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	11090323	Apr 03, 2034	U-3193			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	>A> 7390791	Apr 17, 2025	DS DP			
	>A> 7390791*PED	Oct 17, 2025				
	>A> 8754065	Aug 15, 2032	DS DP U-257			
	>A> 8754065*PED	Feb 15, 2033				
	>A> 9296769	Aug 15, 2032	DS DP U-257			
	>A> 9296769*PED	Feb 15, 2033				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	>A> 7390791	Apr 17, 2025	DS DP			
	>A> 7390791*PED	Oct 17, 2025				
	>A> 8754065	Aug 15, 2032	DS DP U-1259			
	>A> 8754065	Aug 15, 2032	DS DP U-1663			
	>A> 8754065	Aug 15, 2032	DS DP U-257			
	>A> 8754065*PED	Feb 15, 2033				
	>A> 9296769	Aug 15, 2032	DS DP U-1259			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	>A> 9296769	Aug 15, 2032	DS DP U-1663			
	>A> 9296769	Aug 15, 2032	DS DP U-257			
	>A> 9296769*PED	Feb 15, 2033				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 001					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 002					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 003					PC	Mar 09, 2021
<u>ENALAPRIL MALEATE - ENALAPRIL MALEATE</u>						
A 212408 001					PC	Feb 13, 2022
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	11040023	Mar 25, 2036	DP			
	>A> 11141405	Mar 25, 2036	DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11090278	May 16, 2040	U-3183			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	10960155	Jun 25, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERYTHROMYCIN - ERYTHROMYCIN</u>						
A 211975 001					>A> CGT	Apr 02, 2022
<u>ERYTHROMYCIN - ERYTHROMYCIN</u>						
A 211975 002					>A> CGT	Apr 02, 2022
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034			
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10912781	Oct 23, 2028	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	11116717	Jun 18, 2033	DP			
	11123283	Jun 18, 2033	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	11116717	Jun 18, 2033	DP			
	11123283	Jun 18, 2033	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11033551	Sep 29, 2037	U-3129		NCE	Dec 18, 2025
	7300935	Jan 28, 2024	DS		NP	May 26, 2024
	8058280	Jan 28, 2024	DS DP			
	9346822	Feb 17, 2024	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11033626	Nov 21, 2032	DP U-2439			
	11103513	Nov 21, 2032	U-2439			
	11103516	Nov 21, 2032	DP			
	11110099	Nov 21, 2032	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME</u>						
N 209405 001					NDF	Mar 30, 2023
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN</u>						
A 213950 001					CGT	Aug 25, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE</u>						
A 212706 001					CGT	Jul 17, 2021
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10918649	Jun 21, 2039	DP			
	10925882	Jun 21, 2039	DP			
	10940157	Jun 21, 2039	DP			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	7456254	Jun 30, 2025	DP U-2588		PED	Aug 15, 2023
	7456254	Jun 30, 2025	DP U-2589		PED	Jan 22, 2025
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	6824822*PED	Apr 09, 2023			PED	Jan 22, 2025
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8216180	Jan 12, 2028	DP			
	8216180*PED	Jul 12, 2028				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8439864	Mar 25, 2028	DP			
	8439864*PED	Sep 25, 2028				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	8501698*PED	Dec 20, 2027				
	8690837	May 19, 2029	DP			
	8690837*PED	Nov 19, 2029				
	8721615	Jan 18, 2030	DP			
	8721615*PED	Jul 18, 2030				
	8758292	Nov 12, 2027	DP			
	8758292*PED	May 12, 2028				
	8827963	Feb 04, 2029	DP			
	8827963*PED	Aug 04, 2029				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	8998876	Jan 07, 2030	DP			
	8998876*PED	Jul 07, 2030				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9320853	Mar 25, 2028	DP			
	9320853*PED	Sep 25, 2028				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	6824822*PED	Apr 09, 2023			PED	Jan 22, 2025
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2597			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	U-2588			
	8501698*PED	Dec 20, 2027				
	8895033	Oct 04, 2030	DP U-2589			
	8895033	Oct 04, 2030	DP U-2590			
	8895033	Oct 04, 2030	DP U-2597			
	8895033	Oct 04, 2030	DP U-2601			
	8895033	Oct 04, 2030	DP U-2602			
	8895033	Oct 04, 2030	DP U-3188			
	8895033	Oct 04, 2030	DP U-3189			
	8895033	Oct 04, 2030	DP U-3190			
	8895033*PED	Apr 04, 2031				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-2597			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2597			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-2597			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 001	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 002	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 003	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 004	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10452815	Jun 29, 2038			U-2859	
	10947183	Dec 20, 2036	DS DP			
	10950331	Sep 28, 2035			U-3098	
	11040018	Aug 02, 2037			U-2861	
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	>A> 11123321	Oct 20, 2023	DS DP U-2555			
	>A> 11123321	Oct 20, 2023	DS DP U-2557			
	7754702	Feb 15, 2028			U-1432	
	7754702	Feb 15, 2028			U-2555	
	7754702	Feb 15, 2028			U-2556	
	7754702	Feb 15, 2028			U-2557	
	8895612	Jan 08, 2027			U-1620	
	8895612	Jan 08, 2027			U-3050	
	8895612	Jan 08, 2027			U-3051	
	8895612	Jan 08, 2027			U-3115	
	8895612	Jan 08, 2027			U-3116	
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	>A> 11123321	Oct 20, 2023	DS DP U-2555			
	>A> 11123321	Oct 20, 2023	DS DP U-2557			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028			U-2555	
	7754702	Feb 15, 2028			U-2556	
	7754702	Feb 15, 2028			U-2557	
	8895612	Jan 08, 2027			U-1620	
	8895612	Jan 08, 2027			U-3050	
	8895612	Jan 08, 2027			U-3051	
	8895612	Jan 08, 2027			U-3115	
	8895612	Jan 08, 2027			U-3116	
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	>A> 11123321	Oct 20, 2023	DS DP U-2555		NS	Apr 28, 2024
	>A> 11123321	Oct 20, 2023	DS DP U-2557			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028			U-2555	
	7754702	Feb 15, 2028			U-2556	
	7754702	Feb 15, 2028			U-2557	
	8895612	Jan 08, 2027			U-1620	
	8895612	Jan 08, 2027			U-3050	
	8895612	Jan 08, 2027			U-3051	
	8895612	Jan 08, 2027			U-3115	
	8895612	Jan 08, 2027			U-3116	
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034	DP			
	10624855*PED	May 26, 2035				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				
	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8501723	Jun 07, 2027	DP		I-861	Jun 17, 2024
	8501723*PED	Dec 07, 2027			PED	Dec 17, 2024
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8501723	Jun 07, 2027	DP		I-861	Jun 17, 2024
	8501723*PED	Dec 07, 2027			PED	Dec 17, 2024
<u>FEXINIDAZOLE - FEXINIDAZOLE</u>						
N 214429 001					NCE ODE-359	Jul 16, 2026 Jul 16, 2028
<u>FINERENONE - KERENDIA</u>						
N 215341 001	8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
<u>FINERENONE - KERENDIA</u>						
N 215341 002	8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10933147	Dec 30, 2035	U-2450			
	10953112	Nov 28, 2026	U-1879			
	10967077	Dec 30, 2035	U-2450			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	11090294	Nov 29, 2030	U-3202			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	>A> 11116721	Feb 26, 2029	DP U-1401			
	>A> 11116721	Feb 26, 2029	DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	>A> 11116721	Feb 26, 2029	DP U-1691			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	10022510	May 18, 2031	DP		NPP	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	10022510	May 18, 2031	DP		NS	Jul 09, 2024
	10124131	May 18, 2031	DP		PED	Jan 09, 2025
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10765820	May 19, 2025	DP			
	7540282	May 06, 2023	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11033696	May 20, 2033	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10022510	May 18, 2031	DP		M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP		>A> M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			>A> PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FOSCARNET SODIUM - FOSCARNET SODIUM</u>						
A 213001 001					CGT	Dec 28, 2021
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001	7504095	Jan 31, 2025	DP U-3092		NCE ODE-342	Feb 26, 2026 Feb 26, 2028
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212642 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212643 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		D-175	Sep 26, 2022
	10028937	Jun 10, 2030	U-2532		M-259	Apr 10, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937*PED	Dec 10, 2030			NCE	Aug 03, 2022
	10039754	Jun 10, 2030	U-2141		NPP	Apr 30, 2022
	10039754	Jun 10, 2030	U-2532		ODE-232	Apr 30, 2026
	10039754*PED	Dec 10, 2030			ODE-233	Apr 30, 2026
	10286029	Mar 14, 2034	U-2532		PED	Oct 30, 2022
	10286029*PED	Sep 14, 2034			PED	Feb 03, 2023
	8648037	Jan 19, 2032	DS DP U-2141		PED	Mar 26, 2023
	8648037	Jan 19, 2032	DS DP U-2532		PED	Oct 10, 2023
	8648037*PED	Jul 19, 2032			PED	Oct 30, 2026
	8937150	May 18, 2032	DS DP		PED	Oct 30, 2026
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS			
	9321807*PED	Dec 05, 2035				
	>A> 9586978	Nov 06, 2030	U-2141			
	>A> 9586978	Nov 06, 2030	U-2532			
	>A> 9586978	Nov 06, 2030	U-3237			
	>A> 9586978*PED	May 06, 2031				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	10028937	Jun 10, 2030	U-3167			
	10028937*PED	Dec 10, 2030				
	10039754	Jun 10, 2030	U-3167			
	10039754*PED	Dec 10, 2030				
	10286029	Mar 14, 2034	U-3167			
	10286029*PED	Sep 14, 2034				
	8648037	Jan 19, 2032	DS DP U-3167			
	8648037*PED	Jul 19, 2032				
	8937150	May 18, 2032	DS DP			
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS DP			
	9321807*PED	Dec 05, 2035				
	>A> 9586978	Nov 06, 2030	U-3167			
	>A> 9586978	Nov 06, 2030	U-3238			
	>A> 9586978*PED	May 06, 2031				
<u>GLUCAGON - BAQSIMI</u>						
N 210134 001	10894133	Jan 03, 2038	DP			
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001					NPP	Dec 21, 2021
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10940110	Feb 26, 2029	DP U-1773			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10968450	Jun 28, 2025	DS DP			
	10995337	Jun 28, 2025	DP U-2675			
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001	10857159	Nov 30, 2036	DP			
	10857159*PED	May 30, 2037				
	11020407	Nov 30, 2036	DP U-3143			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 001	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 002	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 003	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 004	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>IBREXAFUNGERP CITRATE - BREXAFEMME</u>						
N 214900 001	10174074	Jan 19, 2035	DS DP		NCE	Jun 01, 2026
	10370406	Jan 19, 2035	U-3159		GAIN	Jun 01, 2031
	10927142	Jan 19, 2035	DS			
	8188085	Aug 28, 2030	DS DP U-3159			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10961251	Jun 03, 2033	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	>A> 11116742	Jun 28, 2033	U-3221			
	>A> 11154526	Apr 29, 2030	U-3240			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	>A> 11116742	Jun 28, 2033	U-3221			
	>A> 11154526	Apr 29, 2030	U-3240			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10918635	Apr 30, 2030	U-1455			
	10918635	Apr 30, 2030	U-172			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIO</u>						
N 214622 001	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	8552002	Aug 25, 2029	DS DP		ODE-353	May 28, 2028
	9067896	Aug 06, 2028	DS			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIO</u>						
N 214622 002	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	8552002	Aug 25, 2029	DS DP		ODE-353	May 28, 2028
	9067896	Aug 06, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	10980795	Jun 12, 2033	U-1848			
	10993914	Oct 15, 2036	DP			
	8329213	Jan 06, 2027	DS DP			
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001	10688291	Dec 20, 2034	DP U-1397		M-268	Jun 24, 2024
	8226971	May 06, 2025	DP			
	8389583	Aug 09, 2029	U-1397			
	8703828	May 23, 2028	DP			
	9011897	Feb 08, 2025	DP			
	9629368	May 23, 2028	U-1397			
	9844654	Apr 24, 2036	DP U-1397			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003					ODE-338	Dec 21, 2027
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	11052075	Dec 04, 2028	DP U-3181			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	11052075	Dec 04, 2028	DP U-3181			
<u>IVERMECTIN - IVERMECTIN</u>						
A 210720 001					PC	May 29, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	11033565	Apr 22, 2024	DP			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10717764	Jan 18, 2033	U-3215		>A> I-875	Aug 25, 2024
	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
	10980788	Jun 07, 2039	U-3214			
	9474779	Aug 19, 2033	DS DP U-2350			
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9474779	Aug 19, 2033	DS DP U-3213			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-3213			
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001	11077055	Apr 21, 2036	DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10799505	Aug 15, 2036	DS			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	11053214	Dec 05, 2037	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	11053214	Dec 05, 2037	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Apr 06, 2025	DS DP U-1719			
	8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002					ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 24, 2025	DS DP		I-868 M-269	Aug 10, 2024 Jul 21, 2024
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 24, 2025	DS DP		I-868 M-269	Aug 10, 2024 Jul 21, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 24, 2025	DS DP		I-868 M-269	Aug 10, 2024 Jul 21, 2024
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001	10646572	Jan 16, 2027	DP		NP	May 25, 2024
	9572857	Jan 16, 2027	DP			
	9744207	Jan 16, 2027	DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	10987244	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	10987244	Apr 01, 2031	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	11090186	Oct 24, 2033		U-2348		
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	10987244	Apr 01, 2031	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 013	11096913	Feb 28, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 014	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 015	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001 >A>	11135190	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002 >A>	11135190	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003 >A>	11135190	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 214253 001 >A>	11154498	Jul 20, 2036	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	11058677	Dec 18, 2033	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11033552	May 04, 2027	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	10973827	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	10973827	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	10973827	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	11097063	Jul 17, 2026	DP		NPP	Dec 04, 2023
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-1034			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-842			
	7718619*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	10940177	Nov 06, 2035	DP			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LOPERAMIDE HYDROCHLORIDE - LOPERAMIDE HYDROCHLORIDE</u>						
A 213070 001					>A> CGT	Apr 20, 2022
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 001	8999393	Jan 08, 2034	DP U-3210			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 002	8999393	Jan 08, 2034	DP U-3210			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 003	8999393	Jan 08, 2034	DP U-3210			
<u>LORLATINIB - LORBRENA</u>						
N 210868 001	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	11020376	Jul 27, 2036	DP			
<u>LORLATINIB - LORBRENA</u>						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	11020376	Jul 27, 2036	DP			
<u>LOTEPREDNOL ETABONATE - LOTE PREDNOL ETABONATE</u>						
A 212450 001					CGT	Nov 02, 2021
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	10940108	May 03, 2033	U-2985			
	10945948	May 03, 2033	U-2985			
	10993908	May 03, 2033	U-3117			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001	11060093	Dec 26, 2034	DS DP U-2995		ODE-339	Nov 23, 2027
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10960009	Dec 03, 2034	U-814			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	10946015	Sep 11, 2026	DP U-1445			
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB (COPACKAGED)</u>						
N 213135 001	11033498	Aug 04, 2037	U-3164			
<u>MANNITOL - BRONCHITOL</u>						
N 202049 001					NP ODE-327	Oct 30, 2023 Oct 30, 2027
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001					>A> NCE	Sep 29, 2026
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10881663	Mar 08, 2039	U-3038			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	10285946	Apr 25, 2032	DP		NCE	Feb 26, 2026
	10322182	Apr 25, 2032	DP		ODE-348	Feb 26, 2028
	10543274	Apr 25, 2032	U-3093			
	10869928	Apr 25, 2032	DP			
	6992207	Jun 25, 2022	DS DP U-3093			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	10940128	Jun 14, 2030	DP U-3086			
	11020363	May 28, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	11007206	Aug 08, 2031	U-3128		NCE	Aug 29, 2022
	8680136	Aug 29, 2031	DS DP		GAIN	Aug 29, 2027
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					ODE*	Apr 08, 2023
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001					M-82	Jun 28, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	002				M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	003				M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	004				M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	005				M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	006				M-82	Jun 28, 2024
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388	001	11020361	Dec 22, 2029	U-2843		
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844	001	10966990	Jun 20, 2038	DP		
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844	002	10966990	Jun 20, 2038	DP		
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623	001	10874655	May 30, 2038	U-2371		
		10874656	May 30, 2038	U-2371		
		10874657	May 30, 2038	U-2371		
		10925866	Apr 28, 2028	U-2371		
		11033538	Apr 28, 2028	U-2371		
		RE48608	Feb 12, 2029	U-2371		
<u>MINOCYCLINE HYDROCHLORIDE - MINOLIRA</u>						
N 209269	001	11103517	Apr 07, 2036	DP		
<u>MINOCYCLINE HYDROCHLORIDE - MINOLIRA</u>						
N 209269	002	11103517	Apr 07, 2036	DP		
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690	001	10946101	Oct 01, 2030	U-1631		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	001	10842780	Sep 28, 2029	DP U-2996	I-777	Apr 27, 2021
		10842780*PED	Mar 28, 2030		I-855	Mar 25, 2024
		6346532	Mar 27, 2022	DS DP	PED	Sep 25, 2024
		6346532*PED	Sep 27, 2022			
		8772315	Oct 30, 2028		U-2300	
		8772315*PED	Apr 30, 2029			
		8835474	Nov 04, 2023		U-1527	
		8835474*PED	May 04, 2024			
		RE44872	Nov 04, 2023		U-1527	
		RE44872*PED	May 04, 2024			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	002	10842780	Sep 28, 2029	DP U-2996	I-777	Apr 27, 2021
		10842780*PED	Mar 28, 2030		I-855	Mar 25, 2024
		6346532	Mar 27, 2022	DS DP	PED	Sep 25, 2024
		6346532*PED	Sep 27, 2022			
		8772315	Oct 30, 2028		U-2300	
		8772315*PED	Apr 30, 2029			
		8835474	Nov 04, 2023		U-1527	
		8835474*PED	May 04, 2024			
		RE44872	Nov 04, 2023		U-1527	
		RE44872*PED	May 04, 2024			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028		U-2300		
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023		U-1527		
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023		U-1527		
	RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIO GRANULES</u>						
N 213801 001	10058536	Mar 31, 2036	DP U-3108		NP	Mar 25, 2024
	10058536*PED	Oct 01, 2036			PED	Sep 25, 2024
	6346532	Mar 27, 2022	DS			
	6346532*PED	Sep 27, 2022				
	7342117	Nov 04, 2023	DS			
	7342117*PED	May 04, 2024				
	7982049	Nov 04, 2023	DP			
	7982049*PED	May 04, 2024				
<u>MOBOCERTINIB SUCCINATE - EXKIVITY</u>						
N 215310 001	10227342	May 13, 2035	DS DP U-3220		NCE	Sep 15, 2026
	9796712	May 13, 2035	DS DP			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035	U-1384			
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 001					CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 002					CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022195 001					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022195 002					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022207 001					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022207 002					NPP	Jun 02, 2024
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	10952968	May 13, 2033	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	10722510	Aug 26, 2034	DP U-3110			
	10973814	Aug 26, 2034	DP U-3110			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
	11090280	Mar 03, 2026	DP U-3195			
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 001					PC	Dec 17, 2021
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 002					PC	Dec 17, 2021
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 003					PC	Dec 17, 2021
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 004					PC	Dec 17, 2021
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	10035788	Oct 15, 2028	U-2043		>A> D-182	Jun 28, 2024
	10035788	Oct 15, 2028	U-3047			
	10035788	Oct 15, 2028	U-3097			
	7982043	Oct 08, 2025	U-2043			
	7982043	Oct 08, 2025	U-3047			
	7982043	Oct 08, 2025	U-3097			
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			
	8790708	Nov 05, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-3047			
	8790708	Nov 05, 2030	DP U-3097			
	9139558	Oct 15, 2028	U-2043			
	9139558	Oct 15, 2028	U-3047			
	9139558	Oct 15, 2028	U-3097			
	9211291	Mar 24, 2030	U-2043			
	9211291	Mar 24, 2030	U-3097			
	9265784	Aug 04, 2029	U-3047			
	9630946	Oct 15, 2028	U-2043			
	9630946	Oct 15, 2028	U-3047			
	9630946	Oct 15, 2028	U-3097			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10961195	Sep 25, 2035	DS DP			
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 001					ODE-319	Aug 06, 2027
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 002					ODE-319	Aug 06, 2027
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001	>A> 8389537	Jul 18, 2026	U-1374			
	>A> 8389537*PED	Jan 18, 2027				
	>A> 8415363	Jul 18, 2026	DS DP U-1374			
	>A> 8415363	Jul 18, 2026	DS DP U-1407			
	>A> 8415363*PED	Jan 18, 2027				
	>A> 8501760	Jul 18, 2026	DP			
	>A> 8501760*PED	Jan 18, 2027				
	>A> 9061029	Apr 07, 2032	DS U-1374			
	>A> 9061029	Apr 07, 2032	DS U-3231			
	>A> 9061029*PED	Oct 07, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001	>A> 8389537	Jul 18, 2026	U-1374			
	>A> 8389537*PED	Jan 18, 2027				
	>A> 8415363	Jul 18, 2026	DS DP U-1374			
	>A> 8415363	Jul 18, 2026	DS DP U-1407			
	>A> 8415363*PED	Jan 18, 2027				
	>A> 8501760	Jul 18, 2026	DP			
	>A> 8501760*PED	Jan 18, 2027				
	>A> 9061029	Apr 07, 2032	DS U-1374			
	>A> 9061029	Apr 07, 2032	DS U-3231			
	>A> 9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002	>A> 8389537	Jul 18, 2026	U-1374			
	>A> 8389537*PED	Jan 18, 2027				
	>A> 8415363	Jul 18, 2026	DS DP U-1374			
	>A> 8415363	Jul 18, 2026	DS DP U-1407			
	>A> 8415363*PED	Jan 18, 2027				
	>A> 8501760	Jul 18, 2026	DP			
	>A> 8501760*PED	Jan 18, 2027				
	>A> 9061029	Apr 07, 2032	DS U-1374			
	>A> 9061029	Apr 07, 2032	DS U-3231			
	>A> 9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003	>A> 8389537	Jul 18, 2026	U-1374			
	>A> 8389537*PED	Jan 18, 2027				
	>A> 8415363	Jul 18, 2026	DS DP U-1374			
	>A> 8415363	Jul 18, 2026	DS DP U-1407			
	>A> 8415363*PED	Jan 18, 2027				
	>A> 8501760	Jul 18, 2026	DP			
	>A> 8501760*PED	Jan 18, 2027				
	>A> 9061029	Apr 07, 2032	DS U-1374			
	>A> 9061029	Apr 07, 2032	DS U-3231			
	>A> 9061029*PED	Oct 07, 2032				
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	11091459	Mar 27, 2038	DP			
	8071623	Mar 27, 2031	DS DP			
<u>NITAZOXANIDE - NITAZOXANIDE</u>						
A 213820 001					CGT	Jun 05, 2021
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10124142	Aug 18, 2025	U-3037			
	10814092	Oct 17, 2025	U-3037			
	10926054	Aug 13, 2029	DP			
	11103669	Jun 21, 2030	DP			
	7947227	Oct 17, 2026	U-3037			
	8057742	Jan 18, 2026	U-3037			
	8226916	Aug 18, 2025	U-3037			
	8607785	Jul 14, 2030	DP			
	8609028	Aug 18, 2025	U-3037			
	8821801	Aug 18, 2025	DP			
	8944049	Aug 13, 2029	DP			
	9522249	Aug 18, 2025	DP			
	9701538	Jan 28, 2029	DP			
	9956373	Aug 18, 2025	U-3037			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Nov 16, 2027	DS DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Nov 16, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11052126	Feb 03, 2036	U-2857			
	>A> 11141457	Dec 28, 2040	U-3232			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	8420592	Aug 29, 2029	U-3101		NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DS DP		NP	Mar 12, 2024
	9682061	Apr 26, 2030	U-3101		GAIN	Aug 06, 2024
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9566252	Nov 02, 2022	U-1370			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031	U-2849			
	10940138	Dec 16, 2039	U-2849			
	11103482	Dec 16, 2039	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Nov 09, 2023	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	11065250	May 24, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	11065250	May 24, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	11065250	May 24, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005					NS	Aug 30, 2024
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006					NS	Aug 30, 2024
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 001					ODE*	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 002					ODE*	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 003					ODE*	Oct 18, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>						
A 215003 001					CGT	Mar 12, 2022
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 001	11123363	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 002	11123363	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 003	11123363	Oct 08, 2033	U-1766			
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001	10240152	Oct 20, 2029	DS DP U-2378			
	11079379	Aug 27, 2035	DS DP U-2378			
	>A> 11141378	Apr 15, 2029	DP			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		ODE-351	May 14, 2028
	10875893	Nov 15, 2033	DS	U-3124		
	11040107	Apr 09, 2038	DP	U-3172		
	11040107	Apr 09, 2038	DP	U-3173		
	11040107	Apr 09, 2038	DP	U-3174		
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	9169307	Nov 18, 2027	DS	U-3123		
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	10391075	Feb 12, 2027	U-3069			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
	8778997	May 07, 2027	U-3069			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	10947197	Jun 09, 2037	DS DP U-3130		NCE	May 26, 2026
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3130			
	9861713	Jul 31, 2029	DS DP U-3130			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10953000	Mar 23, 2037	U-1974			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					ODE-331	Oct 13, 2027
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					ODE-331	Oct 13, 2027
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	>A> 11142549	Jun 05, 2034	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					M-14 PED	Nov 20, 2023 May 20, 2024
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-849	Dec 18, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
	9029533	Dec 22, 2026		U-1283		
	9029533	Dec 22, 2026		U-1699		
	9029533	Dec 22, 2026		U-1700		
	9029533	Dec 22, 2026		U-1701		
	9029533	Dec 22, 2026		U-836		
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONESIMOD - PONVORY</u>						
N 213498 001	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	10220023	Dec 10, 2035		U-3103	NCE	Mar 18, 2026
	8273779	Dec 17, 2025		U-2774		
	9000018	Nov 16, 2024		U-3102		
	9062014	May 06, 2032	DS DP	U-2774		
	RE43728	Nov 16, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 008	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					NPP ODE-355	May 31, 2024 Jun 17, 2028
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698		NPP	May 31, 2024
	9023790	Jul 04, 2031	DP U-3160		ODE-355	Jun 17, 2028
	9023790	Jul 04, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					NP	May 31, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001					ODE-340 ODE-341	Dec 01, 2027 Dec 01, 2027
<u>PYRIMETHAMINE - PYRIMETHAMINE</u>						
A 211271 001					CGT	Apr 02, 2022
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
	10449191	Sep 29, 2037	U-3020			
	10786501	Sep 29, 2037	U-3020			
	7300935	Jan 28, 2024	DS			
	8058280	Jan 28, 2024	DS DP			
	8735401	Feb 04, 2024	U-3019			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	11007208	Sep 16, 2036	U-2984			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	11007208	Sep 16, 2036	U-2984			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001					NCE	Oct 06, 2025
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11008289	Jul 14, 2030	U-2440			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	10314828	Jul 24, 2029	U-1481			
	10335397	Jul 24, 2029	U-2579			
	10456384	Feb 26, 2029	U-2643			
	10456384	Feb 26, 2029	U-2644			
	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			
	10703763	Feb 27, 2026	U-2848			
	10709694	Jul 24, 2029	U-2579			
	10765667	Feb 26, 2029	U-2643			
	10765667	Feb 26, 2029	U-2644			
	7045620	Jun 19, 2024	DS			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029	U-1481			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8829017	Jul 24, 2029	U-1562			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
	9271968	Feb 27, 2026	DP			
	9421195	Jul 24, 2029	U-1481			
	9629828	Jul 24, 2029	U-1994			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3068			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	11083724	Mar 25, 2039	DP U-2718		I-865	May 27, 2024
	11083724	Mar 25, 2039	DP U-3142			
	8314117	Feb 22, 2031	DS DP U-2718			
	8314117	Feb 22, 2031	DS DP U-3142			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	10966966	Aug 12, 2040	U-3153			
	RE48731	Jun 07, 2032	U-3219			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001					ODE-334	Aug 07, 2027
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001					I-867	Aug 23, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002					I-867	Aug 23, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003					I-867	Aug 23, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004	10828310	Jan 31, 2039	U-3207		I-867	Aug 23, 2024
	10828310	Jan 31, 2039	U-3208			
	9415053	Nov 13, 2024	DP U-2435			
	9415053	Nov 13, 2024	DP U-3205			
	9415053	Nov 13, 2024	DP U-3206			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 001					PC	Nov 28, 2021
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 002					PC	Nov 28, 2021
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	>A> 10016429	Jun 12, 2028	U-3226		>A> I-872	Sep 22, 2024
	>A> 10016429	Jun 12, 2028	U-3230			
	>A> 7598257	Dec 24, 2027	DS DP U-3227			
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-1573			
	>A> 9079912	Dec 12, 2026	U-1721			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	>A> 10016429	Jun 12, 2028	U-3226		>A> I-872	Sep 22, 2024
	>A> 10016429	Jun 12, 2028	U-3230			
	>A> 7598257	Dec 24, 2027	DS DP U-3227			
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-1573			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	>A> 9079912	Dec 12, 2026	U-1721			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	>A> 10016429	Jun 12, 2028	U-3226			
	>A> 10016429	Jun 12, 2028	U-3230			
	>A> 7598257	Dec 24, 2027	DS DP U-3227			
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-1573			
	>A> 9079912	Dec 12, 2026	U-1721			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	>A> 10016429	Jun 12, 2028	U-3226			
	>A> 10016429	Jun 12, 2028	U-3230			
	>A> 7598257	Dec 24, 2027	DS DP U-3227			
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
	>A> 8829013	Jun 12, 2028	U-3227			
	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-1573			
	>A> 9079912	Dec 12, 2026	U-1721			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	>A> 10016429	Jun 12, 2028	U-3226			
	>A> 10016429	Jun 12, 2028	U-3230			
	>A> 7598257	Dec 24, 2027	DS DP U-3227			
	>A> 7598257	Dec 24, 2027	DS DP U-3228			
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8822481	Jun 12, 2028	U-3226			
	>A> 8822481	Jun 12, 2028	U-3227			
	>A> 8822481	Jun 12, 2028	U-3228			
	>A> 8822481	Jun 12, 2028	U-3230			
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
	>A> 8829013	Jun 12, 2028	U-3227			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	>A> 8829013	Jun 12, 2028	U-3228			
	>A> 9079912	Dec 12, 2026	U-1573			
	>A> 9079912	Dec 12, 2026	U-1721			
	>A> 9079912	Dec 12, 2026	U-3226			
	>A> 9079912	Dec 12, 2026	U-3227			
	>A> 9079912	Dec 12, 2026	U-3228			
	>A> 9079912	Dec 12, 2026	U-3230			
	>A> 9814722	Dec 12, 2026	U-3226			
	>A> 9814722	Dec 12, 2026	U-3230			
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	>A> 10610530	Jun 12, 2028	U-3229			
	>A> 10639310	Dec 12, 2026	U-3229			
	>A> 10758543	May 20, 2031	DP			
	>A> 10869870	May 20, 2031	U-3229			
	>A> 7598257	Dec 24, 2027	DS DP			
	>A> 8415362	Dec 24, 2027	DS DP			
	>A> 8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-3229			
	>A> 9079912	Dec 12, 2026	U-3229			
	>A> 9974790	Dec 12, 2026	U-3229			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	>A> 11135192	Aug 22, 2033	U-3084			
	>A> 8101659	Jan 15, 2025	DP			
	>A> 8101659*PED	Jul 15, 2025				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	>A> 11135192	Aug 22, 2033	U-3084			
	>A> 8101659	Jan 15, 2025	DP			
	>A> 8101659*PED	Jul 15, 2025				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	>A> 11135192	Aug 22, 2033	U-3084			
	>A> 8101659	Jan 15, 2025	DP			
	>A> 8101659*PED	Jul 15, 2025				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8283380	Mar 21, 2031	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8283380	Mar 21, 2031	U-1993			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10849884	Sep 04, 2035	DP U-2583		I-866	Jun 30, 2024
	10849884	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002					NCE	Apr 30, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379	003				NCE	Apr 30, 2024
<u>SELEXIPAG - UPTRAVI</u>						
N 214275	001	7205302	Apr 04, 2023	DS DP U-1797		
		8791122	Aug 01, 2030	DS DP		
		9173881	Aug 12, 2029	U-1798		
		9284280	Jun 25, 2030	U-1831		
<u>SELINEXOR - XPOVIO</u>						
N 212306	001	10519139	Aug 14, 2035	DS DP U-2584	ODE-346	Dec 18, 2027
		10519139	Aug 14, 2035	DS DP U-2855		
		10519139	Aug 14, 2035	DS DP U-3018		
		10544108	Jul 26, 2032	U-2584		
		10544108	Jul 26, 2032	U-3018		
		11034660	Jul 26, 2032	U-2584		
		11034660	Jul 26, 2032	U-3018		
		9079865	Jul 26, 2032	U-2584		
		9079865	Jul 26, 2032	U-2855		
		9079865	Jul 26, 2032	U-3018		
<u>SELINEXOR - XPOVIO</u>						
N 212306	002	10519139	Aug 14, 2035	DS DP U-2584	>A> ODE*	Jul 03, 2026
		10519139	Aug 14, 2035	DS DP U-2855	>A> ODE*	Jun 22, 2027
		10519139	Aug 14, 2035	DS DP U-3018	>A> ODE*	Dec 18, 2027
		10544108	Jul 26, 2032	U-2584		
		10544108	Jul 26, 2032	U-3018		
		11034660	Jul 26, 2032	U-2584		
		11034660	Jul 26, 2032	U-3018		
		8999996	Sep 15, 2032	DS DP		
		9079865	Jul 26, 2032	U-2584		
		9079865	Jul 26, 2032	U-2855		
		9079865	Jul 26, 2032	U-3018		
		9714226	Jul 26, 2032	DS DP		
<u>SELINEXOR - XPOVIO</u>						
N 212306	003	10519139	Aug 14, 2035	DS DP U-2584	>A> ODE*	Jul 03, 2026
		10519139	Aug 14, 2035	DS DP U-2855	>A> ODE*	Jun 22, 2027
		10519139	Aug 14, 2035	DS DP U-3018	>A> ODE*	Dec 18, 2027
		10544108	Jul 26, 2032	U-2584		
		10544108	Jul 26, 2032	U-3018		
		11034660	Jul 26, 2032	U-2584		
		11034660	Jul 26, 2032	U-3018		
		8999996	Sep 15, 2032	DS DP		
		9079865	Jul 26, 2032	U-2584		
		9079865	Jul 26, 2032	U-2855		
		9079865	Jul 26, 2032	U-3018		
		9714226	Jul 26, 2032	DS DP		
<u>SELINEXOR - XPOVIO</u>						
N 212306	004	10519139	Aug 14, 2035	DS DP U-2584	>A> ODE*	Jul 03, 2026
		10519139	Aug 14, 2035	DS DP U-2855	>A> ODE*	Jun 22, 2027
		10519139	Aug 14, 2035	DS DP U-3018	>A> ODE*	Dec 18, 2027
		10544108	Jul 26, 2032	U-2584		
		10544108	Jul 26, 2032	U-3018		
		11034660	Jul 26, 2032	U-2584		
		11034660	Jul 26, 2032	U-3018		
		8999996	Sep 15, 2032	DS DP		
		9079865	Jul 26, 2032	U-2584		
		9079865	Jul 26, 2032	U-2855		
		9079865	Jul 26, 2032	U-3018		
		9714226	Jul 26, 2032	DS DP		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637	001	11097063	Jul 17, 2026	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	11097063	Jul 17, 2026	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001	>A> 11129869	Jul 04, 2034	DP		ODE-336	Nov 25, 2027
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 003	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-187 PED	Dec 04, 2023 Jun 04, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 214805 001					CGT	Jan 03, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10864181	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001					ODE*	Aug 28, 2026
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002					ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	10086011	Jan 30, 2034	U-1470		D-177	Nov 15, 2022
	10086011*PED	Jul 30, 2034			M-264	Jul 14, 2023
	>A> 11116783	Jan 30, 2034	DP U-1470		NPP	Mar 19, 2023
	>A> 11116783*PED	Jul 30, 2034			PED	May 15, 2023
	8575135	Nov 16, 2032	DS DP U-1470		PED	Sep 19, 2023
	8575135*PED	May 16, 2033			PED	Jan 14, 2024
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	10086011	Jan 30, 2034	U-1470		M-264	Jul 14, 2023
	10086011*PED	Jul 30, 2034			NS	Mar 19, 2023
	>A> 11116783	Jan 30, 2034	DP U-1470		PED	Sep 19, 2023
	>A> 11116783*PED	Jul 30, 2034			PED	Jan 14, 2024
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	11116783	Jan 30, 2034	DP U-1470			
	11116783*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002	11116783	Jan 30, 2034	DP U-1470			
	11116783*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	10912814	Jun 01, 2037	DP			
	11116783	Jan 30, 2034	DP U-2039			
	11116783	Jan 30, 2034	DP U-2040			
	11116783*PED	Jul 30, 2034				
	8575135	Nov 16, 2032	DS DP U-2039			
	8575135	Nov 16, 2032	DS DP U-2040			
	8575135*PED	May 16, 2033				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8735372*PED	Sep 21, 2028				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	8940718*PED	May 16, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE Ls</u>						
N 209529 001	9918970	May 18, 2031	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	10959976	Jun 01, 2038	U-3151			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10912754	Jun 01, 2038	U-3082			
	10959976	Jun 01, 2038	U-3151			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10799138	Apr 05, 2039	U-3125			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	11013703	Apr 01, 2034	DP			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001					NCE ODE-352	May 28, 2026 May 28, 2028
<u>SPINOSAD - NATROBA</u>						
N 022408 001					I-858	Apr 28, 2024
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10888570	Oct 28, 2036	DP			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10896751	Mar 16, 2030	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					NPP	Jun 25, 2024
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					NPP	Jun 25, 2024
<u>TACROLIMUS - PROGRAF</u>						
N 050708 001					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050708 002					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050708 003					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050709 001					ODE-360	Jul 16, 2028
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001					ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002					ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003					ODE*	May 24, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 001	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 002	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 003	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
<u>TACROLIMUS - PROGRAF</u>						
N 210115 001					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 210115 002					ODE-360	Jul 16, 2028
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10888558	Dec 02, 2035	U-2582			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	10864159	May 28, 2029	DP U-778			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 003	>A> 10189837	Oct 20, 2031	DS DP		>A> NCE	Oct 16, 2023
	>A> 8012976	Oct 19, 2029	DS DP			
	>A> 8420650	Jul 27, 2029	DS DP			
	>A> 8735392	Oct 20, 2031	DS DP			
	>A> 9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 004	>A> 10189837	Oct 20, 2031	DS DP		>A> NCE	Oct 16, 2023
	>A> 8012976	Oct 19, 2029	DS DP			
	>A> 8420650	Jul 27, 2029	DS DP			
	>A> 8735392	Oct 20, 2031	DS DP			
	>A> 9820985	Jul 27, 2029	U-2437			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610511	Oct 10, 2034	U-2615		I-850	Dec 01, 2023
	10610511	Oct 10, 2034	U-3007		ODE-330	Dec 01, 2027
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	>A> 11141400	Oct 10, 2034	U-2615			
	>A> 11141400	Oct 10, 2034	U-3007			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	10980770	Jan 25, 2033	U-3106		NP	Dec 01, 2023
	>A> 11141400	Oct 10, 2034	U-3007		ODE-329	Dec 01, 2027
<u>TAVABOROLE - TAVABOROLE</u>						
A 211963 001					PC	Apr 17, 2021
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10786511	Dec 19, 2035	DP			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-3179			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					NPP	May 19, 2024
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	>A> 7390791	Apr 17, 2025	DS DP			
	>A> 7390791*PED	Oct 17, 2025				
	>A> 8754065	Aug 15, 2032	DS DP U-999			
	>A> 8754065*PED	Feb 15, 2033				
	>A> 9296769	Aug 15, 2032	DS DP U-999			
	>A> 9296769*PED	Feb 15, 2033				
<u>TEPOTINIB HYDROCHLORIDE - TEPMETKO</u>						
N 214096 001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
	8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
	8658643	Jul 04, 2028	U-3077			
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028	U-3078			
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028	U-3077			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Sep 12, 2026	U-1285		M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Sep 12, 2026	U-1285		M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	11090312	Mar 17, 2034	U-1616			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<u>THEOPHYLLINE - THEOPHYLLINE</u>						
A 212184 002					CGT	Dec 08, 2021
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-851	May 28, 2023
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002					I-851	May 28, 2023
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP U-3015			
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	10905694	Apr 07, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	10905694	Apr 07, 2030	DP			
<u>TORSEMIDE - SOAANZ</u>						
N 213218 001	10154963	Oct 06, 2033	DP			
<u>TORSEMIDE - SOAANZ</u>						
N 213218 002	10154963	Oct 06, 2033	DP			
<u>TRAMADOL HYDROCHLORIDE - QDOLO</u>						
N 214044 001	11103452	Sep 01, 2040	DP U-3197			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	10869869	Aug 30, 2033				U-3184
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869	Aug 30, 2033				U-3184
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	10869869	Aug 30, 2033				U-3184
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 005	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024				U-2845
	7999007	Mar 29, 2029	DP			U-1437
	8653137	Sep 05, 2028				U-1437
	8658694	Sep 05, 2028				U-1437
	9199908	May 24, 2024				U-1771
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024				U-2036
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001					I-856	Mar 31, 2024
<u>TRIAMCINOLONE ACETONIDE - XIPERE</u>						
N 211950 001	>A> 8636713	May 02, 2027				U-3234
	>A> 9636332	Nov 08, 2033				U-3234
	>A> 9937075	May 02, 2034	DP			
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	9498465	May 30, 2033	DP U-1033			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	10085992	Mar 14, 2034				U-3081
	10189849	Oct 25, 2031	DS			
	10189850	Oct 25, 2031				DP
	10927120	Oct 25, 2031				DP
	10966984	Mar 14, 2034				U-3079
	10966984	Mar 14, 2034				U-3080
	11040042	Mar 14, 2034				DP
	8598186	Oct 25, 2031	DS DP			
	8598197	Oct 25, 2031	DS DP			
	9487530	Mar 14, 2034				U-3079
	9487530	Mar 14, 2034				U-3080
	9957276	Oct 25, 2031	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMBRALISIB TOSYLATE - UKONIO</u>						
N 213176 001	10072013	Jul 02, 2033	U-3063		NCE	Feb 05, 2026
	10072013	Jul 02, 2033	U-3064		ODE-343	Feb 05, 2028
	10414773	May 26, 2035	DS DP U-3063		ODE-344	Feb 05, 2028
	10414773	May 26, 2035	DS DP U-3064			
	10570142	Jul 02, 2033	DS DP U-3063			
	10570142	Jul 02, 2033	DS DP U-3064			
	10947244	May 26, 2035	U-3063			
	10947244	May 26, 2035	U-3064			
	9150579	Jul 02, 2033	DS DP			
	9669033	Jul 02, 2033	U-3063			
	9669033	Jul 02, 2033	U-3064			
	9969740	May 26, 2035	DS DP U-3063			
	9969740	May 26, 2035	DS DP U-3064			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	11090294	Nov 29, 2030	U-3203			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
	8039627	Oct 06, 2029	DS DP			
	8357697	Nov 08, 2027	U-1995			
<u>VALSARTAN - DIOVAN</u>						
N 021283 001					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 002					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 004					NPP	Apr 19, 2024
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11000567	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	>A> 10456396	Oct 19, 2035	DP U-1900			
	>A> 9504644	Oct 19, 2035	U-1900			
	>A> 9504645	Oct 19, 2035	DP			
	>A> 9532944	Oct 19, 2035	U-1900			
	>A> 9597284	Oct 19, 2035	U-1900			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	10993942	Sep 06, 2033	U-3114			
	>A> 11110087	Sep 06, 2033	U-3222			
	>A> 11110087	Sep 06, 2033	U-3223			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	10993942	Sep 06, 2033	U-3114			
	>A> 11110087	Sep 06, 2033	U-3222			
	>A> 11110087	Sep 06, 2033	U-3223			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	10993942	Sep 06, 2033	U-3114			
	>A> 11110087	Sep 06, 2033	U-3222			
	>A> 11110087	Sep 06, 2033	U-3223			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031		U-3062		
	9604948	Nov 26, 2032	DS DP	U-3062		
	9993476	May 19, 2031		U-3062		
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031		U-3062		
	9604948	Nov 26, 2032	DS DP	U-3062		
	9993476	May 19, 2031		U-3062		
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031		U-3062		
	9604948	Nov 26, 2032	DS DP	U-3062		
	9993476	May 19, 2031		U-3062		
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP	U-3045	NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VIGABATRIN - VIGABATRIN</u>						
A 211539 001					CGT	Jul 31, 2021
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033		U-727		
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033		U-727		
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033		U-727		
	9662338	Feb 07, 2033	DP			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP	U-3039	ODE-280	Aug 12, 2027
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9790183	Sep 02, 2025		U-3109		
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	10286036	Dec 07, 2037		U-3056	NCE	Jan 22, 2026
	7332472	Oct 17, 2022	DS DP	U-3056		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003					M-187	Jan 22, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004					M-187	Jan 22, 2024
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	DS DP U-2145		>A> I-871	Aug 31, 2024
	10927117	Aug 15, 2037	DS DP		>A> I-874	Sep 14, 2024

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41ST Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm